omeprazole has been researched along with Infections, Helicobacter in 2109 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this multicenter, randomized, double-blind, double-dummy, positive-drug parallel-controlled, phase III study, Chinese patients with duodenal ulcers were randomized 1:1 to receive rabeprazole 10 mg + anaprazole placebo or rabeprazole placebo + anaprazole 20 mg once daily for 4 weeks." | 9.51 | Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study. ( Ding, J; Du, Y; Fan, H; Huang, C; Li, Z; Lyu, N; Pan, X; Pan, Z; Shi, Z; Sun, H; Wang, Q; Zhang, L; Zhu, H, 2022) |
| "To assess the efficacy and safety of omeprazole given with the new single capsule of bismuth, metronidazole and tetracycline (OBMT) compared with quadruple treatment consisting of omeprazole, bismuth, amoxicillin and clarithromycin (OBAC) for Helicobacter pylori eradication in duodenal ulcer patients." | 9.27 | New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese pro ( Chen, Y; Du, Y; Li, Y; Liu, D; Lv, N; Pan, X; Wang, H; Wang, J; Wu, K; Xie, Y; Xu, J; Zeng, Z; Zhang, G, 2018) |
| " pylori-associated gastritis were randomly assigned to one of three arms for a 14-day treatment: Arm A triple therapy (omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily; Arm B triple therapy plus polaprezinc 150 mg twice daily, or Arm C triple therapy alone." | 9.24 | Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. ( Fang, JY; Ji, F; Li, JS; Li, YQ; Luo, HQ; Luo, HS; Lv, NH; Qian, JM; Ren, JL; Shi, RH; Tan, B; Xu, H; Zou, YY, 2017) |
| "Patients with Helicobacter pylori positive peptic ulcer disease were randomly allocated into two groups: amoxicillin 1 g b." | 9.15 | Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease. ( Ghadir, MR; Iranikhah, A; Joukar, F; Mansour-Ghanaei, F; Pakdin, A; Shafaghi, A, 2011) |
| " The aim of this study was to evaluate the efficacy and tolerability of a levofloxacin-based regimen in patients with peptic ulcer after failure of the standard first-line H." | 9.15 | Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. ( Akyuz, F; Ermis, F; Kaymakoglu, S; Kurt, R; Mungan, Z; Nazik, H; Pinarbasi, B; Uyanikoglu, A, 2011) |
| "Melatonin (MT) and its precursor L-tryptophan (TRP) are implicated in the protection of gastric mucosa against aspirin-induced lesions and in the acceleration of healing of idiopathic gastro-duodenal ulcers, but no information is available whether these agents are also effective in healing of gastroduodenal ulcers accompanied by Helicobacter pylori (H." | 9.15 | Effects of melatonin and tryptophan on healing of gastric and duodenal ulcers with Helicobacter pylori infection in humans. ( Bielanski, W; Brzozowski, T; Celinski, K; Cichoz-Lach, H; Konturek, PC; Konturek, SJ; Slomka, M, 2011) |
| "To establish the efficacy and safety of a 7-d therapeutic regimen using omeprazole, bismuth subcitrate, furazolidone and amoxicillin in patients with peptic ulcer disease who had been previously treated with other therapeutic regimens without success." | 9.13 | Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. ( Barbuti, RC; Eisig, JN; Felga, GE; Navarro-Rodriguez, T; Silva, FM; Zaterka, S, 2008) |
| "To evaluate the furazolidone-based triple therapy in children with symptomatic H pylori gastritis." | 9.12 | Furazolidone-based triple therapy for H pylori gastritis in children. ( Bonucci, VC; Carelli, AP; Fukushima, E; Kawakami, E; Langner, M; Machado, RS; Ogata, SK; Patricio, FR, 2006) |
| " pylori) gastritis in children by the adjunction of omeprazole (OAC) was studied." | 9.12 | Improvement of the eradication rate of Helicobacter pylori gastritis in children is by adjunction of omeprazole to a dual antibiotherapy. ( Alliet, P; Bontemps, P; Cadranel, S; Lauvau, D; Van Biervliet, S; Vandenhoven, G; Vandenplas, Y, 2007) |
| " pylori-positive patients with an active duodenal ulcer (DU) received esomeprazole, 20 mg twice daily (bid), or omeprazole, 20 mg bid, with amoxicillin, 1000 mg bid, and clarithromycin, 500 mg bid, for 1 week (EAC and OAC, respectively)." | 9.12 | One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients. ( Arigbabu, A; Bachelet, E; Cardona, HJ; Hammour, AA; Miller, T; Subei, IM; Useche, E, 2007) |
| " This prospective randomised study aimed to investigate whether H pylori eradication can influence gastritis and its sequelae during long term omeprazole therapy for gastro-oesophageal reflux disease (GORD)." | 9.11 | Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. ( Dent, J; Festen, HP; Goldfain, D; Havu, N; Klinkenberg-Knol, EC; Kolkman, JJ; Kuipers, EJ; Lamm, M; Nelis, GF; Snel, P; Walan, A; Zeitoun, P, 2004) |
| " pylori infection on effectiveness of rabeprazole in primary and secondary care patients with gastro-oesophageal reflux disease." | 9.11 | Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? ( Bergmans, P; Boer, WA; Geldof, H; Hazelhoff, B; Smout, AJ; Tytgat, GN; Wit, NJ, 2004) |
| "Sixty-seven patients (49 with Zollinger-Ellison syndrome [ZES], 18 without), with basal acid output (BAO) >15 mmol/h or >5 mmol/h if post-antrectomy (n = 9, all ZES), were treated with individually optimized doses of lansoprazole (7." | 9.11 | Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. ( Hirschowitz, BI; Mohnen, J; Simmons, J, 2005) |
| "To investigate the effect of Helicobacter pylori eradication on endothelin-1 (ET-1) and nitric oxide (NO) in duodenal ulcer (DU) patients." | 9.11 | Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication. ( Chang, FY; Chen, CY; Lee, SD; Lu, CL; Lu, RH; Luo, JC, 2005) |
| " pylori-positive peptic ulcer were randomly divided into two groups, and accepted triple therapy with omeprazole 20 mg, amoxicillin 1000 mg and either clarithromycin 500 mg (OAC group, n = 58) or metronidazole 400 mg (OAM group, n = 45)." | 9.11 | Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. ( Cao, DZ; Fu, XL; Hu, JM; Ou, XL; Su, H; Sun, WH; Sun, YL; Yu, Q; Yu, T; Zhu, F, 2005) |
| "To study the efficacy and safety of rabeprazole in peptic ulcer patients alone or combined with anti-Helicobacter pylori (Hp) agents." | 9.11 | [The clinical applications of rabeprazole either alone or combined with anti-Helicobacter pylori agents in peptic ulcer patients]. ( Lin, SR, 2005) |
| "To compare the efficacy of famotidine and omeprazole in Japanese patients with non-erosive gastro-oesophageal reflux disease by a prospective randomized multicentre trial." | 9.11 | Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. ( Arakawa, T; Chono, S; Fujiwara, Y; Higuchi, K; Kitada, K; Kobayashi, K; Nakagawa, K; Nebiki, H; Oshitani, N; Satoh, H; Tominaga, K; Uno, H; Watanabe, T, 2005) |
| "To investigate the effect of esomeprazole- and omeprazole-based triple therapy regimens in the treatment of duodenal ulcer with Helicobacter pylori (Hp) infection." | 9.11 | [Comparison of esomeprazole- and omeprazole-based triple therapy regimens for duodenal ulcer with Helicobacter pylori infection]. ( Chen, YH; Li, HY; Wang, H; Wang, WM, 2005) |
| "To evaluate the efficacy of different doses of lansoprazole for the treatment of functional dyspepsia in Chinese patients." | 9.10 | Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. ( Fung, FM; Hu, WH; Hung, WK; Lai, KC; Lam, SK; Szeto, ML; Tong, TS; Wong, BC; Wong, WM; Yee, YK; Yip, AW; Yuen, MF, 2002) |
| "Comparison of two treatment regimens of eradication treatment of duodenal ulcer (DU) associated with Helicobacter pylori based on fromilid (clarithromycin)." | 9.10 | [Fromilid (clarithromycin) in eradication patients in patients with duodenal ulcer associated with Helicobacter pylori (comparison of two treatment variations)]. ( Firsanova, VIu; Kolomiets, EV; Vasil'ev, IuV; Zvenigorodskaia, LA, 2002) |
| "One hundred and forty-nine consecutive patients with active duodenal ulcer were randomized to receive omeprazole (20 mg b." | 9.10 | Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. ( Amberiadis, P; Archavlis, E; Chiotakakou, E; Christoforidis, P; Kourtessas, D; Mantzaris, GJ; Petraki, K; Triantafyllou, G, 2002) |
| "It was to determine the efficacy of rabeprazole at 20 and 40 mg in addition to amoxicillin and clarithromycin in the treatment of active Helicobacter pylori-positive duodenal ulcers compared with omeprazole 40 mg." | 9.10 | Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Scalia, A; Terminella, C, 2002) |
| "To compare the efficacy and safety of two doses of rabeprazole with 20 mg omeprazole in the maintenance treatment of erosive gastro-oesophageal reflux disease over 5 years." | 9.10 | A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. ( Bardhan, KD; Fiocca, R; Humphries, TJ; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2003) |
| "This multicenter, randomized, active-controlled trial assessed efficacy of bismuth-based quadruple therapy with omeprazole, bismuth biskalcitrate, metronidazole, and tetracycline (OBMT) using a single-triple capsule of BMT compared with triple therapy with omeprazole, amoxicillin, and clarithromycin (OAC) in treatment of patients with Helicobacter pylori infection and duodenal ulcers." | 9.10 | Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a ( El-Zimaity, H; Hunt, R; Laine, L; Nguyen, B; Osato, M; Spénard, J, 2003) |
| "To assess efficiency of esomeprazole in the treatment of duodenal ulcer (DU) associated with H." | 9.10 | [Esomeprazole in treating duodenal ulcer in various modes of anti-Helicobacter therapy]. ( Kurilo, AE; Maev, IV; Shchekina, MI; V'iuchnova, ES, 2003) |
| "Omeprazole, clarithromycin and tinidazole for 7 days heals active duodenal ulcer and eradicates H." | 9.10 | Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial. ( Angelucci, D; Cellini, L; Marzio, L, 2003) |
| " pylori-positive patients with active gastric ulcer were randomized to receive pantoprazole (40 mg) (P) and two of three antibiotics: clarithromycin (500 mg) (C), metronidazole (500 mg) (M) or amoxicillin (1000 mg) (A)." | 9.10 | Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. ( Bohuschke, M; Gatz, G; Kirchner, T; Kist, M; Leodolter, A; Malfertheiner, P; Peitz, U; Strobel, S, 2003) |
| "To compare the efficacy of a "Helicobacter pylori test and treat" strategy with that of an empirical trial of omeprazole in the non-endoscopic management by empirical prescribing of young patients with dyspepsia." | 9.10 | Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment. ( Balzano, A; de Nucci, C; Manes, G; Menchise, A, 2003) |
| " pylori-positive patients with peptic ulcer bleeding (n = 101) were randomized to receive either a regular dose (20 mg/day for 3 days) (n = 51) or a high dose of omeprazole (80 mg bolus + 8 mg/h infusion/day for 3 days) (n = 50)." | 9.10 | Effect of short-term treatment with regular or high doses of omeprazole on the detection of Helicobacter pylori in bleeding peptic ulcer patients. ( Julkunen, R; Miettinen, P; Palmu, A; Udd, M, 2003) |
| "The aim of this study was to compare the effect of a combination of lansoprazole, clarithromycin, and amoxicillin (LCA) versus placebo on the severity of symptoms in functional dyspepsia patients who were positive for Helicobacter pylori (H." | 9.10 | Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. ( Cohen, L; Fedorak, RN; Lambert, J; Vanjaka, A; Veldhuyzen van Zanten, S, 2003) |
| " pylori-positive patients with peptic ulcer disease were received rabeprazole 10 mg bid, amoxicillin 1,000 mg bid and clarithromycin 500 mg bid for a week." | 9.10 | [A prospective study on rabeprazole-based triple therapy for Helicobacter pylori eradication in patients with peptic ulcer]. ( Choi, BK; Chung, JM; Jang, YS; Lee, SH; Lee, YJ; Park, ET; Seol, SY; Yang, SY, 2003) |
| "To compare the short-term (7-day) safety and efficacy of two triple-therapy regimens using pantoprazole with those of two dual-therapy regimens (one with pantoprazole and one without), for Helicobacter pylori eradication in patients with peptic ulcer disease." | 9.10 | Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. ( Bochenek, WJ; Davis, KD; El-Zimaity, HM; Fraga, PD; Graham, DY; Mack, ME; Osato, MS; Peters, S; Wang, W, 2003) |
| " pylori-infected peptic ulcer patients were randomly assigned to 1 of 3 groups: RAC4 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 4 days), RAC7 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days), and OAC7 (omeprazole 20mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days)." | 9.10 | Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. ( Chen, JH; Chen, TJ; Lee, SC; Wang, GM; Yang, KC, 2003) |
| "To investigate the eradication rate of Helicobacter pylori with omeprazole, amoxicillin and clarithromycin during 6 days in patients with duodenal ulcer." | 9.09 | [Treatment with omeprazole, clarithromycin and amoxicillin over 6 days in patients with Helicobacter pylori-infected duodenal ulcer]. ( Barrachina, M; Bixquert, M; Cuquerella, J; del Val, A; García-Romero, E; Garrigues, V; Higón, MD; Ponce, J; Pons, V, 1999) |
| "Thirty-eight children with Helicobacter pylori gastritis diagnosed by histopathology, and/or bacteriological culture were treated with omeprazole, amoxicillin and clarithromycin." | 9.09 | Helicobacter pylori gastritis in children: efficacy of 2 weeks of treatment with clarithromycin, amoxicillin and omeprazole. ( Finkel, Y; Sandstedt, B; Tirén, U, 1999) |
| "To investigate the efficacy of two omeprazole triple therapies for the eradication of Helicobacter pylori, ulcer healing and ulcer relapse during a 6-month treatment-free period in patients with active duodenal ulcer." | 9.09 | The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. ( Bayerdörffer, E; Bradette, M; Farley, A; Leddin, D; Lind, T; O'Morain, C; Sinclair, P; Sipponen, P; Spiller, RC; Unge, P; Wrangstadh, M; Zanten, SJ; Zeijlon, L, 1999) |
| "To evaluate the efficacy of 1-week triple therapy with omeprazole, clarithromycin,and tinidazole (OCT) in Helicobacter pylori-positive older patients with dyspepsia." | 9.09 | The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive older patients with dyspepsia. ( Arber, N; Brill, S; Halpern, Z; Konikoff, FM; Moshkowitz, M; Reif, S, 1999) |
| " pylori-positive duodenal ulcer were allocated randomly to receive one of four regimens: metronidazole, 200 mg; amoxicillin, 250 mg; and colloidal bismuth subcitrate (CBS), 120 mg (group 1), or CBP, 100 mg qid (group 2) for 2 weeks, then continued CBS, 240 mg, or CBP, 200 mg bid for a further 2 weeks." | 9.09 | Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer. ( Dai, S; Du, H; Li, Q; Li, Y; Nie, Y; Sha, W; Wang, H; Wu, H, 1999) |
| "To study the efficacy of omeprazole triple therapy in the eradication of Helicobacter pylori in patients with active gastric ulcer, and to assess healing and relapse of gastric ulcer." | 9.09 | The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. ( Bayerdörffer, E; Diete, U; Gil, J; Lind, T; Malfertheiner, P; Misiuna, P; O'Morain, C; Sipponen, P; Spiller, RC; Stasiewicz, J; Treichel, H; Ujszászy, L; Unge, P; Zanten, SJ; Zeijlon, L, 1999) |
| " pylori-positive duodenal ulcer and randomized them into three treatment groups: 84 patients (group Ome40) were assigned to receive omeprazole, 20 mg twice daily, plus amoxicillin, 1 gm twice daily, and clarithromycin, 500 mg twice daily for 10 days; 79 patients (group Pan40) were treated with pantoprazole, 40 mg daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40; and 80 patients (group Pan80) were treated with pantoprazole, 40 mg twice daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40." | 9.09 | Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Catanzaro, R; Cipolla, R; Nuciforo, G, 1999) |
| " Our main objective was to study the outcome of a non-metronidazole and omeprazole-based antibiotic regimen in eradicating Helicobacter pylori in patients with duodenal ulcer." | 9.09 | The outcome of a 2-week treatment of Helicobacter pylori-positive duodenal ulcer with omeprazole-based antibiotic regimen in a region with high metronidazole resistance rate. ( Abdulle, AM; Adeyemi, EO; Benedict, S; Danial, MF; Helal, T, 1999) |
| " pylori-positive patients with non-ulcer dyspepsia were treated for 7 days with clarithromycin 500 mg b." | 9.09 | Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. ( De Mascarel, A; Lamouliatte, H; Megraud, F; Samoyeau, R, 1999) |
| "To evaluate the efficacy of omeprazole plus clarithromycin and furazolidone in Helicobacter pylori eradication and duodenal ulcer healing in Brazilian patients." | 9.09 | Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. ( Cabral, MM; Dani, R; De Castro, LP; Dias, MG; Franco, JM; Magalhães, LC; Mendes, GS; Moreira, LS; Queiroz, DM; Rocha, GA; Salles, PG; Toppa, NH, 1999) |
| "This study was a comparison of 1-week and 2-week triple therapies with omeprazole, amoxicillin, and clarithromycin (OAC) in patients with peptic ulcer disease and Helicobacter pylori infection." | 9.09 | Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection: results of a randomized controlled trial. ( Habu, Y; Inokuchi, H; Kawai, K; Kimoto, K; Kiyota, K; Mizuno, S; Sugano, Y, 1999) |
| "To compare two lansoprazole-based non-clarithromycin triple therapies and one dual therapy in a prospective double-blind placebo-controlled study of Helicobacter pylori eradication and duodenal ulcer healing." | 9.09 | Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. ( Carpio, RE; Fock, KM; Ho, J; Hu, FL; Hu, PJ; Huang, NX; Kachintorn, U; Kullavanijaya, P; Lam, SK; Lesmana, L; Li, YY; Manan, C; Perez, JY; Phornphutkul, K; Qian, SC; Wong, BC; Xiao, SD, 2000) |
| " pylori positive active peptic ulcer disease were randomly assigned to receive lansoprazole 30 mg o." | 9.09 | Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. ( Beglinger, C; Drewe, J; Lehmann, FS; Terracciano, L, 2000) |
| "To investigate the efficacy of a 1-week triple therapy with amoxycillin, clarithromycin, and omeprazole or ranitidine bismuth citrate (RBC) in curing Helicobacter pylori infection and healing duodenal ulcers." | 9.09 | Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study. ( Ballardini, G; Boni, F; Bortoli, A; Colombo, E; Minoli, G; Spinzi, GC; Venturelli, R, 2000) |
| "Lansoprazole 30 mg, amoxicillin 1000 mg, and tinidazole 500 mg were given twice daily to 39 peptic ulcer patients (26 duodenal and 13 gastric ulcer, mean age 52." | 9.09 | Eradication of Helicobacter pylori with lansoprazole based triple therapy in peptic ulcer disease. ( Gonlachanvit, S; Kladchareon, N; Kullavanijaya, P; Mahachai, V, 2000) |
| "In patients who require continuous treatment with NSAIDs, lansoprazole is superior to ranitidine for healing of NSAID-associated gastric ulcers." | 9.09 | Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. ( Agrawal, NM; Campbell, DR; Haber, MM; Huang, B; Lukasik, NL; Safdi, MA, 2000) |
| "The primary objective of the present study was to evaluate the efficacy of 30 and 60 mg of lansoprazole administered in combination with two antibiotics for 7 or 10 days in eradicating Helicobacter pylori in duodenal ulcer patients." | 9.09 | [Treatment of Helicobacter pylori infection with lansoprazole 30 mg or 60 mg combined with two antibiotics for duodenal ulcers]. ( Joubert-Collin, M; Lamouliatte, H; Perie, F, 2000) |
| "The aim of this study was to compare in an open, controlled and prospective trial the efficacy of one-week regimen using either lansoprazole (2 x 30 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group I, 60 cases) or ranitidine bismuth citrate (2 x 400 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group II, 61 cases) on the eradication of Hp infection in duodenal ulcer patients." | 9.09 | [Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer]. ( Buzás György, M; Illyés, G; Székely, E; Széles, I, 2000) |
| "To clarify whether the depth of ulceration evaluated by endoscopic ultrasonography (EUS) influences a modified dual therapy with amoxicillin and lansoprazole for the treatment of Helicobacter pylori-positive patients with gastric ulcer." | 9.09 | Does the depth of gastric ulceration influence a modified dual therapy with amoxicillin and lansoprazole for Helicobacter pylori-associated gastric ulcer? ( Kawashima, A; Motoo, Y; Ohtsubo, K; Okai, T; Sakai, J; Sawabu, N; Watanabe, H, 2000) |
| "Seven-day triple therapy with omeprazole, amoxicillin, and clarithromycin was efficacious for treating Asian and African patients with duodenal ulcer disease associated with H." | 9.09 | Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. ( Abbas, Z; Abid, S; Chang, FY; Chen, PC; Destefano, M; Hamid, SS; Lam, SK; Lin, BR; Schneider, H; Seebaran, A; Simjee, AE; Van Rensburg, C; Wong, BC; Zhang, J, 2000) |
| "Four hundred and forty eight duodenal ulcer patients with Helicobacter pylori infection, confirmed by 13C-urea breath test (UBT), and no current ulcer, were randomised to double-blind treatment with esomeprazole 20 mg twice daily (b." | 9.09 | One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. ( Cockeram, A; De Argila, CM; Delchier, JC; Göthe, L; Hasselgren, G; Labenz, J; Lauritsen, K; Lind, T; Sinclair, P; Stubberöd, A; Treichel, HC; Veldhuyzen Van Zanten, S; Wrangstadh, M, 2000) |
| " Fifty patients with active or scarred duodenal ulcer were randomized to lansoprazole or omeprazole for 1 to 4 weeks, with clarithromycin 250 mg twice a day and tinidazole 500 mg twice a day for the first week." | 9.09 | Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer. ( Fanti, L; Guslandi, M; Ieri, R; Mezzi, G; Passaretti, S; Testoni, PA, 2001) |
| "Little is known about the efficacy and safety of different formulations of omeprazole-based triple therapy regimens for the treatment of Helicobacter pylori-positive peptic ulcer." | 9.09 | Comparison of the efficacy and safety of different formulations of omeprazole-based triple therapies in the treatment of Helicobacter pylori-positive peptic ulcer. ( Baik, SK; Cho, MY; Jeong, YS; Kim, HS; Kim, JW; Kim, KH; Kwon, SO; Lee, DK; Seo, JI, 2001) |
| "A total of 59 consecutive Helicobacter pylori infected non-ulcer dyspepsia patients were randomly selected to receive either one of two triple therapy regimens, including metronidazole, amoxycillin plus ranitidine bismuth citrate (RAM group) or omeprazole (OAM group)." | 9.09 | Ranitidine bismuth citrate or omeprazole-based triple therapy for Helicobacter pylori eradication in Helicobacter pylori-infected non-ulcer dyspepsia. ( Chuang, CH; Lin, XZ; Sheu, BS; Wu, JJ; Yang, HB, 2001) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 9.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| " pylori positive duodenal ulcer were enrolled and randomly allocated into one of the five treatment groups: 1) group A: received lansoprazole 30 mg once daily for 2 weeks plus amoxicillin (AM) 500 mg and metronidazole (MZ) 500 mg twice daily for one week in the first week; 2) group B: the AM in group A was replaced by clarithromycin (CM) 250 mg; 3) group C: the MZ in group A was replaced by CM 250 mg; 4) group D: the AM and CM in group C was used for 2 wk; 5) group E: the CM in group D was doubled to 500 mg twice daily." | 9.09 | A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy. ( Hsu, CT; Kuo, CF; Wang, CS; Wang, TH; Yang, JC; Yang, KC, 1999) |
| "Helicobacter pylori-positive patients (n=323) with non-ulcer dyspepsia were randomized to receive one of four 1-week regimens consisting of omeprazole, 20 mg b." | 9.09 | A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. ( Barthélemy, P; Caekaert, A; Fléjou, JF; Laurent, J; Mégraud, F, 2001) |
| "The aim of this multicenter prospective, randomized, double-blind study was to assess the efficacy of the combination of omeprazole, amoxicillin, and clarithromycin (OAC) for the treatment of Helicobacter pylori gastritis in children." | 9.09 | Omeprazole combined with amoxicillin and clarithromycin in the eradication of Helicobacter pylori in children with gastritis: A prospective randomized double-blind trial. ( Barthélemy, P; Dupont, C; Gottrand, F; Guimber, D; Husson, MO; Kalach, N; Lachaux, A; Lenaerts, C; Maurage, C; Morali, A; Mougenot, JF; Roquelaure, B; Spyckerelle, C; Tounian, P, 2001) |
| " pylori infection in patients with duodenal ulcers, compared with treatment based on pantoprazole, in a randomized controlled multicenter study." | 9.09 | Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial). ( Barbir, A; Hovat, D; Ivandić, A; Kurbel, S; Mihaljević, S; Ostojić, R; Stimac, D; Takac, B; Vcev, A; Vceva, A, 2001) |
| "Satisfactory antral biopsies were obtained from 119 duodenal ulcer patients before and after 4 wk of therapy with lansoprazole, ranitidine, or placebo." | 9.08 | The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients. ( Atkinson, BF; Brightman, SA; Jhala, NC; McFarland, MM; Morale, B; Rubin, W, 1995) |
| "We examined the effects of lansoprazole and famotidine on gastric basic fibroblast growth factor (bFGF) levels and ulcer healing in patients with gastric ulcer." | 9.08 | Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine. ( Fukuda, M; Higashi, T; Imaizumi, T; Kawano, S; Miura, N; Miyajima, K; Mukuda, T; Noguchi, M; Tatsumi, T; Tsuji, S, 1995) |
| "This study attempted to determine the efficacy of lansoprazole plus clarithromycin therapy in the eradication of Helicobacter pylori in gastric ulcer patients." | 9.08 | Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients. ( Aisawa, T; Akagi, T; Fukuda, S; Fukushi, M; Mizuki, I; Munakata, A; Ohkawa, K; Sakata, Y; Shimoyama, T; Yoshida, Y, 1995) |
| "We studied the effects of lansoprazole on ulcer healing and Helicobacter pylori infection in elderly patients with peptic ulcers." | 9.08 | Therapeutic effects of lansoprazole on peptic ulcers in elderly patients. ( Asagoe, K; Dekigai, H; Kusaka, S; Maeda, S; Matsumoto, M; Mizuno, M; Murakami, M; Saita, H; Seki, M; Takahashi, Y, 1995) |
| "Thirty-five patients with duodenal ulcer bleeding and Helicobacter pylori-colonization were assigned to receive 2 x 20 mg omeprazole and 3 x 750 mg amoxycillin daily for 2 weeks." | 9.08 | Omeprazole-amoxycillin therapy for eradication of Helicobacter pylori in duodenal ulcer bleeding: preliminary results of a pilot study. ( Brennenstuhl, M; Hammar, CH; Jaspersen, D; Körner, T; Schorr, W, 1995) |
| " The aim of this controlled, randomized, prospective study was to compare the effect of these two regimens and a further regimen for metronidazole-resistant patients on duodenal ulcer healing, H." | 9.08 | Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized ( Dehbashi, N; Etaati, H; Fattahi, M; Javan, A; Massarrat, S; Saberi-Firoozi, M; Zare, S, 1995) |
| "To establish the efficacy of omeprazole combined with two antibiotics for Helicobacter pylori eradication and duodenal ulcer relapse." | 9.08 | Efficacy of omeprazole combined with antibiotics for Helicobacter pylori eradication and duodenal ulcer recurrence. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M; Maconi, G; Minguzzi, M, 1995) |
| " pylori-associated duodenal ulcer were treated with 40 mg omeprazole three times a day and 750 mg amoxicillin three times a day for the first 14 days (n = 139) followed by 20 mg omeprazole once daily until day 42 or with omeprazole plus 750 mg amoxicillin placebo three times a day for the same time period (n = 131)." | 9.08 | Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. ( Bayerdörffer, E; Heldwein, W; Höchter, W; Klann, H; Mannes, GA; Miehlke, S; Schmitt, W; Simon, T; Sommer, A; Weingart, J, 1995) |
| "Omeprazole is less effective in healthy subjects than in patients with duodenal ulcers." | 9.08 | Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. ( Blum, AL; Börsch, G; Idström, JP; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B; Verdú, EF, 1996) |
| " pylori-positive duodenal ulcer were randomly assigned to receive one of the following three antiulcer regimens: (1) lansoprazole 30 mg b." | 9.08 | Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients. ( Bargiggia, S; Bianchi Porro, G; Colombo, E; Maconi, G; Parente, F, 1996) |
| " pylori-positive out-patients (n = 231) with duodenal ulcers were treated randomly and double-blind with either omeprazole 20, 40 or 80 mg b." | 9.08 | Dose-response of omeprazole combined with amoxycillin on duodenal ulcer healing and eradication of Helicobacter pylori. ( Braden, B; Lembcke, B; Londong, W; Pommerien, W; Schultze, V; Wrangstadh, M, 1996) |
| "Twelve duodenal ulcer patients in remission were randomized to receive in single-blind fashion either placebo, omeprazole 20 mg or omeprazole 40 mg twice daily (08." | 9.08 | The effects of omeprazole 20 and 40 mg twice daily on intragastric acidity in duodenal ulcer patients. ( Celle, G; Mansi, C; Mela, GS; Mele, MR; Savarino, V; Vigneri, S; Zentilin, P, 1996) |
| "To determine the effect of Helicobacter pylori eradication with omeprazole and amoxycillin, with or without metronidazole, on the 12-month course of duodenal ulcer disease." | 9.08 | Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole. ( Axon, AT; Bate, CM; Bell, GD; Martin, JL; Richardson, PD; Taylor, MD; Tildesley, G, 1996) |
| "Patients with a history of dyspepsia or uncomplicated peptic ulcer disease and with a need for continuous NSAID treatment were randomized to receive either 20 mg omeprazole once daily or placebo." | 9.08 | Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. ( Anker-Hansen, O; Carling, L; Ekström, P; Lundegårdh, G; Thorhallsson, E; Unge, P; Wetterhus, S; Wingren, PE, 1996) |
| " The present study was designed to test the hypothesis that a triple therapy with pantoprazole, clarithromycin and amoxycillin cures the infection in > or = 80% of duodenal ulcer patients infected with H." | 9.08 | Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. ( Labenz, J; Lütke, A; Stolte, M; Tillenburg, B; Weismüller, J, 1997) |
| "Eighty patients with endoscopically proven active duodenal ulcer were randomized to take ranitidine or lansoprazole for 4-8 wk, together with clarithromycin 250 mg b." | 9.08 | Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M, 1997) |
| "In this prospective controlled study conducted in a single center, 78 symptomatic peptic ulcer patients were treated for 4 wk with omeprazole 40 mg o." | 9.08 | Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients? ( Anania, MC; Annibale, B; D'Ambra, G; Delle Fave, G; Iannoni, C; Luzzi, I; Marcheggiano, A; Marignani, M; Paoletti, M, 1997) |
| "In patients with active duodenal ulcer, a 10-day course of amoxycillin-clarithromycin-based triple therapy without additional acid suppression is highly effective in eradicating H." | 9.08 | Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. ( Archambault, A; Archimandritis, A; Bazzoli, F; Fedorak, R; Hentschel, E; Megraud, F; Mora, P; Rodrigo, L; Rokkas, T; Skandalis, N; Stamler, D; Wurzer, H, 1997) |
| " pylori from the gastric mucosa, and omeprazole frequently is used for the treatment of duodenal ulcer disease, prompting the interest to investigate rigorously the combination of clarithromycin and omeprazole for eradicating H." | 9.08 | Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer. ( Dettmer, A; Fraser, AG; O'Morain, C; Rambow, A; von Fritsch, E, 1996) |
| "To estimate and compare the efficacy of 'triple' 1-week regimens--omeprazole, clarithromycin and a nitroimidazole (metronidazole or ornidazole)--followed by omeprazole, for an additional 3 weeks, on Helicobacter pylori eradication and duodenal ulcer (DU) healing, in a country with a high resistance rate of H." | 9.08 | One-week therapy with omeprazole, clarithromycin and metronidazole or ornidazole, followed by 3 weeks' treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer. ( Archimandritis, A; Balatsos, V; Davaris, P; Delis, V; Kanellopoulou, E; Manika, Z; Skandalis, N; Souyioultzis, S; Tzivras, M, 1997) |
| "Our aim was to investigate the efficacy of omeprazole and amoxicillin in curing Helicobacter pylori infection in gastric ulcer patients." | 9.08 | Double-blind trial of omeprazole and amoxicillin in the cure of Helicobacter pylori infection in gastric ulcer patients. The Ulcer Study Group, Germany. ( Bayerdörffer, E; Bolle, KH; Fischer, G; Hatz, R; Höchter, W; Huber, F; Klann, H; Lehn, N; Meining, A; Simon, T; Sommer, A; Stolte, M; Weingart, J, 1998) |
| "In this randomized multicentre study, 267 duodenal ulcer patients were treated for 2 weeks with omeprazole 40 bid (Group A) or 20 mg bid (Group B), respectively, and with amoxycillin 0." | 9.08 | Dual therapy with high or low doses of omeprazole does not achieve an acceptable rate of Helicobacter pylori eradication in duodenal ulcer patients. A multicentre randomized long-term detailed study. ( Annibale, B; Bordi, C; Cesana, B; Damilano, I; Franceschi, M; Maconi, G; Pilato, FP, 1997) |
| " pylori and with gastro-oesophageal reflux disease we investigated the gastritis parameters in antral and corpus mucosa before and after 2, 6 and 12 months of treatment with 15 or 30 mg lansoprazole or 20 mg omeprazole/day." | 9.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. ( Alexandridis, T; Meining, A; Schmitz, JM; Seifert, E; Stolte, M, 1998) |
| "Rabeprazole, a new proton pump inhibitor, was studied in patients with acid-peptic-related diseases (duodenal ulcer, gastric ulcer, GERD) in three placebo-controlled, double-blind, randomized clinical trials." | 9.08 | Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. ( Bassion, S; Cloud, ML; Enas, N; Humphries, TJ, 1998) |
| " Omeprazole was significantly superior to sucralfate in inducing gastric ulcer healing after both 4 (87 vs." | 9.08 | Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. ( Bianchi Porro, G; Lazzaroni, M; Manzionna, G; Petrillo, M, 1998) |
| " pylori-infected duodenal ulcer patients we investigated the gastritis parameters in antral and corpus mucosa before treatment, after 6 and 12 months of therapy, and 6 months after termination of treatment with 15 mg lansoprazole or 150 mg ranitidine/day." | 9.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. ( Kiel, G; Meining, A; Stolte, M, 1998) |
| " pylori-positive gastric ulcer patients were assigned at random to two groups; in addition to dual therapy (amoxicillin 500 mg thrice daily and lansoprazole 30 mg every morning for two weeks), one group received rebamipide 100 mg thrice daily for eight weeks, while the other group received teprenone 50 mg thrice daily for eight weeks." | 9.08 | Effects of rebamipide in combination with lansoprazole and amoxicillin on Helicobacter pylori-infected gastric ulcer patients. ( Asaka, M; Hokari, K; Kagaya, H; Katagiri, M; Kato, M; Kudo, M; Nishikawa, K; Sato, F; Sugiyama, T; Sukegawa, M; Takeda, H, 1998) |
| "Rabeprazole is a new fast acting proton pump inhibitor that has recently been proven to be effective in the treatment of peptic ulceration and reflux esophagitis." | 9.08 | Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. ( Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998) |
| " pylori-infected patients with one or more duodenal ulcer(s) at endoscopy (studies 1, 2) or with a documented duodenal ulcer history and no duodenal ulcer or erosions at endoscopy (study 3) were randomly assigned to 10-day courses of omeprazole 20 mg b." | 9.08 | Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. ( Connors, A; Frantz, J; Laine, L; Neil, G; Suchower, L, 1998) |
| "Patients (n = 1262) with a clinical diagnosis of functional dyspepsia (persistent or recurrent epigastric pain or discomfort for at least 1 month and a normal upper gastrointestinal endoscopy) were randomized to receive omeprazole 20 mg, 10 mg or identical placebo, for 4 weeks." | 9.08 | Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). ( Duckworth, M; Kordecki, H; Meineche-Schmidt, V; Pap, A; Paré, P; Räisänen, P; Schmid, V; Talley, NJ, 1998) |
| "Two 4-week triple-therapy treatment regimens, metronidazole+tetracycline+bismuth subcitrate and omeprazole+amoxycillin+bismuth subcitrate, were compared in a randomly allocated double-blind trial for their efficacy in eradicating Helicobacter pylori from the gastric mucosa of patients with gastritis and/or peptic ulcer disease." | 9.07 | Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease. ( Hahm, JS; Kim, HJ; Park, KN, 1994) |
| " In study II 22 duodenal ulcer patients were given bismuth subnitrate, oxytetracycline, and metronidazole (triple therapy) for 2 weeks to eradicate H." | 9.07 | Effects of omeprazole and eradication of Helicobacter pylori on gastric and duodenal mucosal enzyme activities and DNA in duodenal ulcer patients. ( Aase, S; Andersen, KJ; Mowinckel, P; Schrumpf, E; Vetvik, K, 1994) |
| "The purpose of the present study was to investigate the Helicobacter pylori eradication potency of combined amoxicillin-omeprazole treatment in patients with duodenal ulcer disease and to compare the efficacy of two omeprazole and amoxicillin doses concerning H." | 9.07 | Medium- and high-dose omeprazole plus amoxicillin for eradication of Helicobacter pylori in duodenal ulcer disease. ( Bertrams, J; Börsch, G; Labenz, J; Rühl, GH, 1994) |
| "To compare the efficacy of two omeprazole/amoxicillin regimens concerning Helicobacter pylori eradication, ulcer healing, pain relief, and safety in patients with gastric ulcer disease." | 9.07 | Medium- or high-dose omeprazole plus amoxicillin eradicates Helicobacter pylori in gastric ulcer disease. ( Bertrams, J; Börsch, G; Labenz, J; Rühl, GH, 1994) |
| "Sixty patients with symptomatic duodenal ulcer were randomized to receive either omeprazole (20 mg each morning) or famotidine (40 mg at night time) for 2-4 weeks in a double-blind parallel group clinical trial." | 9.07 | Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. ( Dasarathy, S; Misra, SC; Sharma, MP, 1993) |
| "In a controlled, prospective, randomized trial, 10 patients with Helicobacter pylori positive gastritis were treated either with triple therapy (tetracycline, ornidazole, bismuth subcitrate; T, Or, CBS), or omeprazole/CBS (O/CBS) to test the eradication rate of each treatment, its effect on gastritis and meal stimulated gastrin release." | 9.07 | [Comparison of the efficacy of omeprazole/bismuth subcitrate or triple therapy in Helicobacter pylori gastritis. A prospective controlled study]. ( Bertschinger, P; Brunner, J; Flury, R; Häcki, WH; Jost, R; Lammer, F, 1992) |
| "Forty-three patients with active duodenal ulcer and Helicobacter pylori positivity in gastric antrum were randomly assigned to either omeprazole treatment (20 mg once a day) or ranitidine treatment (300 mg once a day) for 28 days." | 9.07 | Omeprazole vs. ranitidine in short-term treatment of Helicobacter pylori positive duodenal ulcer patients. ( Ayoubi Khajekini, M; Blasi, A; Brogna, A; Catalano, F; Inserra, G; Mangiameli, A; Monello, S; Rizzo, G; Sofia, M, 1991) |
| "This study set out to investigate the effects of omeprazole or ranitidine on the progression of antral gastritis and Helicobacter pylori in patients with active duodenal ulcer." | 9.07 | Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori. ( Branicki, FJ; Ho, J; Hui, WM; Lai, CL; Lam, SK; Lau, WY; Lok, AS; Ng, MM, 1991) |
| " This meta-analysis sought to assess the clinical and safety profiles of esomeprazole versus omeprazole at pharmacologically equivalent doses in healing gastroesophageal reflux disease (GERD), peptic ulcer disease and eradicating Helicobacter pylori (H." | 8.91 | Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection. ( Dan, YY; Khoo, AL; Lim, BP; Lin, L; Teng, M; Wu, TS; Zhao, YJ, 2015) |
| "This article presents considerations currently under discussion about the probability of HP participation in the ulcer causation as well as information about Rabeprazole efficiency for anti-helicobacter therapy of non-complicated duodenal ulcer (as a result of 7-day anti-helicobacter therapy, the healing of duodenal bulbs was recorded in 82." | 8.82 | [Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)]. ( Vasil'ev, IuB, 2004) |
| "To compare the safety and efficacy of pantoprazole, placebo and the H2 antagonist nizatidine in relieving symptoms in patients with erosive oesophagitis." | 8.82 | Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004) |
| "A 53-year old female patient with duodenal ulcer and Helicobacter pylori infection was treated three times with a proton pump inhibitor-based triple therapy, such as lansoprazole-clarithromycin-amoxicillin (INN, amoxicilline) and lansoprazole-minocycline-cefaclor." | 8.80 | Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. ( Furuta, T; Hanai, H; Ishizaki, T; Ohashi, K; Shirai, N; Takashima, M; Xiao, F, 2000) |
| "To observe the effect of lansoprazole and omeprazole combined with antibiotics on gastric juice pH and inflammatory factors in elderly patients with Hp positive gastric ulcer." | 8.31 | Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer. ( Chen, B; Gao, N; Yan, S, 2023) |
| "In this prospective open-label comparative observational study, gastroesophageal reflux disease (GERD) patients were evaluated using 24-h dual-channel pH-impedance monitoring while on dexlansoprazole (60 mg, n = 39) and omeprazole (20 mg, n = 41) to study the degree of gastric acid suppression, esophageal acid exposure, and NAB (primary outcome measures)." | 8.12 | Nocturnal acid breakthrough and esophageal acidification during treatment with dexlansoprazole as compared to omeprazole in patients with gastroesophageal reflux disease. ( Blaachandran, A; Ghoshal, UC; Misra, A; Rai, S, 2022) |
| "Two drugs commonly used in triple-drug therapy for treatment of a Helicobacter pylori infection, clarithromycin and omeprazole, have rarely been associated with hypoglycemia when given alone." | 7.79 | Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction. ( Otsuka, SH, 2013) |
| "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease." | 7.73 | Lansoprazole-associated collagenous colitis: a case report. ( Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M, 2005) |
| "Helicobacter pylori eradication was recommended for the prevention of atrophic gastritis in gastroesophageal reflux disease (GERD) patients on long-term omeprazole treatment." | 7.73 | Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients. ( Celikel, CA; Giral, A; Kalayci, C; Ozdogan, O; Tözün, N; Ulusoy, NB, 2005) |
| "To confirm the immediate-type mechanism of recurrent anaphylactic reactions to the repeated administration of omeprazole using skin testing and to enable safe administration of the drug after successful oral desensitization." | 7.73 | Anaphylaxis to omeprazole: diagnosis and desensitization protocol. ( Confino-Cohen, R; Goldberg, A, 2006) |
| "Six captive cheetahs (Acinonyx jubatus) with severe gastritis diagnosed by gastric endoscopy and mucosal histopathology were treated with omeprazole, metronidazole, and amoxicillin for 3 wk." | 7.72 | Treatment with omeprazole, metronidazole, and amoxicillin in captive South African cheetahs (Acinonyx jubatus) with spiral bacteria infection and gastritis. ( Burroughs, R; Lane, E; Lobetti, R, 2004) |
| " pylori infection in active peptic ulcer in Korea (30 mg of lansoprazole, 250 mg of clarithromycin, and 400 mg of metronidazole, all twice daily)." | 7.70 | One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. ( El-Zimaity, HM; Graham, DY; Kim, JG; Osato, MS; Perng, CL, 1998) |
| "To investigate whether CYP2C19 genotype status is associated with cure rates for Helicobacterpylori infection and peptic ulcer achieved by using dual therapy with omeprazole and amoxicillin." | 7.70 | Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. ( Furuta, T; Hanai, H; Ishizaki, T; Kamata, T; Kaneko, E; Kawasaki, T; Kosuge, K; Kubota, T; Ohashi, K; Takashima, M, 1998) |
| " pylori status of patients with gastroesophageal reflux disease (GERD) affects the severity of disease and the efficacy of omeprazole therapy to maintain disease remission, we conducted this study." | 7.70 | Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. ( Eskes, SA; Klinkenberg-Knol, EC; Kuipers, EJ; Meuwissen, SG; Schenk, BE, 1999) |
| "A prospective trial was designed to study the effectiveness of the 1-week combination of lansoprazole, clarithromycin and amoxycillin in 102 consecutive patients with active peptic ulcer." | 7.70 | Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. ( Ducóns, JA; Ferrero, M; Gomollón, F; Guirao, R; Montoro, M; Santolaria, S, 1999) |
| " We report data from patients with refractory reflux esophagitis who were undergoing maintenance therapy with >/=20 mg omeprazole daily for a mean period of 6." | 7.70 | Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. ( Dent, J; Frame, MH; Havu, N; Klinkenberg-Knol, EC; Lloyd, D; Mitchell, B; Nelis, F; Prichard, P; Romàn, J; Snel, P; Walan, A, 2000) |
| "An antibiotic combination that includes a proton pump inhibitor such as omeprazole and an antibiotic such as clarithromycin is likely to become the new standard regimen for treatment of Helicobacter pylori gastritis because this combination is extremely effective and very well tolerated." | 7.69 | Helicobacter pylori gastritis therapy with omeprazole and clarithromycin increases serum carbamazepine levels. ( Getz, HD; Metz, DC, 1995) |
| "One-week therapy with lansoprazole, amoxicillin and clarithromycin is highly effective in duodenal ulcer healing and symptom improvement." | 7.69 | Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. ( Hentschel, E; Schütze, K, 1995) |
| "To study the efficiency of the combination lansoprazole and amoxicillin on the eradication of Helicobacter pylori and duodenal ulcer healing." | 7.69 | [Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients]. ( Aller, R; Alvarez Baleriola, I; Bermejo, F; Boixeda, D; Gisbert, JP; Martín de Argila, C, 1996) |
| " pylori represents an important factor for the progression of fundic gastritis and the development of argyrophil cell hyperplasia during long-term treatment with lansoprazole." | 7.69 | Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. ( Arnold, R; Brunner, G; Eissele, R; Simon, B; Solcia, E, 1997) |
| "We have previously shown that, in duodenal ulcer patients, pH control by omeprazole is less pronounced after cure of Helicobacter pylori infection." | 7.69 | Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. ( Blum, AL; Börsch, G; Idström, JP; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B; Verdú, E, 1997) |
| "To evaluate the efficacy of one-week therapy with omeprazole, clarithromycin and amoxycillin in eradicating Helicobacter pylori and healing duodenal ulcer." | 7.69 | [One-week treatment with omeprazole, clarithromycin and amoxicillin: high efficacy in the eradication of Helicobacter pylori and cicatrization of duodenal ulcer]. ( Abraira, V; Alvarez Baleriola, I; Boixeda, D; Ceña, G; García Plaza, A; Gisbert, JP; Martín de Argila, C; Mur, M, 1997) |
| "In patients with duodenal ulcer cure of Helicobacter pylori infection resulted in a pronounced decrease in intragastric pH during treatment with omeprazole." | 7.69 | Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer. ( Blum, AL; Börsch, G; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B; Verdú, E, 1997) |
| "To study the prevalence of Helicobacter pylori infection in patients with erosive duodenitis (ED), the associated gastric histological lesions and their response to eradication therapy with omeprazole plus two antibiotics." | 7.69 | Erosive duodenitis: prevalence of Helicobacter pylori infection and response to eradication therapy with omeprazole plus two antibiotics. ( Bermejo, F; Boixeda, D; de Argila, CM; de Rafael, L; Gisbert, JP; Redondo, C, 1997) |
| "A marked increase in body gastritis was observed in H pylori infected individuals during long term treatment with the proton pump inhibitor lansoprazole." | 7.69 | Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. ( Berstad, A; Berstad, AE; Brandtzaeg, P; Hatlebakk, JG; Maartmann-Moe, H, 1997) |
| "Omeprazole heals most duodenal ulcers after 4 weeks of treatment but relapse is common." | 7.68 | Short report: treatment of Helicobacter pylori-associated duodenal ulcer with omeprazole plus antibiotics. ( Beattie, S; Collins, R; Hamilton, H; McCarthy, CJ; O'Morain, C, 1993) |
| "Thirteen consecutive patients with active duodenal ulcer disease were assigned to a treatment schedule with high-dose omeprazole and amoxycillin." | 7.68 | Short report: high-dose omeprazole and amoxycillin in the treatment of Helicobacter pylori-associated duodenal ulcer. ( Beattie, S; Collins, R; O'Morain, C; Xia, HX, 1993) |
| "Long-term omeprazole therapy in humans results in moderate hypergastrinemia and a significant argyrophil cell hyperplasia, which are correlated to the grade of corpus gastritis." | 7.68 | Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. ( Brunner, G; Creutzfeldt, W; Lamberts, R; Solcia, E; Strüber, HG, 1993) |
| "Thirty patients with active duodenal ulcer who were Helicobacter pylori positive (HP+) by HLO test and by histology (Giemsa stain) were given omeprazole (OME) 20 mg/d for a two-week period." | 7.68 | Preliminary observations in the fasting serum gastrin in patients with duodenal ulcer; further evidence of the "clearing" effect of omeprazole on H pylori? ( Alevizou, V; Archimandritis, A; Davaris, P; Fertakis, A; Kapsalas, D; Kyriaki, D; Tjivras, M, 1992) |
| "Twenty-one patients with endoscopically confirmed duodenal ulceration, who had failed to heal with an H2-antagonist, were given omeprazole 20 mg o." | 7.68 | Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis. ( Daw, MA; Deegan, P; Leen, E; O'Moráin, C, 1991) |
| "3%) and there were no serious adverse events." | 6.71 | The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing. ( Akarsu, M; Bozbas, A; Hulagu, S; Kadayifci, A; Koruk, M; Savas, MC; Simsek, I; Sivri, B; Tozun, N; Uraz, S, 2004) |
| "In the intention-to-treat analysis, duodenal ulcers were completely healed in 45 (90%) patients in the RAC group and 43 (89." | 6.69 | One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. ( Chan, FK; Cheng, AF; Chung, SC; Lee, YT; Leung, WK; Ling, TK; Sung, JJ; Yung, MY, 1998) |
| "Treatment with omeprazole (OME), azithromycin (AZI) and amoxicillin (AMO) resulted in encouraging Helicobacter pylori cure rates in pilot and control studies." | 6.69 | Omeprazole, azithromycin and amoxicillin or amoxicillin plus clavulanic acid in eradication of Helicobacter pylori in duodenal ulcer disease. ( Blazanović, A; Dmitrović, B; Ivandić, A; Karner, I; Kovac, D; Pezerović, D; Stimac, D; Stimac, T; Takac, B; Vcev, A; Vceva, A, 1998) |
| " The optimal dosage and duration of treatment need to be specified." | 6.68 | Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer. ( Fujita, N; Hisano, K; Kobayashi, T; Kurokawa, I; Ochiai, T; Sugiyama, T; Yabana, T; Yachi, A, 1995) |
| "Lansoprazole 30 mg/day was administered to 124 gastric ulcer (GU) patients and 57 duodenal ulcer (DU) patients." | 6.68 | Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication. ( Kato, T; Ogoshi, K; Sakagawa, T, 1995) |
| " HP was eradicated by combined treatment with high-dose omeprazole (2 x 40 mg) and amoxicillin (2 x 1,000 mg; n = 27) administered for 10 days (OME + AMX); alternatively, patients were treated with omeprazole monotherapy (OME) using the same dosage (n = 25)." | 6.68 | Two-year follow-up of duodenal ulcer patients treated with omeprazole and amoxicillin. ( Bayerdörffer, E; Dirschedl, P; Hatz, R; Höchter, W; Lehn, N; Mannes, GA; Miehlke, S; Ruckdeschel, G; Sommer, A; Weingart, J, 1995) |
| "Treatment with omeprazole plus amoxicillin or clarithromycin resulted in encouraging Helicobacter pylori cure rates in pilot and controlled studies." | 6.68 | High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease. ( Bertrams, J; Börsch, G; Domian, C; Labenz, J; Stolte, M, 1995) |
| "Lansoprazole is a potent antisecretory drug also possessing anti-Helicobacter pylori activity in vitro." | 6.68 | Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. ( Bang, CJ; Berstad, A; Hatlebakk, JG; Hausken, T; Nesje, LB, 1995) |
| " Thus, a true dose-response relationship exists between omeprazole and treatment success." | 6.68 | Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients. ( Beker, JA; Dekker, CP; Farley, A; Jönsson, A; Klör, HU; Labenz, J, 1997) |
| "For H." | 6.68 | Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. ( Bardhan, KD; Graham, DY; Hunt, RH; O'Morain, CA, 1997) |
| "Omeprazole is a well studied proton pump inhibitor that reduces gastric acid secretion." | 6.40 | Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. ( Langtry, HD; Wilde, MI, 1998) |
| "In this multicenter, randomized, double-blind, double-dummy, positive-drug parallel-controlled, phase III study, Chinese patients with duodenal ulcers were randomized 1:1 to receive rabeprazole 10 mg + anaprazole placebo or rabeprazole placebo + anaprazole 20 mg once daily for 4 weeks." | 5.51 | Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study. ( Ding, J; Du, Y; Fan, H; Huang, C; Li, Z; Lyu, N; Pan, X; Pan, Z; Shi, Z; Sun, H; Wang, Q; Zhang, L; Zhu, H, 2022) |
| "Furazolidone was tried in several developing countries and showed good results in some trials." | 5.37 | To compare the efficacy of triple therapy with furazolidone, amoxicillin and omeprazole for two weeks and three weeks in the eradication of Helicobacter pylori in Bangladeshi duodenal ulcer patients. ( Hasan, M; Islam, N; Masud, H; Raihan, AS; Roy, PK; Saha, SK, 2011) |
| "pylori-infected gastro-oesophageal reflux disease patients does not increase or accelerate gastric autoimmunity." | 5.33 | Long-term acid suppression by omeprazole in gastro-oesophageal reflux disease patients does not lead to anti-gastric autoantibody production. ( Aar, A; Appelmelk, BJ; Bergman, MP; Faller, G; Klinkenberg-Knol, EC; Kuipers, EJ; Lakhai, W; Vandenbroucke-Grauls, CM, 2005) |
| "In most patients with GERD esophagitis is not detected by endoscopy, which represents GERD with a negative endoscopy or non-erosive reflux disease (NERD)." | 5.33 | Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori. ( Castro Fernández, M; García Díaz, E; Lamas Rojas, E; Larraona, JL; Núñez Hospital, D; Pallarés Querol, M; Rodríguez Hornillo, MC, 2006) |
| "Thirty one patients with gastroesophageal reflux disease were treated with a daily oral dose of 20 mg OMP for 28 days." | 5.33 | [Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease]. ( Choi, SK; Joo, YE; Kim, HS; Kim, SJ; Lee, WS; Park, CH; Rew, JS; Sohn, YH, 2006) |
| "A total of 65 patients with GERD (grades A-D) completed treatment with lansoprazole, by taking 30 mg orally once a day for 8 weeks." | 5.31 | Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. ( Furuta, T; Futami, H; Hanai, H; Honda, S; Iida, T; Ishizaki, T; Kajimura, M; Ohashi, K; Sato, Y; Shirai, N; Takayanagi, S; Takeuchi, K; Watanabe, F; Yamada, M, 2002) |
| "Treatment with clarithromycin, metronidazole and pantoprazole eradicated H." | 5.31 | Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole. ( Kaddu, S; Kränke, B; Mayr-Kanhäuser, S; Müllegger, RR, 2001) |
| "It is used for treatment of gastroduodenal ulcers, reflux oesophagitis and Zollinger Ellison's syndrome." | 5.29 | [The effect of omeprazole on healing of duodenal ulcers, Helicobacter pylori and gastritis]. ( Drábek, J; Hanika, J; Soucková, A; Vejvalka, J; Zelenková, J; Zeman, V, 1993) |
| "Pre-treatment metronidazole susceptible H pylori were significantly more likely to respond to the triple therapy used than those with the metronidazole resistant ones (14 of 15 v five of 10) (p = 0." | 5.29 | Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. ( Ching, CK; Lai, CL; Lai, KC; Lam, SK; Leung, KP; Wong, BC; Yung, RW, 1996) |
| "Omeprazole treatment produces lower intragastric pH values 4 weeks after cure of Helicobacter pylori infection than before." | 5.29 | Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. ( Armstrong, D; Blum, AL; Börsch, G; Idström, JP; Labenz, J; Stolte, M; Verdú, EF, 1996) |
| "To assess the efficacy and safety of omeprazole given with the new single capsule of bismuth, metronidazole and tetracycline (OBMT) compared with quadruple treatment consisting of omeprazole, bismuth, amoxicillin and clarithromycin (OBAC) for Helicobacter pylori eradication in duodenal ulcer patients." | 5.27 | New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese pro ( Chen, Y; Du, Y; Li, Y; Liu, D; Lv, N; Pan, X; Wang, H; Wang, J; Wu, K; Xie, Y; Xu, J; Zeng, Z; Zhang, G, 2018) |
| " pylori-associated gastritis were randomly assigned to one of three arms for a 14-day treatment: Arm A triple therapy (omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily; Arm B triple therapy plus polaprezinc 150 mg twice daily, or Arm C triple therapy alone." | 5.24 | Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. ( Fang, JY; Ji, F; Li, JS; Li, YQ; Luo, HQ; Luo, HS; Lv, NH; Qian, JM; Ren, JL; Shi, RH; Tan, B; Xu, H; Zou, YY, 2017) |
| " pylori-related chronic gastritis who were randomly provided either 10-day omeprazole-based triple therapy (OM-triple; omeprazole 20 mg twice daily, clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily) or 10-day B-quadruple therapy (OM-triple + bismuth subcitrate 120 mg four times daily)." | 5.24 | Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori-related chronic gastritis: a prospective randomized study in China. ( Chen, C; Chen, S; Ding, J; Du, Q; Huang, Z; Jiang, Y; Li, J; Li, W; Lin, Z; Meng, L; Si, J; Wang, L; Wu, L; Ye, B, 2017) |
| " Patients with Helicobacter pylori infection and a history of peptic ulcer were assigned dual antiplatelet combination with omeprazole." | 5.17 | Effect of clopidogrel with or without omeprazole in patients with carotid artery stenting. ( Chen, G; Du, Y; Hang, L; Ma, B, 2013) |
| " pylori infection was statistically significantly dependent on omeprazole dosage, CYP2C19 genotype, age, gastritis status, and H." | 5.15 | Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. ( Chern, HD; Lin, BR; Lin, CJ; Shun, CT; Wang, HL; Wang, TH; Yang, JC, 2011) |
| "Patients with Helicobacter pylori positive peptic ulcer disease were randomly allocated into two groups: amoxicillin 1 g b." | 5.15 | Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease. ( Ghadir, MR; Iranikhah, A; Joukar, F; Mansour-Ghanaei, F; Pakdin, A; Shafaghi, A, 2011) |
| " The aim of this study was to evaluate the efficacy and tolerability of a levofloxacin-based regimen in patients with peptic ulcer after failure of the standard first-line H." | 5.15 | Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. ( Akyuz, F; Ermis, F; Kaymakoglu, S; Kurt, R; Mungan, Z; Nazik, H; Pinarbasi, B; Uyanikoglu, A, 2011) |
| "Helicobacter pylori -positive adult patients with functional dyspepsia meeting the Rome III International Consensus criteria were randomly assigned to receive omeprazole, amoxicillin trihydrate, and clarithromycin, or omeprazole plus placebo for 10 days." | 5.15 | Helicobacter pylori eradication in functional dyspepsia: HEROES trial. ( Berwanger, O; Birkhan, OA; Bressel, M; Colombo, Bda S; Dahmer, FD; De Bona, LR; Edelweiss, MI; Folador, L; Francesconi, CF; Grando, E; Guerrieri, PP; Heck, R; Hocevar de Moura, B; Katz, N; Lunkes, RP; Marini, SS; Mazzoleni, F; Mazzoleni, LE; Milbradt, TC; Molina, CG; Prolla, JC; Rauber, J; Renck, LB; Sander, GB; Spindler, BM; Uchoa, DM; Von Reisswitz, PS, 2011) |
| "Melatonin (MT) and its precursor L-tryptophan (TRP) are implicated in the protection of gastric mucosa against aspirin-induced lesions and in the acceleration of healing of idiopathic gastro-duodenal ulcers, but no information is available whether these agents are also effective in healing of gastroduodenal ulcers accompanied by Helicobacter pylori (H." | 5.15 | Effects of melatonin and tryptophan on healing of gastric and duodenal ulcers with Helicobacter pylori infection in humans. ( Bielanski, W; Brzozowski, T; Celinski, K; Cichoz-Lach, H; Konturek, PC; Konturek, SJ; Slomka, M, 2011) |
| "Two hundred and forty Chinese with peptic ulcer disease were randomly assigned to the following regimens: amoxicillin and clarithromycin together with omeprazole (OAC) or rabeprazole (RAC)." | 5.14 | The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people. ( Hu, YM; Li, QS; Mei, Q; Xu, JM; Zhang, L, 2010) |
| "To establish the efficacy and safety of a 7-d therapeutic regimen using omeprazole, bismuth subcitrate, furazolidone and amoxicillin in patients with peptic ulcer disease who had been previously treated with other therapeutic regimens without success." | 5.13 | Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. ( Barbuti, RC; Eisig, JN; Felga, GE; Navarro-Rodriguez, T; Silva, FM; Zaterka, S, 2008) |
| "Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo." | 5.12 | Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study. ( Barros, SG; Cartell, A; Edelweiss, MI; Francesconi, CF; Fritscher, LG; Mazzoleni, LE; Ott, EA; Polanczyk, CA; Prolla, JC; Rivero, LF; Sander, GB; Theil, AL; Uchôa, DM; Wortmann, AC, 2006) |
| " Intention-to-treat analysis revealed a trend to a higher healing rate of lymphocytic gastritis 3 months after triple therapy compared with omeprazole/placebo (83." | 5.12 | Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. ( Bayerdörffer, E; Kuhlisch, E; Lehn, N; Madisch, A; Miehlke, S; Morgner, A; Neuber, F; Rappel, S; Seitz, G; Stolte, M, 2006) |
| "Forty-eight patients with hyperplastic gastric polyps (3-10 mm in diameter) infected with H pylori were randomly assigned to a treatment group (n = 24) which received proton-pump inhibitor (omeprazole or lansoprazole), clarithromycin, bismuth citrate and tinidazole, and a control group (n = 24) which received protective agent of gastric mucosa (tepretone)." | 5.12 | Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. ( Chen, JY; Ji, F; Li, YM; Ning, JW; Wang, QY; Wang, ZW, 2006) |
| "To evaluate the furazolidone-based triple therapy in children with symptomatic H pylori gastritis." | 5.12 | Furazolidone-based triple therapy for H pylori gastritis in children. ( Bonucci, VC; Carelli, AP; Fukushima, E; Kawakami, E; Langner, M; Machado, RS; Ogata, SK; Patricio, FR, 2006) |
| "A total of 909 H pylori-positive patients with duodenal ulcer, enrolled in 81 endoscopy units in Italy, were randomised to receive omeprazole, amoxicillin and clarithromycin for either 1 week (OAC1W) or 2 weeks (OAC2W) or omeprazole and amoxicillin for 2 weeks." | 5.12 | Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. ( Bazzoli, F; Bianchi-Porro, G; Fiocca, R; Gasbarrini, G; Roda, E; Zagari, RM, 2007) |
| " pylori) gastritis in children by the adjunction of omeprazole (OAC) was studied." | 5.12 | Improvement of the eradication rate of Helicobacter pylori gastritis in children is by adjunction of omeprazole to a dual antibiotherapy. ( Alliet, P; Bontemps, P; Cadranel, S; Lauvau, D; Van Biervliet, S; Vandenhoven, G; Vandenplas, Y, 2007) |
| "The study was performed in 137 patients with peptic ulcer who had undergone a 7-day course of eradication treatment with one of two sets of drugs: 1, omeprazole, amoxicillin, and tinidazole or 2, omeprazole, clarithromycin, and tinidazole." | 5.12 | Oral health status and oral hygiene practices of patients with peptic ulcer and how these affect Helicobacter pylori eradication from the stomach. ( Bucki, R; Gotebiewska, M; Kemona, A; Namiot, DB; Namiot, Z, 2007) |
| " pylori-positive patients with an active duodenal ulcer (DU) received esomeprazole, 20 mg twice daily (bid), or omeprazole, 20 mg bid, with amoxicillin, 1000 mg bid, and clarithromycin, 500 mg bid, for 1 week (EAC and OAC, respectively)." | 5.12 | One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients. ( Arigbabu, A; Bachelet, E; Cardona, HJ; Hammour, AA; Miller, T; Subei, IM; Useche, E, 2007) |
| " This prospective randomised study aimed to investigate whether H pylori eradication can influence gastritis and its sequelae during long term omeprazole therapy for gastro-oesophageal reflux disease (GORD)." | 5.11 | Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. ( Dent, J; Festen, HP; Goldfain, D; Havu, N; Klinkenberg-Knol, EC; Kolkman, JJ; Kuipers, EJ; Lamm, M; Nelis, GF; Snel, P; Walan, A; Zeitoun, P, 2004) |
| "Adult Helicobacter pylori-positive patients by 13C-urea breath test with uninvestigated dyspepsia symptoms were randomized to 1-week eradication treatment with omeprazole, metronidazole and clarithromycin (OMC) vs." | 5.11 | Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. ( Armstrong, D; Barkun, A; Chiba, N; Escobedo, S; Grace, E; Lee, J; Sinclair, P; Thomson, AB; Veldhuyzen Van Zanten, SJ, 2004) |
| "The purpose of this study was to compare the efficacy of tinidazole- versus clarithromycin-based triple regimens for eradication of Helicobacter pylori in North Indian patients of peptic ulcer disease, and to correlate the outcome with in vitro antibiotic susceptibility." | 5.11 | Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity. ( Ahuja, V; Bal, C; Bhatia, V; Das, B; Sharma, MP, 2004) |
| " pylori infection on effectiveness of rabeprazole in primary and secondary care patients with gastro-oesophageal reflux disease." | 5.11 | Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? ( Bergmans, P; Boer, WA; Geldof, H; Hazelhoff, B; Smout, AJ; Tytgat, GN; Wit, NJ, 2004) |
| "248 patients with Hp-associated active duodenal ulcer confirmed by endoscopy, 193 males and 55 females, were randomized to receive OAC(250): omeprazole (0." | 5.11 | [Effects of different triple therapies on duodenal ulcer-associated Helicobacter pylori infection and a one-year follow-up study]. ( , 2004) |
| " pylori positive peptic ulcer disease or functional dyspepsia were treated with two-day quadruple therapy (lansoprazole 30 mg twice daily, and colloidal bismuth subcitrate 120 mg, tetracycline 250 mg and metronidazole 250 mg, all eight times a day)." | 5.11 | The influence of pretreatment on cure rates of Helicobacter pylori eradication. ( de Boer, WA; Jansen, JB; Janssen, MJ; Laheij, RJ, 2004) |
| "The main purpose of this study was to compare omeprazole (ome) plus two antibiotics (OMC) with omeprazole plus placebo (OP) with regard to gastric ulcer relapse for a period of 2 years in patients who were Helicobacter pylori-positive at inclusion." | 5.11 | Long-term effects of eradication of Helicobacter pylori on relapse and histology in gastric ulcer patients: a two-year follow-up study. ( Backman, M; Befrits, R; Hedenborg, L; Leijonmarck, CE; Sjöstedt, S; Tour, R, 2004) |
| "Sixty-seven patients (49 with Zollinger-Ellison syndrome [ZES], 18 without), with basal acid output (BAO) >15 mmol/h or >5 mmol/h if post-antrectomy (n = 9, all ZES), were treated with individually optimized doses of lansoprazole (7." | 5.11 | Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. ( Hirschowitz, BI; Mohnen, J; Simmons, J, 2005) |
| "To investigate the effect of Helicobacter pylori eradication on endothelin-1 (ET-1) and nitric oxide (NO) in duodenal ulcer (DU) patients." | 5.11 | Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication. ( Chang, FY; Chen, CY; Lee, SD; Lu, CL; Lu, RH; Luo, JC, 2005) |
| "Two hundred and forty-three patients received rabeprazole (20 mg or 10 mg) or omeprazole (20 mg) once daily for up to 5 years, for gastro-oesophageal reflux disease and 51% completed the whole 5 year period." | 5.11 | Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. ( Fiocca, R; Jacobs, A; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2005) |
| " pylori-positive peptic ulcer were randomly divided into two groups, and accepted triple therapy with omeprazole 20 mg, amoxicillin 1000 mg and either clarithromycin 500 mg (OAC group, n = 58) or metronidazole 400 mg (OAM group, n = 45)." | 5.11 | Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. ( Cao, DZ; Fu, XL; Hu, JM; Ou, XL; Su, H; Sun, WH; Sun, YL; Yu, Q; Yu, T; Zhu, F, 2005) |
| "To study the efficacy and safety of rabeprazole in peptic ulcer patients alone or combined with anti-Helicobacter pylori (Hp) agents." | 5.11 | [The clinical applications of rabeprazole either alone or combined with anti-Helicobacter pylori agents in peptic ulcer patients]. ( Lin, SR, 2005) |
| "To compare the efficacy of famotidine and omeprazole in Japanese patients with non-erosive gastro-oesophageal reflux disease by a prospective randomized multicentre trial." | 5.11 | Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. ( Arakawa, T; Chono, S; Fujiwara, Y; Higuchi, K; Kitada, K; Kobayashi, K; Nakagawa, K; Nebiki, H; Oshitani, N; Satoh, H; Tominaga, K; Uno, H; Watanabe, T, 2005) |
| " We investigated the heartburn symptoms of patients with gastro-oesophageal reflux disease during sequential treatment with 40 mg of famotidine or 15 mg of lansoprazole to clarify whether H." | 5.11 | Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole. ( Adachi, K; Amano, Y; Fujishiro, H; Furuta, K; Hashimoto, T; Hattori, S; Ishihara, S; Kinoshita, Y; Komazawa, Y; Mihara, T, 2005) |
| "To investigate the effect of esomeprazole- and omeprazole-based triple therapy regimens in the treatment of duodenal ulcer with Helicobacter pylori (Hp) infection." | 5.11 | [Comparison of esomeprazole- and omeprazole-based triple therapy regimens for duodenal ulcer with Helicobacter pylori infection]. ( Chen, YH; Li, HY; Wang, H; Wang, WM, 2005) |
| "Four-hundred and fifty duodenal ulcer patients were randomized to receive: (1) esomeprazole (20 mg b." | 5.11 | Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? ( Domínguez-Martín, A; Domínguez-Muñoz, A; Gisbert, JL; Gisbert, JP; Marcos, S, 2005) |
| " pylori-positive functional dyspepsia were randomized to receive pantoprazole 40 mg b." | 5.11 | Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori. ( Ateş, Y; Bağci, S; Ciğerim, M; Dağalp, K; Kadayifçi, A; Karslioğlu, Y; Savaş, MC; Uygun, A; Yeşilova, Z, 2004) |
| "Celecoxib was as effective as lansoprazole co-therapy in the prevention of recurrences of ulcer complications in subjects with a history of NSAID-related complicated peptic ulcers." | 5.11 | Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. ( Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, J; Wong, WM, 2005) |
| "To evaluate the efficacy of different doses of lansoprazole for the treatment of functional dyspepsia in Chinese patients." | 5.10 | Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. ( Fung, FM; Hu, WH; Hung, WK; Lai, KC; Lam, SK; Szeto, ML; Tong, TS; Wong, BC; Wong, WM; Yee, YK; Yip, AW; Yuen, MF, 2002) |
| "Comparison of two treatment regimens of eradication treatment of duodenal ulcer (DU) associated with Helicobacter pylori based on fromilid (clarithromycin)." | 5.10 | [Fromilid (clarithromycin) in eradication patients in patients with duodenal ulcer associated with Helicobacter pylori (comparison of two treatment variations)]. ( Firsanova, VIu; Kolomiets, EV; Vasil'ev, IuV; Zvenigorodskaia, LA, 2002) |
| "To assess and compare the efficacy and safety of two triple regimes: A) metronidazole, amoxicillin and omeprazole, which is still widely used in Russia, and B) azithromycin, amoxicillin and omeprazole in healing active duodenal ulcer and H." | 5.10 | Azithromycin in a triple therapy for H.pylori eradication in active duodenal ulcer. ( Bondarenko, OY; Fedchenko, VI; Grigoriev, PY; Gulyaev, PV; Ivashkin, VT; Lapina, TL; Sklanskaya, OA; Vasiliev, YV; Yakovenko, EP, 2002) |
| " pylori positive patients with non-ulcer dyspepsia were randomised to one of the following four treatment groups: omeprazole 20 mg + clarithromycin 500 mg + amoxycillin 1000 mg (OCA); ranitidine bismuth citrate 400 mg + clarithromycin 500 mg + amoxycillin 1000 mg (RBCCA); omeprazole 20 mg + clarithromycin 500 mg + metronidazole 500 mg (OCM); ranitidine bismuth citrate 400 mg + clarithromycin 500 mg + metronidazole 500 mg (RBCCM)." | 5.10 | The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial. ( Bago, J; Bevanda, M; Bilić, A; Halle, ZB; Jandrić, D; Kućisec, N; Strinić, D; Tomić, M, 2002) |
| " pylori associated gastritis were randomly divided into pantoprazole triple regimen group (pantoprazole 40 mg, amoxicillin 1 g, and metronidazole 400 mg, bid,for 1-week or 2-weeks) and omeprazole triple regimen (omeprazole 20 mg, amoxicillin 1 g, and metronidazole 400 mg, bid, for 1-week or 2-weeks)." | 5.10 | [Comparison of pantoprazole and omeprazole-based triple therapy regimens in the treatment of Helicobacter pylori infection]. ( Cui, M; Hu, F; Jiang, H; Zheng, X, 2002) |
| "One hundred and forty-nine consecutive patients with active duodenal ulcer were randomized to receive omeprazole (20 mg b." | 5.10 | Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. ( Amberiadis, P; Archavlis, E; Chiotakakou, E; Christoforidis, P; Kourtessas, D; Mantzaris, GJ; Petraki, K; Triantafyllou, G, 2002) |
| "It was to determine the efficacy of rabeprazole at 20 and 40 mg in addition to amoxicillin and clarithromycin in the treatment of active Helicobacter pylori-positive duodenal ulcers compared with omeprazole 40 mg." | 5.10 | Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Scalia, A; Terminella, C, 2002) |
| " pylori-infected peptic ulcer patients were randomly treated with either rabeprazole (10 mg b." | 5.10 | Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. ( Habu, Y; Hayakumo, T; Inokuchi, H; Kawabata, H; Kawai, K; Kimoto, K; Kiyota, K; Kobayashi, M; Kutsumi, H; Mizuno, S; Nakajima, M; Oyasu, K; Tomioka, H, 2003) |
| " pylori-positive gastritis or peptic ulcers were randomly assigned to receive 30 mg lansoprazole twice daily (LAC group), 10 mg rabeprazole twice daily (RAC20 group), or 20 mg rabeprazole twice daily (RAC40 group), with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week." | 5.10 | Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. ( Aoyama, N; Kasuga, M; Kita, T; Kuroda, K; Maekawa, S; Miki, I; Okumura, K; Sakaeda, T; Sakai, T; Shirasaka, D; Tamura, T; Wambura, CM, 2003) |
| "To compare the efficacy and safety of two doses of rabeprazole with 20 mg omeprazole in the maintenance treatment of erosive gastro-oesophageal reflux disease over 5 years." | 5.10 | A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. ( Bardhan, KD; Fiocca, R; Humphries, TJ; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2003) |
| "This multicenter, randomized, active-controlled trial assessed efficacy of bismuth-based quadruple therapy with omeprazole, bismuth biskalcitrate, metronidazole, and tetracycline (OBMT) using a single-triple capsule of BMT compared with triple therapy with omeprazole, amoxicillin, and clarithromycin (OAC) in treatment of patients with Helicobacter pylori infection and duodenal ulcers." | 5.10 | Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a ( El-Zimaity, H; Hunt, R; Laine, L; Nguyen, B; Osato, M; Spénard, J, 2003) |
| " pylori-positive patients with non-ulcer dyspepsia received 1-week omeprazole-based triple therapy, or omeprazole plus placebos." | 5.10 | Clinical and pathological implications of IgG antibody responses to Helicobacter pylori and its virulence factors in non-ulcer dyspepsia. ( Blum, AL; Bolling-Sternevald, E; Mitchell, HM; O'Morain, CA; Stolte, M; Talley, NJ; Xia, HH, 2003) |
| "To assess efficiency of esomeprazole in the treatment of duodenal ulcer (DU) associated with H." | 5.10 | [Esomeprazole in treating duodenal ulcer in various modes of anti-Helicobacter therapy]. ( Kurilo, AE; Maev, IV; Shchekina, MI; V'iuchnova, ES, 2003) |
| "Omeprazole, clarithromycin and tinidazole for 7 days heals active duodenal ulcer and eradicates H." | 5.10 | Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial. ( Angelucci, D; Cellini, L; Marzio, L, 2003) |
| " pylori-positive patients with active gastric ulcer were randomized to receive pantoprazole (40 mg) (P) and two of three antibiotics: clarithromycin (500 mg) (C), metronidazole (500 mg) (M) or amoxicillin (1000 mg) (A)." | 5.10 | Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. ( Bohuschke, M; Gatz, G; Kirchner, T; Kist, M; Leodolter, A; Malfertheiner, P; Peitz, U; Strobel, S, 2003) |
| "To compare the efficacy of a "Helicobacter pylori test and treat" strategy with that of an empirical trial of omeprazole in the non-endoscopic management by empirical prescribing of young patients with dyspepsia." | 5.10 | Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment. ( Balzano, A; de Nucci, C; Manes, G; Menchise, A, 2003) |
| " pylori-positive patients with peptic ulcer bleeding (n = 101) were randomized to receive either a regular dose (20 mg/day for 3 days) (n = 51) or a high dose of omeprazole (80 mg bolus + 8 mg/h infusion/day for 3 days) (n = 50)." | 5.10 | Effect of short-term treatment with regular or high doses of omeprazole on the detection of Helicobacter pylori in bleeding peptic ulcer patients. ( Julkunen, R; Miettinen, P; Palmu, A; Udd, M, 2003) |
| "A randomized, placebo-controlled, treatment trial in Vietnam allocated 296 Helicobacter pylori-infected patients with peptic ulcer of >or= 5 mm to one of three regimens: (i) twice-daily: lansoprazole 30 mg, clarithromycin 250 mg and tinidazole 500 mg; (ii) once-daily: lansoprazole 60 mg, clarithromycin 500 mg and tinidazole 1000 mg; (iii) once-daily: placebo, clarithromycin 500 mg and tinidazole 1000 mg." | 5.10 | Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. ( Björkman, A; Granström, M; Hoang, TT; Phung, DC; Sörberg, M; Wheeldon, TU, 2003) |
| "Data were pooled on patients (n = 826) with a diagnosis of functional dyspepsia from two placebo-controlled trials who were treated with omeprazole, 10 or 20 mg once daily, for 4 weeks." | 5.10 | Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? ( Bolling-Sternevald, E; Glise, H; Junghard, O; Lauritsen, K; Talley, NJ, 2003) |
| "Eight hundred patients with functional dyspepsia were randomized to receive double-blind treatment with twice-daily 30 mg lansoprazole, 1000 mg amoxicillin and 500 mg clarithromycin for 7 days (L30AC), twice-daily 15 mg lansoprazole, 1000 mg amoxicillin and 500 mg clarithromycin for 7 days (L15AC), or once-daily 15 mg lansoprazole for 14 days (LP)." | 5.10 | Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. ( Demleitner, K; Fischbach, W; Fuchs, W; Layer, P; Leodolter, A; Malfertheiner, P; MOssner, J; Stolte, M, 2003) |
| "The aim of this study was to compare the effect of a combination of lansoprazole, clarithromycin, and amoxicillin (LCA) versus placebo on the severity of symptoms in functional dyspepsia patients who were positive for Helicobacter pylori (H." | 5.10 | Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. ( Cohen, L; Fedorak, RN; Lambert, J; Vanjaka, A; Veldhuyzen van Zanten, S, 2003) |
| " pylori-positive patients with peptic ulcer disease were received rabeprazole 10 mg bid, amoxicillin 1,000 mg bid and clarithromycin 500 mg bid for a week." | 5.10 | [A prospective study on rabeprazole-based triple therapy for Helicobacter pylori eradication in patients with peptic ulcer]. ( Choi, BK; Chung, JM; Jang, YS; Lee, SH; Lee, YJ; Park, ET; Seol, SY; Yang, SY, 2003) |
| "To study whether prophylaxis with lansoprazole could prevent relapse of ulcers after eradication of Helicobacter pylori in patients with NSAID-related peptic ulcers." | 5.10 | Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. ( Chan, CK; Chan, OO; Chu, KM; Hu, HC; Hui, WM; Kwok, KF; Lai, KC; Lam, SK; Wong, BC; Wong, WM, 2003) |
| "To compare the short-term (7-day) safety and efficacy of two triple-therapy regimens using pantoprazole with those of two dual-therapy regimens (one with pantoprazole and one without), for Helicobacter pylori eradication in patients with peptic ulcer disease." | 5.10 | Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. ( Bochenek, WJ; Davis, KD; El-Zimaity, HM; Fraga, PD; Graham, DY; Mack, ME; Osato, MS; Peters, S; Wang, W, 2003) |
| " pylori-infected peptic ulcer patients were randomly assigned to 1 of 3 groups: RAC4 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 4 days), RAC7 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days), and OAC7 (omeprazole 20mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days)." | 5.10 | Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer. ( Chen, JH; Chen, TJ; Lee, SC; Wang, GM; Yang, KC, 2003) |
| "To compare the efficacy of lansoprazole and pantoprazole in treatment of active duodenal ulcer and Helicobacterpylori eradication." | 5.10 | In treatment of active duodenal ulcer and Helicobacter pylori eradication. ( Karaoglu, AO; Yasa, MH; Yukselen, V, 2003) |
| " Medical treatment included omeprazole, clarithromycin, and amoxicillin for 7 days followed by omeprazole for 3 weeks for duodenal ulcer and 5 weeks for gastric ulcer." | 5.10 | [Treatment of perforated gastroduodenal ulcer by simple suture followed by Helicobacter pylori eradication]. ( Quandalle, P; Tran, TT, 2002) |
| "In a randomized, multicentre, prospective study, a total of 352 patients with duodenal ulcer or non-ulcer dyspepsia were randomly divided into three groups according to the administered regimen: OAC250 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 250 mg), OAC500 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg) and OTC group (omeprazole, 20 mg, tinidazole, 500 mg, and clarithromycin, 500 mg)." | 5.10 | Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. ( Ahn, DS; Choi, IJ; Choi, KW; Chung, IS; Chung, JM; Hong, WS; Jung, HC; Kim, JH; Lee, SI; Rew, JS; Rhee, JC; Yang, US, 2002) |
| "To investigate the eradication rate of Helicobacter pylori with omeprazole, amoxicillin and clarithromycin during 6 days in patients with duodenal ulcer." | 5.09 | [Treatment with omeprazole, clarithromycin and amoxicillin over 6 days in patients with Helicobacter pylori-infected duodenal ulcer]. ( Barrachina, M; Bixquert, M; Cuquerella, J; del Val, A; García-Romero, E; Garrigues, V; Higón, MD; Ponce, J; Pons, V, 1999) |
| "Thirty-eight children with Helicobacter pylori gastritis diagnosed by histopathology, and/or bacteriological culture were treated with omeprazole, amoxicillin and clarithromycin." | 5.09 | Helicobacter pylori gastritis in children: efficacy of 2 weeks of treatment with clarithromycin, amoxicillin and omeprazole. ( Finkel, Y; Sandstedt, B; Tirén, U, 1999) |
| "To investigate the efficacy of two omeprazole triple therapies for the eradication of Helicobacter pylori, ulcer healing and ulcer relapse during a 6-month treatment-free period in patients with active duodenal ulcer." | 5.09 | The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. ( Bayerdörffer, E; Bradette, M; Farley, A; Leddin, D; Lind, T; O'Morain, C; Sinclair, P; Sipponen, P; Spiller, RC; Unge, P; Wrangstadh, M; Zanten, SJ; Zeijlon, L, 1999) |
| "Bleeding due to duodenal ulcer was not observed in any patients who received clarithromycin plus omeprazole, whereas five patients in the omeprazole treatment group and six patients in the ranitidine treatment group experienced an episode of ulcer-related hemorrhage during follow-up." | 5.09 | The effect of antibiotic therapy on bleeding from duodenal ulcer. ( Olson, CA; Sonnenberg, A; Zhang, J, 1999) |
| "Helicobacter pylori-positive patients (224) with peptic ulcer disease or non-ulcer dyspepsia were randomized to receive one of three different omeprazole or lansoprazole-amoxycillin-clarithromycin (PPI/AC) regimens for 7 days: (1) OAC 20 regimen (n = 76), omeprazole (OPZ) 20 mg daily, amoxycillin (AMOX) 500 mg t." | 5.09 | Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population. ( Miwa, H; Murai, T; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Shimizu, H; Watanabe, S, 1999) |
| "Adult patients with active duodenal ulcer and confirmed H pylori infection were randomized to receive treatment with clarithromycin plus omeprazole, omeprazole alone, or ranitidine alone." | 5.09 | Antibiotic therapy of Helicobacter pylori infection reduces healthcare expenditures related to duodenal ulcer. ( Levenson, SD; Pauly, MP; Schwartz, JS; Sonnenberg, A, 1999) |
| "To evaluate the efficacy of 1-week triple therapy with omeprazole, clarithromycin,and tinidazole (OCT) in Helicobacter pylori-positive older patients with dyspepsia." | 5.09 | The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive older patients with dyspepsia. ( Arber, N; Brill, S; Halpern, Z; Konikoff, FM; Moshkowitz, M; Reif, S, 1999) |
| " pylori-positive duodenal ulcer were allocated randomly to receive one of four regimens: metronidazole, 200 mg; amoxicillin, 250 mg; and colloidal bismuth subcitrate (CBS), 120 mg (group 1), or CBP, 100 mg qid (group 2) for 2 weeks, then continued CBS, 240 mg, or CBP, 200 mg bid for a further 2 weeks." | 5.09 | Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer. ( Dai, S; Du, H; Li, Q; Li, Y; Nie, Y; Sha, W; Wang, H; Wu, H, 1999) |
| "To study the efficacy of omeprazole triple therapy in the eradication of Helicobacter pylori in patients with active gastric ulcer, and to assess healing and relapse of gastric ulcer." | 5.09 | The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. ( Bayerdörffer, E; Diete, U; Gil, J; Lind, T; Malfertheiner, P; Misiuna, P; O'Morain, C; Sipponen, P; Spiller, RC; Stasiewicz, J; Treichel, H; Ujszászy, L; Unge, P; Zanten, SJ; Zeijlon, L, 1999) |
| " All patients belong to a low socioeconomic strata, had multifocal atrophic gastritis documented by gastric biopsies, and had been treated previously and unsuccessfully for 2 weeks with bismuth subsalicylate (262 mg four times a day), amoxicillin (500 mg three times a day), and metronidazole (400 mg three times a day)." | 5.09 | Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed. ( Bravo, LE; Correa, P; DeLany, JP; Mera, R; Realpe, JL, 1999) |
| "A hypothesis suggesting that profound acid inhibition therapy facilitates and hastens the development of gastric glandular atrophy in patients infected with Helicobacter pylori was investigated in this randomized study comparing omeprazole therapy with antireflux surgery (ARS) for chronic gastroesophageal reflux disease (GERD)." | 5.09 | Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. ( Andersson, A; Hattlebakk, J; Havu, N; Janatuinen, E; Levander, K; Liedman, B; Lundell, L; Miettinen, P; Myrvold, HE; Nyström, P; Pedersen, SA; Thor, K, 1999) |
| " pylori infection and duodenal ulcer, gastric ulcer or non-ulcer dyspepsia were randomly assigned to a 1 week course of either famotidine 80 mg b." | 5.09 | Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. ( Brandstätter, G; Dragosics, B; Gschwantler, M; Hentschel, E; Hirschl, AM; Klimpfinger, M; Oberhuber, G; Pasching, E; Schütze, K; Weiss, W; Wimmer, M; Wurzer, H, 1999) |
| " pylori-positive duodenal ulcer and randomized them into three treatment groups: 84 patients (group Ome40) were assigned to receive omeprazole, 20 mg twice daily, plus amoxicillin, 1 gm twice daily, and clarithromycin, 500 mg twice daily for 10 days; 79 patients (group Pan40) were treated with pantoprazole, 40 mg daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40; and 80 patients (group Pan80) were treated with pantoprazole, 40 mg twice daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40." | 5.09 | Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Catanzaro, R; Cipolla, R; Nuciforo, G, 1999) |
| " pylori-infected patients with nonulcer dyspepsia to receive twice-daily treatment with 20 mg of omeprazole, 1000 mg of amoxicillin, and 500 mg of clarithromycin for 14 days and 167 such patients to receive identical-appearing placebos; all patients were then followed through regular visits for 12 months." | 5.09 | Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. ( Ballard, ED; Fennerty, MB; Talley, NJ; Vakil, N, 1999) |
| "A health economic evaluation of triple therapy with lansoprazole, amoxicillin and clarithromycin versus 2 dual therapies (lansoprazole or omeprazole, each with amoxicillin) in the eradication of Helicobacter pylori in patients with duodenal ulcers was performed in parallel with a randomised clinical trial." | 5.09 | Cost effectiveness of Helicobacter pylori eradication therapies in patients with duodenal ulcer. An analysis of triple therapy versus two dual therapy alternatives. ( Norinder, A; Ohlin, B; Tennvall, GR, 1999) |
| " Our main objective was to study the outcome of a non-metronidazole and omeprazole-based antibiotic regimen in eradicating Helicobacter pylori in patients with duodenal ulcer." | 5.09 | The outcome of a 2-week treatment of Helicobacter pylori-positive duodenal ulcer with omeprazole-based antibiotic regimen in a region with high metronidazole resistance rate. ( Abdulle, AM; Adeyemi, EO; Benedict, S; Danial, MF; Helal, T, 1999) |
| " pylori-positive patients with non-ulcer dyspepsia were treated for 7 days with clarithromycin 500 mg b." | 5.09 | Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. ( De Mascarel, A; Lamouliatte, H; Megraud, F; Samoyeau, R, 1999) |
| "To evaluate the efficacy of omeprazole plus clarithromycin and furazolidone in Helicobacter pylori eradication and duodenal ulcer healing in Brazilian patients." | 5.09 | Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. ( Cabral, MM; Dani, R; De Castro, LP; Dias, MG; Franco, JM; Magalhães, LC; Mendes, GS; Moreira, LS; Queiroz, DM; Rocha, GA; Salles, PG; Toppa, NH, 1999) |
| "We conducted a prospective, uncontrolled study of a consecutive series of 21 peptic ulcer patients with failure of 1-week lansoprazole, amoxicillin, and clarithromycin." | 5.09 | Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. ( Ducóns, JA; Ferrero, M; García Cabezudo, J; Gomollón, F; Guirao, R; Montoro, M; Simón, MA, 1999) |
| "In this open, randomized, monocenter, parallel group comparison, 107 patients with duodenal ulcer or functional dyspepsia were assigned to receive one of the following treatment regimens: a 7-day triple therapy with pantoprazole, 40 mg bid; clarithromycin, 250 mg bid; and metronidazole, 400 mg bid, which was either preceded or followed by a 7-day therapy with pantoprazole, 40 mg (P-PCM or PCM-P)." | 5.09 | Pantoprazole suppresses Helicobacter pylori without affecting cure. ( Adamek, RJ; Pfaffenbach, B; Szymanski, C, 1999) |
| "This study was a comparison of 1-week and 2-week triple therapies with omeprazole, amoxicillin, and clarithromycin (OAC) in patients with peptic ulcer disease and Helicobacter pylori infection." | 5.09 | Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection: results of a randomized controlled trial. ( Habu, Y; Inokuchi, H; Kawai, K; Kimoto, K; Kiyota, K; Mizuno, S; Sugano, Y, 1999) |
| " Treating duodenal ulcer with simultaneous administration of omeprazole achieves ulcer pain relief more rapidly." | 5.09 | Does eradication of Helicobacter pylori alone heal duodenal ulcers? ( Chen, Y; Ge, ZZ; Hu, YB; Xiao, SD; Zhang, DZ, 2000) |
| "To compare two lansoprazole-based non-clarithromycin triple therapies and one dual therapy in a prospective double-blind placebo-controlled study of Helicobacter pylori eradication and duodenal ulcer healing." | 5.09 | Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. ( Carpio, RE; Fock, KM; Ho, J; Hu, FL; Hu, PJ; Huang, NX; Kachintorn, U; Kullavanijaya, P; Lam, SK; Lesmana, L; Li, YY; Manan, C; Perez, JY; Phornphutkul, K; Qian, SC; Wong, BC; Xiao, SD, 2000) |
| "To compare the eradication rates of Helicobacter pylori, ulcer healing rates and side-effects of three regimens of omeprazole triple therapy in patients with duodenal ulcer from South-East Asia and to study the impact of metronidazole resistance." | 5.09 | Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. ( Chelvam, P; Fock, KM; Lim, SG, 2000) |
| " pylori positive active peptic ulcer disease were randomly assigned to receive lansoprazole 30 mg o." | 5.09 | Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. ( Beglinger, C; Drewe, J; Lehmann, FS; Terracciano, L, 2000) |
| "To investigate the efficacy of a 1-week triple therapy with amoxycillin, clarithromycin, and omeprazole or ranitidine bismuth citrate (RBC) in curing Helicobacter pylori infection and healing duodenal ulcers." | 5.09 | Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study. ( Ballardini, G; Boni, F; Bortoli, A; Colombo, E; Minoli, G; Spinzi, GC; Venturelli, R, 2000) |
| "Lansoprazole 30 mg, amoxicillin 1000 mg, and tinidazole 500 mg were given twice daily to 39 peptic ulcer patients (26 duodenal and 13 gastric ulcer, mean age 52." | 5.09 | Eradication of Helicobacter pylori with lansoprazole based triple therapy in peptic ulcer disease. ( Gonlachanvit, S; Kladchareon, N; Kullavanijaya, P; Mahachai, V, 2000) |
| "In patients who require continuous treatment with NSAIDs, lansoprazole is superior to ranitidine for healing of NSAID-associated gastric ulcers." | 5.09 | Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. ( Agrawal, NM; Campbell, DR; Haber, MM; Huang, B; Lukasik, NL; Safdi, MA, 2000) |
| "To compare the efficacy of either omeprazole or ranitidine in a second-line quadruple regimen in patients with duodenal ulcer or erosive duodenitis." | 5.09 | Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens. ( Balta, A; Bouzakis, H; Broutet, N; Kralios, N; Michopoulos, S; Tsibouris, P; Vougadiotis, J, 2000) |
| " pylori eradication and duodenal ulcer healing in this region despite the high metronidazole resistance rate." | 5.09 | Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. ( Adamthwaite, D; Davidson, G; Katelaris, PH; Lambert, J; Midolo, P; Yeomans, ND, 2000) |
| "Of 64 patients with an endoscopically diagnosed gastric adenoma and H pylori infection, 32 were treated with omeprazole and antibiotics to eradicate the infection, and 32 were not." | 5.09 | Effect of Helicobacter pylori eradication on malignant transformation of gastric adenoma. ( Arai, K; Kobayashi, R; Mori, M; Ohki, I; Saito, K, 2000) |
| "The primary objective of the present study was to evaluate the efficacy of 30 and 60 mg of lansoprazole administered in combination with two antibiotics for 7 or 10 days in eradicating Helicobacter pylori in duodenal ulcer patients." | 5.09 | [Treatment of Helicobacter pylori infection with lansoprazole 30 mg or 60 mg combined with two antibiotics for duodenal ulcers]. ( Joubert-Collin, M; Lamouliatte, H; Perie, F, 2000) |
| "For this open study, 331 patients with duodenal ulcer were screened and randomly allocated to either pantoprazole 40 mg b." | 5.09 | Eradication of Helicobacter pylori with pantoprazole and two antibiotics: a comparison of two short-term regimens. ( Daake, H; Frevel, M; Janisch, HD; Kellner, HU; Krezdorn, HG; Tanneberger, D; Wack, R, 2000) |
| "The aim of this study was to compare in an open, controlled and prospective trial the efficacy of one-week regimen using either lansoprazole (2 x 30 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group I, 60 cases) or ranitidine bismuth citrate (2 x 400 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group II, 61 cases) on the eradication of Hp infection in duodenal ulcer patients." | 5.09 | [Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer]. ( Buzás György, M; Illyés, G; Székely, E; Széles, I, 2000) |
| "After a complete diagnostic workup, 792 patients with functional dyspepsia unresponsive to one week of low dose antacid treatment were randomised to two weeks of treatment with placebo, ranitidine 150 mg, omeprazole 10 mg, or omeprazole 20 mg daily." | 5.09 | Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group. ( Arnold, R; Blum, AL; Fischer, M; Koelz, HR; Stolte, M, 2000) |
| "To evaluate the efficacy of 3 days of azithromycin 500 mg od, 7 days of amoxycillin 750 mg tid and omeprazole, 20 (Group A) or 40 mg (Group B) on randomization, as a treatment for Helicobacter pylori infection in patients with endoscopically diagnosed peptic ulcer." | 5.09 | [Triple therapy of short-term with azithromycin, amoxycillin and omeprazole for the eradication of Helicobacter pylori]. ( Aguilera, R; Flores, S; Marchese, A; Opazo, H; Valderrama, D; Valderrama, S, 2000) |
| " pylori-positive patients who had peptic ulcers or reflux oesophagitis were treated for 3 years with either omeprazole (20 mg/day) alone (n=7) or with omeprazole for primary therapy (8 weeks), followed by famotidine (40 mg/day) for maintenance therapy (n=134)." | 5.09 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. ( Mashiba, H; Matsumura, N; Okamoto, S; Sasaki, N; Taniyama, K; Uemura, N; Yamaguchi, S; Yamamoto, S, 2000) |
| "To clarify whether the depth of ulceration evaluated by endoscopic ultrasonography (EUS) influences a modified dual therapy with amoxicillin and lansoprazole for the treatment of Helicobacter pylori-positive patients with gastric ulcer." | 5.09 | Does the depth of gastric ulceration influence a modified dual therapy with amoxicillin and lansoprazole for Helicobacter pylori-associated gastric ulcer? ( Kawashima, A; Motoo, Y; Ohtsubo, K; Okai, T; Sakai, J; Sawabu, N; Watanabe, H, 2000) |
| "Seven-day triple therapy with omeprazole, amoxicillin, and clarithromycin was efficacious for treating Asian and African patients with duodenal ulcer disease associated with H." | 5.09 | Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. ( Abbas, Z; Abid, S; Chang, FY; Chen, PC; Destefano, M; Hamid, SS; Lam, SK; Lin, BR; Schneider, H; Seebaran, A; Simjee, AE; Van Rensburg, C; Wong, BC; Zhang, J, 2000) |
| "Patients with active duodenal ulcer were randomized either to omeprazole, 20 mg twice daily until healing, followed by omeprazole, 20 mg/ day for 1 year, or to eradication therapy (metronidazole, amoxicillin, and omeprazole for 2 weeks) followed by placebo for 1 year." | 5.09 | Eradication of Helicobacter pylori compared with long-term acid suppression in duodenal ulcer disease. A randomized trial with 2-year follow-up. The Danish Ulcer Study Group. ( Aalykke, C; Bekker, C; Bonnevie, O; Bytzer, P; Eriksen, J; Gjørup, T; Hansen, J; Justesen, T; Kjaergaard, J; Kromann-Andersen, H; Rask-Madsen, J; Rune, S; Teglbjaerg, PS; Vilien, M; Vyberg, M; Weywadt, L, 2000) |
| "Four hundred and forty eight duodenal ulcer patients with Helicobacter pylori infection, confirmed by 13C-urea breath test (UBT), and no current ulcer, were randomised to double-blind treatment with esomeprazole 20 mg twice daily (b." | 5.09 | One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. ( Cockeram, A; De Argila, CM; Delchier, JC; Göthe, L; Hasselgren, G; Labenz, J; Lauritsen, K; Lind, T; Sinclair, P; Stubberöd, A; Treichel, HC; Veldhuyzen Van Zanten, S; Wrangstadh, M, 2000) |
| " pylori who had functional dyspepsia were randomly assigned to 7 days of treatment with a lansoprazole-based triple therapy or placebo and then followed for 1 year." | 5.09 | Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. ( Chan, HH; Chen, W; Cheng, JS; Chien, EJ; Hsu, PI; Hsu, PN; Ku, MK; Lai, KH; Lin, CK; Lo, CC; Lo, GH; Peng, NJ; Tseng, HH, 2001) |
| " Fifty patients with active or scarred duodenal ulcer were randomized to lansoprazole or omeprazole for 1 to 4 weeks, with clarithromycin 250 mg twice a day and tinidazole 500 mg twice a day for the first week." | 5.09 | Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer. ( Fanti, L; Guslandi, M; Ieri, R; Mezzi, G; Passaretti, S; Testoni, PA, 2001) |
| " pylori was cultured and clarithromycin susceptibility was determined before and after treatment, from duodenal ulcer patients receiving RBC and clarithromycin or omeprazole and clarithromycin for 2 weeks in a multicenter randomized clinical trial." | 5.09 | Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo. ( Mégraud, F; Roberts, P; Williamson, R, 2000) |
| "Among the 15 patients with hemorrhagic acute gastritis who were randomly allocated to group A (eradication therapy) or group B (Lansoprazole, LPZ), 10 of them started to receive treatment within 1 day after the disease onset." | 5.09 | A short-term eradication therapy for Helicobacter pylori acute gastritis. ( Asaka, M; Kashiwagi, S; Miyake, K; Nomura, H; Sugiyama, T, 2000) |
| "Little is known about the efficacy and safety of different formulations of omeprazole-based triple therapy regimens for the treatment of Helicobacter pylori-positive peptic ulcer." | 5.09 | Comparison of the efficacy and safety of different formulations of omeprazole-based triple therapies in the treatment of Helicobacter pylori-positive peptic ulcer. ( Baik, SK; Cho, MY; Jeong, YS; Kim, HS; Kim, JW; Kim, KH; Kwon, SO; Lee, DK; Seo, JI, 2001) |
| "Ninety patients with established peptic ulcer and NUD (with previously proven ulcer) were randomly assigned to receive either bismuth-subcitrate, amoxycillin and metrnidazole (BAM) or lansoprasole, clarithromycine and metronidazole (LCM) for 7 days." | 5.09 | The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication. ( Avidan, B; Bar-Meir, S; Keller, N; Melzer, E, 2001) |
| "A total of 59 consecutive Helicobacter pylori infected non-ulcer dyspepsia patients were randomly selected to receive either one of two triple therapy regimens, including metronidazole, amoxycillin plus ranitidine bismuth citrate (RAM group) or omeprazole (OAM group)." | 5.09 | Ranitidine bismuth citrate or omeprazole-based triple therapy for Helicobacter pylori eradication in Helicobacter pylori-infected non-ulcer dyspepsia. ( Chuang, CH; Lin, XZ; Sheu, BS; Wu, JJ; Yang, HB, 2001) |
| "Non-ulcer dyspepsia patients (n=199), with a normal upper endoscopy and a positive (13)C-urea breath test (UBT) were randomly assigned to either pantoprazole, clarithromycin and metronidazole (PCM) or pantoprazole, clarithromycin and eicosapen (PCE) for 7 days." | 5.09 | Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. ( Drewe, J; Geiser, HR; Meier, R; Wettstein, A, 2001) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 5.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| "A total of 122 consecutive patients with peptic ulcer and Helicobacter pylori infection were treated with omeprazole 20 mg b." | 5.09 | Modified seven-day, quadruple therapy as a first line Helicobacter pylori treatment. ( Brullet, E; Calvet, X; Campo, R; Garcia, N; Gené, E; Sanfeliu, I, 2001) |
| "To investigate Helicobacter pylori eradication in duodenal ulcer patients with a new regimen, lansoprazole 30 mg daily for one or four weeks plus twice daily tetracycline 500 mg, clarithromycin 250 mg, and metronidazole 400 mg." | 5.09 | Quadruple therapy for symptomatic spontaneous duodenal ulcer disease. ( Bateson, MC, 2001) |
| "A total of 120 patients with peptic ulcer and non-ulcer dyspepsia were randomly assigned to a 2-week course of either: famotidine 40 mg twice a day, amoxycillin 1 g twice a day and tinidazole 500 mg twice a day (FAT group; n = 60); or omeprazole 20 mg twice a day, amoxycillin 1 g twice a day and tinidazole 500 mg twice a day (OAT group; n = 60)." | 5.09 | Famotidine versus omeprazole, in combination with amoxycillin and tinidazole, for eradication of Helicobacter pylori infection. ( Changchien, CS; Chen, JJ; Hsu, CC; Hu, TH; Lu, SN, 2001) |
| "To compare the efficacy of one-week versus two-week treatment with lansoprazole, amoxycillin and clarithromycin in inducing healing of Helicobacter pylori-positive duodenal ulcers as well as to investigate the role of several factors, determinant in the ulcer healing process." | 5.09 | Prolonging proton pump inhibitor-based anti-Helicobacter pylori treatment from one to two weeks in duodenal ulcer: is it worthwhile? ( Bianchi Porro, G; Cucino, C; Imbesi, V; Maconi, G; Russo, A, 2000) |
| "A total of 102 Helicobacter pylori-positive patients with gastric ulcer were randomly allocated to three groups: rabeprazole 10 mg (RAC10), rabeprazole 20 mg (RAC20) or rabeprazole 40 mg (RAC40) plus amoxicillin 750 mg and clarithromycin 200 mg twice daily for 7 days." | 5.09 | Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. ( Asaka, M; Hige, S; Hokari, K; Ishizuka, J; Kagaya, H; Kato, M; Komatsu, Y; Kudo, M; Miyagishima, T; Mizushima, T; Nishikawa, K; Saito, M; Sugiyama, T; Takeda, H, 2001) |
| " pylori positive duodenal ulcer were enrolled and randomly allocated into one of the five treatment groups: 1) group A: received lansoprazole 30 mg once daily for 2 weeks plus amoxicillin (AM) 500 mg and metronidazole (MZ) 500 mg twice daily for one week in the first week; 2) group B: the AM in group A was replaced by clarithromycin (CM) 250 mg; 3) group C: the MZ in group A was replaced by CM 250 mg; 4) group D: the AM and CM in group C was used for 2 wk; 5) group E: the CM in group D was doubled to 500 mg twice daily." | 5.09 | A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy. ( Hsu, CT; Kuo, CF; Wang, CS; Wang, TH; Yang, JC; Yang, KC, 1999) |
| "Helicobacter pylori-positive patients (n=323) with non-ulcer dyspepsia were randomized to receive one of four 1-week regimens consisting of omeprazole, 20 mg b." | 5.09 | A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. ( Barthélemy, P; Caekaert, A; Fléjou, JF; Laurent, J; Mégraud, F, 2001) |
| "The aim of this multicenter prospective, randomized, double-blind study was to assess the efficacy of the combination of omeprazole, amoxicillin, and clarithromycin (OAC) for the treatment of Helicobacter pylori gastritis in children." | 5.09 | Omeprazole combined with amoxicillin and clarithromycin in the eradication of Helicobacter pylori in children with gastritis: A prospective randomized double-blind trial. ( Barthélemy, P; Dupont, C; Gottrand, F; Guimber, D; Husson, MO; Kalach, N; Lachaux, A; Lenaerts, C; Maurage, C; Morali, A; Mougenot, JF; Roquelaure, B; Spyckerelle, C; Tounian, P, 2001) |
| "A total of 170 Helicobacter pylori-positive patients with chronic gastritis were randomized to receive one of the following Helicobacter pylori eradication regimens; OAC (omeprazole 20 mg bd, amoxycillin 750 mg bd and clarithromycin 400 mg bd for 1 week) and RAC (rabeprazole 20 mg bd, amoxycillin 750 mg bd and clarithromycin 400 mg bd for 1 week)." | 5.09 | Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. ( Azuma, T; Dojo, M; Kuriyama, M; Muramatsu, A; Ohtani, M; Saito, T, 2001) |
| " pylori infection in patients with duodenal ulcers, compared with treatment based on pantoprazole, in a randomized controlled multicenter study." | 5.09 | Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial). ( Barbir, A; Hovat, D; Ivandić, A; Kurbel, S; Mihaljević, S; Ostojić, R; Stimac, D; Takac, B; Vcev, A; Vceva, A, 2001) |
| " Men between 55 and 65 years of age with a gastric cancer phenotype of Helicobacter pylori gastritis are randomized to receive a 7 day course of omeprazole 2 X 20mg, clarithromycin 2 X 500mg, and amoxicillin 2 X 1g for 7 days, or omeprazole 2 X 20mg plus placebo." | 5.09 | Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study). ( Antos, D; Bayerdörffer, E; Dite, P; Dragosics, B; Ehninger, G; Gschwantler, M; Kirsch, C; Labenz, J; Läuter, J; Leodolter, A; Malfertheiner, P; Miehlke, S; Neubauer, A; Oberhuber, G; Stolte, M, 2001) |
| " pylori) infection is known to affect the gastric microcirculation, and cetraxate is reported to accelerate gastric ulcer healing, possibly by augmenting gastric mucosal blood flow (MBF)." | 5.09 | Influence of Helicobacter pylori infection and cetraxate on gastric mucosal blood flow during healing of endoscopic mucosal resection-induced ulcers. ( Adachi, K; Fujishiro, H; Ishihara, S; Kawamura, A; Kazumori, H; Kinoshita, Y; Moriyama, N; Okuyama, T; Sato, H; Suetsugu, H; Watanabe, M, 2001) |
| "Satisfactory antral biopsies were obtained from 119 duodenal ulcer patients before and after 4 wk of therapy with lansoprazole, ranitidine, or placebo." | 5.08 | The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients. ( Atkinson, BF; Brightman, SA; Jhala, NC; McFarland, MM; Morale, B; Rubin, W, 1995) |
| "The clinical efficacy of lansoprazole plus amoxicillin treatment in eradicating Helicobacter pylori was examined in peptic ulcer patients." | 5.08 | Clinical efficacy of lansoprazole-amoxicillin treatment in eradicating Helicobacter pylori: evaluation by the polymerase chain reaction method. ( Ogura, K; Ota, S; Shimada, T; Terano, A, 1995) |
| "We examined the effects of lansoprazole and famotidine on gastric basic fibroblast growth factor (bFGF) levels and ulcer healing in patients with gastric ulcer." | 5.08 | Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine. ( Fukuda, M; Higashi, T; Imaizumi, T; Kawano, S; Miura, N; Miyajima, K; Mukuda, T; Noguchi, M; Tatsumi, T; Tsuji, S, 1995) |
| "A randomized, single-blind study was designed to assess the effect of lansoprazole alone and lansoprazole plus amoxicillin on the healing and eradication rates in Helicobacter pylori-associated peptic ulcer disease." | 5.08 | Clinical efficacy of lansoprazole in eradication of Helicobacter pylori. ( Asaka, M; Kagaya, H; Katagiri, M; Katoh, M; Kudoh, M; Takeda, H, 1995) |
| "This study attempted to determine the efficacy of lansoprazole plus clarithromycin therapy in the eradication of Helicobacter pylori in gastric ulcer patients." | 5.08 | Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients. ( Aisawa, T; Akagi, T; Fukuda, S; Fukushi, M; Mizuki, I; Munakata, A; Ohkawa, K; Sakata, Y; Shimoyama, T; Yoshida, Y, 1995) |
| "We studied the effects of lansoprazole on ulcer healing and Helicobacter pylori infection in elderly patients with peptic ulcers." | 5.08 | Therapeutic effects of lansoprazole on peptic ulcers in elderly patients. ( Asagoe, K; Dekigai, H; Kusaka, S; Maeda, S; Matsumoto, M; Mizuno, M; Murakami, M; Saita, H; Seki, M; Takahashi, Y, 1995) |
| "pylori positive (histology and/or culture) ulcer disease (n = 17; acute ulcer: n = 11) or functional dyspepsia (n = 13) were treated over one week with pantoprazole 40 mg bd, clarithromycin 250 mg bd and metronidazole 400 mg bd." | 5.08 | [Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori]. ( Becker, T; Börsch, G; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B, 1995) |
| "Thirty-five patients with duodenal ulcer bleeding and Helicobacter pylori-colonization were assigned to receive 2 x 20 mg omeprazole and 3 x 750 mg amoxycillin daily for 2 weeks." | 5.08 | Omeprazole-amoxycillin therapy for eradication of Helicobacter pylori in duodenal ulcer bleeding: preliminary results of a pilot study. ( Brennenstuhl, M; Hammar, CH; Jaspersen, D; Körner, T; Schorr, W, 1995) |
| " The aim of this controlled, randomized, prospective study was to compare the effect of these two regimens and a further regimen for metronidazole-resistant patients on duodenal ulcer healing, H." | 5.08 | Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized ( Dehbashi, N; Etaati, H; Fattahi, M; Javan, A; Massarrat, S; Saberi-Firoozi, M; Zare, S, 1995) |
| "We investigated the effects of omeprazole or lansoprazole on peptic ulcer healing, eradication of Helicobacter pylori (Hp) and abdominal symptoms." | 5.08 | Proton pump inhibitors for Helicobacter pylori eradication in patients with peptic ulcer. ( Fukuda, Y; Okui, M; Shimoyama, T; Tamura, K; Yamamoto, I, 1995) |
| "To establish the efficacy of omeprazole combined with two antibiotics for Helicobacter pylori eradication and duodenal ulcer relapse." | 5.08 | Efficacy of omeprazole combined with antibiotics for Helicobacter pylori eradication and duodenal ulcer recurrence. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M; Maconi, G; Minguzzi, M, 1995) |
| " pylori-associated duodenal ulcer were treated with 40 mg omeprazole three times a day and 750 mg amoxicillin three times a day for the first 14 days (n = 139) followed by 20 mg omeprazole once daily until day 42 or with omeprazole plus 750 mg amoxicillin placebo three times a day for the same time period (n = 131)." | 5.08 | Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. ( Bayerdörffer, E; Heldwein, W; Höchter, W; Klann, H; Mannes, GA; Miehlke, S; Schmitt, W; Simon, T; Sommer, A; Weingart, J, 1995) |
| " pylori infection and gastric ulcers unrelated to the use of nonsteroidal antiinflammatory drugs, one week of antibacterial therapy without acid suppression heals the ulcers as well as omeprazole and reduces the rate of their recurrence." | 5.08 | Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. ( Cheng, AF; Chung, SC; Leung, VK; Li, AK; Li, MK; Ling, TK; Ng, EK; Sung, JJ; Yung, MY, 1995) |
| " pylori infection and peptic ulcer disease (n = 64) or functional dyspepsia (n = 16), with similar demographic and clinical characteristics, were treated for 1 week with either omeprazole 20 mg once in the morning and clarithromycin 250 mg and metronidazole 400 mg twice daily (OCM; n = 40) or with omeprazole 20 mg once in the morning and clarithromycin 250 mg and tetracycline 500 mg twice daily (OCT; n = 40)." | 5.08 | One-week low-dose triple therapy for the eradication of Helicobacter pylori infection. ( Becker, T; Börsch, G; Labenz, J; Rühl, GH; Sollböhmer, M; Stolte, M; Tillenburg, B, 1995) |
| ") in eradicating Helicobacter pylori in patients with duodenal ulcer successfully healed with omeprazole or ranitidine; second, to examine the influence of the eradication on duodenal ulcer recurrence rate after 12 months." | 5.08 | Triple therapy eradicated H. pylori equally in patients pretreated with omeprazole or ranitidine. A 12-month follow-up. ( Archimandritis, A; Balatsos, V; Delis, V; Kastanas, K; Mentis, A; Scandalis, N, 1995) |
| "Eradication of Helicobacter pylori from the stomach by triple therapy with bismuth, tetracycline, and metronidazole cures peptic ulcer disease." | 5.08 | Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. ( de Boer, W; Driessen, W; Jansz, A; Tytgat, G, 1995) |
| "We report the results of seven therapeutic trials combining omeprazole, clarithromycin, amoxycillin, colloidal bismuth subcitrate and tinidazole in 198 patients (peptic ulcer disease/non-ulcerative dyspepsia, 137/61) to eradicate H." | 5.08 | Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients. ( Buset, M; De Koster, E; Deltenre, M; Jonas, C; Otero, J; van Gossum, M, 1995) |
| "In this double-blind trial, conducted in 19 hospitals, 119 patients with symptomatic duodenal ulcer disease were randomized to receive either 14 days treatment with omeprazole 40 mg daily, amoxycillin 500 mg t." | 5.08 | Addition of metronidazole to omeprazole/amoxycillin dual therapy increases the rate of Helicobacter pylori eradication: a double-blind, randomized trial. ( Axon, AT; Bate, CM; Bell, GD; Emmas, CE; Green, JR; Kerr, GD; Taylor, MD; Tildesley, G, 1995) |
| "Omeprazole is less effective in healthy subjects than in patients with duodenal ulcers." | 5.08 | Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. ( Blum, AL; Börsch, G; Idström, JP; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B; Verdú, EF, 1996) |
| "The combined therapy with amoxycillin, metronidazole, and omeprazole is highly effective in both HP eradication and prevention of duodenal ulcer recurrence." | 5.08 | Omeprazole coupled with two antibiotics for Helicobacter pylori eradication and prevention of ulcer recurrence. ( Alvisi, C; Bargiggia, S; Bianchi Porro, G; Cesana, B; Fiocca, R; Franceschi, M; Lazzaroni, M; Luinetti, O; Maconi, G; Perego, M; Solcia, E; Trespi, E; Villani, L, 1996) |
| "Changes in Helicobacter pylori-associated gastritis of the antrum and corpus were investigated in a large number of patients treated with omeprazole, with or without the addition of amoxycillin." | 5.08 | Effects of permanent eradication or transient clearance of Helicobacter pylori on histology of gastric mucosa using omeprazole with or without antibiotics. ( Carlsson, J; Fiocca, R; Rudbäck, A; Solcia, E; Villani, L; Zeijlon, L, 1996) |
| " pylori-positive duodenal ulcer were randomly assigned to receive one of the following three antiulcer regimens: (1) lansoprazole 30 mg b." | 5.08 | Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients. ( Bargiggia, S; Bianchi Porro, G; Colombo, E; Maconi, G; Parente, F, 1996) |
| "During a period of 1 year 152 patients with gastric ulcers were randomly assigned to one of two treatment regimens: omeprazole 20 mg daily in the morning for 8 weeks (74 patients), or bismuth subsalicylate 600 mg three times daily for 8 weeks combined with 500 mg amoxicillin twice daily and 1000 mg tinidazole twice daily for the first 10 days (triple therapy) (78 patients)." | 5.08 | Cure of gastric ulcer disease after cure of Helicobacter pylori infection--German Gastric Ulcer Study. ( Bästlein, E; Bayerdörffer, E; Bolle, KH; Hatz, R; Heldwein, W; Höchter, W; Klann, H; Lehn, N; Mannes, GA; Meining, A; Miehlke, S; Ruckdeschel, G; Simon, T; Sommer, A; Stolte, M; Weingart, J, 1996) |
| " Those patients with active duodenal ulcers present at endoscopy were given omeprazole 20 mg nocte for a further 21 days." | 5.08 | A seven-day Helicobacter pylori treatment regimen using clarithromycin, omeprazole and tripotassium dicitrato bismuthate. ( Broadbent, A; Chambers, S; Gould, SR; Mistry, R; Ranganath, L; Weldon, MJ, 1996) |
| " pylori-positive out-patients (n = 231) with duodenal ulcers were treated randomly and double-blind with either omeprazole 20, 40 or 80 mg b." | 5.08 | Dose-response of omeprazole combined with amoxycillin on duodenal ulcer healing and eradication of Helicobacter pylori. ( Braden, B; Lembcke, B; Londong, W; Pommerien, W; Schultze, V; Wrangstadh, M, 1996) |
| "Twelve duodenal ulcer patients in remission were randomized to receive in single-blind fashion either placebo, omeprazole 20 mg or omeprazole 40 mg twice daily (08." | 5.08 | The effects of omeprazole 20 and 40 mg twice daily on intragastric acidity in duodenal ulcer patients. ( Celle, G; Mansi, C; Mela, GS; Mele, MR; Savarino, V; Vigneri, S; Zentilin, P, 1996) |
| " Sixty duodenal ulcer patients were randomised to receive either standard triple therapy (tripotassium dicitrato bismuthate 120 mg qds+tetracycline 500 mg qds+metronidazole 400 mg qds), quadruple therapy A (triple therapy+omeprazole 20 mg od) or quadruple therapy B (triple therapy+omeprazole 40 mg od), for 7 days." | 5.08 | One week treatment for Helicobacter pylori infection: a randomised study of quadruple therapy versus triple therapy. ( Griffiths, AE; Halliday, D; Jacyna, MR; Phull, PS, 1995) |
| "To determine the effect of Helicobacter pylori eradication with omeprazole and amoxycillin, with or without metronidazole, on the 12-month course of duodenal ulcer disease." | 5.08 | Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole. ( Axon, AT; Bate, CM; Bell, GD; Martin, JL; Richardson, PD; Taylor, MD; Tildesley, G, 1996) |
| "Patients with a history of dyspepsia or uncomplicated peptic ulcer disease and with a need for continuous NSAID treatment were randomized to receive either 20 mg omeprazole once daily or placebo." | 5.08 | Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. ( Anker-Hansen, O; Carling, L; Ekström, P; Lundegårdh, G; Thorhallsson, E; Unge, P; Wetterhus, S; Wingren, PE, 1996) |
| " pylori infection in patients with chronic gastritis (CG), duodenal ulcer (DU), and gastric ulcer (GU) after two dual therapies (omeprazole with either amoxycillin or clarithromycin)." | 5.08 | Significant increase in eradication rates of Helicobacter pylori infection with two consecutive dual therapies (omeprazole and amoxycillin or omeprazole and clarithromycin). A randomized study in 450 Spanish patients. ( Carpintero, P; García Grávalos, R; Hermida, C; Lara, S; Moreno, JA; Pajares, JM; Santander, C, 1996) |
| " pylori-positive gastritis with or without peptic ulcer, and compared with the classic 'Bazzoli regimen' (OCT: omeprazole, clarithromycin, tinidazole) in 60 matched patients." | 5.08 | Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. ( Alvisi, V; Caselli, M; Gasbarrini, G; Gaudenzi, P; Luzzi, I; Ruina, M; Sartori, S; Trevisani, L; Tursi, A, 1997) |
| " After 2 weeks duodenal ulcer healing was confirmed in 91% (95% CI = 80-100%) of patients treated with omeprazole and in 76% (95% CI = 60-91%) in the placebo group (P = 0." | 5.08 | One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. ( Adamek, RJ; Börsch, G; Idström, JP; Labenz, J; Peitz, U; Tillenburg, B, 1997) |
| " The present study was designed to test the hypothesis that a triple therapy with pantoprazole, clarithromycin and amoxycillin cures the infection in > or = 80% of duodenal ulcer patients infected with H." | 5.08 | Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. ( Labenz, J; Lütke, A; Stolte, M; Tillenburg, B; Weismüller, J, 1997) |
| "Eighty patients with endoscopically proven active duodenal ulcer were randomized to take ranitidine or lansoprazole for 4-8 wk, together with clarithromycin 250 mg b." | 5.08 | Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M, 1997) |
| "Eighty-two patients with severe peptic ulcer disease and concurrent Helicobacter pylori infection were treated with a two week regimen of omeprazole (40 mg once daily), amoxycillin (750 mg t." | 5.08 | Immediate repeat course of amoxycillin, metronidazole and omeprazole to eradicate Helicobacter pylori. ( Jönsson, KA; Sörberg, M; Ström, M, 1997) |
| " pylori-associated gastritis were treated with 20 mg omeprazole once daily in the morning, 20 mg omeprazole b." | 5.08 | An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. ( Bayerdörffer, E; Hele, C; Lehn, N; Mannes, GA; Miehlke, S; Stolte, M, 1997) |
| "In this prospective controlled study conducted in a single center, 78 symptomatic peptic ulcer patients were treated for 4 wk with omeprazole 40 mg o." | 5.08 | Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients? ( Anania, MC; Annibale, B; D'Ambra, G; Delle Fave, G; Iannoni, C; Luzzi, I; Marcheggiano, A; Marignani, M; Paoletti, M, 1997) |
| "Fifty-four patients with active duodenal ulcers were treated with amoxycillin tablets, 750 mg three times daily, and omeprazole, either 40 mg twice daily (group 1) or 40 mg three times daily (group 2), for 14 days in a prospective randomized trial." | 5.08 | Eradication of Helicobacter pylori in peptic ulcer disease with amoxycillin, 2.0 g, and omeprazole, 80 or 120 mg: a prospective randomized trial. ( Barnert, J; Busch, R; Demharter, R; Fleischmann, R; Füger, K; Wienbeck, M, 1997) |
| "The purpose of the present study was to examine the association between interleukin-8 (IL-8) in the gastric body due to Helicobacter pylori infection and histological gastritis, as well as elucidating the effect of acid secretion inhibitors on H." | 5.08 | Gastric corpus IL-8 concentration and neutrophil infiltration in duodenal ulcer patients. ( Haruma, K; Kajiyama, G; Mashiba, H; Mukai, T; Okamoto, S; Oomoto, Y; Sasaki, N; Sumii, K; Taniyama, K; Uemura, N; Yamaguchi, S, 1997) |
| "Patients with active HP infection and peptic ulcer, a history of peptic ulcer, or nonulcer dyspepsia were randomized to either lansoprazole 30 mg b." | 5.08 | Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. ( Barnett, JL; Chey, WD; DelValle, J; Elta, GH; Fisher, L; Hasler, WL; Nostrant, T; Scheiman, JM, 1997) |
| "In patients with active duodenal ulcer, a 10-day course of amoxycillin-clarithromycin-based triple therapy without additional acid suppression is highly effective in eradicating H." | 5.08 | Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. ( Archambault, A; Archimandritis, A; Bazzoli, F; Fedorak, R; Hentschel, E; Megraud, F; Mora, P; Rodrigo, L; Rokkas, T; Skandalis, N; Stamler, D; Wurzer, H, 1997) |
| "In a prospective study, 113 patients with peptic ulcer (n = 36) or non-ulcer dyspepsia (n = 77) were randomized to receive 1-wk treatment, composed of omeprazole 20 mg b." | 5.08 | Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study. ( Attili, AF; Diana, F; Pugliano, F; Rinaldi, V; Zullo, A, 1997) |
| " pylori-infected patients with endoscopically documented duodenal ulcer either currently or within the past year were randomized to 14 days of (1) lansoprazole, 30 mg bid, plus amoxicillin, 1 gm tid; (2) lansoprazole, 30 mg tid, plus amoxicillin, 1 gm tid; (3) lansoprazole, 30 mg tid alone; or (4) amoxicillin, 1 gm tid alone." | 5.08 | Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. ( Arora, A; Graham, D; Haber, M; Harford, W; Lanza, F; Rose, P; Siepman, N; Weissfeld, A, 1996) |
| " pylori from the gastric mucosa, and omeprazole frequently is used for the treatment of duodenal ulcer disease, prompting the interest to investigate rigorously the combination of clarithromycin and omeprazole for eradicating H." | 5.08 | Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer. ( Dettmer, A; Fraser, AG; O'Morain, C; Rambow, A; von Fritsch, E, 1996) |
| " Patients (n = 787) with proved duodenal ulcer disease were randomized to treatment twice daily for 1 week with omeprazole, 20 mg (O), plus either placebo (P) or combinations of two of the following antimicrobials: amoxicillin, 1 gm (A), clarithromycin, 250 or 500 mg (C250, C500), or metronidazole, 400 mg (M)." | 5.08 | Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. ( Bardhan, KD; Bayerdörffer, E; Bradette, M; Cederberg, C; Chiba, N; Idström, JP; Lind, T; O'Morain, C; Spiller, R; Unge, P; Veldhuyzen van Zanten, S; Wrangstadh, M, 1996) |
| " pylori-positive peptic ulcer received omeprazole 20 mg twice daily in combination with metronidazole 400 mg twice daily and clarithromycin 500 mg twice daily for seven days." | 5.08 | One week triple therapy for Helicobacter pylori: does high-dose clarithromycin confer additional benefit? ( Bhutta, AS; Bindel, H; Cunnane, K; Loane, J; O'Connor, HJ, 1997) |
| "To estimate and compare the efficacy of 'triple' 1-week regimens--omeprazole, clarithromycin and a nitroimidazole (metronidazole or ornidazole)--followed by omeprazole, for an additional 3 weeks, on Helicobacter pylori eradication and duodenal ulcer (DU) healing, in a country with a high resistance rate of H." | 5.08 | One-week therapy with omeprazole, clarithromycin and metronidazole or ornidazole, followed by 3 weeks' treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer. ( Archimandritis, A; Balatsos, V; Davaris, P; Delis, V; Kanellopoulou, E; Manika, Z; Skandalis, N; Souyioultzis, S; Tzivras, M, 1997) |
| "Our aim was to investigate the efficacy of omeprazole and amoxicillin in curing Helicobacter pylori infection in gastric ulcer patients." | 5.08 | Double-blind trial of omeprazole and amoxicillin in the cure of Helicobacter pylori infection in gastric ulcer patients. The Ulcer Study Group, Germany. ( Bayerdörffer, E; Bolle, KH; Fischer, G; Hatz, R; Höchter, W; Huber, F; Klann, H; Lehn, N; Meining, A; Simon, T; Sommer, A; Stolte, M; Weingart, J, 1998) |
| "In this study, the effect of different periods of amoxicillin (AMPC) treatment on the eradication rate of Helicobacter pylori in 173 patients with peptic ulcers (gastric ulcer, 109; duodenal ulcer, 64) was investigated." | 5.08 | Does Helicobacter pylori eradication depend on the period of amoxicillin treatment? A retrospective study. ( Abe, T; Asai, A; Goto, M; Ito, T; Kawano, S; Kubo, M; Tanabe, J; Tanimura, H, 1998) |
| "In this randomized multicentre study, 267 duodenal ulcer patients were treated for 2 weeks with omeprazole 40 bid (Group A) or 20 mg bid (Group B), respectively, and with amoxycillin 0." | 5.08 | Dual therapy with high or low doses of omeprazole does not achieve an acceptable rate of Helicobacter pylori eradication in duodenal ulcer patients. A multicentre randomized long-term detailed study. ( Annibale, B; Bordi, C; Cesana, B; Damilano, I; Franceschi, M; Maconi, G; Pilato, FP, 1997) |
| "To compare the efficacy of two "new" one-week triple therapies (with omeprazole, metronidazole and clarithromycin or amoxycillin) for the eradication of Helicobacter pylori and healing duodenal ulcer." | 5.08 | [new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic]. ( Abraira, V; Boixeda, D; García Plaza, A; Gisbert, JP; Martín de Argila, C; Moreno, L; Redondo, C, 1998) |
| " pylori and with gastro-oesophageal reflux disease we investigated the gastritis parameters in antral and corpus mucosa before and after 2, 6 and 12 months of treatment with 15 or 30 mg lansoprazole or 20 mg omeprazole/day." | 5.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. ( Alexandridis, T; Meining, A; Schmitz, JM; Seifert, E; Stolte, M, 1998) |
| " pylori-positive peptic ulcer received lansoprazole 30 mg twice daily in combination with metronidazole 400 mg twice daily and clarithromycin 250 mg twice daily for 5 days." | 5.08 | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? ( Cunnane, K; Kelly, S; Laundon, J; McLoughlin, R; O'Connor, HJ, 1998) |
| "Although bismuth was both the first drug shown to alter the natural history of peptic ulcer disease and also a constituent of the first very effective eradication regimens, it has been excluded from the newer regimens, despite its safety and low cost, in favour of two antibiotics." | 5.08 | Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. ( Scott, BB, 1998) |
| "In an open study 66 consecutive infected patients with ulcer disease or non-ulcer dyspepsia were treated with 4-day quadruple therapy after 3 days of lansoprazole pretreatment." | 5.08 | Four-day lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection. ( de Boer, WA; Schneeberger, PM; van Etten, RJ, 1998) |
| "In patients with active or a recent history of duodenal ulcer, a 14-day course of lansoprazole-based triple therapy without additional acid suppression therapy is highly effective in the eradication of H." | 5.08 | Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. ( Freston, J; Haber, M; Krause, R; Rose, P; Sahba, B; Schwartz, H; Siepman, N; Weissfeld, A, 1998) |
| "Rabeprazole, a new proton pump inhibitor, was studied in patients with acid-peptic-related diseases (duodenal ulcer, gastric ulcer, GERD) in three placebo-controlled, double-blind, randomized clinical trials." | 5.08 | Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. ( Bassion, S; Cloud, ML; Enas, N; Humphries, TJ, 1998) |
| "In order to explore the optimal regimens for the eradication of Helicobacter pylori (Hp), eighty-eight patients with duodenal ulcer (DU) or non-ulcer dyspepsia and Hp infection, defined by culture and histology, received the one-week triple therapy with clarithromycin (Cla), furazolidone (Fur) plus lansoprazole (Lan) or colloidal bismuth subcitrate (CBS)." | 5.08 | [Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection]. ( Liu, W; Lü, B; Xiao, S, 1996) |
| " Patients with duodenal ulcer were treated with lansoprazole alone (n = 11) or lansoprazole and amoxycillin (n = 12)." | 5.08 | Amount of Helicobacter pylori in gastric mucus during anti-H. pylori treatment. ( Arai, H; Furuta, T; Futami, H; Hanai, H; Kaneko, E; Takashima, M, 1998) |
| "The aim of the present study was to evaluate the efficacy of omeprazole coupled with amoxicillin in the eradication of Helicobacter pylori and healing and prevention of gastric ulcer recurrence." | 5.08 | Helicobacter pylori eradication in the healing and recurrence of benign gastric ulcer: a two-year, double-blind, placebo controlled study. ( Bargiggia, S; Bianchi Porro, G; Cesana, B; Fiocca, R; Franceschi, M; Lazzaroni, M; Maconi, G; Perego, M; Solcia, E, 1997) |
| " pylori infection and duodenal ulcer bleeding were treated with omeprazole (40 mg/day for 4 wk), colloidal bismuth (480 mg/day for 2 wk), amoxicillin (2 g/day for 1 wk), and metronidazole (750 mg/day for 1 wk), and followed up for 48 months." | 5.08 | Eradication of Helicobacter pylori reduces the rate of duodenal ulcer rebleeding: a long-term follow-up study. ( Macri, G; Milani, S; Passaleva, MT; Salvadori, G; Surrenti, C; Surrenti, E, 1998) |
| " pylori-positive patients with active duodenal ulcer or gastritis, with confirmed history of duodenal ulcer, were randomized to treatment with ranitidine bismuth citrate 400 mg b." | 5.08 | Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. ( Crobach, LF; Geraedts, AA; Kolkman, JJ; Nicolai, JJ; Oudkerk Pool, M; Tan, TG; Timmerman, RJ; Van Der Laan, J; Van Kleef, WA; Wolff, AA, 1997) |
| " Omeprazole was significantly superior to sucralfate in inducing gastric ulcer healing after both 4 (87 vs." | 5.08 | Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. ( Bianchi Porro, G; Lazzaroni, M; Manzionna, G; Petrillo, M, 1998) |
| "elucidate the mechanisms that lead to severe hypergastrinaemia during long-term omeprazole therapy for gastro-oesophageal reflux disease (GERD)." | 5.08 | Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. ( Biemond, I; Bloemena, E; Festen, HP; Jansen, EH; Klinkenberg-Knol, EC; Kuipers, EJ; Lamers, CB; Meuwissen, SG; Nelis, GF; Schenk, BE, 1998) |
| " pylori-infected duodenal ulcer patients we investigated the gastritis parameters in antral and corpus mucosa before treatment, after 6 and 12 months of therapy, and 6 months after termination of treatment with 15 mg lansoprazole or 150 mg ranitidine/day." | 5.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. ( Kiel, G; Meining, A; Stolte, M, 1998) |
| " pylori-associated gastritis, received seven days of lansoprazole, bismuth, tetracycline and metronidazole after three days of lansoprazole pretreatment." | 5.08 | Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection. ( Bolin, TD; Engelman, JL; Korman, MG; Nicholson, FB, 1998) |
| "Ninety patients with active duodenal ulcer disease and H pylori infection, proven with the 13C-urea breath test and CLO test (Campylobacter-like organism test) were treated randomly in three therapeutic groups: Group A, DeNol 120 mg, amoxicillin 500 mg and metronidazole 250 mg four times a day orally for 14 days; Group B, omeprazole 20 mg plus clarithromycin 500 mg twice a day and amoxicillin 500 mg four times a day for 14 days; Group C, omeprazole 20 mg, clarithromycin 250 mg and metronidazole 500 mg twice a day for seven days." | 5.08 | New one-week, low-dose triple therapy for the treatment of duodenal ulcer with Helicobacter pylori infection. ( Ho, AS; Hsu, CT; Huang, WH; Lee, MM; Lee, SC; Shyu, RY, 1998) |
| " pylori-positive gastric ulcer patients were assigned at random to two groups; in addition to dual therapy (amoxicillin 500 mg thrice daily and lansoprazole 30 mg every morning for two weeks), one group received rebamipide 100 mg thrice daily for eight weeks, while the other group received teprenone 50 mg thrice daily for eight weeks." | 5.08 | Effects of rebamipide in combination with lansoprazole and amoxicillin on Helicobacter pylori-infected gastric ulcer patients. ( Asaka, M; Hokari, K; Kagaya, H; Katagiri, M; Kato, M; Kudo, M; Nishikawa, K; Sato, F; Sugiyama, T; Sukegawa, M; Takeda, H, 1998) |
| "Rabeprazole is a new fast acting proton pump inhibitor that has recently been proven to be effective in the treatment of peptic ulceration and reflux esophagitis." | 5.08 | Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. ( Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998) |
| " pylori-infected patients with one or more duodenal ulcer(s) at endoscopy (studies 1, 2) or with a documented duodenal ulcer history and no duodenal ulcer or erosions at endoscopy (study 3) were randomly assigned to 10-day courses of omeprazole 20 mg b." | 5.08 | Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. ( Connors, A; Frantz, J; Laine, L; Neil, G; Suchower, L, 1998) |
| "Patients (n = 1262) with a clinical diagnosis of functional dyspepsia (persistent or recurrent epigastric pain or discomfort for at least 1 month and a normal upper gastrointestinal endoscopy) were randomized to receive omeprazole 20 mg, 10 mg or identical placebo, for 4 weeks." | 5.08 | Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). ( Duckworth, M; Kordecki, H; Meineche-Schmidt, V; Pap, A; Paré, P; Räisänen, P; Schmid, V; Talley, NJ, 1998) |
| "Sixty patients with active duodenal ulcers who tested positive for the rapid urease test had a C-14 UBT at 0 weeks (at enrollment) and at 6 and 12 weeks using 5 microCi (185 KBq) of C-14 urea." | 5.08 | Can the C-14 urea breath test replace follow-up endoscopic biopsies in patients treated for Helicobacter pylori infection? ( Ahuja, V; Bal, CS; Sharma, MP, 1998) |
| "We performed a randomized, placebo-controlled trial comparing the efficacy of treatment for two weeks with 20 mg of omeprazole orally twice daily, 500 mg of amoxicillin three times daily (with 500 mg of tetracycline three times daily substituted for amoxicillin in patients allergic to penicillin), and 400 mg of metronidazole three times daily (160 patients) with that of omeprazole alone (158 patients) for resolving symptoms of dyspepsia in patients with H." | 5.08 | Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. ( Dickson, A; El-Nujumi, A; El-Omar, E; Hilditch, T; Kelman, A; Knill-Jones, R; McColl, K; Murray, L; Penny, C; Wirz, A, 1998) |
| "To assess the effects of the mucoprotective drug sofalcone, which has direct and indirect effects on Helicobacter pylori in vitro, the eradication rate, adverse effects, and the quality of healing peptic ulcers were evaluated." | 5.08 | Preliminary study on a novel quadruple eradication therapy with a mucoprotective drug, sofalcone, for Helicobacter pylori infection. ( Arakawa, T; Kamisawa, T; Kato, H; Kozawa, H; Momma, K; Sakaki, N; Yamada, Y, 1998) |
| "Thirteen patients with esophagitis were given omeprazole for 90 days." | 5.08 | Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients. ( Arnestad, JS; Brenna, E; Qvigstad, G; Waldum, HL, 1998) |
| "Two 4-week triple-therapy treatment regimens, metronidazole+tetracycline+bismuth subcitrate and omeprazole+amoxycillin+bismuth subcitrate, were compared in a randomly allocated double-blind trial for their efficacy in eradicating Helicobacter pylori from the gastric mucosa of patients with gastritis and/or peptic ulcer disease." | 5.07 | Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease. ( Hahm, JS; Kim, HJ; Park, KN, 1994) |
| " pylori-positive gastroduodenal ulcer bleeding, which could be commenced intravenously after endoscopic diagnosis, and to assess the effect of omeprazole pretreatment on bacterial eradication." | 5.07 | Intravenous omeprazole/amoxicillin and omeprazole pretreatment in Helicobacter pylori-positive acute peptide ulcer bleeding. A pilot study. ( Adamek, RJ; Freitag, M; Opferkuch, W; Rühl, GH; Wegener, M, 1994) |
| " In study II 22 duodenal ulcer patients were given bismuth subnitrate, oxytetracycline, and metronidazole (triple therapy) for 2 weeks to eradicate H." | 5.07 | Effects of omeprazole and eradication of Helicobacter pylori on gastric and duodenal mucosal enzyme activities and DNA in duodenal ulcer patients. ( Aase, S; Andersen, KJ; Mowinckel, P; Schrumpf, E; Vetvik, K, 1994) |
| " pylori infection and gastritis were treated with one of the following four regimens: omeprazole 40 mg/day for one week (group A, n = 14); omeprazole 40 mg/day for one week followed by clarithromycin 1 g/day for 2 weeks (group B, n = 26); omeprazole 40 mg/day for one week followed by tripotassium dicitrato bismuthate 480 mg/day and clarithromycin 1 g/day, both for two weeks (group C, n = 26); and tripotassium dicitrato bismuthate 480 mg/day and clarithromycin 1 g/day for two weeks (group D, n = 22)." | 5.07 | Omeprazole, bismuth and clarithromycin in the sequential treatment of Helicobacter pylori infection. ( Cuccurullo, F; Di Iorio, P; Laterza, F; Mezzetti, A; Neri, M; Seccia, G; Susi, D, 1994) |
| "The goals of this study were to assess the effectiveness of a new triple therapy consisting of amoxicillin and metronidazole with plaunotol in the eradication of Helicobacter pylori infection in humans, and to determine whether this treatment regimen reduces the rate of recurrence of gastric ulcer in patients infected with H." | 5.07 | Bismuth-free triple therapy for eradicating Helicobacter pylori and reducing the gastric ulcer recurrence rate. ( Karita, M; Morshed, MG; Okita, K; Ouchi, K, 1994) |
| "The purpose of the present study was to investigate the Helicobacter pylori eradication potency of combined amoxicillin-omeprazole treatment in patients with duodenal ulcer disease and to compare the efficacy of two omeprazole and amoxicillin doses concerning H." | 5.07 | Medium- and high-dose omeprazole plus amoxicillin for eradication of Helicobacter pylori in duodenal ulcer disease. ( Bertrams, J; Börsch, G; Labenz, J; Rühl, GH, 1994) |
| "To compare the efficacy of two omeprazole/amoxicillin regimens concerning Helicobacter pylori eradication, ulcer healing, pain relief, and safety in patients with gastric ulcer disease." | 5.07 | Medium- or high-dose omeprazole plus amoxicillin eradicates Helicobacter pylori in gastric ulcer disease. ( Bertrams, J; Börsch, G; Labenz, J; Rühl, GH, 1994) |
| "Thirty-five consecutive patients (median age: 50 years, 17 men and 18 women) suffering from Helicobacter pylori associated peptic ulcer disease (duodenal ulcer: n = 15, gastric ulcer: n = 13) or severe functional dyspepsia (n = 7) were enrolled in a two-center clinical trial and treated with omeprazole 20 mg bid preprandially and roxithromycin 300 mg bid postprandially over two weeks." | 5.07 | [Omeprazole modified antibiotic therapy of Helicobacter pylori infection: can clarithromycin be replaced by roxithromycin?]. ( Adamek, RJ; Börsch, G; Labenz, J; Opferkuch, W; Rühl, GH; Wegener, M, 1994) |
| "Sixty patients with symptomatic duodenal ulcer were randomized to receive either omeprazole (20 mg each morning) or famotidine (40 mg at night time) for 2-4 weeks in a double-blind parallel group clinical trial." | 5.07 | Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. ( Dasarathy, S; Misra, SC; Sharma, MP, 1993) |
| " pylori-positive gastroduodenal ulcer disease were treated with a 14-day course of 20 mg omeprazole bid orally, combined with either 1 g amoxicillin tid intravenously (n = 15) or 500 mg amoxicillin six times daily orally (n = 16)." | 5.07 | Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy. ( Adamek, RJ; Freitag, M; Labenz, J; Opferkuch, W; Rühl, GH; Wegener, M, 1994) |
| " pylori-positive duodenal ulcers were randomized to receive either triple therapy for 1 wk plus omeprazole for 4 wk (Triple+OMP) (n = 78), or omeprazole alone (OMP) for 4 wk (N = 77)." | 5.07 | One-year follow-up of duodenal ulcers after 1-wk triple therapy for Helicobacter pylori. ( Cheng, AF; Chung, SC; Hosking, SW; Li, AK; Ling, TK; Sung, JJ; Yung, MY, 1994) |
| "A one week regimen of bismuth, tetracycline, and metronidazole is safe and effective in eradicating H pylori and reduces the number of duodenal ulcers four weeks after completing treatment." | 5.07 | Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. ( Cheng, A; Chung, SC; Hosking, SW; Leung, JW; Li, AK; Ling, TK; Yung, MY, 1992) |
| "In a controlled, prospective, randomized trial, 10 patients with Helicobacter pylori positive gastritis were treated either with triple therapy (tetracycline, ornidazole, bismuth subcitrate; T, Or, CBS), or omeprazole/CBS (O/CBS) to test the eradication rate of each treatment, its effect on gastritis and meal stimulated gastrin release." | 5.07 | [Comparison of the efficacy of omeprazole/bismuth subcitrate or triple therapy in Helicobacter pylori gastritis. A prospective controlled study]. ( Bertschinger, P; Brunner, J; Flury, R; Häcki, WH; Jost, R; Lammer, F, 1992) |
| "In an open study, 62 patients with Helicobacter pylori-associated ulcer disease or functional dyspepsia were treated for two weeks with 2 x 20 mg omeprazole preprandially and 4 x 500 mg amoxicillin suspension one hour before meals and at night." | 5.07 | Two weeks treatment with amoxicillin/omeprazole for eradication of Helicobacter pylori. ( Börsch, G; Gyenes, E; Labenz, J; Rühl, GH, 1992) |
| "Forty-three patients with active duodenal ulcer and Helicobacter pylori positivity in gastric antrum were randomly assigned to either omeprazole treatment (20 mg once a day) or ranitidine treatment (300 mg once a day) for 28 days." | 5.07 | Omeprazole vs. ranitidine in short-term treatment of Helicobacter pylori positive duodenal ulcer patients. ( Ayoubi Khajekini, M; Blasi, A; Brogna, A; Catalano, F; Inserra, G; Mangiameli, A; Monello, S; Rizzo, G; Sofia, M, 1991) |
| " pylori-associated gastritis were allocated to one of the following four therapeutic schedules: 1) omeprazole 40 mg/d for 4 weeks (n = 13); 2) bismuth subsalicylate (BSS) 3 x 600 mg for 4 weeks (n = 12); 3) omeprazole plus BSS for 4 weeks (n = 13); 4) triple therapy (BSS for 4 weeks, amoxicillin 3 x 750 mg and metronidazole 3 x 400 mg for 10 days) (n = 12)." | 5.07 | The role of omeprazole (40 mg) in the treatment of gastric Helicobacter pylori infection. ( Bär, W; Gebel, M; Haruma, K; Lange, P; Müller, MJ; Schorn, T; Soudah, B; Varrentrapp, M; Wagner, S, 1991) |
| "This study set out to investigate the effects of omeprazole or ranitidine on the progression of antral gastritis and Helicobacter pylori in patients with active duodenal ulcer." | 5.07 | Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori. ( Branicki, FJ; Ho, J; Hui, WM; Lai, CL; Lam, SK; Lau, WY; Lok, AS; Ng, MM, 1991) |
| " This meta-analysis sought to assess the clinical and safety profiles of esomeprazole versus omeprazole at pharmacologically equivalent doses in healing gastroesophageal reflux disease (GERD), peptic ulcer disease and eradicating Helicobacter pylori (H." | 4.91 | Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection. ( Dan, YY; Khoo, AL; Lim, BP; Lin, L; Teng, M; Wu, TS; Zhao, YJ, 2015) |
| "Esomeprazole (Nexium); S-omeprazole) is a single optical isomer proton-pump inhibitor (PPI) approved for the management of reflux oesophagitis, the symptomatic treatment of gastro-oesophageal reflux disease (GORD), the prevention and healing of NSAID-associated gastric ulcer disease (and the prevention of NSAID-associated duodenal ulcers in the UK), the treatment of Helicobacter pylori infection and associated duodenal ulcer disease (and prevention of relapse of H." | 4.84 | Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults. ( Blick, SK; Croxtall, JD; Keating, GM; Lyseng-Williamson, KA; McKeage, K, 2008) |
| " pylori infection, a new one-week triple therapy regimen (lansoprazole or omeprazole + amoxicillin + clarithromycin) has been approved for use in patients with peptic ulcer disease in Japan." | 4.82 | Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease. ( Hoshino, Y; Ishii, H; Kurabayashi, K; Masaoka, T; Minegishi, Y; Nomura, S; Suzuki, H; Suzuki, M, 2003) |
| " Pharmacodynamic results have also suggested that rabeprazole may be better suited than omeprazole as on-demand therapy for symptomatic gastro-oesophageal reflux disease." | 4.82 | Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole. ( Horn, J, 2004) |
| "This article presents considerations currently under discussion about the probability of HP participation in the ulcer causation as well as information about Rabeprazole efficiency for anti-helicobacter therapy of non-complicated duodenal ulcer (as a result of 7-day anti-helicobacter therapy, the healing of duodenal bulbs was recorded in 82." | 4.82 | [Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)]. ( Vasil'ev, IuB, 2004) |
| "To compare the safety and efficacy of pantoprazole, placebo and the H2 antagonist nizatidine in relieving symptoms in patients with erosive oesophagitis." | 4.82 | Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004) |
| "An 11-year-old boy with Helicobacter pylori-associated duodenal ulcer was successfully treated with a combination of lansoprazole, amoxicillin, and clarithromycin." | 4.82 | Helicobacter heilmannii infection in a child after successful eradication of Helicobacter pylori: case report and review of literature. ( Iinuma, K; Kato, S; Minoura, T; Ohyauchi, M; Ozawa, K; Sekine, H; Shimosegawa, T, 2005) |
| "Two recently reported studies of nonsteroidal anti-inflammatory drugs (NSAIDs), the Omeprazole versus Misoprostol for NSAID-induced Ulcer Management and the Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment studies, concluded that omeprazole was superior to a subtherapeutic misoprostol or an ineffective dose of ranitidine for the endpoint, prevention of gastroduodenal ulcers in chronic NSAID users." | 4.81 | Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs. ( Graham, DY, 2001) |
| "In uncontrolled clinical trials and case reports to date, omeprazole has been effective and well tolerated for the acute and chronic treatment of esophageal and peptic ulcer disease in children, particularly those who had failed to respond to previous treatment with histamine2-receptor antagonists." | 4.81 | A review of omeprazole use in the treatment of acid-related disorders in children. ( Katona, BG; Levine, D; Souney, PE; Walters, JK; Zimmermann, AE, 2001) |
| " pylori infection, indomethacin and their combination affects the healing of gastric ulcers and whether or not such factors provoke a relapse of healed acetic acid ulcers; and 2) whether or not eradication of the bacteria with drugs at specified times after infection prevents the development of mucosal changes, including gastric adenocarcinoma." | 4.81 | [Pharmacological study on the pathological changes of the gastric mucosa in Helicobacter pylori-infected Mongolian gerbils]. ( Ebata, M; Keto, Y; Okabe, S, 2001) |
| " In 8-week studies, among patients with gastro-oesophageal reflux disease (GORD), rabeprazole 20 mg/day or 10mg twice daily was as effective as omeprazole and superior to ranitidine in the healing of GORD." | 4.81 | Rabeprazole: an update of its use in acid-related disorders. ( Carswell, CI; Goa, KL, 2001) |
| " A daily dose of 30 mg lansoprazole reduced epigastric pain faster than omeprazole 20 mg daily in patients with peptic ulcer disease but healing rates at 4 and 8 weeks were similar with both agents at these dosages." | 4.81 | Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses. ( Gremse, DA, 2001) |
| "This meta-analysis reviewed all randomized, controlled clinical trials published as full text articles in English between 1993 and 1996 that reported the efficacy of lansoprazole treatment as monotherapy or in combination with antibiotics in the treatment of peptic ulcer and in eradicating H." | 4.80 | Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis. ( Bazzoli, F; Berretti, D; De Luca, L; Fossi, S; Nicolini, G; Pozzato, P; Ricciardiello, L; Zagari, M, 1998) |
| "A 53-year old female patient with duodenal ulcer and Helicobacter pylori infection was treated three times with a proton pump inhibitor-based triple therapy, such as lansoprazole-clarithromycin-amoxicillin (INN, amoxicilline) and lansoprazole-minocycline-cefaclor." | 4.80 | Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. ( Furuta, T; Hanai, H; Ishizaki, T; Ohashi, K; Shirai, N; Takashima, M; Xiao, F, 2000) |
| " In the treatment of gastric ulcer, analysis of all studies that have compared lansoprazole, a newly developed proton pump inhibitor, and H2-receptor antagonists has shown a statistically significant difference for a higher healing rate with lansoprazole." | 4.78 | Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer. ( Florent, C, 1993) |
| " In triple therapy, two studies used the same regimen in nonulcer dyspepsia patients: lansoprazole 30 mg/day for 2 weeks, amoxicillin 2 g/day for 2 weeks, and tinidazole 1 g/day for 2 weeks." | 4.78 | Effect of lansoprazole on Helicobacter pylori. ( Lamouliatte, H, 1993) |
| "To observe the effect of lansoprazole and omeprazole combined with antibiotics on gastric juice pH and inflammatory factors in elderly patients with Hp positive gastric ulcer." | 4.31 | Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer. ( Chen, B; Gao, N; Yan, S, 2023) |
| "In this prospective open-label comparative observational study, gastroesophageal reflux disease (GERD) patients were evaluated using 24-h dual-channel pH-impedance monitoring while on dexlansoprazole (60 mg, n = 39) and omeprazole (20 mg, n = 41) to study the degree of gastric acid suppression, esophageal acid exposure, and NAB (primary outcome measures)." | 4.12 | Nocturnal acid breakthrough and esophageal acidification during treatment with dexlansoprazole as compared to omeprazole in patients with gastroesophageal reflux disease. ( Blaachandran, A; Ghoshal, UC; Misra, A; Rai, S, 2022) |
| "To investigate the effect of Anwei Qingyou formula on the clinical treatment of patients with peptic ulcer (PU) and its effect on the levels of epidermal growth factor (EGF) and prostaglandin E2 (PGE2)." | 4.12 | Clinical effect of Anwei Qingyou recipe on peptic ulcer and its effect on the levels of EGF and PGE2: A retrospective study. ( Bai, G; Du, H; Yi, J; Yu, Y, 2022) |
| "One of the most likely causes of the lack of effectiveness of eradication therapy of peptic ulcer associated with Helicobacter pylori, is a feature of omeprazole metabolism by cytochrome CYP2C19." | 3.81 | [THE EFFECTIVENESS OF ERADICATION IN PATIENTS WITH PEPTIC ULCER DISEASE ASSOCIATED WITH HELICOBACTER PYLORI, DEPENDING ON THE GENOTYPE OF THE DRUGMETABOLISM OF PROTON PUMP INHIBITORS]. ( Elokhina, EV; Kostenko, MB; Livzan, MA; Scalskiy, SV, 2015) |
| "Both omeprazole and its S enantiomer (esomeprazole) have been available and used to treat symptoms of gastroesophageal reflux disease (GERD) and conditions associated with excessive stomach acid secretion for more than a decade." | 3.81 | Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch. ( Asghar, W; Jamali, F; Pittman, E, 2015) |
| "Two drugs commonly used in triple-drug therapy for treatment of a Helicobacter pylori infection, clarithromycin and omeprazole, have rarely been associated with hypoglycemia when given alone." | 3.79 | Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction. ( Otsuka, SH, 2013) |
| " pylori culture positive dyspeptic patients (64 patients with peptic ulcer, PU) completed a 2-week treatment with omeprazole, amoxicillin and metronidazole and underwent endoscopy again 6-8 weeks after the end of therapy." | 3.78 | Factors modulating the outcome of treatment for the eradication of Helicobacter pylori infection. ( Figura, N; Giordano, N; Langone, F; Moretti, E; Vaglio, L; Vernillo, R; Vindigni, C, 2012) |
| "A case of a 13 year old girl who manifested hyperprolactinaemia and galactorrhea induced by Omeprazole, a commonly used proton pump inhibitor is presented." | 3.76 | Hyperprolactinaemia induced by proton pump inhibitor. ( Farrukh, SN; Jabbar, A; Khan, R, 2010) |
| "Patients with peptic ulcer who failed with first-line triple eradication therapy containing clarithromycin received quadruple therapy with omeprazole (20 mg, twice daily), amoxicillin (750 mg, twice daily), metronidazole (500 mg, twice daily) and ecabet sodium (1000 mg, twice daily) for 14 days." | 3.76 | Quadruple therapy with ecabet sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of Helicobacter pylori after failure of first-line therapy (KDOG0201 Study). ( Ae, T; Azuma, M; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Nakatani, K; Nakayama, N; Nishimura, K; Saigenji, K; Sasaki, T; Tanabe, S, 2010) |
| "The authors made an attempt to find a new approach to Helicobacter pylori (HP) eradication in patients with chronic gastritis and peptic ulcer without application of antibiotics, but using melatonin properties instead." | 3.74 | [Antihelicobacter effects of melatonin]. ( Malinovskaia, NK; Parkhomenko, IE; Postnikova, LI; Rapoport, SI; Rybnikova, SN; Zhernakova, NI, 2007) |
| "Gastric ulcer patients (n=88) were assigned either to the group receiving Helicobacter pylori eradication treatment (54 patients) or to the control group (34 patients; omeprazole treatment for 4 weeks) and were followed up for 1-year or until gastric ulcer relapsed." | 3.74 | Gastroesophageal reflux disease after Helicobacter pylori eradication in gastric ulcer patients: a one-year follow-up study. ( Jonaitis, L; Kiudelis, G; Kupcinskas, L, 2008) |
| "This is our final report on the clinical effectiveness and safety of long-term pantoprazole in patients with severe peptic ulcer or reflux disease during continuous treatment for up to 5 years." | 3.73 | Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment. ( Bardhan, KD; Bishop, AE; Luehmann, R; McCaldin, B; Morris, P; Polak, JM; Romanska, HM; Rowland, A; Schaefer-Preuss, S; Thompson, M, 2005) |
| "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease." | 3.73 | Lansoprazole-associated collagenous colitis: a case report. ( Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M, 2005) |
| "Helicobacter pylori eradication was recommended for the prevention of atrophic gastritis in gastroesophageal reflux disease (GERD) patients on long-term omeprazole treatment." | 3.73 | Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients. ( Celikel, CA; Giral, A; Kalayci, C; Ozdogan, O; Tözün, N; Ulusoy, NB, 2005) |
| "To confirm the immediate-type mechanism of recurrent anaphylactic reactions to the repeated administration of omeprazole using skin testing and to enable safe administration of the drug after successful oral desensitization." | 3.73 | Anaphylaxis to omeprazole: diagnosis and desensitization protocol. ( Confino-Cohen, R; Goldberg, A, 2006) |
| " Patients with a history of peptic ulcers were randomized to 1-week omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg twice daily (eradication group; n = 51) or 1-week omeprazole 20 mg twice daily (omeprazole group; n = 49) before initiation of diclofenac 100 mg daily for 6 months." | 3.73 | Helicobacter pylori eradication prior to initiation of long-term non-steroidal anti-inflammatory drug therapy in Chinese patients-a cost-effectiveness analysis. ( Chan, FK; Ching, JY; Lau, W; Lee, IY; Lee, KK; You, JH; Yung, M, 2006) |
| "46 patients having exacerbation of duodenal ulcer in the presence of Helicobacter pylori (HP) were studied for efficacy of HP eradication treatment which comprised omeprazole (40 mg/day), colloid bismuth subcitrate (480 mg/day) and metronidazole (1000 mg/day) for 2 weeks." | 3.72 | [Effectiveness of eradication anti-helicobacter therapy in patients with duodenal ulcer in different drug dosage regimens]. ( Nurbaev, FE; Orziev, ZM; Rakhimova, GSh, 2003) |
| " pylori infection who had gastritis, duodenal ulcer (DU) or gastric ulcer (GU) received 1 week's triple therapy of lansoprazole 30 g once daily (OD), amoxycillin 250 mg qid and clarithromycin 250 mg tid." | 3.72 | Low dose, one-week triple therapy (lanzoprazole, amoxycillin, clarithromycin) for eradication of Helicobacter pylori infection. ( Uthaisaengsook, W, 2003) |
| " pylori infected patients with gastric ulcer and duodenal ulcer completed the triple therapy with 10 mg of rabeprazole b." | 3.72 | Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype. ( Bae, JS; Jung, HS; Kim, HJ; Lee, JK; Lee, SB; Park, SJ; Park, SM; Ryu, JK, 2003) |
| "Six captive cheetahs (Acinonyx jubatus) with severe gastritis diagnosed by gastric endoscopy and mucosal histopathology were treated with omeprazole, metronidazole, and amoxicillin for 3 wk." | 3.72 | Treatment with omeprazole, metronidazole, and amoxicillin in captive South African cheetahs (Acinonyx jubatus) with spiral bacteria infection and gastritis. ( Burroughs, R; Lane, E; Lobetti, R, 2004) |
| " H pylori infection does not affect duodenal ulcer healing and enhances gastric ulcer healing by ranitidine and possibly other acid suppressing treatments." | 3.71 | Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. ( Hawkey, CJ; Långström, G; Naesdal, J; Swannell, AJ; Wilson, I; Yeomans, ND, 2002) |
| ", omeprazole, misoprostol, and high-dose famotidine) in the prevention of NSAID-induced gastroduodenal ulcers will also be effective in this setting." | 3.71 | Current approaches to reducing gastrointestinal toxicity of low-dose aspirin. ( Lanas, AI, 2001) |
| " Nineteen Helicobacter pylori-positive nonduodenal ulcer subjects, 15 omeprazole chronically treated subjects, and 19 duodenal ulcer patients were studied against 19 controls." | 3.71 | Impairment of gastric secretion modulation in duodenal ulcer and in long-term PPI treatment: quantitative morphologic findings and pathophysiologic implications. ( Amorosi, A; Bacci, S; Bechi, P; Cianchi, F; Dei, R; Nesi, G; Romagnoli, P, 2001) |
| " Therefore, we investigated how the chronic gastritis in mice made hypochlorhydric by either gastrin deficiency or omeprazole treatment modulates epithelial cell function." | 3.71 | Genetic or chemical hypochlorhydria is associated with inflammation that modulates parietal and G-cell populations in mice. ( Ferguson, A; Merchant, JL; Rieder, G; Samuelson, LC; Zavros, Y, 2002) |
| " pylori infection, indomethacin, and their combination affects the healing of gastric ulcers and whether or not such factors provoke a relapse of healed gastric ulcers in Mongolian gerbils." | 3.71 | Influence of Helicobacter pylori infection on healing and relapse of acetic acid ulcers in Mongolian gerbils. ( Ebata, M; Keto, Y; Okabe, S; Tomita, K, 2002) |
| " pylori infection in active peptic ulcer in Korea (30 mg of lansoprazole, 250 mg of clarithromycin, and 400 mg of metronidazole, all twice daily)." | 3.70 | One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. ( El-Zimaity, HM; Graham, DY; Kim, JG; Osato, MS; Perng, CL, 1998) |
| "Thirty-eight clinical strains of Helicobacter pylori were isolated from patients with chronic gastritis and gastroduodenal ulceration, and their susceptibility to macrolide antibiotics (roxithromycin, flurithromycin, azithromycin, erythromycin) in combination with proton-pump inhibitors (lansoprazole and omeprazole) and bismuth subcitrate was assayed." | 3.70 | Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study. ( Campa, M; Favini, P; Malizia, T; Marchetti, F; Pizzarelli, G; Senesi, S; Tejada, M, 1998) |
| "Gastric juice pH, ammonia concentration in gastric juice, serum gastrin level, and grade of gastritis in accordance with the Sydney System were determined for patients with gastric ulcer (GU) and duodenal ulcer (DU) before and after treatment with lansoprazole and amoxicillin, and results were compared with those of H." | 3.70 | Effect of Helicobacter pylori infection on gastric juice pH. ( Arai, H; Baba, S; Furuta, T; Futami, H; Hanai, H; Kajimura, M; Kaneko, E; Takashima, M, 1998) |
| "We isolated strains of Helicobacter pylori from gastric mucosa of patients with peptic ulcer before and after eradication therapy, and studied their sensitivity to amoxicillin (AMPC) and clarythromycin (CAM)." | 3.70 | [Sensitivity of Helicobacter pylori to amoxicillin and clarythromycin with special reference to eradication therapy]. ( Honda, T; Matsumoto, T; Mori, K; Nagatomi, Y; Takaba, M; Tsuneoka, H, 1998) |
| " pylori strain (34 duodenal ulcer and 37 nonulcer dyspepsia) received omeprazole 40 mg o." | 3.70 | Weekend therapy for the treatment of Helicobacter pylori infection. ( Agosti, R; Bocus, P; Caletti, G; Grigioni, WF; Mazzoni, C; Orcioni, GF; Paparo, GF; Poli, L; Sottili, S; Togliani, T; Tucci, A, 1998) |
| "We describe a 54-year-old man with Helicobacter pylori (+) duodenal ulcer who developed Clostridium difficile associated colitis, 5 days after commencing a 'triple' regimen consisting of omeprazole 20 mg b." | 3.70 | Clostridium difficile colitis associated with a 'triple' regimen, containing clarithromycin and metronidazole, to eradicate Helicobacter pylori. ( Archimandritis, A; Katsorida, M; Souyioultzis, S; Tzivras, M, 1998) |
| "To investigate whether CYP2C19 genotype status is associated with cure rates for Helicobacterpylori infection and peptic ulcer achieved by using dual therapy with omeprazole and amoxicillin." | 3.70 | Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. ( Furuta, T; Hanai, H; Ishizaki, T; Kamata, T; Kaneko, E; Kawasaki, T; Kosuge, K; Kubota, T; Ohashi, K; Takashima, M, 1998) |
| " pylori status of patients with gastroesophageal reflux disease (GERD) affects the severity of disease and the efficacy of omeprazole therapy to maintain disease remission, we conducted this study." | 3.70 | Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. ( Eskes, SA; Klinkenberg-Knol, EC; Kuipers, EJ; Meuwissen, SG; Schenk, BE, 1999) |
| "A prospective trial was designed to study the effectiveness of the 1-week combination of lansoprazole, clarithromycin and amoxycillin in 102 consecutive patients with active peptic ulcer." | 3.70 | Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. ( Ducóns, JA; Ferrero, M; Gomollón, F; Guirao, R; Montoro, M; Santolaria, S, 1999) |
| " Treatment for gastric ulcer with proton pump inhibitor (omeprazole) and aluminium hydroxide gel improved her eruptions and her pruritus resolved." | 3.70 | A case of prurigo and lichenified plaques successfully treated with proton pump inhibitor. ( Ohtsuka, T; Yamakage, A; Yamazaki, S, 1999) |
| "One hundred eight patients with cultured H pylori-positive gastritis or peptic ulcer were treated with three regimens: quadruple treatment without proton pump inhibitors (n = 25), dual treatment with omeprazole and amoxicillin (INN, amoxicilline) (n = 26), and triple treatment with omeprazole, amoxicillin, and clarithromycin (n = 57)." | 3.70 | CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. ( Aoyama, N; Kasuga, M; Kita, T; Komada, F; Okumura, K; Shirakawa, K; Tanigawara, Y, 1999) |
| " pylori-infected patients with duodenal ulcer were treated with either omeprazole or famotidine plus two antibiotics for 2 wk." | 3.70 | The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country. ( Acevedo, C; Duarte, I; Figueroa, C; Fuster, F; Giancaspero, R; Hola, K; Rollan, A; Schulz, M, 2000) |
| " We report data from patients with refractory reflux esophagitis who were undergoing maintenance therapy with >/=20 mg omeprazole daily for a mean period of 6." | 3.70 | Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. ( Dent, J; Frame, MH; Havu, N; Klinkenberg-Knol, EC; Lloyd, D; Mitchell, B; Nelis, F; Prichard, P; Romàn, J; Snel, P; Walan, A, 2000) |
| " Given the histology and the fact that rapid urease test results were positive, chronic active gastritis with H." | 3.70 | Iron-deficiency anemia associated with Helicobacter pylori gastritis. ( Imai, T; Konno, M; Muraoka, S; Takahashi, M, 2000) |
| "Ulcer-healing drugs should be continued after a 2-week course of omeprazole-containing anti-Helicobacter therapy for gastric ulcers and large peptic ulcers that have bled, but can be omitted in most patients with a bleeding duodenal ulcer." | 3.70 | Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. ( Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC, 2000) |
| " pylori with omeprazole and amoxicillin, the skin changes, gastric complaints, and proteinuria disappeared." | 3.69 | Schönlein-Henoch purpura associated with gastric Helicobacter pylori infection. ( Borchard, F; Goerz, G; Megahed, M; Reinauer, H; Reinauer, S; Ruzicka, T; Susanto, F, 1995) |
| " pylori testing in patients on profound acid suppressive therapy should be performed on combined corpus and antral specimens, and 2) that omeprazole therapy leads to a strong increase in corpus gastritis, which may explain the observed development of corpus atrophy in a substantial number of patients after several years of continuous acid suppressive treatment." | 3.69 | Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. ( Bloemena, E; Hazenberg, HJ; Klinkenberg-Knol, EC; Kuipers, EJ; Lindeman, J; Meuwissen, SG; Peña, AS; Uyterlinde, AM, 1995) |
| "An antibiotic combination that includes a proton pump inhibitor such as omeprazole and an antibiotic such as clarithromycin is likely to become the new standard regimen for treatment of Helicobacter pylori gastritis because this combination is extremely effective and very well tolerated." | 3.69 | Helicobacter pylori gastritis therapy with omeprazole and clarithromycin increases serum carbamazepine levels. ( Getz, HD; Metz, DC, 1995) |
| " 33 patients with primary gastric low-grade MALT lymphoma associated with H pylori gastritis were treated with omeprazole (120 mg daily) and amoxycillin (2." | 3.69 | Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. ( Bayerdörffer, E; Eidt, S; Lehn, N; Neubauer, A; Rudolph, B; Stolte, M; Thiede, C, 1995) |
| "These findings indicate that (1) peptic esophagitis was a common cause of chronic abdominal pain in pediatric patients and (2) omeprazole was effective in the treatment of esophagitis in children and adolescents that was resistant to high-dose histamine2-receptor antagonists." | 3.69 | Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. ( Kane, R; Karjoo, M, 1995) |
| "One-week therapy with lansoprazole, amoxicillin and clarithromycin is highly effective in duodenal ulcer healing and symptom improvement." | 3.69 | Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. ( Hentschel, E; Schütze, K, 1995) |
| "To evaluate the efficiency of omeprazole (20 mg/12 h) plus amoxycillin (1 gr/12 h) in eradicating Helicobacter pylori in duodenal ulcer patients studied in four hospitals in our country." | 3.69 | [Is the omeprazole and amoxicillin combination useful in the treatment eradicating Helicobacter pylori in Spain?]. ( Boixeda, D; Ceña, G; Gisbert, JP; Martín, C; Monés, J; Mur, M; Sainz, R; Sainz, S, 1996) |
| "The efficacy of omeprazole, 20 mg once daily, in suppressing Helicobacter pylori colonization was studied in 33 patients with peptic ulcers." | 3.69 | Suppression of Helicobacter pylori colonization with omeprazole. ( Fukuda, Y, 1996) |
| " pylori infection and peptic ulcer disease or functional dyspepsia were treated with either omeprazole 20 mg b." | 3.69 | One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. ( Becker, T; Börsch, G; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B, 1996) |
| "To study a possible correlation between the urea breath test values prior to treatment and the response to Helicobacter pylori eradication therapy in patients with duodenal ulcer." | 3.69 | [Is there a correlation between the values of breath tests and the response to the treatment for the eradication of Helicobacter pylori?]. ( Bermejo, F; Boixeda, D; Gisbert, JP; Jiménez, I; Martín de Argila, C; Pérez, T, 1996) |
| " Sixty-six patients (with nonulcer dyspepsia, inactive ulcer, or active ulcer) were given lansoprazole (30 mg, h." | 3.69 | Endoscopic topical therapy for the treatment of Helicobacter pylori infection. ( Ishino, Y; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y; Yamamoto, H; Yoshida, Y, 1996) |
| "Two patients who developed gastric giardiasis after 2 weeks of treatment with omeprazole 20 mg b." | 3.69 | Proton-pump inhibition and gastric giardiasis: a causal or casual association? ( Bourgain, C; Devis, G; Fernandes, E; Reynaert, H; Smekens, L, 1995) |
| "To study the efficiency of the combination lansoprazole and amoxicillin on the eradication of Helicobacter pylori and duodenal ulcer healing." | 3.69 | [Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients]. ( Aller, R; Alvarez Baleriola, I; Bermejo, F; Boixeda, D; Gisbert, JP; Martín de Argila, C, 1996) |
| " pylori represents an important factor for the progression of fundic gastritis and the development of argyrophil cell hyperplasia during long-term treatment with lansoprazole." | 3.69 | Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. ( Arnold, R; Brunner, G; Eissele, R; Simon, B; Solcia, E, 1997) |
| "Fifty-two patients with peptic ulcer disease and antral biopsies containing Helicobacter pylori sensitive to metronidazole were given a 7-day course of treatment: omeprazole 20 mg b." | 3.69 | A one-week quadruple eradication regimen for Helicobacter pylori in routine clinical practice. ( Scott, BB; Vautier, G, 1997) |
| "We have previously shown that, in duodenal ulcer patients, pH control by omeprazole is less pronounced after cure of Helicobacter pylori infection." | 3.69 | Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. ( Blum, AL; Börsch, G; Idström, JP; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B; Verdú, E, 1997) |
| "To evaluate the efficacy of one-week therapy with omeprazole, clarithromycin and amoxycillin in eradicating Helicobacter pylori and healing duodenal ulcer." | 3.69 | [One-week treatment with omeprazole, clarithromycin and amoxicillin: high efficacy in the eradication of Helicobacter pylori and cicatrization of duodenal ulcer]. ( Abraira, V; Alvarez Baleriola, I; Boixeda, D; Ceña, G; García Plaza, A; Gisbert, JP; Martín de Argila, C; Mur, M, 1997) |
| "In patients with duodenal ulcer cure of Helicobacter pylori infection resulted in a pronounced decrease in intragastric pH during treatment with omeprazole." | 3.69 | Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer. ( Blum, AL; Börsch, G; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B; Verdú, E, 1997) |
| " and omeprazole 20 mg daily for one week, followed by 20 mg omeprazole daily for further 3 weeks) in a prospective study of 36 patients with Helicobacter pylori-associated ulcers (10 gastric ulcers, 26 duodenal ulcers)." | 3.69 | [Effectiveness of short-term triple therapy for healing Helicobacter pylori infection in ulcer disease]. ( Kobler, E; Reinhart, WH; Werth, B; Wüst, W, 1997) |
| "To study the prevalence of Helicobacter pylori infection in patients with erosive duodenitis (ED), the associated gastric histological lesions and their response to eradication therapy with omeprazole plus two antibiotics." | 3.69 | Erosive duodenitis: prevalence of Helicobacter pylori infection and response to eradication therapy with omeprazole plus two antibiotics. ( Bermejo, F; Boixeda, D; de Argila, CM; de Rafael, L; Gisbert, JP; Redondo, C, 1997) |
| "A marked increase in body gastritis was observed in H pylori infected individuals during long term treatment with the proton pump inhibitor lansoprazole." | 3.69 | Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. ( Berstad, A; Berstad, AE; Brandtzaeg, P; Hatlebakk, JG; Maartmann-Moe, H, 1997) |
| "In patients with duodenal ulcer, omeprazole plus clarithromycin (OC) has achieved Helicobacter pylori eradication rates of about 80%, compared with 50% for omeprazole plus amoxicillin (OA)." | 3.69 | Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin. ( Craig, AM; Davey, P; Malek, M; Murray, F, 1996) |
| "Omeprazole heals most duodenal ulcers after 4 weeks of treatment but relapse is common." | 3.68 | Short report: treatment of Helicobacter pylori-associated duodenal ulcer with omeprazole plus antibiotics. ( Beattie, S; Collins, R; Hamilton, H; McCarthy, CJ; O'Morain, C, 1993) |
| " Thirty-two consecutive patients (suffering from either peptic ulcer or nonulcer dyspepsia) with Helicobacter pylori infection received omeprazole (40 mg) + bismuth subcitrate (240 mg x 4) + amoxicillin suspension (2000 mg x 4) + metronidazole (500 mg x 4), for only one day." | 3.68 | One-day therapy for treatment of Helicobacter pylori infection. ( Barbara, L; Biasco, G; Corinaldesi, R; Gasperoni, S; Paparo, GF; Ricci-Maccarini, M; Stanghellini, V; Tucci, A; Varoli, O, 1993) |
| "Thirteen consecutive patients with active duodenal ulcer disease were assigned to a treatment schedule with high-dose omeprazole and amoxycillin." | 3.68 | Short report: high-dose omeprazole and amoxycillin in the treatment of Helicobacter pylori-associated duodenal ulcer. ( Beattie, S; Collins, R; O'Morain, C; Xia, HX, 1993) |
| "Thirty-six patients with nonhealing or recurrent duodenal ulcers (DU) were treated with omeprazole; 20 mg/day for one month followed by triple therapies (metronidazole, 400 mg three times a day, tetracycline, 500 mg four times a day with either colloidal bismuth, 120 mg four times a day or sucralfate 1 g four times a day." | 3.68 | Local cellular and immune response by antral mucosa in patients undergoing treatment for eradication of Helicobacter pylori. ( Jaskiewicz, K; Louw, JA; Marks, IN, 1993) |
| "Long-term omeprazole therapy in humans results in moderate hypergastrinemia and a significant argyrophil cell hyperplasia, which are correlated to the grade of corpus gastritis." | 3.68 | Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. ( Brunner, G; Creutzfeldt, W; Lamberts, R; Solcia, E; Strüber, HG, 1993) |
| "Thirty patients with active duodenal ulcer who were Helicobacter pylori positive (HP+) by HLO test and by histology (Giemsa stain) were given omeprazole (OME) 20 mg/d for a two-week period." | 3.68 | Preliminary observations in the fasting serum gastrin in patients with duodenal ulcer; further evidence of the "clearing" effect of omeprazole on H pylori? ( Alevizou, V; Archimandritis, A; Davaris, P; Fertakis, A; Kapsalas, D; Kyriaki, D; Tjivras, M, 1992) |
| "pylori positive peptic ulcer disease were treated with a two weeks regimen consisting of 20 mg omeprazole twice daily and 500 mg amoxicillin six times daily." | 3.68 | [Modified combined omeprazole/amoxicillin therapy for Helicobacter pylori eradication: a pilot study]. ( Adamek, RJ; Birkholz, S; Opferkuch, W; Ricken, D; Rühl, GH; Wegener, M, 1992) |
| "The rise in serum gastrin and pepsinogen I after 5 days' treatment with the proton pump inhibitor pantoprazole (40 mg/day) was examined in eight duodenal ulcer patients with Helicobacter pylori infection and compared with eight in whom it had been eradicated." | 3.68 | Helicobacter pylori and hypergastrinaemia during proton pump inhibitor therapy. ( Dorrian, CA; Fullarton, GM; Harwood, J; Macdonald, AM; McColl, KE; Nujumi, AM, 1992) |
| "Twenty-one patients with endoscopically confirmed duodenal ulceration, who had failed to heal with an H2-antagonist, were given omeprazole 20 mg o." | 3.68 | Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis. ( Daw, MA; Deegan, P; Leen, E; O'Moráin, C, 1991) |
| "Biopsies from the stomachs (antrum and corpus) of 201 patients with peptic ulcers or reflux oesophagitis were retrospectively investigated for the effect of treatment with omeprazole on the elimination of Helicobacter pylori (HP) and on gastritis." | 3.68 | Elimination of Helicobacter pylori under treatment with omeprazole. ( Bethke, B; Stolte, M, 1990) |
| " The inclusion of Bifiform in the eradication scheme dramatically reduces the frequency of adverse events and increases patient compliance, and also maintains the protective factors of the gastrointestinal mucosa at a higher level." | 3.01 | [A prospective randomized comparative study of the efficacy and safety of a two-week bismuth-based quadrotherapy of ( Iakovenko, AV; Ivanov, AN; Soluyanova, IP; Strokova, TV; Vasilyev, NN; Yakovenko, EP, 2021) |
| " Secondary outcomes included adverse events, dropout rate, and subgroup analysis." | 3.01 | Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis. ( Ding, YM; Han, ZX; Ji, R; Li, YY; Lin, BS; Zhang, WL, 2023) |
| "Rabeprazole (20 mg) has proved similar Helicobacter pylori eradication rates compared with omeprazole (40 mg) when co-administered with of antibiotics (amoxicillin and clarithromycin) for two weeks." | 2.94 | Comparative Study on Effect of Rabeprazole Versus Omeprazole in Acid-peptic Disorder with Helicobacter pylori Infection. ( Amatya, GL; Gurung, SB; Gyawali, P; Kc, SR, 2020) |
| " Adverse events were recorded by patients in specially developed diaries." | 2.87 | Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study. ( Andreev, DN; Dicheva, DT; Maev, IV; Partzvania-Vinogradova, EV; Samsonov, AA, 2018) |
| " Adverse events were recorded by patients in specially developed diaries." | 2.87 | Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection. ( Andreev, DN; Dicheva, DT; Maiev, IV; Partzvania-Vinogradova, EV; Yurenev, GL, 2018) |
| " About 76% of the patients experienced adverse events (35% diarrhea, 14% nausea and 24% metallic taste), none of which was serious." | 2.84 | Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. ( Donday, MG; Gisbert, JP; McNicholl, AG; Ramas, M, 2017) |
| "Dyspepsia is a common symptom with a broad differential diagnosis and complex pathophysiology which annually affect about 25% of the general population." | 2.82 | Helicobacter pylori eradication effect on patients with functional dyspepsia symptoms. ( Hemati, K; Jodaki, A; Peyman, H; Sahraie, A; Yasemi, M; Yasemi, MR, 2016) |
| "Gemifloxacin is a fluoroquinolone antibiotic with documented in vitro activity against H pylori." | 2.82 | High efficacy of gemifloxacin-containing therapy in Helicobacter Pylori eradication: A pilot empirical second-line rescue therapy. ( Ejtehadi, F; Farshad, S; Mahmoudi, L; Mahmoudi, P; Niknam, R; Seddigh, M, 2016) |
| " No serious adverse events were observed in any of the patients in either group." | 2.80 | Efficacy and safety of 1-week Helicobacter pylori eradication therapy and 7-week rebamipide treatment after endoscopic submucosal dissection of early gastric cancer in comparison with 8-week PPI standard treatment: a randomized, controlled, prospective, m ( Azuma, T; Higuchi, K; Iguchi, M; Machida, H; Morita, Y; Naito, Y; Takeuchi, T; Takeuchi, Y; Tamada, T; Tominaga, K; Uedo, N; Yagi, N; Yamao, J; Yazumi, S, 2015) |
| "To evaluate the clinical effect of proton pump inhibitor-based triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori (Hp) infection among children in terms of Hp eradication rate and incidence of adverse events." | 2.79 | [Clinical effect of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori infection in children]. ( Chen, ZY; Duan, BP; Ou-Yang, HJ; Tang, J; Xu, B; You, JY; Zhao, HM, 2014) |
| "Metronidazole resistance was observed in 16/49 (32." | 2.79 | Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. ( Delchier, JC; Malfertheiner, P; Thieroff-Ekerdt, R, 2014) |
| "Here we report 14." | 2.77 | Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. ( Blot, WJ; Brown, LM; Crystal-Mansour, S; Fraumeni, JF; Gail, MH; Han, ZX; Hu, Y; Li, JY; Liu, WD; Ma, JL; Pan, KF; Pee, D; Shen, L; You, WC; Zhang, L, 2012) |
| "The acute cerebral infarction patients with positive urease test were randomly divided into a treatment group (conventional therapy+anti-Helicobacter pylori therapy) and a control group (conventional therapy)." | 2.76 | [Effect of anti-Helicobacter pylori on the prognosis in patients with acute cerebral infarction]. ( Pan, G, 2011) |
| " No major adverse events occurred in both groups." | 2.75 | A randomized controlled trial: efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection. ( Davarpanah Jazi, AH; Fatahi, F; Minakari, M; Moghareabed, N; Shavakhi, A, 2010) |
| " There was no difference among the treatment groups with regard to the incidence and severity of adverse events reported." | 2.75 | Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study. ( Abdelfatah, M; Assem, M; El Azab, G; Rasheed, MA; Shastery, M, 2010) |
| "Gastritis was assessed according to the updated Sydney classification for activity, chronic inflammation, gastric glandular atrophy, intestinal metaplasia, and H." | 2.74 | Helicobacter pylori eradication in patients on long-term treatment with NSAIDs reduces the severity of gastritis: a randomized controlled trial. ( Bijlsma, JW; Bloemena, E; Boers, M; De Leest, HT; Dijkmans, BA; Houben, HH; Janssen, M; Kostense, PJ; Kuipers, EJ; Lems, WF; Steen, KS; Van de Laar, MA, 2009) |
| " The secondary outcome measure was the proportion of patients who experienced therapy-related adverse effects during anti-H pylori treatment." | 2.74 | Randomized, double-blind, placebo-controlled trial: effect of lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. ( Albrecht, P; Szajewska, H; Topczewska-Cabanek, A, 2009) |
| "pylori eradication on migraine symptoms in patients with hepatitis-B-virus-related cirrhosis." | 2.73 | Reversal of migraine symptoms by Helicobacter pylori eradication therapy in patients with hepatitis-B-related liver cirrhosis. ( Fan, D; Guo, W; Han, Y; Hong, L; Li, X; Wang, J; Zhao, Y, 2007) |
| "At endoscopy, gastroduodenal ulcers were diagnosed in 6 (4%) and 8 (5%) patients in the eradication and placebo group, respectively (p = ." | 2.73 | Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. ( Bijlsma, JW; Boers, M; de Leest, HT; Dijkmans, BA; Houben, HH; Huisman, AM; Kadir, SW; Kostense, PJ; Kuipers, EJ; Lems, WF; Steen, KS; van de Laar, MA; van Tulder, MW; Vonkeman, HE, 2007) |
| "Rabeprazole is a proton pump inhibitor which is particularly suitable for use in short-term Helicobacter pylori eradication treatment." | 2.72 | Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. ( Bilardi, C; Dulbecco, P; Giannini, EG; Mamone, M; Mansi, C; Santi, ML; Savarino, V; Testa, R, 2006) |
| " No significant adverse effects were reported." | 2.72 | Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication. ( Abdul-Baki, H; Aoun, E; Araj, GF; Chaar, HF; Kanj, SS; Sharara, AI, 2006) |
| "Levodopa was prescribed for groups 1 and 3." | 2.72 | Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial. ( Alizadeh, M; Arj, A; Bagheri-Lankarani, K; Bahri-Najafi, R; Dehbashi, N; Emami, MH; Esmaeili, A; Fattahi, MR; Geramizadeh, B; Kaviani, MJ; Saberfiroozi, MM; Taghavi, AR, 2006) |
| "pylori in family members of gastric cancer patients." | 2.71 | Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients. ( Bueno, ML; Castro, LP; Coelho, LG; Lopes, LG; Martins, GM; Miranda, CH; Passos, MC; Sanches, BS, 2003) |
| "Rabeprazole is a potent proton pump inhibitor that may not be affected as greatly by H." | 2.71 | Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo. ( Chilton, A; Nwokolo, CU; Pounder, RE; Sercombe, J; Usselmann, B; Williams, MP, 2003) |
| " Both drugs induced similar false-negative UBTs on day 14 of dosing (P = 0." | 2.71 | Impact of long-term ranitidine and pantoprazole on accuracy of [13C]urea breath test. ( Biagini, R; Bilardi, C; Dulbecco, P; Gambaro, C; Iiritano, E; Mansi, C; Mele, MR; Savarino, V; Tessieri, L; Usai, P; Vigneri, S; Zentilin, P, 2003) |
| "Lafutidine is a novel potent H2 receptor antagonist with gastroprotective activities such as enhancement of gastric mucosal blood flow." | 2.71 | Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori. ( Furusu, H; Inoue, K; Isomoto, H; Kohno, S; Mizuta, Y; Murase, K; Murata, I; Nishiyama, H; Omagari, K; Shikuwa, S, 2003) |
| "Furazolidone is a very good substitute for metronidazole and clarithromycin, but its many side-effects limit widespread use." | 2.71 | Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori. ( Butorab, Z; Massarrat, S; Roghani, HS; Shirekhoda, M, 2003) |
| " The absorption rate is not related to food." | 2.71 | [Therapeutic effect of gastrozolum in stomach ulcers]. ( Dolgova, NIu; Goncharenko, LS; Kuz'mina, OS; Lopatina, IN; Manannikov, IV; Melik-Ogandzhanian, NB; Serova, TI; Sukhareva, GV; Trubitsina, IE; Tsaregorodtseva, TM; Zarudnaia, SI, 2003) |
| "Rabeprazole is a new proton pump inhibitor, which has been reported to induce a faster acid suppression than other drugs of the same category." | 2.71 | Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. ( Bilardi, C; Dulbecco, P; Gambaro, C; Iiritano, E; Mansia, C; Savarino, V; Usai, P; Vigneri, S; Zentilin, P, 2003) |
| "Among the 18 new cases of gastric cancers that developed, no overall reduction was observed in participants who received H pylori eradication treatment (n = 7) compared with those who did not (n = 11) (P =." | 2.71 | Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. ( Chen, JS; Ching, CK; Feng, RE; Fong, DY; Ho, J; Hu, WH; Lai, KC; Lam, SK; Leung, SY; Wong, BC; Wong, WM; Yuen, ST; Zheng, TT, 2004) |
| "Omeprazole 20 mg daily was given for eight weeks for healing of oesophagitis and symptom relief." | 2.71 | Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. ( Chan, FK; Ching, JY; Chung, SC; Hui, Y; Leong, R; Leung, WK; Sung, JJ; Wu, JC, 2004) |
| "pylori decreases gastric cancer risk, using preneoplastic conditions as surrogate markers." | 2.71 | Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. ( Figueroa, LS; Guarner, J; Halperin, D; Herrera-Goepfert, R; Johnstone, I; Ley, C; Mohar, A; Parsonnet, J, 2004) |
| "Clarithromycin resistance was detected in all of 8 (100%) RLC-1 failures and in 1 out of 3 (33%) RLC-2 failures." | 2.71 | High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication. ( Branca, G; Cammarota, G; Cannizzaro, O; Cesaro, P; Cianci, R; di Caro, S; Fedeli, P; Gasbarrini, G; Lecca, PG; Martino, A, 2004) |
| "Peptic ulcer was found in 6." | 2.71 | Does the 'test-and-treat' strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients. ( Färkkilä, M; Sarna, S; Sipponen, P; Valtonen, V, 2004) |
| "Esomeprazole has higher oral bioavailability and increased antimicrobial activity against Helicobacter pylori than omeprazole." | 2.71 | Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study. ( Anagnostopoulos, GK; Arvanitidis, D; Kostopoulos, P; Margantinis, G; Tsiakos, S, 2004) |
| "Treatment with omeprazole or pantoprazole prior to urea breath test (UBT) was associated with low false negative results, while lansoprazole and esomeprazole caused clinically unacceptable high false negative rates (pantoprazole 2." | 2.71 | Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. ( Aeed, H; Avni, Y; Boaz, M; Levine, A; Moss, SF; Niv, Y; Shabat-Sehayek, V; Shevah, O; Shirin, H, 2004) |
| "3%) and there were no serious adverse events." | 2.71 | The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing. ( Akarsu, M; Bozbas, A; Hulagu, S; Kadayifci, A; Koruk, M; Savas, MC; Simsek, I; Sivri, B; Tozun, N; Uraz, S, 2004) |
| "pylori) eradication on gastroesophageal reflux disease is controversial." | 2.71 | The effect of Helicobacter pylori eradication on gastroesophageal reflux disease. ( Güliter, S; Kandilci, U, 2004) |
| "Lansoprazole (LAN) is a proton pump inhibitor drug (PPI) metabolized by the P-450 liver cytochrome (CYP-450) system." | 2.71 | Effects of the association of lansoprazole, clarithromycin and metronidazole for helicobacter Pylori eradication therapy, measured by the 13C Aminopyrine breath test. ( Bellotti, M; Botta, F; Chiarbonello, B; Cotelessa, T; Emanuela, T; Fumagalli, A; Giannini, E; Malfatti, F; Milazzo, S; Podestà, E; Polegato, S; Testa, R, 2005) |
| "To determine whether an increased dosage of esomeprazole 40 mg twice daily in triple therapy improved the Helicobacter pylori eradication rate for patients with different genotypes of S-mephenytoin 4'-hydroxylase (CYP2C19)." | 2.71 | Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. ( Chen, TW; Cheng, HC; Hunag, SF; Kao, AW; Lu, CC; Sheu, BS; Wu, JJ, 2005) |
| " We determined the therapeutic effects of sofalcone and polaprezinc when combined with rabeprazole, amoxicillin and clarithromycin for Helicobacter pylori infection." | 2.71 | Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. ( Furusu, H; Inoue, K; Isomoto, H; Kohno, S; Ohnita, K; Wen, CY, 2005) |
| "A urea breath test was performed 1-2 months after eradication." | 2.71 | Eradication rate of Helicobacter pylori in dyspeptic patients. ( Amini, M; Khedmat, H; Yari, F, 2005) |
| "A cross-over study was made in 27 GERD patients (12 males and 15 females)." | 2.71 | [Esomeprasol and rabeprasol effects on esophageal acidification in patients with gastroesophageal reflux disease, intensively metabolizing inhibitors of proton pump]. ( Gushchin, AE; Isakov, VA; Morozov, SV; Shipulin, GA; Tereshchenko, SG; Tsodikova, OM, 2005) |
| "To determine whether elevation of intragastric pH reduces the bioavailability of dietary vitamin C." | 2.71 | Proton pump inhibitors reduce the bioavailability of dietary vitamin C. ( Carswell, A; Fyffe, V; Henry, EB; McColl, KE; Wirz, A, 2005) |
| " dosing of rabeprazole." | 2.71 | Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus. ( Hall, M; Higbee, A; Mathur, S; Sampliner, RE; Sharma, P; Wani, S; Weston, AP, 2005) |
| " A therapeutical scheme (omeprazole, metronidazole, amoxicilline) obtained a further pathogenetic substantiation of B type CG patient treatment with additional antioxidant vitamin E use at the dosage of 300 mg/day for three weeks." | 2.71 | [Lipid peroxidation and antioxidant system in treatment dynamics of patients with chronic gastritis]. ( Postavnyĭ, VE, 2005) |
| "Duodenal ulcers were healed in nine of 10 (90%) patients in the BTF group and in all patients (12/12) (100%) in the OBTM group (P = N." | 2.70 | Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole. ( Domareva, I; Ganskaya, Z; Isakov, V; Koudryavtseva, L; Maev, I, 2002) |
| "Helicobacter pylori gastritis is usually a lifelong disease which can cause different topographical inflammatory reactions and induce divergent effects on acid secretion in humans." | 2.70 | Helicobacter pylori and different topographic types of gastritis: treatment response after successful eradication therapy in functional dyspepsia. ( Färkkilä, M; Koskenpato, J; Sipponen, P, 2002) |
| " pylori status on the incidence of gastrointestinal (GI) events in rheumatic patients receiving longterm conventional nonsteroidal antiinflammatory drug (NSAID) therapy combined with omeprazole." | 2.70 | Influence of Helicobacter pylori eradication therapy on the occurrence of gastrointestinal events in patients treated with conventional nonsteroidal antiinflammatory drugs combined with omeprazole. ( Bannwarth, B; Barthelemy, P; Caekaert, A; Dorval, E, 2002) |
| "pylori at 6 wk were infected at 1 yr (recurrence rates 10." | 2.70 | Eradication rate of Helicobacter pylori in a Mexican population at high risk for gastric cancer and use of serology to assess cure. ( Figueroa, LS; Guarner, J; Halperin, D; Herrera-Goepfert, R; Ley, C; Mohar, A; Parsonnet, J, 2002) |
| "Omeprazole was given (40 mg/day) for 2 or 4 weeks." | 2.70 | Low incidence of Helicobacter pylori infection in patients with duodenal ulcer and chronic liver disease. ( Abdel-Baset, EZ; Atta, MM; Kabil, SM; Murray, JA; Nassar, AK; Shahin, WA, 2001) |
| " Based on the metabolic and pharmacokinetic differences among other proton pump inhibitors such as omeprazole, lansoprazole and pantoprazole, rabeprazole appears to be the least affected proton pump inhibitor by the CYP2C19-related genetic polymorphism." | 2.70 | Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. ( Furuie, H; Horai, Y; Irie, S; Ishizaki, T; Kimura, M; Koga, Y; Matsuguma, K; Matsui, T; Murakami, M; Nagahama, T; Urae, A; Yao, T, 2001) |
| " We performed serial endoscopy, checked for adverse events, and laboratory values." | 2.70 | Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. ( Bardhan, KD; Bishop, AE; Cherian, P; Fischer, R; Lühmann, R; McCaldin, B; Morris, P; Ng, W; Perry, MJ; Polak, JM; Romanska, H; Rowland, A; Schneider, A; Thompson, M, 2001) |
| " No studies have yet compared the effects of different dosages of clarithromycin in combination with a proton pump inhibitor and amoxicillin in elderly patients." | 2.70 | Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. ( Bozzola, L; Di Mario, F; Franceschi, M; Leandro, G; Pilotto, A; Rassu, M; Soffiati, G; Valerio, G, 2001) |
| "Forty of the patients with ESRD (50%) and 48 patients in the control group (60%) were proven to be infected with H pylori." | 2.70 | Noninvasive stool antigen assay can effectively screen Helicobacter pylori Infection and assess success of eradication therapy in hemodialysis patients. ( Huang, JJ; Sheu, BS; Wang, YL; Yang, HB, 2001) |
| "Gastric cancer is the second most frequent cause of death from cancer in the world and the leading cause of death from cancer in China." | 2.70 | An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. ( Brown, LM; Chang, YS; Fraumeni, JF; Gail, MH; Heinrich, J; Liu, WD; Ma, JL; Xu, GW; Yang, CS; You, WC; Zhang, L, 2001) |
| "pylori eradication, in preventing GERD, since no data exist so far." | 2.70 | Effectiveness of acid suppression in preventing gastroesophageal reflux disease (GERD) after successful treatment of Helicobacter pylori infection. ( Karameris, A; Ladas, SD; Liatsos, C; Panagou, E; Raptis, SA; Rokkas, T, 2001) |
| "Furazolidone was rapidly absorbed after oral administration." | 2.70 | Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers. ( Calafatti, SA; Deguer, M; Martinez, M; Ortiz, RA; Pedrazzoli, J, 2001) |
| "Omeprazole was discontinued at 8 weeks and patients were followed up for a further 10 months." | 2.70 | Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. ( Axon, AT; Bardhan, C; Brown, L; Dixon, MF; Moayyedi, P; Young, L, 2001) |
| "When lansoprazole 30 mg was given once daily, the mean 24-hour intragastric pH values in the subjects who were homozygous extensive metabolizers, heterozygous extensive metabolizers, and poor metabolizers were 4." | 2.70 | Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. ( Furuta, T; Ishizaki, T; Ohashi, K; Shirai, N; Xiao, F, 2001) |
| "Rabeprazole is a new proton pump inhibitor with more potent acid suppressive and anti-Helicobacter effects." | 2.70 | Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. ( Fung, FM; Hu, WH; Hui, CK; Hung, WK; Lai, KC; Lam, SK; Lau, P; Li, KF; Szeto, ML; Tong, TS; Wong, BC; Wong, WM; Yee, YK; Yip, AW; Yuen, MF, 2001) |
| "Omeprazole treatment further augmented clarithromycin Cmax and AUC0-2h in gastric juice approximately 2-fold (P < 0." | 2.70 | Transfer of clarithromycin to gastric juice is enhanced by omeprazole in Helicobacter pylori-infected individuals. ( Bento, AP; Calafatti, SA; de Nucci, G; Deguer, M; Dias, FE; Ferraz, JG; Lerner, F; Mendes, FD; Ortiz, RA; Pedrazzoli, J; Pereira, AA; Piovesana, H, 2001) |
| "Active duodenal ulcer recurrence was identified in seven of 23 H." | 2.70 | Effect of Helicobacter pylori eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer. ( Choi, IJ; Jung, HC; Kim, BG; Kim, JS; Kim, SG; Park, MJ; Song, IS, 2002) |
| "Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections." | 2.70 | Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. ( Bartolozzi, F; Cammarota, G; Candelli, M; Cremonini, F; Di Caro, S; Gasbarrini, A; Lupascu, A; Nista, EC; Ojetti, V; Zocco, MA, 2002) |
| "Amoxicillin resistance was not found." | 2.70 | One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. ( Fung, FM; Gu, Q; Lai, KC; Lam, SK; Lu, H; Wang, WH; Wong, BC; Wong, WM; Xia, HH; Xiao, SD; Yin, Y, 2002) |
| "A urea breath test was performed 1 month after the end of therapy; patients and investigators were blind to the results." | 2.70 | Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. ( Dhir, V; Laine, L, 2002) |
| " pylori infection interfered with the plasma bioavailability of amoxicillin or ampicillin, as assessed by the AUC0-2 h." | 2.70 | Amoxicillin and ampicillin are not transferred to gastric juice irrespective of Helicobacter pylori status or acid blockade by omeprazole. ( Bernasconi, G; Calafatti, SA; Corazzi, A; De Souza, CA; Deguer, M; Ferraz, JG; Marchioretto, MA; Ortiz, RA; Pedrazzoli, J; Souza, JM, 2002) |
| " Sixty-eight patients received 30 mg of lansoprazole once daily, 500 mg of amoxicillin and 250 mg of metronidazole thrice daily for 2 weeks (LAM group), while the other 67 patients received the same dosage of those agents plus 18,000 tyrosine units of pronase thrice daily for 2 weeks (LAMP group)." | 2.70 | Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. ( Akamatsu, T; Gotoh, A; Ikeno, T; Ishida, K; Kaneko, T; Katsuyama, T; Kawakami, Y; Kiyosawa, K; Ota, H; Shimizu, T; Shimodaira, K; Sugiyama, A, 2002) |
| "Metronidazole resistance was found in 32 of 65 (49%) patients in whom H." | 2.69 | Short duration therapy for Helicobacter pylori in Western Australia: the impact of metronidazole resistance. ( Collins, BJ; Coombs, GW; Forbes, GM; McCullough, CA; Robins, PD, 1998) |
| "We hypothesized that treatment of duodenal ulcer disease with antibiotic therapy directed toward Helicobacter pylori infection is more cost-effective than therapy with antisecretory agents." | 2.69 | Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. ( Bloom, BS; Cutler, AF; Schwartz, JS; Sonnenberg, A; Vakil, N, 1998) |
| "Miconazole is an antimycotic agent with bacteriocidal activity against Helicobacter pylori in vitro." | 2.69 | Miconazole gel increases the cure rate of Helicobacter pylori infection when added to lansoprazole and amoxicillin in a randomized trial. ( Ikezawa, K; Kashimura, H; Mahmudul, H; Matsuzaki, Y; Mutoh, H; Nakahara, A; Tanaka, N; Yanaka, A, 1998) |
| "In the intention-to-treat analysis, duodenal ulcers were completely healed in 45 (90%) patients in the RAC group and 43 (89." | 2.69 | One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. ( Chan, FK; Cheng, AF; Chung, SC; Lee, YT; Leung, WK; Ling, TK; Sung, JJ; Yung, MY, 1998) |
| " Sixty patients received 40 mg of omeprazole twice a day, 1500 mg of amoxicillin three times a day, and 300 mg of rebamipide three times a day (group OAR); the other 60 patients received the same dosage of omeprazole and amoxicillin but no rebamipide for two weeks (group OA)." | 2.69 | Effect of rebamipide on Helicobacter pylori infection in patients with peptic ulcer. ( Ando, K; Arakawa, T; Harihara, S; Higuchi, K; Ito, H; Kobayashi, K; Kuroki, T; Nebiki, H; Uchida, T, 1998) |
| "Pretreatment with omeprazole did not reduce the cure rate for this new quadruple therapy." | 2.69 | A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. ( Maeda, K; Nishimura, H; Oda, K; Ohkuma, K; Okabe, N; Okada, M; Oki, K; Seo, M; Shirotani, T, 1998) |
| "Omeprazole pretreatment did not influence eradication rates." | 2.69 | Dual versus triple therapy: comparison of five antibiotic regimens for eradication of Helicobacter pylori in a prospective, randomized study. ( Bojarski, C; Epple, HJ; Fromm, M; Kirstein, FW; Riecken, EO; Schulzke, JD; Victor, L, 1998) |
| "All peptic ulcers were healed." | 2.69 | Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. ( De Fanis, C; Di Virgilio, M; Pantaleone, U; Pizzicanella, G; Russo, L; Sciampa, G; Silla, M; Spadaccini, A, 1998) |
| "The 1-week triple therapy was safe and effective for eradicating H." | 2.69 | Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children. ( Asaka, M; Iinuma, K; Kato, S; Ohnuma, K; Ritsuno, H; Sugiyama, T, 1998) |
| "Treatment with omeprazole (OME), azithromycin (AZI) and amoxicillin (AMO) resulted in encouraging Helicobacter pylori cure rates in pilot and control studies." | 2.69 | Omeprazole, azithromycin and amoxicillin or amoxicillin plus clavulanic acid in eradication of Helicobacter pylori in duodenal ulcer disease. ( Blazanović, A; Dmitrović, B; Ivandić, A; Karner, I; Kovac, D; Pezerović, D; Stimac, D; Stimac, T; Takac, B; Vcev, A; Vceva, A, 1998) |
| "pylori recurrence rate." | 2.69 | [Recurrence rate of H. pylori after successful eradication and second eradication therapy after initial failure of treatment]. ( Iijima, K; Kato, K; Ohara, S; Sekine, H, 1999) |
| "pylori eradication for the treatment of peptic ulcer disease, a randomized controlled trial to compare the efficacy of proton pump inhibitor-based dual and triple regimens was conducted." | 2.69 | [Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H. pylori eradication in peptic ulcer disease]. ( Habu, Y; Inokuchi, H; Kiyota, K; Ko, K; Sugano, Y; Waki, S, 1999) |
| "Fibrinogen changes were also significantly and negatively correlated with age." | 2.69 | Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. ( Arosio, C; Bertinieri, G; Blasi, F; Ceriani, G; Cosentini, R; Mandelli, C; Perondi, R; Ranzi, ML; Tarsia, P; Tien, TV; Torgano, G, 1999) |
| " Further study may permit development of optimal once-daily dosing and enhance eradication rates." | 2.69 | Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. ( Cheybani, K; Estrada, R; Laine, L; Neil, G; Smith, S; Trujillo, M; Yeramian, P, 1999) |
| "pylori-related gastritis, have focused mainly on medium and long-term change following eradication therapies." | 2.69 | Rapid elimination of Helicobacter pylori and reduction of histocompatibility leucocyte antigen-DR expression 12 h after a single dose of omeprazole, amoxycillin and metronidazole triple therapy. ( Chadwick, VS; Chen, W; Shu, D; Tie, A; Wilson, IR, 1999) |
| "To evaluate the efficacy of polaprezinc, a mucosal protective agent, in combination with a 7-day triple therapy containing lansoprazole, amoxycillin and clarithromycin, as a treatment for Helicobacter pylori." | 2.69 | Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. ( Hassan, M; Ikezawa, K; Kashimura, H; Mutoh, H; Nakahara, A; Sawahata, T; Suzuki, K; Tanaka, N; Watanabe, T, 1999) |
| "pylori functional dyspepsia is prevalent in people over 60 years old." | 2.69 | Helicobacter pylori-positive functional dyspepsia in elderly patients: comparison of two treatments. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Chodash, HB; Dawson, BK; Luca, S; Michalos, A; Terranova, R, 1999) |
| "Chronic urticaria is one of the most frequent skin diseases." | 2.69 | Helicobacter pylori as a possible bacterial focus of chronic urticaria. ( Brehler, R; Domschke, W; Foerster, E; Luger, TA; Pohle, T; Wustlich, S, 1999) |
| "Chronic urticaria is a common disease, though only few data on its natural course are available." | 2.69 | Chronic idiopathic urticaria: natural course and association with Helicobacter pylori infection. ( Helbling, A; Pichler, WJ; Schnyder, B, 1999) |
| "Metronidazole resistance was present in 29." | 2.69 | Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. ( Are, BM; Atzei, A; Carta, M; Cugia, L; Dore, MP; Graham, DY; Maida, A; Manca, A; Massarelli, G; Mura, I; Piana, A; Realdi, G, 1999) |
| " Pre-treatment with a proton pump inhibitor, higher doses or more frequent dosing may be necessary to increase the cure rate of short duration regimens." | 2.69 | Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. ( Cross, R; Grimley, CE; Illing, RC; Lismore, JR; Loft, DE; Nwokolo, CU; O'sullivan, M; Penny, A; Shebani, M, 1999) |
| "Omeprazole treatment resulted in a decrease of acid reflux per 24 h from 23." | 2.69 | The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy. ( Ganesh, S; Kleibeuker, JH; Klinkenberg-Knol, EC; Kuipers, EJ; Lamers, CB; Peters, FT; Sluiter, WJ, 1999) |
| "Animal experiments suggest that omeprazole dosing increases shedding of Helicobacter into the gastric lumen, and hence into gastric juice." | 2.69 | The effect of omeprazole dosing on the isolation of Helicobacter pylori from gastric aspirates. ( Lawson, AJ; Owen, RJ; Pounder, RE; Sercombe, JC; Slater, E; Williams, MP, 1999) |
| "Clarithromycin resistance was uncommon." | 2.69 | The OAC and OMC options. ( Unge, P, 1999) |
| "pylori eradication rate and ulcer recurrence rate were compared." | 2.69 | Assessment of decisions in the treatment of Helicobacter pylori-related duodenal ulcer: a cost-effectiveness study. ( Chen, J; Chen, SY; Wang, JY; Zhang, SS; Zhang, XD, 1999) |
| "The ulcer recurrences appeared in patients with H." | 2.69 | [Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication]. ( Mach, T; Zahradnik-Bilska, J, 1999) |
| "Twenty nine patients with type 1 diabetes mellitus and H." | 2.69 | Improvement in lipid and haemostasis patterns after Helicobacter pylori infection eradication in type 1 diabetic patients. ( Aller, R; Boixeda de Miquel, D; de la Calle, H; de Luis, DA; Garcia Avello, A; Lasuncion, MA; Martin de Argila, C, 1999) |
| "While addition of metronidazole to the omeprazole-amoxycillin combination has been shown to be advantageous, the optimal dosage and drug distribution of the antimicrobials has not been sufficiently evaluated." | 2.69 | Efficacy of two different dosage regimens of omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection. ( Bayerdörffer, E; Burman, CF; Díete, U; Dité, P; Domján, L; Kisfalvi, I; Lonovics, J; Mégraud, F; Pap, A; Sipponen, P; Zeijlon, L, 1999) |
| " The aim of this study was to determine the optimal dose and duration of lansoprazole (LA) administration in combination with amoxicillin (AMPC) and metronidazole (MNZ)." | 2.69 | Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy. ( Asaka, M; Ishizuka, J; Kagaya, H; Katagiri, M; Kato, M; Komatsu, Y; Kudo, M; Kudo, T; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H; Toyota, J, 1999) |
| "Metronidazole resistance was found in 44% of pre-treatment cultures of H." | 2.69 | Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. ( Axon, AT; Bardhan, KD; Braun, W; Cooper, BT; Dillon, J; Gatz, G; Tildesley, G; Wyatt, JI, 2000) |
| "Eradication of H." | 2.69 | Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial. ( Chan, AC; Chung, SC; Lam, YH; Lau, JY; Lau, WY; Law, BK; Lee, DW; Ling, TK; Ng, EK; Sung, JJ; To, KF; Yung, MY, 2000) |
| "After eradication, 51 out of 53 treated rosacea patients became Hp negative." | 2.69 | Helicobacter pylori and its eradication in rosacea. ( Bielański, W; Karczewska, E; Konturek, SJ; Pytko-Polonczyk, J; Sliwowski, Z; Szlachcic, A, 1999) |
| " In this study, we focused on whether 20 mg of rabeprazole is effective in our patient population by comparing that dosage with 40 mg of rabeprazole and 60 mg of lansoprazole." | 2.69 | Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. ( Miwa, H; Murai, T; Nagahara, A; Ogihara, T; Ohkura, R; Ohta, K; Sato, K; Sato, N; Takei, Y; Yamada, T, 2000) |
| "The urea breath test was performed at baseline, on day 14, while patients were still taking the antisecretory drugs, and on day 21, 1 week after their cessation." | 2.69 | Effect of gastric acid suppression on 13C-urea breath test: comparison of ranitidine with omeprazole. ( Bilardi, C; Bisso, G; Dulbecco, P; Mele, MR; Pivari, M; Savarino, V; Tracci, D; Vigneri, S; Zentilin, P, 2000) |
| " pylori eradication rate with a standard triple therapy regardless of the regimen utilized, the dosage and/or the duration of the therapy used appearing not to be sufficient to eradicate the infection efficiently." | 2.69 | Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. ( Armuzzi, A; Gasbarrini, A; Gasbarrini, G; Ghirlanda, G; Ojetti, V; Pitocco, D; Pola, P; Silveri, NG, 2000) |
| "Rabeprazole sodium is a proton pump inhibitor." | 2.69 | Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. ( Fukazawa, K; Ishino, Y; Kawakami, S; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Sugano, K, 2000) |
| "Cetraxate is an anti-ulcer drug that increases gastric mucosal blood flow." | 2.69 | Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. ( Haruma, K; Hattori, N; Kajiyama, G; Kamada, T; Kawamura, Y; Kitadai, Y; Mihara, M; Miyoshi, E; Mukai, T; Sumii, K; Tahara, K; Yoshihara, M, 2000) |
| " However, eradication rates with different dosages and dosing vary, and data on the impact of resistance are sparse." | 2.69 | The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. ( Bardhan, K; Bayerdörffer, E; Burman, CF; Delchier, JC; Gromark, P; Hellblom, M; Lind, T; Mégraud, F; Stubberöd, A; Veldhuyzen Van Zanten, SJ; Zeijlon, L, 2000) |
| "We present data on development of GERD from a controlled study of H." | 2.69 | Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease. ( Befrits, R; Lindberg, G; Odman, B; Sjöstedt, S; Sörngård, H, 2000) |
| "pylori-positive GERD patients randomly assigned to either an eradication or omeprazole-alone regime." | 2.69 | Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. ( Axon, AT; Bardhan, K; Dixon, MF; Moayyedi, P; Peacock, R; Walan, A; Wason, C, 2000) |
| "Patients were divided into 2 groups, one group received Lansoprazole (30 mg) once a day, and amoxycilline (500 mg) three times a day (group I), while the second group received Lansoparazole and amoxycillin in similar dosage with the addition of Roxythromycin (150 mg) twice a day (group II)." | 2.69 | Two weeks triple therapy with lansoprazole, amoxycillin and roxythromycin is better than dual therapy with lansoprazole and amoxycillin for H. pylori infection: a randomised, clinical trial. ( Alam, E; Mehdi, I; Qureshi, H, 2000) |
| " This study is designed to determine the efficacy of omeprazole 20 mg bd in combination with amoxycillin 500 mg tid (Group A), amoxycillin 750 mg tds (Group B) and clarithromycin 500 mg tid (Group C) in Singapore." | 2.69 | A randomised trial of amoxycillin versus clarithromycin in combination with omeprazole for eradication of Helicobacter pylori infection in Singapore. ( Fock, KM; Law, NM; Lim, CC; Ng, HS; Ng, TM, 2000) |
| "Omeprazole can enhance efficacy of single and double antibiotic protocols and is particularly effective when combined with clarithromycin and a nitroimidazole." | 2.68 | Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. ( Andrews, P; Bae, H; Borody, TJ; Brandl, S; Fracchia, G; Shortis, NP, 1995) |
| " The optimal dosage and duration of treatment need to be specified." | 2.68 | Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer. ( Fujita, N; Hisano, K; Kobayashi, T; Kurokawa, I; Ochiai, T; Sugiyama, T; Yabana, T; Yachi, A, 1995) |
| "Lansoprazole was found to be effective in patients who exhibited peak 13CO2 values that were at least two-thirds less than the pretreatment values." | 2.68 | 13C-UBT using an infrared spectrometer for detection of Helicobacter pylori and for monitoring the effects of lansoprazole. ( Kajiwara, M; Kokubun, N; Murai, S; Nakagawa, T; Ohara, H; Saito, N; Suzuki, T; Tsujino, D; Yamamoto, M; Yoneshima, M, 1995) |
| "We investigated the eradication and recurrence rate of Helicobacter pylori-infected gastric ulcer patients by combination therapies." | 2.68 | Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients. ( Fukuda, Y; Okui, M; Shimoyama, T; Tonokatsu, Y; Yamamoto, I, 1995) |
| "Lansoprazole 30 mg/day was administered to 124 gastric ulcer (GU) patients and 57 duodenal ulcer (DU) patients." | 2.68 | Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication. ( Kato, T; Ogoshi, K; Sakagawa, T, 1995) |
| " HP was eradicated by combined treatment with high-dose omeprazole (2 x 40 mg) and amoxicillin (2 x 1,000 mg; n = 27) administered for 10 days (OME + AMX); alternatively, patients were treated with omeprazole monotherapy (OME) using the same dosage (n = 25)." | 2.68 | Two-year follow-up of duodenal ulcer patients treated with omeprazole and amoxicillin. ( Bayerdörffer, E; Dirschedl, P; Hatz, R; Höchter, W; Lehn, N; Mannes, GA; Miehlke, S; Ruckdeschel, G; Sommer, A; Weingart, J, 1995) |
| "Treatment with omeprazole plus amoxicillin or clarithromycin resulted in encouraging Helicobacter pylori cure rates in pilot and controlled studies." | 2.68 | High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease. ( Bertrams, J; Börsch, G; Domian, C; Labenz, J; Stolte, M, 1995) |
| "Lansoprazole is a potent antisecretory drug also possessing anti-Helicobacter pylori activity in vitro." | 2.68 | Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. ( Bang, CJ; Berstad, A; Hatlebakk, JG; Hausken, T; Nesje, LB, 1995) |
| "Duodenal ulcers were healed in 44 of 49 (89." | 2.68 | Dual therapy versus triple therapy for Helicobacter pylori-associated duodenal ulcers. ( Cheng, AF; Chung, SC; Lau, JY; Leung, VK; Li, AK; Ling, TK; Suen, R; Sung, JJ, 1996) |
| "91%)." | 2.68 | Low H. pylori reinfection rate after triple therapy in Chilean duodenal ulcer patients. ( Acuña, R; Albornoz, V; Figueroa, G; Portell, DP; Toledo, MS; Troncoso, M; Vigneaux, J, 1996) |
| "Cure of HP infection reduces the recurrence of peptic ulcer and of rebleeding from ulcer disease more effectively than does long-term maintenance therapy." | 2.68 | Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. ( Cantero, J; Gómez-Cedenilla, A; Grávalos, RG; Pajares, JM; Santander, C, 1996) |
| "Omeprazole has been shown to have a suppressive effect on Helicobacter pylori." | 2.68 | Prolonged treatment with omeprazole does not improve the eradication rate of Helicobacter pylori infection--a short report [corrected]. ( Anderson, PE; Goh, KL; Parasakthi, N; Peh, SC; Tan, KK, 1995) |
| " Addition of clarithromycin at low dosage (250 mg b." | 2.68 | Omeprazole-amoxycillin versus omeprazole-amoxycillin-clarithromycin in the eradication of Helicobacter pylori. ( Barthelemy, P; Chaussade, S; Delchier, JC; Elamine, I; Goldfain, D; Idström, JP, 1996) |
| " Limited information exists about intragastric pH and bioavailability of amoxycillin during combination therapy." | 2.68 | Pharmacokinetic and pharmacodynamic interactions between omeprazole and amoxycillin in Helicobacter pylori-positive healthy subjects. ( Braun, M; Idström, JP; Londong, W; Pommerien, W; Wrangstadh, M, 1996) |
| "Pretreatment clarithromycin resistance averaged 5% and had not been acquired by any strains post-therapy." | 2.68 | One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. ( el-Zimaity, HM; Genta, RM; Graham, DY; Yousfi, MM, 1996) |
| " Post-prandial dosing with antibiotics prolongs their gastric residence time and improves their intragastric distribution, leading to improved local delivery compared with pre-prandial dosing." | 2.68 | Enhanced eradication of Helicobacter pylori by pre- versus post-prandial amoxycillin suspension with omeprazole: implications for antibiotic delivery. ( Atherton, JC; Cullen, DJ; Hawkey, CJ; Kirk, GE; Spiller, RC, 1996) |
| "Some recent studies have reported high recurrence rates after apparent cure." | 2.68 | Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy. ( De Boer, WA; Driessen, WM; Geuskens, LM; Lai, JY, 1996) |
| "Cumulative recurrence rates at six months did not statistically differ among the three different groups (27% in H pylori negative, 46% in H pylori positive, and 31% in those where H pylori was eradicated during the healing phase), although a numerical trend in favour of a higher recurrence rate in infected patients was evident." | 2.68 | Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy. ( Bianchi Porro, G; Caruso, I; Imbesi, V; Montrone, F; Parente, F, 1996) |
| "pylori infection and the ulcer recurrence rate after 1 year were investigated." | 2.68 | Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients. ( Asaka, M; Hokari, K; Kagaya, H; Katagiri, M; Kato, M; Koshiyama, T; Kudo, M; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H, 1996) |
| "Metronidazole is an important component of combination antimicrobial therapies used in the eradication of Helicobacter pylori, a recognized cause of gastritis and duodenal ulcer." | 2.68 | A liquid chromatography assay for the study of serum and gastric juice metronidazole concentrations in the treatment of Helicobacter pylori. ( Pollak, PT, 1996) |
| " In conclusion, H pylori eradication rates using high dose ranitidine plus amoxycillin and metronidazole may be similar to that of low dose omeprazole in combination with the same antibiotics for omeprazole with clarithromycin." | 2.68 | Randomised controlled trial of ranitidine versus omeprazole in combination with antibiotics for eradication of Helicobacter pylori. ( Bamford, KB; Collins, JS; Molloy, C; Sloan, JM; Tham, TC; Watson, RG, 1996) |
| "Shallow duodenal ulcers were noted in three patients at 1-year follow-up, two of whom admitted to taking non-steroidal anti-inflammatory drugs (NSAIDs); H." | 2.68 | Reinfection and duodenal ulcer relapse in south-east Asian patients following successful Helicobacter pylori eradication: results of a 2-year follow-up. ( Goh, KL; Navaratnam, P; Peh, SC, 1996) |
| "Treatment with omeprazole 20 mg and amoxycillin 1000 mg twice daily for 14 days altered the normal microflora in the oral, gastric and intestinal tract and antibiotic resistant microorganisms increased in numbers in the intestinal microflora." | 2.68 | Effects of omeprazole and amoxycillin on the human oral and gastrointestinal microflora in patients with Helicobacter pylori infection. ( Adamsson, I; Edlund, C; Nord, CE; Seensalu, R; Sjösted, S; Stark, CA; Wikström, B, 1996) |
| "Metronidazole resistance was induced in 8 out of 16 with a sensitive strain." | 2.68 | One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. ( de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ; van Unnik, AJ, 1997) |
| "In five of 20 patients, MALT lymphomas were finally diagnosed." | 2.68 | Is the polymerase chain reaction or cure of Helicobacter pylori infection of help in the differential diagnosis of early gastric mucosa-associated lymphatic tissue lymphoma? ( Bayerdörffer, E; Hatz, R; Lehn, N; Müller, S; Neubauer, A; Neubauer, B; Otto, P; Ritter, M; Rudolph, B; Seifert, E; Stolte, M; Thiede, C, 1997) |
| "Clarithromycin is a new macrolide antibiotic which is known to be highly effective in eradicating Helicobacter pylori (H." | 2.68 | Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease. ( Lee, SD; Lin, HJ; Lo, WC; Perng, CL; Wang, K, 1997) |
| " Thus, a true dose-response relationship exists between omeprazole and treatment success." | 2.68 | Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients. ( Beker, JA; Dekker, CP; Farley, A; Jönsson, A; Klör, HU; Labenz, J, 1997) |
| " Intragastric pH and plasma levels of the administered drugs were monitored over a dosing interval of 12 h." | 2.68 | Age-dependent eradication of Helicobacter pylori with dual therapy. ( Ammon, S; Klotz, U; Treiber, G, 1997) |
| " Possibly, 14-day therapy or a higher dosage of metronidazole provide better results with metronidazole-resistant H." | 2.68 | Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. ( el-Zimaity, HM; Graham, DP; Graham, DY; Hoffman, J; Osato, M, 1997) |
| "Posttreatment clarithromycin resistance is common in patients who do not experience success with therapy." | 2.68 | Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori. ( Axon, AT; Chalmers, DM; Dixon, MF; Langworthy, H; Moayyedi, P; Shanahan, K; Tompkins, DS, 1996) |
| "Lansoprazole has superior anti-Helicobacter activity in vitro and possibly also in vivo; therefore we investigated quadruple therapy with lansoprazole." | 2.68 | Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection. ( de Boer, WA; Driessen, WM; Lai, JY; Schneeberger, PM; van de Wouw, BA; van Etten, RJ, 1996) |
| "For H." | 2.68 | Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. ( Bardhan, KD; Graham, DY; Hunt, RH; O'Morain, CA, 1997) |
| "The LCM1 regimen consisting of 30 mg lansoprazole once daily, 200 mg clarithromycin twice daily, and 250 mg metronidazole twice daily (the regular doses in ordinary use in Japan) is a highly effective and safe regimen for Japanese patients." | 2.68 | The efficacy and safety of one-week triple therapy with lansoprazole, clarithromycin, and metronidazole for the treatment of Helicobacter pylori infection in Japanese patients. ( Ido, K; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Seki, M; Takimoto, T; Taniguchi, Y; Yoshida, Y, 1997) |
| " Group II (n = 47) treated with the same drug and dosage for 2 weeks." | 2.68 | [Omeprazole, clarithromycin and amoxicillin therapy for Helicobacter pylori infection]. ( Bei, L; Chen, S; Chen, Z, 1996) |
| "Pre-treatment metronidazole resistance was encountered in 34/63 (54." | 2.68 | Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection? ( Cheah, PL; Chin, SC; Chuah, SY; Goh, KL; Lo, YL; Parasakthi, N, 1997) |
| " Amoxycillin dosing was randomised to either 1 h before or 10 min after food." | 2.67 | Amoxycillin capsules with omeprazole for the eradication of Helicobacter pylori. Assessment of the importance of antibiotic dose timing in relation to meals. ( Atherton, JC; Hawkey, CK; Hudson, N; Kirk, GE; Spiller, RC, 1994) |
| "Metronidazole resistance was defined as a minimal inhibitory concentration (MIC) of metronidazole of > 8 micrograms/ml." | 2.67 | [Eradication of metronidazole-resistant Helicobacter pylori: is omeprazole/amoxicillin a therapeutic alternative?]. ( Ammann, R; Bauer, S; Flury, R; Meyenberger, C; Wirth, HP; Wüst, J; Zala, G, 1994) |
| "pylori-positive after treatment, and duodenal ulcer relapsed in 16 out of 25 (64%) patients within the median follow-up of 18 months." | 2.67 | Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin. ( Bayerdörffer, E; Dirschedl, P; Hatz, R; Höchter, W; Lehn, N; Mannes, GA; Ruckdeschel, G; Sommer, A; Stolte, M; Weingart, J, 1993) |
| "Treatment with amoxicillin and omeprazole resulted in encouraging Helicobacter pylori eradication rates in pilot studies that included medium term follow up." | 2.67 | Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. ( Börsch, G; Gyenes, E; Labenz, J; Rühl, GH, 1993) |
| "Those without recurrence during this treatment were followed up for another 6 months." | 2.67 | Prevention of duodenal ulcer recurrence with penicillin. A double-blind, placebo-controlled trial. ( Bonnevie, O; Bremmelgaard, A; Eriksen, J; Hansen, JM; Jensen, TG; Justesen, T; Rune, SJ; Scheibel, J; Thomsen, OO; Vilien, M, 1993) |
| " There is also some evidence that proton pump inhibitors may reduce the bioavailability of ingested vitamin C." | 2.45 | Effect of proton pump inhibitors on vitamins and iron. ( McColl, KE, 2009) |
| "Gastric acid is pathogenic in many gastrointestinal disorders, such as gastroesophageal reflux disease and peptic ulcer disease." | 2.43 | Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. ( Robinson, M, 2005) |
| " For the better PPI-based treatment, doses and dosing schemes of PPIs should be optimized based on CYP2C19 genotype status." | 2.43 | Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. ( Furuta, T; Hishida, A; Ishizaki, T; Nakamura, A; Shirai, N; Sugimoto, M, 2005) |
| "Rabeprazole (Pariet) is a substituted benzimidazole proton pump inhibitor with potent gastric acid suppression properties." | 2.43 | Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication. ( Sharara, AI, 2005) |
| "Pantoprazole (Protonix) is an irreversible proton pump inhibitor (PPI) that reduces gastric acid secretion." | 2.42 | Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. ( Cheer, SM; Faulds, D; Lamb, HM; Prakash, A, 2003) |
| "Esomeprazole has an improved pharmacokinetic profile, resulting in increased systemic exposure and less interindividual variability compared with omeprazole, and more effective suppression of gastric acid production compared with other proton pump inhibitors." | 2.42 | Review of esomeprazole in the treatment of acid disorders. ( Johnson, DA, 2003) |
| "Primary thyroid MALT lymphoma occurring in Hasimoto's thyroiditis was diagnosed." | 2.42 | Extragastric mucosa-associated lymphoid tissue lymphoma showing the regression by Helicobacter pylori eradication therapy. ( Arima, N; Tsudo, M, 2003) |
| "We undertook a broad data review of the efficacy of nine different 7-day triple therapies consisting of a proton pump inhibitor (lansoprazole, pantoprazole, omeprazole) in its standard dosage and two antibiotics." | 2.42 | Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review. ( Beckerling, A; Gatz, G; Ulmer, HJ, 2003) |
| " Multicentre randomised controlled studies are needed to better define the efficacy profile, the optimal dosage with respect to the different indications and the safety profile for chronic therapy of proton pump inhibitors in children." | 2.42 | Proton pump inhibitors in children: a review. ( Gerarduzzi, T; Marchetti, F; Ventura, A, 2003) |
| "pylori infection and idiopathic thrombocytopenic purpura (ITP)." | 2.42 | [Evaluation of the efficacy of an Helicobacter pylori eradication treatment for idiopathic thrombocytopenic purpura patients]. ( Hirashima, N; Ito, K; Kato, A; Kato, H; Kondo, H; Matsunaga, S; Nukaya, H; Sakakibara, K; Sakamoto, T; Tanaka, Y, 2004) |
| "It is more effective in treating erosive esophagitis in patients with GERD than omeprazole." | 2.41 | Esomeprazole magnesium (Nexium). ( Baker, DE, 2001) |
| "Esomeprazole has FDA-approved labeling for use in the treatment of symptomatic gastroesophageal reflux disease (GERD), including healing and maintenance of healing of erosive esophagitis and as part of a triple-drug regimen for Helicobocter pylori infection." | 2.41 | Esomeprazole: a clinical review. ( Hedge, DD; Johnson, TJ, 2002) |
| "Studies that appeared to show that GERD could be provoked by antimicrobial therapy of duodenal ulcers also have methodological weaknesses." | 2.41 | Motion--Helicobacter pylori worsens GERD: arguments for the motion. ( O'Morain, CA; Qasim, A, 2002) |
| "Pantoprazole has similar efficacy to other PPIs in the healing of gastric and duodenal ulcers, as well as erosive esophagitis, and as part of triple-drug regimens for the eradication of Helicobacter pylori from the gastric mucosa." | 2.41 | Pantoprazole: a new proton pump inhibitor. ( Jungnickel, PW, 2000) |
| "The base of the treatment of reflux esophagitis is the inhibition of the gastric acid secretion with proton pump inhibitors (PPI) or by H2-receptor antagonist." | 2.41 | [Long-term results of conservative management of reflux esophagitis]. ( Dorta, G; Viani, F, 2001) |
| " Herewith, we present an overview of these intragastric changes, particularly during long-term administration of acid-suppresive medication and concurrent infection with Helicobacter pylori." | 2.41 | Changes in gastric mucosa and luminal environment during acid-suppressive therapy: a review in depth. ( de Bruïne, A; Hameeteman, W; Jonkers, D; Sanduleanu, S; Stockbrügger, RW, 2001) |
| " However, the consequences of very long-term use of proton pump inhibitors remain unknown." | 2.41 | Problems associated with the clinical use of proton pump inhibitors. ( Gillen, D; McColl, KE, 2001) |
| "Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion in a dose-dependent manner via inhibition of H+/K+-adenosine triphosphatase in gastric parietal cells." | 2.41 | An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. ( Bown, RL, 2002) |
| "Rabeprazole is a proton pump inhibitor with antisecretory properties." | 2.40 | Rabeprazole. ( Faulds, D; Prakash, A, 1998) |
| " Conversely, several studies have shown that long-term use of proton pump inhibitors is associated with progression and worsening of body gastritis exclusively in Helicobacter pylori-positives." | 2.40 | Should Helicobacter pylori be eradicated before starting long-term proton pump inhibitors? ( Rauws, EA, 1997) |
| " pylori-negative patients, current dosing with a proton-pump inhibitor may result in insufficient acid control for optimal treatment of gastro-oesophageal reflux disease (GORD)." | 2.40 | Is the sensitivity to gastric acid inhibition Helicobacter pylori status-dependent? ( Smout, AJ, 1998) |
| "Clarithromycin seems to be a better choice than amoxycillin to achieve this goal." | 2.40 | Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. ( Doermann, HP; Mégraud, F, 1998) |
| "Omeprazole is a well studied proton pump inhibitor that reduces gastric acid secretion." | 2.40 | Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. ( Langtry, HD; Wilde, MI, 1998) |
| "Eradication rate of Helicobacter pylori in dual therapy (omeprazole/amoxicillin) are reported in the range of 28-91%, side effect such as loose stool and skin reaction are reported 3." | 2.40 | [Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy]. ( Iwasaki, A, 1999) |
| "pylori and GERD and its potential implications for the management of GERD." | 2.40 | Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management. ( O'Connor, HJ, 1999) |
| "Rabeprazole sodium is a new substituted benzimidazole proton pump inhibitor with several differences compared with existing proton pump inhibitors." | 2.40 | Review article: the pharmacology of rabeprazole. ( Pounder, RE; Williams, MP, 1999) |
| "Rabeprazole is an inhibitor of the gastric proton pump." | 2.40 | Rabeprazole: a review of its use in acid-related gastrointestinal disorders. ( Langtry, HD; Markham, A, 1999) |
| "When lansoprazole was used as monotherapy, the mean Hp eradication was 6% in four studies." | 2.39 | Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole in clinical studies. ( Lamouliatte, H, 1995) |
| " Considerably more work, however, is required to identify the ideal dosage and combination that will give the best eradication rates with the simplest regimen and fewest side effects." | 2.39 | The potential value of lansoprazole in Helicobacter pylori eradication. ( Axon, AT, 1995) |
| "Treatment with omeprazole plus two different antibiotics has also been used in a number of studies." | 2.39 | The role of omeprazole and antibiotic combinations in the eradication of Helicobacter pylori--an update. ( Axon, AT, 1994) |
| "Although ulcer recurrence and complications can be prevented, many patients with peptic ulcer disease fail to receive the benefits of modern therapeutic regimens." | 2.39 | Review article: Helicobacter pylori eradication--understandable caution but no excuse for inertia. ( Penston, JG, 1994) |
| "This review provides an updated overview on Helicobacter pylori (HP) trials, focusing on drug dosage and cost:benefit ratio." | 2.39 | The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. ( Treiber, G, 1996) |
| " A number of studies have now been undertaken using an acid inhibitor in combination with two antibiotics." | 2.39 | Eradication of Helicobacter pylori: omeprazole in combination with antibiotics. ( Axon, AT; Moayyedi, P, 1996) |
| " The bioavailability of lansoprazole is 85%; that of omeprazole is 54%." | 2.39 | Lansoprazole and omeprazole in the treatment of acid peptic disorders. ( Blum, RA, 1996) |
| "Clarithromycin is useful for treatment of H." | 2.39 | Efficacy of clarithromycin in eradicating Helicobacter pylori. ( Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y, 1996) |
| " Tests of gastric acidity, in particular 24-h acidity studies, have provided considerable insight into normal and abnormal gastric physiology, and have largely determined the dosing regimens for the management of acid-peptic diseases." | 2.38 | Gastric acid secretion and intragastric acidity: measurement in health and disease. ( Fraser, AG; Pounder, RE, 1993) |
| "Lansoprazole, one of PPIs, is a strong antacid and it cures stomach and duodenal ulcers at early stages as well as having antibiotic action towards HP." | 2.38 | [Activity of Lansoprazole (new proton pump inhibitor) against Helicobacter pylori and its therapeutic efficacy]. ( Kawano, S; Murai, M; Tamura, K; Tanaka, M, 1993) |
| "Treatment with omeprazole and amoxycillin could provide both rapid healing of ulcers and eradication of H." | 2.38 | Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. ( Malfertheiner, P, 1993) |
| "Gastric ulcer is associated with weakening of the mucous coating of the stomach and damages to the intestinal lining." | 1.91 | ( Alshehri, MM; Atanda, H; Balogun, TA; Cárdenas-Cárdenas, R; Chenet-Zuta, M; Delgado Wong, H; Olivos-Ramirez, G; Ropón-Palacios, G; Umar, HI; Vilca-Quispe, J, 2023) |
| "To compare intragastric rifabutin concentrations between low-dose rifabutin (50 mg three time daily; as in RHB-105) and generically dosed rifabutin 150 mg once daily, 150 mg twice daily, and 300 mg once daily using a validated Physiologically-based pharmacokinetic (PBPK) model." | 1.91 | Physiologically-based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infection. ( Almenoff, JS; Howden, CW; Offman, E; Pendse, SN; Shah, S; Sheldon, KL, 2023) |
| " Although the result of the current study improves, a high dosage of aqueous extracts of plants has more effectiveness than a low dosage of aqueous extracts plants." | 1.91 | Gastro-Protective and Therapeutic Effect of Punica granatum against Stomach Ulcer Caused by Helicobacter Pylori. ( Alamri, ZZ; Faraj, RK; Hussein, MM; M Hussein, A; Mojarradgandoukmolla, S; Muhialdin, AJ; Taha, ZB, 2023) |
| "A sensitive and selective method needs to be developed and validated for simultaneous determination of four drugs (amoxacillin, tinidazole, naproxen and lansoprazole), used for treating Helicobacter pylori infection, in their combined dosage forms." | 1.72 | RP-HPLC-DAD Method Development and Validation for Simultaneous Determination of Lansoprazole, Tinidazole, Amoxicillin, and Naproxen in Their Raw Materials and Combined Dosage Form: DOE Approach for Optimization of the Proposed Method. ( Hassib, ST; Mostafa, EA; Sharf, MG; Taha, EA, 2022) |
| "Clarithromycin resistance was more frequently observed in the H." | 1.72 | Helicobacter pylori resistance to antibiotics before and after treatment: Incidence of eradication failure. ( Florholmen, JR; Goll, R; Halvorsen, FA; Johnsen, KM; Melby, KK; Moayeri, B; Nestegard, O; Paulssen, E; Sørbye, SW; Tønnesen, T, 2022) |
| "Gastritis is a common inflammation of stomach with multiple pathogenesis." | 1.72 | Octreotide-based therapies effectively protect mice from acute and chronic gastritis. ( Cao, LJ; Cao, WL; Che, Y; Ding, CJ; Huang, H; Wang, Y; Wu, JW; Xu, WF; Zhang, Q, 2022) |
| "A 56-year-old man with gastroesophageal reflux disease (GERD) was referred to our hospital." | 1.46 | Gastric Hyperplastic Polyps Associated with Proton Pump Inhibitor Use in a Case without a History of Helicobacter pylori Infection. ( Abiko, S; Hatanaka, KC; Kato, M; Kudo, T; Matsuda, K; Miyamoto, S; Mizushima, T; Ono, S; Sakamoto, N; Shimizu, Y; Tsuda, M; Tsunematsu, I; Yamamoto, K, 2017) |
| "pylori-induced gastric cancer, irrespective of the timing of antibiotic administration." | 1.42 | Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. ( Aponte-Pieras, JR; Lee, DS; Morrissey, R; Moss, SF; Rogers, AB; Zhang, S, 2015) |
| " Examination of eradication rates according to CAM dosage revealed an eradication rate of 65." | 1.40 | Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). ( Asaoka, D; Ito, M; Kawai, T; Kawakami, K; Kurihara, N; Masaoaka, T; Matsuhisa, T; Mine, T; Mizuno, S; Nagahara, A; Nishizawa, T; Ohkusa, T; Omata, F; Sakaki, N; Sasaki, H; Suzuki, H; Suzuki, M; Takahashi, S; Tokunaga, K; Torii, A, 2014) |
| "Chronic urticaria is one of the most frequent skin diseases in medical practice." | 1.37 | Helicobacter pylori associated with chronic urticaria. ( Ben Mahmoud, L; Ghozzi, H; Hakim, A; Sahnoun, Z; Zeghal, K, 2011) |
| "Alopecia areata is a disease of the hair follicles, with strong evidence supporting autoimmune etiology." | 1.37 | Cure of alopecia areata after eradication of Helicobacter pylori: a new association? ( Campuzano-Maya, G, 2011) |
| "Studying role of duodenogastric reflux (DGR) in pathogenesis and sanogenesis of duodenal ulcer (DU)." | 1.37 | [Characteristics of duodenogastric reflux in duodenal ulcer patients and its dynamics after Helicobacter pylori eradication]. ( Kolesnikova, IIu; Liubskaia, LA; Volkov, VS, 2011) |
| "Furazolidone was tried in several developing countries and showed good results in some trials." | 1.37 | To compare the efficacy of triple therapy with furazolidone, amoxicillin and omeprazole for two weeks and three weeks in the eradication of Helicobacter pylori in Bangladeshi duodenal ulcer patients. ( Hasan, M; Islam, N; Masud, H; Raihan, AS; Roy, PK; Saha, SK, 2011) |
| "Pre-existing nonerosive gastroesophageal reflux disease, smoking, and older age are important predictors of de novo development of erosive esophagitis." | 1.36 | De novo erosive esophagitis in duodenal ulcer patients related to pre-existing reflux symptoms, smoking, and patient age, but not to Helicobacter pylori eradication: a one-year follow-up study. ( Jonaitis, L; Kiudelis, G; Kupčinskas, J; Kupčinskas, L, 2010) |
| "Chronic urticaria is a persistent urticaria lasting longer than 6 weeks, affecting 20% of the general population." | 1.35 | Helicobacter pylori infection in patients with chronic urticaria: correlation with pathologic findings in gastric biopsies. ( Abdou, AG; Elnaidany, NF; Elshayeb, EI; Farag, AG, 2009) |
| " Application of a combined preparation, consisting of 20 mg of omeprazol, 500 mg of clarithromycin, 1000 mg amoxicillin, in a standard dosage of 3 tablets twice a day during 7 days have permitted to achieve the H." | 1.35 | [Antihelicobacteric therapy for the patients with recurrent complicated postoperative gastroduodenal ulcer: indications, principles of conduction, efficacy]. ( Buka, GIu; Veligotskiĭ, NN, 2009) |
| "In developing countries the recurrence rate of Helicobacter pylori after successful eradication therapy is as high as 42%, while in developed countries it is estimated to be less than 3%." | 1.35 | Helicobacter pylori recurrence and infection rate in Israeli adults. ( Achiel, K; Hazazi, R; Lederfein, T; Niv, Y; Waked, A, 2008) |
| " For eradication, European, Canadian, and American guidelines recommend a regimen consisting of a proton pump inhibitor, clarithromycin, and metronidazole or amoxicillin dosed twice daily for at least 7 days." | 1.35 | An alternative salvage regimen for Helicobacter pylori-resistant patients with heart failure. ( Cantu, M; Ferguson, D; Page, RL, 2008) |
| "pylori eradication prevented gastric cancer to the greatest extent when antibiotics are given at an early point of infection, but that eradication therapy given at a later time point delayed the development of severe dysplastic lesions." | 1.35 | Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. ( Fox, JG; Ge, Z; Lee, CW; Rickman, B; Rogers, AB; Wang, TC, 2008) |
| "The study included 100 youth with type 1 diabetes and seropositive for Hp (European Caucasians: n=49; Moghrabin Caucasians: n=51)." | 1.34 | [Helicobacter pylori infection and eradication are not related to glycosylated hemoglobin levels (HbA1c) in young patients with type 1 diabetes]. ( Dorchy, H; Khalil, T; Melot, C; Scaillon, M, 2007) |
| "Omeprazole treatment increased bacteria colonization and MPO activity in mice stomachs." | 1.34 | Effects of a one-week treatment with acid gastric inhibitors on Helicobacter pylori-infected mice. ( Arçari, DP; Bartchewsky, W; Gambero, A; Hoehr, NF; Maróstica, M; Pedrazzoli, J; Ribeiro, ML; Trevisan, M, 2007) |
| "Gastroesophageal reflux disease is a common and chronic disorder but long term, prospective studies of the fate of patients seeking medical advice are scarce." | 1.34 | Prospective Acid Reflux Study of Iran (PARSI): methodology and study design. ( Abedi, B; Alimohamadi, SM; Ghotbi, MH; Malekzadeh, R; Mamarabadi, M; Mofid, A; Mostajabi, P; Nasseri-Moghaddam, S; Nouraie, M; Razjouyan, H; Sohrabpour, AA; Sotoudeh, M; Tofangchiha, S, 2007) |
| "pylori-infected gastro-oesophageal reflux disease patients does not increase or accelerate gastric autoimmunity." | 1.33 | Long-term acid suppression by omeprazole in gastro-oesophageal reflux disease patients does not lead to anti-gastric autoantibody production. ( Aar, A; Appelmelk, BJ; Bergman, MP; Faller, G; Klinkenberg-Knol, EC; Kuipers, EJ; Lakhai, W; Vandenbroucke-Grauls, CM, 2005) |
| " On logistic regression analysis, none of the confounding factors (sex, age, indication, chronic use of PPI, eradication protocol) were found to contribute to the discrimination between a negative (successful eradication) and a positive (failed eradication) 13CUBT." | 1.33 | Effectiveness of omeprazole- versus lansoprazole-based triple therapy for Helicobacter pylori eradication. ( Niv, Y, 2005) |
| "In two patients with MALT lymphoma, H." | 1.33 | Helicobacter heilmannii infection: clinical, endoscopic and histopathological features in Japanese patients. ( Akamatsu, T; Hidaka, E; Matsuzawa, K; Okiyama, Y; Ota, H; Sano, K, 2005) |
| "Proton pump inhibitors play an important role in increasing the bioavailability of antibiotics in the gastric mucus by altering gastric volumes and increasing the stability of some antibiotics, e." | 1.33 | Helicobacter pylori: factors affecting eradication and recurrence. ( Vakil, N, 2005) |
| "Fundic gland polyps have been described either in association with genetic polyposis syndromes of the colon, or in a sporadic form." | 1.33 | Sporadic fundic gland polyps: clinico-pathologic features and associated diseases. ( Bellone, S; Caruso, S; Declich, P; Ferrara, A; Tavani, E, 2005) |
| "Clarithromycin resistance was uncommon." | 1.33 | Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. ( Campos, A; Cardenas, VM; Chavez, A; El-Zimaity, HM; Graham, DY; Guerrero, L; Opekun, AR, 2006) |
| "Blepharitis was diagnosed on the basis of findings in ophthalmic and dermatologic examinations." | 1.33 | Prevalence and treatment of Helicobacter pylori in patients with blepharitis. ( Baldi, F; Bilardi, C; Brusati, C; Mastromarino, A; Pascotto, A; Prigione, G; Rebora, A; Saccà, SC; Savarino, V; Venturino, GM, 2006) |
| "Seventy-one H." | 1.33 | Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients. ( Castro-Fernández, M; Cosme, A; Gisbert, JP; Gómez, B; Herrerías, JM; Luna, M; Monés, J; Olivares, D; Pajares, JM; Sánchez-Pobre, P, 2006) |
| "In most patients with GERD esophagitis is not detected by endoscopy, which represents GERD with a negative endoscopy or non-erosive reflux disease (NERD)." | 1.33 | Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori. ( Castro Fernández, M; García Díaz, E; Lamas Rojas, E; Larraona, JL; Núñez Hospital, D; Pallarés Querol, M; Rodríguez Hornillo, MC, 2006) |
| "pylori for low-grade MALT lymphoma of the gastric stump without other modalities such as surgery and systemic chemotherapy." | 1.33 | Complete regression of low-grade mucosa-associated lymphoid tissue (MALT) lymphoma in the gastric stump after eradication of Helicobacter pylori. ( Hirakawa, K; Inoue, T; Komoto, M; Nakata, B; Takashima, T; Tominaga, K, 2006) |
| "Chronic gastritis was evaluated according to sydney system." | 1.33 | [Prospective study of 420 biopsies realised in patients with duodenal ulcer with positive Helicobacter pylori]. ( Ben Ayed, M; Ben Khelifa, H; Chedly-Debbiche, A; Gargouri, D; Ghorbel, AJ; Kharrat, J; Khayat, O; Kilani, A; Souissi, A; Zeddini, A, 2006) |
| "Thirty one patients with gastroesophageal reflux disease were treated with a daily oral dose of 20 mg OMP for 28 days." | 1.33 | [Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease]. ( Choi, SK; Joo, YE; Kim, HS; Kim, SJ; Lee, WS; Park, CH; Rew, JS; Sohn, YH, 2006) |
| "Omeprazole, 20 mg b." | 1.32 | Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. ( el-Zimaity, HM; Graham, DY; Opekun, AR; Osato, MS; Yamaoka, Y, 2003) |
| "Complete regression of MALT lymphoma following treatment for H." | 1.32 | Long-term follow up of gastric low-grade mucosa-associated lymphoid tissue lymphoma by endosonography emphasizing the application of a miniature ultrasound probe. ( Chang, CS; Chang, WD; Chen, GH; Chou, G; Lien, HC; Poon, SK; Yang, SS; Yeh, HZ, 2003) |
| "Esomeprazole is an enantiomorph of omeprazole, which inhibits gastric acid secretion more effectively than omeprazole." | 1.32 | Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori. ( D'Anna, L; Figura, N; Gatta, L; Holton, J; Miglioli, M; Perna, F; Ricci, C; Vaira, D, 2003) |
| "Gastric metaplasia was endoscopically and histologically evaluated before and after eradication of this bacterium." | 1.32 | Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori. ( Sano, T; Urakami, Y, 2003) |
| "Sixty-eight gastroesophageal reflux disease patients (age range 18-61 years) were studied by upper endoscopy." | 1.32 | Acid exposure and altered acid clearance in GERD patients treated for Helicobacter pylori infection. ( Bottiglieri, ME; Budillon, G; Cuomo, R; Grasso, R; Ierardi, E; Nardone, G; Sarnelli, G; Verde, C, 2003) |
| "To determine the pharmacokinetic and pharmacodynamic rationale for the optimum regimen of rabeprazole in the treatment of Helicobacter pylori infection in patients who are cytochrome P450 (CYP) 2C19 poor metabolizers or extensive metabolizers." | 1.32 | Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. ( Chern, HD; Lin, CJ; Uang, YS; Wang, TH; Yang, JC, 2003) |
| "Presence of gastro-oesophageal reflux symptoms and medication of proton pump inhibitors, H2-blockers or prokinetics were investigated at final endoscopy." | 1.32 | Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. ( Chayama, K; Haruma, K; Manabe, N; Sasaki, A; Tanaka, S; Yoshihara, M, 2003) |
| "Hyponatremia is a frequent finding and asks for a rapid diagnostic evaluation." | 1.32 | [Hyponatremia: an unusual case report]. ( Berwert, L; Kaeser, P; Livio, F; Vollenweider, P; Waeber, G, 2003) |
| "To characterize posttreatment recurrence of Helicobacter pylori in Peru, 192 adults with H." | 1.32 | Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapy. ( Bautista, CT; Berg, DE; Dailide, G; Gilman, RH; Katz, U; Meza, R; Monath, TP; Ogura, M; Razuri, M; Roth, DE; Soto, G; Taylor, DN; Velapatiño, B, 2003) |
| "To achieve more potent and long-lasting acid suppression, different dosage regimens of rabeprazole were compared in relation to the CYP2C19 genotype status." | 1.32 | Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. ( Horikawa, Y; Inoue, M; Kuroiwa, T; Shimatani, T, 2004) |
| "pylori in children with type 1 diabetes mellitus improves their metabolic control." | 1.32 | Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes. ( Cammarota, G; Candelli, M; Crea, F; Gasbarrini, A; Gasbarrini, G; Marietti, G; Nista, EC; Petrucci, S; Pignataro, G; Rigante, D; Schiavino, A, 2004) |
| "Metronidazole resistance was significantly more common in women (P < 0." | 1.32 | Helicobacter pylori: antibiotic resistance and eradication rates in Suffolk, UK, 1991-2001. ( Baldwin, L; Bell, GD; Cameron, EAB; Jones, P; Powell, KU; Williams, SGJ, 2004) |
| "Although profound hypochlorhydria is considered to be an important risk factor for development of gastric cancer, long-term effect of Helicobacter pylori eradication on its reversibility remains uncertain." | 1.32 | Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. ( Iijima, K; Imatani, A; Koike, T; Ohara, S; Sekine, H; Shimosegawa, T, 2004) |
| "Effective therapy for gastro-oesophageal reflux disease (GERD) is associated with improvement in health-related quality of life." | 1.32 | Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan. ( Azuma, T; Dojo, M; Kuriyama, M; Muramatsu, A; Ohtani, M; Okajima, T; Yamazaki, Y, 2004) |
| " pylori-infected mucosa and that inhibited the loss of CAM bioavailability in the acidic environment." | 1.32 | Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice. ( Fujioka, T; Kashimura, K; Kodama, M; Miura, M; Miyajima, H; Murakami, K; Nasu, M; Okimoto, T; Ootsu, S; Sato, R; Watanabe, K, 2004) |
| "Metronidazole is a good substitute for clarithromycin as the second-line option for children." | 1.32 | Results of triple eradication therapy in Japanese children: a retrospective multicenter study. ( Iinuma, K; Kato, S; Konno, M; Maisawa, S; Nakayama, Y; Shimizu, T; Tajiri, H; Toyoda, S; Yoshimura, N, 2004) |
| " After each dose was administered, the pharmacokinetic profiles of omeprazole and its two metabolites were significantly different between extensive metabolizers and poor metabolizers." | 1.31 | Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. ( Aoyama, N; Kasuga, M; Kawahara, Y; Kita, T; Okumura, K; Sakaeda, T; Sakai, T, 2002) |
| "A total of 65 patients with GERD (grades A-D) completed treatment with lansoprazole, by taking 30 mg orally once a day for 8 weeks." | 1.31 | Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. ( Furuta, T; Futami, H; Hanai, H; Honda, S; Iida, T; Ishizaki, T; Kajimura, M; Ohashi, K; Sato, Y; Shirai, N; Takayanagi, S; Takeuchi, K; Watanabe, F; Yamada, M, 2002) |
| "A case of severe thrombocytopenic purpura is described in a 56-year-old female following Helicobacter pylori eradication therapy consisting of omeprazole, clarithromycin and amoxycillin." | 1.31 | Thrombocytopenic purpura: an unusual complication of eradication therapy for Helicobacter pylori. ( Bellini, M; Costa, F; De Bortoli, N; Maltinti, G; Marchi, S; Petrini, M, 2002) |
| "Fibrinogen is an important risk factor for ischaemic heart disease (IHD) (1) and an elevated fibrinogen level has been reported in younger patients infected with Helicobacter pylori (H pylori) infection (2, 3)." | 1.31 | Effect of Helicobacter pylori infection on fibrinogen level in elderly patients with ischaemic heart disease. ( Mishra, RM; Yusuf, SW, 2002) |
| "pylori induces de novo GERD symptoms in ulcer patients." | 1.31 | Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. ( Dickson, A; El-Nujumi, A; El-Omar, E; Kelman, A; McColl, KE, 2000) |
| "pylori treatment on MALT lymphoma and chronic gastritis at the histologic and molecular levels." | 1.31 | Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases. ( Begum, S; Endo, H; Kawamata, H; Sano, T; Urakami, Y, 2000) |
| "Trough steady state serum levels of lansoprazole or ranitidine, amoxycillin, clarithromycin and metronidazole were monitored in 232 patients during the last dosing interval of a 5-day quadruple H." | 1.31 | Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. ( Ammon, S; Kees, F; Klotz, U; Treiber, G, 2000) |
| "pylori and oesophagitis is mediated by the effect of H." | 1.31 | Should we eradicate Helicobacter pylori in patients with recurrent gastro-oesophageal reflux disease? ( Bianchi Porro, G; Pace, F, 2000) |
| " pylori infection appears to be closely related to the occurrence of nocturnal gastric acid breakthrough during dosing with a proton pump inhibitor." | 1.31 | Helicobacter pylori infection influences nocturnal gastric acid breakthrough. ( Adachi, K; Amano, K; Katsube, T; Kawamura, A; Kinoshita, Y; Uchida, Y; Watanabe, M, 2000) |
| "Cumulative ulcer recurrence rate for 12 months, respectively for patients with eradication success and failure, was 2." | 1.31 | [Effects of Helicobacter pylori eradication on the recurrence of gastric ulcer during a 12-month follow up]. ( Bermejo, F; Boixeda, D; Defarges, V; García Plaza, A; Gisbert, JP; Martín de Argila, C; Sanz, JM, 2000) |
| "Pre-treatment metronidazole resistance was encountered in 57/74 strains (77." | 1.31 | Efficacy of a 1-week pantoprazole triple therapy in eradicating Helicobacter pylori in Asian patients. ( Cheah, P; Chin, S; Goh, K; Parasakthi, N; Ranjeev, C; Rosmawati, M; Tan, Y, 2000) |
| "Treatment with omeprazole, amoxicillin, and clarithromycin resulted in eradication of the infection in all and in resolution of the clinical symptoms in 15 (80%) of 19 patients who had a follow-up examination." | 1.31 | Helicobacter pylori infection in recurrent abdominal pain. ( Braegger, CP; Frank, F; Stallmach, T; Stricker, T, 2000) |
| "pylori eradication on low-grade gastric MALT lymphoma and to investigate the whitish mucosa that appeared with regression of the lesions." | 1.31 | Endoscopic characteristics of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori. ( Begum, S; Endo, H; Kawamata, H; Oki, Y; Sano, T; Urakami, Y, 2000) |
| "It was concluded that the recurrence of HP infection is low at the end of one year after successful eradication therapy in this urban East Asian population." | 1.31 | Recurrence of Helicobacter pylori infection and duodenal ulcer relapse, following successful eradication in an urban east Asian population. ( Fock, KM; Khor, CJ; Ng, A; Ng, TM; Sim, CS; Tan, AL; Teo, EK, 2000) |
| "Rabeprazole is a potent proton pump inhibitor and is mainly reduced to thioether rabeprazole by a non-enzymatic pathway and partially metabolized to demethylated rabeprazole by CYP2C19 in the liver." | 1.31 | Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. ( Furuta, T; Hanai, H; Ishizaki, T; Nakagawa, K; Ohashi, K; Shirai, N; Sugimura, H; Takashima, M; Xiao, F, 2001) |
| "H pylori was detected in the dental plaque with camphylobacter-like organism test gels." | 1.31 | The relationship between gastric-oral Helicobacter pylori and oral hygiene in patients with vitamin B12-deficiency anemia. ( Avcu, F; Avcu, N; Beyan, C; Kaptan , K; Nevruz, O; Ozyurt, M; Ural, AU; Yalçin, A, 2001) |
| "1 year after drug therapy the recurrence of CDU is revealed in 16." | 1.31 | [Current principles of the use of laparoscopic surgery in gastroduodenal ulcer]. ( Fedorov, AV; Sazhin, VP, 2001) |
| "We determined late recrudescence rates, true reinfection, and ulcer recurrence." | 1.31 | Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults. ( Ahmad, MM; Arefin, MS; Bardhan, P; Bauerfeind, P; Beglinger, C; Glatz-Krieger, K; Gyr, N; Hasan, M; Hildebrand, P; Khan, AK; Parvin, S; Rahman, A; Rossi, L; Terracciano, L, 2001) |
| "Treatment with clarithromycin, metronidazole and pantoprazole eradicated H." | 1.31 | Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole. ( Kaddu, S; Kränke, B; Mayr-Kanhäuser, S; Müllegger, RR, 2001) |
| "When omeprazole-treated mice were treated with antibiotics alone, elevated plasma gastrin levels returned to baseline and D cell numbers returned to resting levels despite persistent hypochlorhydria." | 1.31 | Hypergastrinemia in response to gastric inflammation suppresses somatostatin. ( Ferguson, A; Merchant, JL; Rieder, G; Samuelson, LC; Zavros, Y, 2002) |
| "pylori-positive low-grade gastric MALT lymphoma (stage I E1)." | 1.31 | Regression of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: possible association with p16 hypermethylation. ( Jung, HC; Kim, CW; Kim, CY; Kim, JS; Kim, YS; Lee, CH; Song, IS, 2002) |
| "Omeprazole was also not statistically different from misoprostol for gastric ulcer prevention in those whose NSAID use was complicated by an active H." | 1.31 | Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users. ( Graham, DY, 2002) |
| "Presence of a gastroduodenal ulcer, age, gender and smoking habit did not differ significantly between the eradicated and noneradicated groups." | 1.31 | Failure of Helicobacter pylori eradication: is poor compliance the main cause? ( Baumann, R; Buri, P; Cunningham, M; Dederding, JP; Gallaz, L; Girard, L; Godin, N; Merki, H; Metry, JM; Sitavanc, R; Wermeille, J; Zelger, G, 2002) |
| "Esomeprazole is an effective and well tolerated treatment for managing GORD and for eradicating H." | 1.31 | Esomeprazole: a review of its use in the management of acid-related disorders in the US. ( Dunn, CJ; Mallarkey, G; Scott, LJ; Sharpe, M, 2002) |
| "To evaluate management of dyspepsia, gastroduodenal ulcer and Helicobacter pylori infection in the setting of family practice." | 1.31 | [Management of dyspepsia, gastroduodenal ulcer and Helicobacter pylori infection in primary care]. ( Azagra, R; Calvet, X; Cubells, MJ; Gené, E; López, T, 2002) |
| "Chronic gastritis was diagnosed in 63 (77." | 1.31 | Detection of Helicobacter pylori colonization in dental plaques and tongue scrapings of patients with chronic gastritis. ( Ateşkan, U; Mas, MR; Ozdemir, A; Sağlamkaya, U; Sahin, S, 2001) |
| "Of the 83 smokers, 3 (3." | 1.30 | Does smoking predispose to peptic ulcer relapse after eradication of Helicobacter pylori? ( Chan, FK; Chan, LY; Chung, SC; Lee, YT; Leung, WK; Sung, JJ; Yung, MY, 1997) |
| "Lactoferrin (Lf) is an iron-binding glycoprotein present in milk, lacrimae, saliva, and gastroduodenal secretions." | 1.30 | Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. ( Ikemura, N; Imoto, I; Misaki, M; Nakao, K; Shibata, T; Taguchi, Y; Takaji, S; Yamauchi, K; Yamazaki, N, 1997) |
| "Furazolidone is an inexpensive antibiotic that has considerable anti-Helicobacter pylori activity in vitro." | 1.30 | Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week. ( Kooy, A; Thijs, JC; van der Wouden, EJ; Van Zwet, AA, 1997) |
| "Endoscopy after ER detected no new gastric cancers in these patients." | 1.30 | Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. ( Haruma, K; Kajiyama, G; Mashiba, H; Mukai, T; Okamoto, S; Sasaki, N; Sumii, K; Taniyama, K; Uemura, N; Yamaguchi, S, 1997) |
| "More than 90% of gastric MALT lymphomas are diagnosed in patients with chronic, Helicobacter pylori-associated gastritis." | 1.30 | Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. ( Alpen, B; Bayerdörffer, E; Ehninger, G; Morgner, A; Neubauer, A; Neubauer, B; Ritter, M; Stolte, M; Thiede, C; Wündisch, T, 1997) |
| "pylori with low-grade gastric B-cell MALT lymphoma were examined by echoendoscopy at the time of diagnosis." | 1.30 | Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. ( Bayerdoerffer, E; Boersch, G; Kraemer, W; Morgner, A; Neubauer, A; Rohde, P; Rudolph, B; Sackmann, M; Schulz, H; Seifert, E; Stolte, M; Thiede, C, 1997) |
| "Gastritis was scored according to Sydney criteria." | 1.30 | Anti-Helicobacter pylori specific antibody immunohistochemistry improves the diagnostic accuracy of Helicobacter pylori in biopsy specimen from patients treated with triple therapy. ( Angelucci, D; Cellini, L; Di Campli, E; Diodoro, MG; Grossi, L; Marzio, L, 1998) |
| "pylori infection is associated with hepatic encephalopathy, especially in younger patients with decompensated liver disease." | 1.30 | Analysis of risk factors for chronic hepatic encephalopathy: the role of Helicobacter pylori infection. ( Dasani, BM; Lieber, CS; Sigal, SH, 1998) |
| "The laryngitis was clinically and endoscopically unchanged in ten of the twelve (83." | 1.30 | [Is chronic laryngitis associated with Helicobacter pylori? Results of a prospective study]. ( Arps, H; Diehl, KL; Draf, W; Jaspersen, D; Kind, M; Weber, R, 1998) |
| "The urea breath test was repeated at 28 days." | 1.30 | Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. ( Estrada, R; Fennerty, MB; Knigge, K; Laine, L; Trujillo, M, 1998) |
| "[14C]Urea breath tests were performed in 20 H." | 1.30 | Current or recent proton pump inhibitor therapy markedly impairs the accuracy of the [14C]urea breath test. ( El-Nujumi, A; Hilditch, TE; McColl, KE; Williams, C, 1998) |
| "Omeprazole has a greater intragastric pH elevating effect in Helicobacter pylori positive than negative subjects." | 1.30 | Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. ( Ardill, JE; Gillen, D; McColl, KE; Neithercut, WD; Wirz, AA, 1999) |
| " Discouraging the use of over-the-counter H2 antagonists, ruling out long-term use of nonsteroidal anti-inflammatory drugs before selecting the treatment regimen, and considering expected treatment compliance are important aspects of PUD management that emerged from this case." | 1.30 | Understanding peptic ulcer disease pharmacotherapeutics. ( Navuluri, R; Yue, S, 1999) |
| "Hyperemesis gravidarum is the most severe spectrum of gastrointestinal complaints in pregnant women." | 1.30 | Helicobacter pylori infection and persistent hyperemesis gravidarum. ( Jacoby, EB; Porter, KB, 1999) |
| "To determine the response of gastric MALT lymphoma to antibiotic treatment." | 1.30 | Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. ( Cabanillas, FF; Ford, R; Genta, RM; Glober, G; Graham, DY; Hagemeister, FB; Johnson, CM; Lahoti, S; Lee, JE; Luthra, R; Lynch, PM; Manning, JT; McLaughlin, PW; Rodriguez, MA; Romaguera, JE; Sample, D; Sarris, AH; Shen, Y; Steinbach, G; Winn, RJ; Younes, A, 1999) |
| " Primary metronidazole resistance may reduce its effectiveness, but an increased daily dosing of metronidazole may partly overcome this problem." | 1.30 | Omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection. ( Bardhan, KD; Bayerdörffer, E; Delchier, JC; Díte, P; Lind, T; Mégraud, F; O'Morain, C; Sipponen, P; Spiller, R; Veldhuyzen van Zanten, S; Zeijlon, L, 1999) |
| "Omeprazole does increase intragastric pH in bleeding peptic ulcer patients with H." | 1.30 | Will Helicobacter pylori affect short-term rebleeding rate in peptic ulcer bleeding patients after successful endoscopic therapy? ( Chang, FY; Hsieh, YH; Lee, FY; Lee, SD; Lin, HJ; Perng, CL; Tseng, GY, 1999) |
| "After 1 year, no patient had H." | 1.30 | Duodenal ulcer relapse is not always associated with recurrence of H. pylori infection: a prospective three-year follow-up study. ( Annibale, B; D'Ambra, G; Delle Fave, G; Marcheggiano, A; Martino, G; Paoletti, M, 1999) |
| "pylori)with an increased risk of gastric cancer has been well documented, the exact mechanisms of this association have not been fully elucidated." | 1.30 | Proliferating cell nuclear antigen (PCNA) immunostaining in Helicobacter pylori infection: impact of eradication. ( Antoniades, D; Kalafatis, E; Karameris, A; Lazaris, A; Liatsos, C; Petridou, E; Rokkas, T, 1999) |
| "H." | 1.29 | Prevalence of Helicobacter pylori infection in patients with large gastric folds: evaluation and follow-up with endoscopic ultrasound before and after antimicrobial therapy. ( Avunduk, C; Coughlin, B; Hampf, F; Navab, F, 1995) |
| "Duodenal ulcers were healed with omeprazole, 20 mg/day." | 1.29 | Helicobacter pylori eradication in the African setting, with special reference to reinfection and duodenal ulcer recurrence. ( Jaskiewicz, K; Lastovica, AJ; Louw, JA; Lucke, W; Marks, IN; Winter, TA, 1995) |
| "In patients with systemic sclerosis peristaltic abnormalities may delay gastric emptying, giving rise to bacterial overgrowth, including possibly Helicobacter pylori (HP)." | 1.29 | Helicobacter pylori in patients with systemic sclerosis: detection with the 13C-urea breath test and eradication. ( Goerz, G; Humfeld, S; Reinauer, H; Reinauer, S; Ruzicka, T; Susanto, F, 1994) |
| "The H." | 1.29 | Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection. ( Börsch, G; Labenz, J, 1994) |
| "It is used for treatment of gastroduodenal ulcers, reflux oesophagitis and Zollinger Ellison's syndrome." | 1.29 | [The effect of omeprazole on healing of duodenal ulcers, Helicobacter pylori and gastritis]. ( Drábek, J; Hanika, J; Soucková, A; Vejvalka, J; Zelenková, J; Zeman, V, 1993) |
| "Pre-treatment metronidazole susceptible H pylori were significantly more likely to respond to the triple therapy used than those with the metronidazole resistant ones (14 of 15 v five of 10) (p = 0." | 1.29 | Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. ( Ching, CK; Lai, CL; Lai, KC; Lam, SK; Leung, KP; Wong, BC; Yung, RW, 1996) |
| "To verify the effectiveness and side-effect profile of an eradicating regimen consisting of omeprazole 20 mg daily for 4 weeks and, during the first week, combination antimicrobial treatment with tinidazole 500 mg b." | 1.29 | High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication. ( Carli, G; Dalla Libera, M; Gamberini, S; Gullini, S; Merighi, A; Pazzi, P; Scagliarini, R, 1996) |
| "Lansoprazole has a cytotoxic action against this organism, the MIC being 2." | 1.29 | Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication. ( Kawano, S; Murakami, M; Saita, H; Tsuji, S, 1996) |
| "Omeprazole treatment produces lower intragastric pH values 4 weeks after cure of Helicobacter pylori infection than before." | 1.29 | Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. ( Armstrong, D; Blum, AL; Börsch, G; Idström, JP; Labenz, J; Stolte, M; Verdú, EF, 1996) |
| "An agar dilution checkerboard method was used to evaluate the in vitro activity of omeprazole combined with clarithromycin, amoxicillin, and ceftibuten, respectively, against clinical isolates of Helicobacter pylori." | 1.29 | In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori. ( Alarcón, T; Díaz de Rojas, F; Domingo, D; López-Brea, M; Sánchez, I, 1996) |
| "2." | 1.28 | [Current perspectives in ulcer disease]. ( Beglinger, C, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 880 (41.73) | 18.2507 |
| 2000's | 1031 (48.89) | 29.6817 |
| 2010's | 166 (7.87) | 24.3611 |
| 2020's | 32 (1.52) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, KS | 1 |
| Shah, AK | 1 |
| Bariwal, J | 1 |
| Shelke, SM | 1 |
| Kale, AP | 1 |
| Jagtap, JR | 1 |
| Bhosale, AV | 1 |
| Azevedo-Vethacke, M | 1 |
| Garten, D | 1 |
| Groll, C | 1 |
| Schreiber, S | 1 |
| Ma, Z | 1 |
| He, S | 1 |
| Yuan, Y | 2 |
| Zhuang, Z | 1 |
| Liu, Y | 1 |
| Wang, H | 5 |
| Chen, J | 3 |
| Xu, X | 1 |
| Ding, C | 1 |
| Molodtsov, V | 1 |
| Lin, W | 1 |
| Robertson, GT | 1 |
| Weiss, WJ | 1 |
| Pulse, M | 1 |
| Nguyen, P | 1 |
| Duncan, L | 1 |
| Doyle, T | 1 |
| Ebright, RH | 1 |
| Lynch, AS | 1 |
| Bunchorntavakul, C | 1 |
| Buranathawornsom, A | 1 |
| Hassib, ST | 1 |
| Taha, EA | 1 |
| Sharf, MG | 1 |
| Mostafa, EA | 1 |
| Nestegard, O | 2 |
| Moayeri, B | 1 |
| Halvorsen, FA | 1 |
| Tønnesen, T | 2 |
| Sørbye, SW | 1 |
| Paulssen, E | 1 |
| Johnsen, KM | 1 |
| Goll, R | 2 |
| Florholmen, JR | 1 |
| Melby, KK | 1 |
| Xu, WF | 1 |
| Wang, Y | 4 |
| Huang, H | 2 |
| Wu, JW | 1 |
| Che, Y | 1 |
| Ding, CJ | 1 |
| Zhang, Q | 1 |
| Cao, WL | 1 |
| Cao, LJ | 1 |
| Ghoshal, UC | 1 |
| Blaachandran, A | 1 |
| Rai, S | 2 |
| Misra, A | 1 |
| Bai, G | 1 |
| Yi, J | 1 |
| Yu, Y | 1 |
| Du, H | 2 |
| Yakovenko, EP | 2 |
| Strokova, TV | 1 |
| Iakovenko, AV | 1 |
| Ivanov, AN | 1 |
| Soluyanova, IP | 1 |
| Vasilyev, NN | 1 |
| Gao, N | 2 |
| Yan, S | 2 |
| Chen, B | 2 |
| Atanda, H | 1 |
| Balogun, TA | 1 |
| Alshehri, MM | 1 |
| Olivos-Ramirez, G | 1 |
| Vilca-Quispe, J | 1 |
| Chenet-Zuta, M | 1 |
| Cárdenas-Cárdenas, R | 1 |
| Delgado Wong, H | 1 |
| Ropón-Palacios, G | 1 |
| Umar, HI | 1 |
| Zhu, H | 1 |
| Pan, X | 2 |
| Zhang, L | 18 |
| Sun, H | 2 |
| Fan, H | 1 |
| Pan, Z | 1 |
| Huang, C | 1 |
| Shi, Z | 1 |
| Ding, J | 2 |
| Wang, Q | 1 |
| Du, Y | 3 |
| Lyu, N | 1 |
| Li, Z | 2 |
| Shah, S | 2 |
| Cappell, K | 1 |
| Sedgley, R | 1 |
| Pelletier, C | 1 |
| Jacob, R | 1 |
| Bonafede, M | 1 |
| Yadlapati, R | 1 |
| Zhang, WL | 1 |
| Lin, BS | 1 |
| Li, YY | 2 |
| Ding, YM | 1 |
| Han, ZX | 3 |
| Ji, R | 2 |
| Howden, CW | 6 |
| Pendse, SN | 1 |
| Offman, E | 1 |
| Almenoff, JS | 1 |
| Sheldon, KL | 1 |
| Muhialdin, AJ | 1 |
| Alamri, ZZ | 1 |
| M Hussein, A | 1 |
| Faraj, RK | 1 |
| Taha, ZB | 1 |
| Hussein, MM | 1 |
| Mojarradgandoukmolla, S | 1 |
| Valencia, ME | 1 |
| Montejano, R | 1 |
| Moreno, V | 3 |
| Martín Carbonero, L | 1 |
| Bernardino, JI | 1 |
| Serrano, L | 1 |
| Zhou, Y | 2 |
| Ye, Z | 2 |
| Zhang, Y | 3 |
| Tang, Z | 1 |
| Yan, W | 1 |
| Jiang, Y | 2 |
| Huang, Y | 3 |
| Gurung, SB | 1 |
| Kc, SR | 1 |
| Gyawali, P | 1 |
| Amatya, GL | 1 |
| Vilaichone, RK | 2 |
| Aumpan, N | 1 |
| Ratanachu-Ek, T | 1 |
| Gamnarai, P | 1 |
| Uchida, T | 4 |
| Tshering, L | 1 |
| Mahachai, V | 5 |
| Yamaoka, Y | 4 |
| Graham, DY | 36 |
| Canaan, Y | 1 |
| Maher, J | 1 |
| Wiener, G | 1 |
| Hulten, KG | 1 |
| Kalfus, IN | 1 |
| Kim, SE | 1 |
| Memon, A | 1 |
| Kim, BY | 1 |
| Jeon, H | 1 |
| Lee, WK | 1 |
| Kang, SC | 1 |
| Lu, J | 1 |
| Miao, S | 1 |
| Lu, X | 2 |
| Wu, J | 1 |
| Cisarò, F | 1 |
| Pizzol, A | 1 |
| Calvo, PL | 1 |
| Chen, P | 1 |
| Li, L | 1 |
| Zhao, J | 1 |
| Cheng, Y | 1 |
| Xie, J | 1 |
| Cao, M | 1 |
| Huang, L | 1 |
| Yang, F | 1 |
| Chen, H | 1 |
| Su, M | 1 |
| Xu, Y | 1 |
| Zheng, F | 1 |
| Geng, L | 2 |
| Xu, W | 1 |
| Gong, S | 1 |
| Jr, JM | 1 |
| Elhendawy, M | 1 |
| Hagras, MM | 1 |
| Soliman, SS | 1 |
| Shaker, ESE | 1 |
| Razavizadeh, M | 1 |
| Arj, A | 2 |
| Madani, M | 1 |
| Gilassi, H | 1 |
| Damanhuri, NS | 1 |
| Kumolosasi, E | 1 |
| Omar, MS | 1 |
| Razak, AFA | 1 |
| Mansor, AH | 1 |
| Kodama, M | 10 |
| Okimoto, T | 12 |
| Mizukami, K | 1 |
| Hirashita, Y | 1 |
| Wada, Y | 1 |
| Fukuda, M | 3 |
| Matsunari, O | 1 |
| Okamoto, K | 1 |
| Ogawa, R | 1 |
| Fukuda, K | 1 |
| Kudo, Y | 1 |
| Kawahara, Y | 2 |
| Murakami, K | 14 |
| Bustamante-Rengifo, JA | 1 |
| Matta, AJ | 1 |
| Pazos, AJ | 1 |
| Bravo, LE | 3 |
| Tan, B | 1 |
| Luo, HQ | 1 |
| Xu, H | 1 |
| Lv, NH | 1 |
| Shi, RH | 1 |
| Luo, HS | 1 |
| Li, JS | 1 |
| Ren, JL | 1 |
| Zou, YY | 1 |
| Li, YQ | 2 |
| Ji, F | 3 |
| Fang, JY | 2 |
| Qian, JM | 1 |
| Sharifi, R | 1 |
| Nouri, M | 1 |
| Eidi, A | 1 |
| Noormohammadi, Z | 1 |
| Dolatkhah, H | 1 |
| Shirmohammadi, M | 1 |
| Ozturk, O | 1 |
| Doganay, L | 1 |
| Colak, Y | 1 |
| Yilmaz Enc, F | 1 |
| Ulasoglu, C | 1 |
| Ozdil, K | 1 |
| Tuncer, I | 1 |
| Gómez Rodríguez, BJ | 1 |
| Castro Laria, L | 1 |
| Argüelles Arias, F | 1 |
| Castro Márquez, C | 1 |
| Caunedo Álvarez, Á | 1 |
| Romero Gómez, M | 3 |
| Miyamoto, S | 1 |
| Kato, M | 14 |
| Matsuda, K | 1 |
| Abiko, S | 1 |
| Tsuda, M | 1 |
| Mizushima, T | 3 |
| Yamamoto, K | 3 |
| Ono, S | 1 |
| Kudo, T | 3 |
| Shimizu, Y | 3 |
| Hatanaka, KC | 1 |
| Tsunematsu, I | 1 |
| Sakamoto, N | 1 |
| Ramas, M | 1 |
| Donday, MG | 1 |
| McNicholl, AG | 3 |
| Gisbert, JP | 45 |
| Xie, Y | 3 |
| Li, Y | 4 |
| Xu, J | 3 |
| Wang, J | 4 |
| Zeng, Z | 1 |
| Chen, Y | 4 |
| Zhang, G | 2 |
| Wu, K | 1 |
| Liu, D | 1 |
| Lv, N | 1 |
| Gutiérrez-Espíndola, G | 1 |
| Gallardo-Wong, I | 1 |
| Morán-Villota, S | 1 |
| Álvarez-Pantoja, E | 1 |
| Guerrero-Rivera, S | 1 |
| Medrano-Contreras, J | 1 |
| Gallardo-Montoya, JM | 1 |
| Maillón-García, LA | 1 |
| Ramadan, M | 1 |
| Chen, L | 1 |
| He, J | 1 |
| Wang, L | 2 |
| Ge, Q | 1 |
| Chu, H | 1 |
| Chen, X | 2 |
| Long, Y | 1 |
| Deng, Y | 1 |
| He, H | 1 |
| Li, A | 1 |
| Chen, S | 3 |
| Salmanroghani, H | 1 |
| Mirvakili, M | 1 |
| Baghbanian, M | 1 |
| Salmanroghani, R | 1 |
| Sanati, G | 1 |
| Yazdian, P | 1 |
| Agudo-Fernández, S | 1 |
| González Blanco, A | 1 |
| Kabakambira, JD | 1 |
| Hategeka, C | 1 |
| Page, C | 1 |
| Ntirenganya, C | 1 |
| Dusabejambo, V | 1 |
| Ndoli, J | 1 |
| Ngabonziza, F | 1 |
| Hale, D | 1 |
| Bayingana, C | 1 |
| Walker, T | 1 |
| Salar, A | 1 |
| Seddik, H | 2 |
| Boutallaka, H | 1 |
| Elkoti, I | 1 |
| Nejjari, F | 1 |
| Berraida, R | 1 |
| Berrag, S | 1 |
| Loubaris, K | 1 |
| Sentissi, S | 1 |
| Benkirane, A | 2 |
| Andreev, DN | 2 |
| Maev, IV | 4 |
| Dicheva, DT | 2 |
| Samsonov, AA | 1 |
| Partzvania-Vinogradova, EV | 2 |
| Yurenev, GL | 1 |
| Maiev, IV | 1 |
| Arévalo Galvis, A | 1 |
| Trespalacios Rangel, AA | 1 |
| Otero Regino, W | 1 |
| Martín-Núñez, GM | 1 |
| Cornejo-Pareja, I | 1 |
| Coin-Aragüez, L | 1 |
| Roca-Rodríguez, MDM | 1 |
| Muñoz-Garach, A | 1 |
| Clemente-Postigo, M | 1 |
| Cardona, F | 1 |
| Moreno-Indias, I | 1 |
| Tinahones, FJ | 1 |
| Hang, X | 1 |
| Jiang, X | 1 |
| Zeng, L | 1 |
| Jia, J | 1 |
| Li, F | 1 |
| Bi, H | 1 |
| Tseng, DS | 1 |
| Li, D | 1 |
| Cholleti, SM | 1 |
| Wei, JC | 1 |
| Jodesty, Y | 1 |
| Pham, HV | 1 |
| Callus, R | 1 |
| Felice, T | 1 |
| Balzan, D | 1 |
| Delicata, L | 1 |
| Mazzoleni, F | 3 |
| Mazzoleni, LE | 5 |
| de Magalhães Francesconi, CF | 1 |
| Sander, GB | 5 |
| Von Reisswitz, PS | 2 |
| Milbradt, TC | 2 |
| da Veiga Chaves Picon, R | 1 |
| Uchoa, DM | 4 |
| De Bona, LR | 2 |
| Andreolla, HF | 1 |
| Breyer, HP | 1 |
| Spinato Torresini, R | 1 |
| Ott, EA | 3 |
| Wortmann, AC | 3 |
| de Lucena Theil, A | 1 |
| Stifft, J | 1 |
| Zenker, RP | 1 |
| Krumel, CF | 1 |
| Michalczuk, MT | 1 |
| De Araujo, A | 1 |
| Canevese, AP | 1 |
| Volpato, N | 1 |
| da Silva, CA | 1 |
| Schaefer, PG | 1 |
| Titton, NF | 1 |
| Longo, L | 1 |
| Edelweiss, MI | 4 |
| Simon, D | 2 |
| Talley, NJ | 9 |
| Valle Muñoz, J | 1 |
| Muñoz Gómez, P | 1 |
| Sierra Bernal, C | 1 |
| de Andrés, E | 1 |
| Gómez Hernando, C | 1 |
| Gómez Rodríguez, R | 1 |
| Attia, TZ | 1 |
| Yamashita, T | 1 |
| Tsujino, H | 1 |
| Derayea, SM | 1 |
| Tsutsumi, Y | 3 |
| Uno, T | 1 |
| Otsuka, SH | 1 |
| Konorev, MR | 2 |
| Benajah, DA | 1 |
| Lahbabi, M | 1 |
| Alaoui, S | 1 |
| El Rhazi, K | 1 |
| El Abkari, M | 1 |
| Nejjari, C | 1 |
| Amarti, A | 1 |
| Bennani, B | 1 |
| Mahmoud, M | 1 |
| Ibrahimi, SA | 1 |
| Wu, Y | 1 |
| Tao, Z | 1 |
| Song, C | 1 |
| Jia, Q | 1 |
| Bai, J | 1 |
| Zhi, K | 1 |
| Qu, L | 1 |
| Seyedmajidi, S | 1 |
| Mirsattari, D | 3 |
| Zojaji, H | 3 |
| Zanganeh, E | 1 |
| Seyyedmajidi, M | 3 |
| Almasi, S | 1 |
| Zali, M | 2 |
| Köksal, AS | 2 |
| Onder, FO | 1 |
| Torun, S | 1 |
| Parlak, E | 2 |
| Sayilir, A | 1 |
| Tayfur, O | 1 |
| Yildiz, H | 1 |
| Ozbalci, GS | 1 |
| Kayaçetin, E | 1 |
| Marin, AC | 2 |
| Molina-Infante, J | 3 |
| Castro, M | 2 |
| Barrio, J | 5 |
| Ducons, J | 6 |
| Calvet, X | 21 |
| de la Coba, C | 1 |
| Montoro, M | 5 |
| Bory, F | 7 |
| Perez-Aisa, A | 5 |
| Forné, M | 3 |
| Ahid, S | 1 |
| El Adioui, T | 1 |
| El Hamdi, FZ | 1 |
| Hassar, M | 1 |
| Abouqal, R | 1 |
| Cherrah, Y | 1 |
| Zullo, A | 18 |
| Scaccianoce, G | 3 |
| De Francesco, V | 15 |
| Ruggiero, V | 1 |
| D'Ambrosio, P | 1 |
| Castorani, L | 1 |
| Bonfrate, L | 1 |
| Vannella, L | 1 |
| Hassan, C | 13 |
| Portincasa, P | 1 |
| Asaoka, D | 3 |
| Nagahara, A | 16 |
| Matsuhisa, T | 2 |
| Takahashi, S | 11 |
| Tokunaga, K | 6 |
| Kawai, T | 5 |
| Kawakami, K | 5 |
| Suzuki, H | 10 |
| Suzuki, M | 8 |
| Nishizawa, T | 2 |
| Kurihara, N | 2 |
| Ito, M | 6 |
| Sasaki, H | 2 |
| Omata, F | 2 |
| Mizuno, S | 4 |
| Torii, A | 2 |
| Ohkusa, T | 9 |
| Mine, T | 3 |
| Sakaki, N | 5 |
| Sarkeshikian, SS | 1 |
| Iranikhah, A | 2 |
| Ghadir, MR | 2 |
| Labenz, J | 44 |
| Huang, J | 5 |
| Zhou, L | 2 |
| Yang, M | 1 |
| Xu, XW | 1 |
| Ding, ZL | 1 |
| Mao, M | 1 |
| Wang, ZL | 1 |
| Li, ZL | 1 |
| Li, DY | 1 |
| Gong, ST | 2 |
| Hsiang, J | 1 |
| Selvaratnam, S | 1 |
| Taylor, S | 1 |
| Yeoh, J | 1 |
| Tan, YM | 1 |
| Patrick, A | 1 |
| Nashaat, EH | 1 |
| Mansour, GM | 1 |
| Vafaeimanesh, J | 2 |
| Jalalzadeh, M | 1 |
| Nazarian, M | 1 |
| Jung, YS | 1 |
| Lee, SH | 3 |
| Park, CS | 1 |
| Oh, MJ | 1 |
| Kim, KO | 1 |
| Jang, BI | 1 |
| Jeon, SW | 1 |
| Jung, MK | 1 |
| Park, KS | 1 |
| Kim, ES | 1 |
| Cho, KB | 1 |
| Jung, JT | 1 |
| Kwon, JG | 1 |
| Kim, EY | 1 |
| Kim, WJ | 1 |
| Yang, CH | 1 |
| Ma, B | 1 |
| Hang, L | 1 |
| Chen, G | 2 |
| Telaku, S | 1 |
| Manxhuka-Kerliu, S | 1 |
| Kraja, B | 1 |
| Qirjako, G | 1 |
| Prifti, S | 1 |
| Fejza, H | 1 |
| Zhao, HM | 1 |
| Ou-Yang, HJ | 1 |
| Duan, BP | 1 |
| Xu, B | 1 |
| Chen, ZY | 1 |
| Tang, J | 1 |
| You, JY | 1 |
| Liu, KY | 1 |
| Du, FC | 1 |
| Fu, Q | 1 |
| Zhang, WJ | 1 |
| Sun, HW | 1 |
| Gan, le L | 1 |
| Yue, ZY | 1 |
| Zou, QM | 1 |
| Guo, G | 1 |
| Sezgin, O | 2 |
| Barlas, IO | 1 |
| Uçbilek, E | 1 |
| Yengel, E | 1 |
| Altintaş, E | 2 |
| Lin, S | 1 |
| Ding, S | 1 |
| Huang, X | 1 |
| Jin, Z | 1 |
| Cui, R | 1 |
| Meng, L | 2 |
| Guo, C | 1 |
| Xue, Y | 1 |
| Yan, X | 2 |
| Zhang, J | 4 |
| Sachs, G | 1 |
| Shin, JM | 1 |
| Munson, K | 1 |
| Scott, DR | 1 |
| Delchier, JC | 12 |
| Malfertheiner, P | 20 |
| Thieroff-Ekerdt, R | 1 |
| Hosseini, SM | 1 |
| Sharifipoor, F | 1 |
| Nazemian, F | 1 |
| Ghanei, H | 1 |
| Zivarifar, HR | 1 |
| Fakharian, T | 1 |
| Li, WQ | 1 |
| Ma, JL | 10 |
| Brown, LM | 8 |
| Li, JY | 6 |
| Shen, L | 6 |
| Pan, KF | 8 |
| Liu, WD | 8 |
| Hu, Y | 4 |
| Crystal-Mansour, S | 3 |
| Pee, D | 4 |
| Blot, WJ | 4 |
| Fraumeni, JF | 5 |
| You, WC | 11 |
| Gail, MH | 8 |
| Khamraev, AA | 1 |
| Rustamova, MT | 1 |
| Khaĭrullaeva, SS | 1 |
| Tian, A | 1 |
| Xu, T | 1 |
| Liu, K | 1 |
| Zou, Q | 1 |
| Lambert, D | 1 |
| Rouger, C | 1 |
| Diebold, MD | 2 |
| Ramaholimihaso, F | 1 |
| Boulagnon, C | 1 |
| Nguyen, Y | 1 |
| Hentzien, M | 1 |
| Jaussaud, R | 1 |
| Bani-Sadr, F | 1 |
| Patel, SK | 1 |
| Mishra, GN | 1 |
| Pratap, CB | 1 |
| Jain, AK | 1 |
| Nath, G | 1 |
| Higuchi, K | 10 |
| Takeuchi, T | 1 |
| Uedo, N | 1 |
| Takeuchi, Y | 2 |
| Naito, Y | 2 |
| Yagi, N | 1 |
| Tominaga, K | 5 |
| Machida, H | 1 |
| Tamada, T | 1 |
| Morita, Y | 1 |
| Yazumi, S | 1 |
| Yamao, J | 1 |
| Iguchi, M | 1 |
| Azuma, T | 7 |
| Martos, M | 2 |
| Bujanda, L | 5 |
| Salicio, Y | 2 |
| Sarasqueta, C | 2 |
| Ibarra, B | 2 |
| Mendarte, U | 2 |
| Fernández-Reyes, M | 1 |
| Cosme, A | 10 |
| Modolell, I | 3 |
| Aisa, AP | 1 |
| Castro-Fernández, M | 6 |
| Rodrigo, L | 5 |
| Gisbert, JL | 7 |
| Fernández-Bermejo, M | 5 |
| Marcos, S | 7 |
| Polinkevych, BS | 1 |
| Pikas, PB | 1 |
| Khoshnood, A | 1 |
| Hakimi, P | 1 |
| Salman-Roghani, H | 1 |
| Reza Mirjalili, M | 1 |
| El-Garem, Y | 1 |
| El-Sawy, M | 1 |
| Mostafa, T | 1 |
| Ahmed, S | 1 |
| Atia, NN | 1 |
| Masaoaka, T | 1 |
| Hajaghamohammadi, A | 1 |
| Safiabadi Tali, SH | 1 |
| Samimi, R | 1 |
| Oveisi, S | 1 |
| Kazemifar, AM | 1 |
| Zhang, S | 2 |
| Lee, DS | 1 |
| Morrissey, R | 1 |
| Aponte-Pieras, JR | 1 |
| Rogers, AB | 2 |
| Moss, SF | 3 |
| Teng, M | 1 |
| Khoo, AL | 1 |
| Zhao, YJ | 1 |
| Lin, L | 1 |
| Lim, BP | 1 |
| Wu, TS | 1 |
| Dan, YY | 1 |
| Hauser, G | 1 |
| Salkic, N | 1 |
| Vukelic, K | 1 |
| JajacKnez, A | 1 |
| Stimac, D | 6 |
| Elokhina, EV | 1 |
| Kostenko, MB | 1 |
| Livzan, MA | 2 |
| Scalskiy, SV | 1 |
| Haider, RB | 1 |
| Brennan, DE | 1 |
| Omorogbe, J | 1 |
| Holleran, G | 1 |
| Hall, B | 1 |
| O'Morain, C | 17 |
| Breslin, N | 1 |
| O'Connor, HJ | 7 |
| Smith, SM | 1 |
| McNamara, D | 1 |
| Asif, HM | 1 |
| Zaidi, SF | 1 |
| Sugiyama, T | 16 |
| Akhtar, N | 1 |
| Usmanghani, K | 1 |
| Dingemanse, C | 1 |
| Belzer, C | 1 |
| van Hijum, SA | 1 |
| Günthel, M | 1 |
| Salvatori, D | 1 |
| den Dunnen, JT | 1 |
| Kuijper, EJ | 1 |
| Devilee, P | 1 |
| de Vos, WM | 1 |
| van Ommen, GB | 1 |
| Robanus-Maandag, EC | 1 |
| Zhou, T | 3 |
| John, A | 1 |
| Al Kaabi, S | 1 |
| Doiphode, S | 1 |
| Chandra, P | 1 |
| Sharma, M | 1 |
| Babu, R | 1 |
| Yacoub, R | 1 |
| Derbala, M | 1 |
| Alimadadi, M | 1 |
| Amirkhanlou, S | 1 |
| Hafezi, AA | 1 |
| Homapour, S | 1 |
| Vakili, MA | 1 |
| Asghar, W | 1 |
| Pittman, E | 1 |
| Jamali, F | 1 |
| Muller, N | 1 |
| Amiot, A | 1 |
| Le Thuaut, A | 1 |
| Bastuji-Garin, S | 1 |
| Deforges, L | 1 |
| Dai, GZ | 1 |
| Fan, XJ | 1 |
| Tian, QS | 1 |
| Zhu, SK | 1 |
| Zhao, KX | 1 |
| Shen, DL | 1 |
| Amiri, M | 1 |
| Ormeci, A | 1 |
| Emrence, Z | 1 |
| Baran, B | 1 |
| Gokturk, S | 1 |
| Soyer, OM | 1 |
| Evirgen, S | 1 |
| Akyuz, F | 3 |
| Karaca, C | 1 |
| Besisik, F | 2 |
| Kaymakoglu, S | 2 |
| Ustek, D | 1 |
| Demir, K | 1 |
| Jodaki, A | 1 |
| Sahraie, A | 1 |
| Yasemi, M | 1 |
| Peyman, H | 1 |
| Yasemi, MR | 1 |
| Hemati, K | 1 |
| Abd-Elsalam, S | 1 |
| Kobtan, A | 1 |
| El-Kalla, F | 1 |
| Elkhalawany, W | 1 |
| Nawasany, SE | 1 |
| Saif, SA | 1 |
| Yousef, M | 1 |
| Ali, LA | 1 |
| Soliman, S | 1 |
| Mansour, L | 1 |
| Habba, E | 1 |
| Soliman, H | 1 |
| Rizk, F | 1 |
| Shehata, MA | 1 |
| Chwiesko, A | 1 |
| Charkiewicz, R | 1 |
| Niklinski, J | 1 |
| Luczaj, W | 1 |
| Skrzydlewska, E | 1 |
| Milewski, R | 1 |
| Baniukiewicz, A | 2 |
| Wroblewski, E | 1 |
| Rosolowski, M | 1 |
| Dabrowski, A | 1 |
| Paroni Sterbini, F | 1 |
| Palladini, A | 1 |
| Masucci, L | 1 |
| Cannistraci, CV | 1 |
| Pastorino, R | 1 |
| Ianiro, G | 1 |
| Bugli, F | 1 |
| Martini, C | 1 |
| Ricciardi, W | 1 |
| Gasbarrini, A | 11 |
| Sanguinetti, M | 1 |
| Cammarota, G | 19 |
| Posteraro, B | 1 |
| Nabinger, DD | 1 |
| Osório, MC | 1 |
| Klein, MG | 1 |
| Rech, TF | 1 |
| Basso da Silva, L | 1 |
| de Moraes, GS | 1 |
| Cristovam, RA | 1 |
| Nardelli, EF | 1 |
| Francesconi, CF | 4 |
| Mahmoudi, L | 1 |
| Farshad, S | 1 |
| Seddigh, M | 1 |
| Mahmoudi, P | 1 |
| Ejtehadi, F | 1 |
| Niknam, R | 1 |
| Lau, J | 1 |
| Lind, T | 8 |
| Persson, T | 1 |
| Eklund, S | 1 |
| Lin, Z | 2 |
| Li, J | 3 |
| Chen, C | 1 |
| Huang, Z | 2 |
| Ye, B | 1 |
| Li, W | 1 |
| Wu, L | 1 |
| Du, Q | 1 |
| Si, J | 1 |
| Liu, Z | 1 |
| Shen, J | 2 |
| Li, Q | 2 |
| Zhang, B | 1 |
| Zhou, J | 1 |
| Gu, L | 1 |
| Feng, G | 1 |
| Ma, J | 3 |
| Deng, D | 1 |
| Körber, A | 1 |
| Dissemond, J | 1 |
| Silva, FM | 3 |
| Eisig, JN | 3 |
| Teixeira, AC | 1 |
| Barbuti, RC | 4 |
| Navarro-Rodriguez, T | 3 |
| Mattar, R | 1 |
| Choi, WH | 2 |
| Park, DI | 4 |
| Oh, SJ | 2 |
| Baek, YH | 1 |
| Hong, CH | 2 |
| Hong, EJ | 2 |
| Song, MJ | 2 |
| Park, SK | 1 |
| Park, JH | 3 |
| Kim, HJ | 6 |
| Cho, YK | 4 |
| Sohn, CI | 3 |
| Jeon, WK | 4 |
| Kim, BI | 4 |
| Geva, A | 1 |
| Sabo, E | 1 |
| Levy, J | 1 |
| Blumenthal, M | 1 |
| Ophir, E | 1 |
| Geva, H | 1 |
| Bornstein, J | 1 |
| Taghavi, SA | 1 |
| Jafari, A | 1 |
| Eshraghian, A | 1 |
| McKeage, K | 1 |
| Blick, SK | 1 |
| Croxtall, JD | 1 |
| Lyseng-Williamson, KA | 1 |
| Keating, GM | 1 |
| Egan, BJ | 1 |
| O'Morain, CA | 9 |
| Villoria, A | 1 |
| Garcia, P | 1 |
| Vergara, M | 5 |
| Hurduc, V | 1 |
| Plesca, D | 1 |
| Dragomir, D | 1 |
| Sajin, M | 1 |
| Vandenplas, Y | 2 |
| Kuloğlu, Z | 1 |
| Kansu, A | 1 |
| Kirsaçlioğlu, CT | 1 |
| Ustündağ, G | 1 |
| Aysev, D | 1 |
| Ensari, A | 1 |
| Küçük, NO | 1 |
| Girgin, N | 1 |
| Komaroff, AL | 1 |
| De Leest, HT | 2 |
| Steen, KS | 2 |
| Bloemena, E | 7 |
| Lems, WF | 2 |
| Kuipers, EJ | 21 |
| Van de Laar, MA | 2 |
| Bijlsma, JW | 2 |
| Janssen, M | 1 |
| Houben, HH | 2 |
| Kostense, PJ | 2 |
| Boers, M | 2 |
| Dijkmans, BA | 2 |
| Mortazavi, F | 1 |
| Rafeey, M | 1 |
| Ramteke, S | 3 |
| Ganesh, N | 2 |
| Bhattacharya, S | 3 |
| Jain, NK | 3 |
| Felga, GE | 1 |
| Zaterka, S | 2 |
| Dehghani, SM | 1 |
| Erjaee, A | 1 |
| Imanieh, MH | 1 |
| Haghighat, M | 1 |
| Moslehi, R | 2 |
| Pan, K | 2 |
| Liu, W | 5 |
| You, W | 2 |
| Shon, CI | 1 |
| Medhi, B | 1 |
| Prakash, A | 3 |
| Tong, JL | 1 |
| Ran, ZH | 1 |
| Xiao, SD | 8 |
| Aladag, I | 1 |
| Eyibilen, A | 1 |
| Guven, M | 1 |
| Erkokmaz, U | 1 |
| El-Nakeeb, A | 1 |
| Fikry, A | 1 |
| Abd El-Hamed, TM | 1 |
| Fouda, el Y | 1 |
| El Awady, S | 1 |
| Youssef, T | 1 |
| Sherief, D | 1 |
| Farid, M | 1 |
| Baranov, AA | 1 |
| Shcherbakov, PL | 2 |
| Oganesian, TS | 1 |
| Zhao, F | 1 |
| Yang, Y | 1 |
| Wang, X | 2 |
| Shi, R | 1 |
| Xu, Z | 1 |
| Kountouras, J | 3 |
| Boziki, M | 1 |
| Gavalas, E | 1 |
| Zavos, C | 2 |
| Grigoriadis, N | 1 |
| Deretzi, G | 1 |
| Tzilves, D | 1 |
| Katsinelos, P | 2 |
| Tsolaki, M | 1 |
| Chatzopoulos, D | 2 |
| Venizelos, I | 1 |
| McColl, KE | 16 |
| Bago, J | 3 |
| Pevec, B | 1 |
| Tomić, M | 2 |
| Marusić, M | 2 |
| Bakula, V | 1 |
| Bago, P | 2 |
| Pellicano, R | 1 |
| Ntaios, G | 1 |
| Chatzinikolaou, A | 1 |
| Kaiafa, G | 1 |
| Savopoulos, C | 1 |
| Hatzitolios, A | 1 |
| Karamitsos, D | 1 |
| Szajewska, H | 2 |
| Albrecht, P | 2 |
| Topczewska-Cabanek, A | 1 |
| Gwee, KA | 1 |
| Teng, L | 1 |
| Wong, RK | 1 |
| Ho, KY | 1 |
| Sutedja, DS | 1 |
| Yeoh, KG | 1 |
| Abdou, AG | 1 |
| Elshayeb, EI | 1 |
| Farag, AG | 1 |
| Elnaidany, NF | 1 |
| Talaie, R | 1 |
| Haghazali, M | 1 |
| Molaei, M | 1 |
| Mohsenian, N | 1 |
| Derakhshan, F | 1 |
| Zali, MR | 1 |
| Iwai, H | 1 |
| Nakamichi, N | 1 |
| Nakae, K | 1 |
| Konishi, M | 1 |
| Inaba, M | 1 |
| Hoshino, S | 1 |
| Baba, S | 3 |
| Amakawa, R | 1 |
| Moreno-Otero, R | 2 |
| Veligotskiĭ, NN | 1 |
| Buka, GIu | 1 |
| Esedov, EM | 1 |
| Magomedéminova, AS | 1 |
| Saleem, A | 1 |
| Qasim, A | 2 |
| Waghray, M | 1 |
| Zavros, Y | 3 |
| Saqui-Salces, M | 1 |
| El-Zaatari, M | 1 |
| Alamelumangapuram, CB | 1 |
| Todisco, A | 2 |
| Eaton, KA | 1 |
| Merchant, JL | 3 |
| Chaudhry, AS | 1 |
| Kochhar, R | 2 |
| Kohli, KK | 1 |
| Kucheriavyĭ, IuA | 1 |
| Zhao, H | 1 |
| Winawer, S | 1 |
| Zauber, A | 1 |
| Classen, M | 3 |
| Wu, S | 1 |
| Jian, Z | 1 |
| Tang, F | 1 |
| Alazmi, WM | 1 |
| Buhaimed, W | 1 |
| Al-Mekhaizeem, K | 1 |
| Siddique, I | 1 |
| Perez-Gallardo, B | 1 |
| Hernandez-Alonso, M | 1 |
| Vinagre, G | 1 |
| Dueñas, C | 1 |
| Mateos-Rodriguez, JM | 1 |
| Gonzalez-Garcia, G | 1 |
| Abadia, EG | 1 |
| Dutta, U | 1 |
| Udawat, H | 1 |
| Noor, MT | 1 |
| Sidhu, GS | 1 |
| Vaiphei, K | 3 |
| Singh, K | 3 |
| Minakari, M | 1 |
| Davarpanah Jazi, AH | 1 |
| Shavakhi, A | 1 |
| Moghareabed, N | 1 |
| Fatahi, F | 1 |
| Duque, X | 1 |
| Moran, S | 1 |
| Mera, R | 3 |
| Medina, M | 1 |
| Martinez, H | 1 |
| Mendoza, ME | 1 |
| Torres, J | 1 |
| Correa, P | 3 |
| Koosirirat, C | 1 |
| Linpisarn, S | 1 |
| Changsom, D | 1 |
| Chawansuntati, K | 1 |
| Wipasa, J | 1 |
| van Zanten, SV | 3 |
| Desai, S | 1 |
| Best, L | 1 |
| Cooper-Lesins, G | 1 |
| Malatjalian, D | 2 |
| Haldane, D | 1 |
| Peltekian, K | 1 |
| Sun, Q | 1 |
| Liang, X | 1 |
| Zheng, Q | 2 |
| Xiao, S | 2 |
| Gu, W | 1 |
| Lu, H | 3 |
| Nam, SY | 1 |
| Choi, IJ | 3 |
| Ryu, KH | 1 |
| Kim, BC | 1 |
| Kim, CG | 1 |
| Nam, BH | 1 |
| Del Carmen Martino-Cardona, M | 1 |
| Beck, SE | 1 |
| Brayton, C | 1 |
| Watson, J | 1 |
| Manes, G | 5 |
| Cristofari, F | 1 |
| Assem, M | 1 |
| El Azab, G | 1 |
| Rasheed, MA | 1 |
| Abdelfatah, M | 1 |
| Shastery, M | 1 |
| Chang, WC | 2 |
| Jo, YI | 1 |
| Park, HS | 1 |
| Jegal, J | 1 |
| Lee, JH | 4 |
| Jin, CJ | 1 |
| Jabbar, A | 1 |
| Khan, R | 1 |
| Farrukh, SN | 1 |
| Gao, XZ | 1 |
| Qiao, XL | 1 |
| Song, WC | 1 |
| Wang, XF | 1 |
| Liu, F | 1 |
| Russo, G | 1 |
| Miraglia, V | 1 |
| Branciforte, F | 1 |
| Matarese, SM | 1 |
| Zecca, M | 1 |
| Bisogno, G | 1 |
| Parodi, E | 1 |
| Amendola, G | 1 |
| Giordano, P | 1 |
| Jankovic, M | 1 |
| Corti, A | 1 |
| Nardi, M | 1 |
| Farruggia, P | 1 |
| Battisti, L | 1 |
| Baronci, C | 1 |
| Palazzi, G | 1 |
| Tucci, F | 1 |
| Ceppi, S | 1 |
| Nobili, B | 1 |
| Ramenghi, U | 1 |
| De Mattia, D | 1 |
| Notarangelo, L | 1 |
| Koizumi, W | 3 |
| Tanabe, S | 3 |
| Nakatani, K | 1 |
| Ishido, K | 1 |
| Nishimura, K | 1 |
| Azuma, M | 1 |
| Ae, T | 1 |
| Sasaki, T | 1 |
| Katada, C | 1 |
| Nakayama, N | 1 |
| Saigenji, K | 3 |
| Chen, WJ | 1 |
| Sun, QJ | 1 |
| Jonaitis, L | 2 |
| Kupčinskas, J | 1 |
| Kiudelis, G | 2 |
| Kupčinskas, L | 2 |
| Mei, Q | 1 |
| Li, QS | 1 |
| Hu, YM | 1 |
| Xu, JM | 2 |
| CAI, Y | 1 |
| CONG, X | 1 |
| FEI, R | 1 |
| WANG, JT | 1 |
| Khoshnegah, J | 1 |
| Jamshidi, S | 1 |
| Mohammadi, M | 1 |
| Sasani, F | 1 |
| Felga, G | 1 |
| Allam, MA | 1 |
| El-Shafie, AM | 1 |
| Elwan, AM | 1 |
| Soliman, GM | 1 |
| Abu-Alfotuh, A | 1 |
| Al Shabrawi, H | 1 |
| Al Furaikh, SS | 1 |
| Lee, BH | 1 |
| Kim, N | 3 |
| Bazzoli, F | 9 |
| Celiñski, K | 2 |
| Giguère, M | 1 |
| Rivière, M | 1 |
| Mégraud, F | 21 |
| Yang, JC | 3 |
| Wang, HL | 1 |
| Chern, HD | 2 |
| Shun, CT | 1 |
| Lin, BR | 2 |
| Lin, CJ | 2 |
| Wang, TH | 4 |
| Kotowska, M | 1 |
| Buonavolontà, R | 1 |
| Miele, E | 1 |
| Russo, D | 1 |
| Vecchione, R | 1 |
| Staiano, A | 1 |
| Mehri, N | 1 |
| Kambiz, E | 1 |
| Ahmad, K | 1 |
| Fatemeh, F | 1 |
| Farzaneh, M | 1 |
| Hossein, FG | 1 |
| Fatemeh, M | 1 |
| Shafaghi, A | 1 |
| Pakdin, A | 1 |
| Joukar, F | 1 |
| Mansour-Ghanaei, F | 1 |
| Schmilovitz-Weiss, H | 1 |
| Schmiloviz-Weiss, H | 1 |
| Shalev, T | 1 |
| Chechoulin, Y | 1 |
| Levi, Z | 1 |
| Yishai, R | 1 |
| Sehayek-Shabbat, V | 1 |
| Niv, Y | 8 |
| Shirin, H | 3 |
| Valooran, GJ | 1 |
| Kate, V | 2 |
| Jagdish, S | 1 |
| Basu, D | 1 |
| Choi, KH | 1 |
| Chung, WC | 1 |
| Lee, KM | 1 |
| Paik, CN | 1 |
| Kim, EJ | 1 |
| Kang, BK | 1 |
| Oak, JH | 1 |
| Jung, SH | 2 |
| Bontems, P | 2 |
| Kalach, N | 7 |
| Oderda, G | 3 |
| Salame, A | 1 |
| Muyshont, L | 1 |
| Miendje, DY | 1 |
| Raymond, J | 5 |
| Cadranel, S | 3 |
| Scaillon, M | 2 |
| Song, KH | 1 |
| Lee, YC | 2 |
| Fan, DM | 1 |
| Ge, ZZ | 3 |
| Chen, MH | 2 |
| Jung, HC | 7 |
| Bo, J | 1 |
| Lee, SW | 3 |
| Kim, JH | 3 |
| Urgesi, R | 1 |
| Pelecca, G | 1 |
| Cianci, R | 6 |
| Masini, A | 1 |
| Zampaletta, C | 1 |
| Riccioni, ME | 1 |
| Faggiani, R | 1 |
| Attumi, TA | 1 |
| Ben Mahmoud, L | 1 |
| Ghozzi, H | 1 |
| Hakim, A | 1 |
| Sahnoun, Z | 1 |
| Zeghal, K | 1 |
| Kim, JY | 1 |
| Park, HK | 1 |
| Jo, HJ | 1 |
| Shin, CM | 1 |
| Park, YS | 2 |
| Hwang, JH | 2 |
| Kim, JW | 3 |
| Jeong, SH | 1 |
| Lee, DH | 3 |
| Nam, RH | 1 |
| Kim, JM | 1 |
| Song, IS | 4 |
| Ermis, F | 2 |
| Uyanikoglu, A | 1 |
| Kurt, R | 1 |
| Pinarbasi, B | 1 |
| Nazik, H | 1 |
| Mungan, Z | 2 |
| Malik, R | 1 |
| Guleria, K | 1 |
| Kaur, I | 1 |
| Sikka, M | 1 |
| Radhakrishnan, G | 1 |
| Campuzano-Maya, G | 1 |
| Kolesnikova, IIu | 1 |
| Volkov, VS | 1 |
| Liubskaia, LA | 1 |
| Wong, BC | 22 |
| Feng, GS | 1 |
| Zhang, XD | 2 |
| Lu, AP | 1 |
| Xia, HH | 8 |
| Lam, S | 1 |
| Pan, G | 1 |
| Basu, PP | 1 |
| Rayapudi, K | 1 |
| Pacana, T | 1 |
| Shah, NJ | 1 |
| Krishnaswamy, N | 1 |
| Flynn, M | 1 |
| Tian, XL | 1 |
| Zhang, JZ | 1 |
| Zhou, LY | 3 |
| Geng, QM | 1 |
| Han, YJ | 1 |
| Falaknazi, K | 1 |
| Roshani, M | 1 |
| Lahmi, F | 1 |
| Orimi, PG | 1 |
| Hadizadeh, M | 1 |
| Berwanger, O | 1 |
| Bressel, M | 1 |
| Marini, SS | 1 |
| Molina, CG | 1 |
| Folador, L | 1 |
| Lunkes, RP | 1 |
| Heck, R | 1 |
| Birkhan, OA | 1 |
| Spindler, BM | 1 |
| Katz, N | 1 |
| Colombo, Bda S | 1 |
| Guerrieri, PP | 1 |
| Renck, LB | 1 |
| Grando, E | 1 |
| Hocevar de Moura, B | 1 |
| Dahmer, FD | 1 |
| Rauber, J | 1 |
| Prolla, JC | 3 |
| Miura, S | 4 |
| Hokari, R | 1 |
| Chelly, I | 1 |
| Adouni, O | 1 |
| Chouaib, S | 1 |
| Azouz, H | 1 |
| Nfoussi, H | 1 |
| Haouet, S | 1 |
| Zitouna, M | 1 |
| Kchir, N | 1 |
| Konturek, PC | 5 |
| Konturek, SJ | 7 |
| Slomka, M | 1 |
| Cichoz-Lach, H | 1 |
| Brzozowski, T | 3 |
| Bielanski, W | 7 |
| Korownyk, C | 1 |
| Kolber, MR | 1 |
| Loghmari, H | 1 |
| Bdioui, F | 1 |
| Bouhlel, W | 1 |
| Melki, W | 1 |
| Hellara, O | 1 |
| Ben Chaabane, N | 1 |
| Safer, L | 1 |
| Zakhama, A | 1 |
| Saffar, H | 1 |
| Zuo, XL | 1 |
| Yu, T | 2 |
| Gu, XM | 1 |
| Zhou, CJ | 1 |
| Lachter, J | 1 |
| Yampolsky, Y | 1 |
| Gafni-Schieber, R | 1 |
| Wasser, SP | 1 |
| Saha, SK | 2 |
| Masud, H | 1 |
| Islam, N | 1 |
| Raihan, AS | 1 |
| Roy, PK | 1 |
| Hasan, M | 2 |
| Visruthan, NK | 1 |
| Boo, PK | 1 |
| Kader, A | 1 |
| Ping, CH | 1 |
| Ong, C | 1 |
| Montes, M | 1 |
| Gil, I | 1 |
| Piñeiro, L | 1 |
| Recasens, MT | 1 |
| Nseir, W | 1 |
| Diab, H | 1 |
| Mahamid, M | 1 |
| Abu-Elheja, O | 1 |
| Samara, M | 1 |
| Abid, A | 1 |
| Mograbi, J | 1 |
| Bermejo, F | 12 |
| Almela, P | 2 |
| Ortuño, J | 2 |
| Sánchez-Pobre, P | 3 |
| Khorrami, S | 4 |
| Franco, A | 2 |
| Tomas, A | 2 |
| Guerra, I | 1 |
| Lamas, E | 3 |
| Ponce, J | 5 |
| Manfredi, M | 2 |
| Bizzarri, B | 1 |
| de'Angelis, GL | 3 |
| Figura, N | 4 |
| Moretti, E | 1 |
| Vaglio, L | 1 |
| Langone, F | 1 |
| Vernillo, R | 1 |
| Vindigni, C | 1 |
| Giordano, N | 1 |
| Shidfar, F | 1 |
| Agah, S | 1 |
| Ekhlasi, G | 1 |
| Salehpour, A | 1 |
| Ghourchian, S | 1 |
| Salazar, CO | 1 |
| Cardenas, VM | 2 |
| Reddy, RK | 1 |
| Dominguez, DC | 1 |
| Snyder, LK | 1 |
| Tsimmerman, IaS | 1 |
| Gao, W | 1 |
| Cheng, H | 1 |
| Hu, FL | 3 |
| Lü, NH | 1 |
| Sheng, JQ | 1 |
| Zhang, LX | 1 |
| Zhang, ZY | 1 |
| Zhang, GX | 1 |
| Cui, MH | 1 |
| Yang, GB | 1 |
| Gao, HJ | 1 |
| Yang, L | 1 |
| Ou, WJ | 1 |
| Pan, RF | 1 |
| Geng, LL | 1 |
| He, WE | 1 |
| Chen, PY | 1 |
| Liu, LY | 1 |
| Baker, DE | 2 |
| Inaba, T | 2 |
| Mizuno, M | 4 |
| Kawai, K | 3 |
| Yokota, K | 5 |
| Oguma, K | 3 |
| Miyoshi, M | 2 |
| Take, S | 2 |
| Okada, H | 3 |
| Tsuji, T | 2 |
| Schilling, D | 3 |
| Adamek, HE | 1 |
| Riemann, JF | 3 |
| Johnson, TJ | 1 |
| Hedge, DD | 1 |
| Kita, T | 5 |
| Sakaeda, T | 2 |
| Aoyama, N | 9 |
| Sakai, T | 3 |
| Kasuga, M | 6 |
| Okumura, K | 5 |
| Scholte, GH | 1 |
| van Doorn, LJ | 3 |
| Cats, A | 1 |
| Lindeman, J | 5 |
| Quint, WG | 2 |
| Meuwissen, SG | 14 |
| Tsuchida, M | 1 |
| Shimodan, M | 1 |
| Asaka, M | 23 |
| Kohda, K | 1 |
| Kuga, T | 1 |
| Kogawa, K | 1 |
| Kanisawa, Y | 1 |
| Koike, K | 1 |
| Kuroiwa, G | 1 |
| Hirayama, Y | 1 |
| Sato, Y | 4 |
| Niitsu, Y | 1 |
| Guardiola, J | 2 |
| Tito, L | 3 |
| Andreu, V | 1 |
| Guirao, R | 4 |
| Isakov, V | 1 |
| Domareva, I | 1 |
| Koudryavtseva, L | 1 |
| Maev, I | 1 |
| Ganskaya, Z | 1 |
| Malnick, SD | 1 |
| Gottesfeld, F | 1 |
| Walpart, A | 1 |
| Keter, D | 1 |
| Lurie, Y | 1 |
| Beergabel, M | 1 |
| Picot, S | 1 |
| Sapin, G | 1 |
| Michault, A | 1 |
| Faulques, B | 1 |
| Becquart, JP | 1 |
| Simac, C | 1 |
| Amat, C | 1 |
| Ancelin-Malbreil, E | 1 |
| Ushiama, H | 1 |
| Echizen, H | 1 |
| Nachi, S | 1 |
| Ohnishi, A | 1 |
| Ishibashi, S | 1 |
| Iwakiri, R | 1 |
| Shimoda, R | 1 |
| Ootani, H | 1 |
| Kawasaki, S | 1 |
| Tadano, J | 1 |
| Kikkawa, A | 1 |
| Ootani, A | 1 |
| Oda, K | 2 |
| Fujise, T | 1 |
| Yoshida, T | 2 |
| Tsunada, S | 1 |
| Sakata, H | 1 |
| Fujimoto, K | 1 |
| Bettoni, L | 1 |
| Rizzini, FL | 1 |
| Tosoni, C | 1 |
| Cattaneo, R | 1 |
| Hiraishi, H | 2 |
| Ota, S | 2 |
| Terano, A | 6 |
| Blum, AL | 19 |
| Bolten, WW | 1 |
| Dragosics, B | 4 |
| Rösch, W | 1 |
| Stolte, M | 59 |
| Koelz, HR | 3 |
| Hawkey, CJ | 6 |
| Naesdal, J | 2 |
| Wilson, I | 2 |
| Långström, G | 2 |
| Swannell, AJ | 2 |
| Peacock, RA | 2 |
| Yeomans, ND | 3 |
| Boixeda, D | 25 |
| Martín-De-Argila, C | 1 |
| López-Sanromán, A | 1 |
| Defarges, V | 2 |
| Hernández-Ranz, F | 1 |
| Milicua, JM | 1 |
| García-Plaza, A | 1 |
| Mitsunaga, A | 1 |
| Matsumoto, R | 1 |
| Hoshino, Y | 2 |
| Nakamura, S | 6 |
| Murata, Y | 2 |
| Oi, I | 1 |
| Hayashi, N | 1 |
| Nakamura, T | 4 |
| Kinoshita, Y | 9 |
| Fujishiro, H | 5 |
| Amano, Y | 2 |
| Adachi, K | 9 |
| Koskenpato, J | 2 |
| Färkkilä, M | 4 |
| Sipponen, P | 10 |
| Sheu, BS | 11 |
| Wu, JJ | 8 |
| Lo, CY | 1 |
| Wu, HW | 1 |
| Chen, JH | 2 |
| Lin, YS | 1 |
| Lin, MD | 1 |
| Mak, SK | 2 |
| Loo, CK | 3 |
| Wong, AM | 2 |
| Wong, PN | 2 |
| Lo, KY | 2 |
| Tong, GM | 2 |
| Lam, EK | 2 |
| Wong, AK | 2 |
| Bannwarth, B | 1 |
| Dorval, E | 1 |
| Caekaert, A | 2 |
| Barthelemy, P | 6 |
| Nyrén, O | 2 |
| Wong, WM | 14 |
| Hung, WK | 2 |
| Yee, YK | 4 |
| Yip, AW | 2 |
| Szeto, ML | 2 |
| Fung, FM | 8 |
| Tong, TS | 4 |
| Lai, KC | 18 |
| Hu, WH | 12 |
| Yuen, MF | 7 |
| Lam, SK | 20 |
| Fischbach, W | 5 |
| Goebeler-Kolve, M | 1 |
| Starostik, P | 1 |
| Greiner, A | 5 |
| Müller-Hermelink, HK | 1 |
| Cuena Boy, R | 1 |
| Queiroz, DM | 2 |
| Dani, R | 2 |
| Silva, LD | 1 |
| Santos, A | 2 |
| Moreira, LS | 2 |
| Rocha, GA | 2 |
| Corrêa, PR | 1 |
| Reis, LF | 1 |
| Nogueira, AM | 1 |
| Alvares Cabral, MM | 1 |
| Esteves, AM | 1 |
| Tanure, J | 1 |
| Vasil'ev, IuV | 3 |
| Kas'ianenko, VI | 1 |
| Minushkin, ON | 2 |
| Zverkov, IV | 2 |
| Aronova, OV | 1 |
| Shuleshova, AG | 2 |
| Campbell, DR | 2 |
| Haber, MM | 2 |
| Sheldon, E | 1 |
| Collis, C | 1 |
| Lukasik, N | 1 |
| Huang, B | 2 |
| Goldstein, JL | 1 |
| Zvenigorodskaia, LA | 2 |
| Kolomiets, EV | 1 |
| Firsanova, VIu | 1 |
| Ivashkin, VT | 1 |
| Lapina, TL | 2 |
| Bondarenko, OY | 1 |
| Sklanskaya, OA | 1 |
| Grigoriev, PY | 1 |
| Vasiliev, YV | 1 |
| Gulyaev, PV | 1 |
| Fedchenko, VI | 1 |
| Rosandić, M | 2 |
| Pilas, V | 1 |
| Bevanda, M | 3 |
| Falisevac, V | 1 |
| Korać, B | 1 |
| Mohar, A | 2 |
| Ley, C | 2 |
| Guarner, J | 2 |
| Herrera-Goepfert, R | 2 |
| Figueroa, LS | 2 |
| Halperin, D | 2 |
| Parsonnet, J | 2 |
| Sullivan, B | 1 |
| Coyle, W | 2 |
| Nemec, R | 3 |
| Dunteman, T | 1 |
| Faleo, D | 5 |
| Panella, C | 7 |
| Ierardi, E | 13 |
| Margiotta, M | 3 |
| Furuta, T | 20 |
| Shirai, N | 15 |
| Watanabe, F | 1 |
| Honda, S | 1 |
| Takeuchi, K | 1 |
| Iida, T | 1 |
| Kajimura, M | 3 |
| Futami, H | 4 |
| Takayanagi, S | 1 |
| Yamada, M | 3 |
| Ohashi, K | 10 |
| Ishizaki, T | 14 |
| Hanai, H | 9 |
| Sato, R | 9 |
| Nasu, M | 10 |
| Fujioka, T | 15 |
| Kagawa, J | 4 |
| Sato, S | 2 |
| Abe, H | 1 |
| Arita, T | 2 |
| Chuang, CH | 3 |
| Huang, AH | 5 |
| Yang, HB | 8 |
| Marchi, S | 2 |
| Bellini, M | 2 |
| Costa, F | 2 |
| De Bortoli, N | 1 |
| Petrini, M | 1 |
| Maltinti, G | 2 |
| Yusuf, SW | 1 |
| Mishra, RM | 1 |
| Ogiahara, S | 1 |
| Handa, Y | 1 |
| Moriyasu, F | 3 |
| Gorshkov, VA | 1 |
| Halle, ZB | 1 |
| Strinić, D | 1 |
| Kućisec, N | 1 |
| Jandrić, D | 1 |
| Bilić, A | 2 |
| Hirayama, F | 2 |
| Takagi, S | 2 |
| Yokoyama, Y | 2 |
| Iwao, E | 1 |
| Haga, K | 1 |
| Cui, M | 1 |
| Hu, F | 1 |
| Jiang, H | 1 |
| Zheng, X | 2 |
| Domingo, D | 2 |
| Alarcón, T | 2 |
| Vega, AE | 1 |
| García, JA | 1 |
| Martínez, MJ | 1 |
| López-Brea, M | 2 |
| Maiden, LP | 1 |
| Harris, AW | 5 |
| Mantzaris, GJ | 1 |
| Petraki, K | 1 |
| Archavlis, E | 1 |
| Amberiadis, P | 1 |
| Christoforidis, P | 1 |
| Kourtessas, D | 1 |
| Chiotakakou, E | 1 |
| Triantafyllou, G | 2 |
| Louis, E | 1 |
| Kawano, S | 7 |
| Tsukada, K | 2 |
| Miyazaki, T | 2 |
| Katoh, H | 2 |
| Masuda, N | 1 |
| Ojima, H | 1 |
| Fukai, Y | 1 |
| Nakajima, M | 2 |
| Manda, R | 1 |
| Fukuchi, M | 1 |
| Kuwano, H | 2 |
| Tsukada, O | 1 |
| Arnold, R | 5 |
| Fischer, M | 2 |
| Catalano, F | 6 |
| Terminella, C | 1 |
| Branciforte, G | 5 |
| Bentivegna, C | 5 |
| Brogna, A | 6 |
| Scalia, A | 1 |
| Kim, JI | 1 |
| Park, SH | 2 |
| Kim, JK | 1 |
| Chung, IS | 2 |
| Chung, KW | 1 |
| Sun, HS | 1 |
| Felley, CP | 1 |
| Pignatelli, B | 1 |
| Van Melle, GD | 1 |
| Crabtree, JE | 2 |
| Diezi, J | 1 |
| Corthesy-Theulaz, I | 2 |
| Michetti, P | 2 |
| Bancel, B | 1 |
| Patricot, LM | 1 |
| Ohshima, H | 1 |
| Felley-Bosco, E | 1 |
| Rai, R | 1 |
| Cheer, SM | 1 |
| Faulds, D | 2 |
| Lamb, HM | 1 |
| Guda, N | 1 |
| Vakil, N | 9 |
| Coelho, LG | 3 |
| Martins, GM | 2 |
| Passos, MC | 3 |
| Bueno, ML | 2 |
| Sanches, BS | 1 |
| Lopes, LG | 2 |
| Miranda, CH | 1 |
| Castro, LP | 4 |
| Patel, AS | 1 |
| Pohl, JF | 1 |
| Easley, DJ | 1 |
| Farup, PG | 2 |
| Tholfsen, J | 1 |
| Wetternus, S | 1 |
| Torp, R | 2 |
| Høie, O | 2 |
| Lange, OJ | 1 |
| Wepner, U | 1 |
| Opekun, AR | 5 |
| Osato, MS | 10 |
| el-Zimaity, HM | 16 |
| Kawabata, H | 1 |
| Habu, Y | 3 |
| Tomioka, H | 1 |
| Kutsumi, H | 1 |
| Kobayashi, M | 1 |
| Oyasu, K | 1 |
| Hayakumo, T | 2 |
| Kiyota, K | 3 |
| Kimoto, K | 2 |
| Inokuchi, H | 3 |
| Mihara, T | 2 |
| Komazawa, Y | 2 |
| Yeh, HZ | 2 |
| Chen, GH | 3 |
| Chang, WD | 1 |
| Poon, SK | 2 |
| Yang, SS | 3 |
| Lien, HC | 1 |
| Chang, CS | 2 |
| Chou, G | 1 |
| Chaudhuri, S | 1 |
| Chowdhury, A | 1 |
| Datta, S | 1 |
| Mukhopadhyay, AK | 1 |
| Chattopadhya, S | 1 |
| Saha, DR | 1 |
| Dhali, G | 1 |
| Santra, A | 1 |
| Nair, GB | 1 |
| Berg, DE | 4 |
| Miki, I | 3 |
| Shirasaka, D | 6 |
| Wambura, CM | 1 |
| Maekawa, S | 3 |
| Kuroda, K | 3 |
| Tamura, T | 3 |
| Johnson, DA | 1 |
| Thjodleifsson, B | 3 |
| Rindi, G | 2 |
| Fiocca, R | 9 |
| Humphries, TJ | 3 |
| Morocutti, A | 2 |
| Miller, N | 2 |
| Bardhan, KD | 14 |
| Loughlin, MF | 1 |
| Ala'Aldeen, DA | 1 |
| Jenks, PJ | 1 |
| Gatta, L | 6 |
| Perna, F | 4 |
| Ricci, C | 7 |
| Holton, J | 2 |
| D'Anna, L | 1 |
| Miglioli, M | 6 |
| Vaira, D | 8 |
| Orr, CF | 1 |
| Rowe, DB | 1 |
| Thomson, AB | 4 |
| Keelan, M | 3 |
| Lastiwka, R | 2 |
| Appelman-Eszcuck, S | 1 |
| Zuk, L | 2 |
| Drozdowski, L | 2 |
| Prentice, A | 2 |
| Sinclair, P | 7 |
| Satoh, K | 13 |
| Arima, N | 1 |
| Tsudo, M | 1 |
| Gu, Q | 5 |
| Chan, CK | 9 |
| Urakami, Y | 3 |
| Sano, T | 3 |
| Pajares, JM | 12 |
| Williams, MP | 4 |
| Usselmann, B | 1 |
| Chilton, A | 1 |
| Sercombe, J | 1 |
| Nwokolo, CU | 2 |
| Pounder, RE | 7 |
| Menegatti, M | 2 |
| Tampieri, A | 3 |
| Rinaldi, V | 6 |
| Perri, F | 11 |
| Papadìa, C | 1 |
| Fornari, F | 1 |
| Pilati, S | 1 |
| Mete, LS | 1 |
| Merla, A | 3 |
| Potì, R | 1 |
| Marinone, G | 1 |
| Savioli, A | 1 |
| Campo, SM | 1 |
| Morini, S | 10 |
| Anagnostopoulos, GK | 2 |
| Kostopoulos, P | 2 |
| Margantinis, G | 2 |
| Tsiakos, S | 2 |
| Arvanitidis, D | 2 |
| Dulbecco, P | 5 |
| Gambaro, C | 2 |
| Bilardi, C | 6 |
| Zentilin, P | 7 |
| Mele, MR | 4 |
| Mansi, C | 6 |
| Biagini, R | 1 |
| Tessieri, L | 1 |
| Iiritano, E | 2 |
| Usai, P | 2 |
| Vigneri, S | 12 |
| Savarino, V | 17 |
| Rembiasz, K | 1 |
| Stachura, J | 6 |
| Galuschka, K | 1 |
| Karcz, D | 1 |
| Hahn, EG | 5 |
| Laine, L | 13 |
| Hunt, R | 2 |
| El-Zimaity, H | 2 |
| Nguyen, B | 2 |
| Osato, M | 3 |
| Spénard, J | 2 |
| Bolling-Sternevald, E | 5 |
| Mitchell, HM | 3 |
| Ozgenc, F | 1 |
| Akman, SA | 1 |
| Arikan, C | 1 |
| Alkanat, MB | 1 |
| Aydogdu, S | 1 |
| Yagci, RV | 1 |
| Ulmer, HJ | 1 |
| Beckerling, A | 1 |
| Gatz, G | 3 |
| Isomoto, H | 6 |
| Inoue, K | 6 |
| Furusu, H | 4 |
| Nishiyama, H | 1 |
| Shikuwa, S | 1 |
| Omagari, K | 3 |
| Mizuta, Y | 4 |
| Murase, K | 3 |
| Murata, I | 4 |
| Kohno, S | 6 |
| Matsuda, M | 1 |
| Noda, Y | 1 |
| Takemori, Y | 1 |
| Kwiecien, S | 2 |
| Pajdo, R | 1 |
| Drozdowicz, D | 2 |
| Ptak, A | 1 |
| Pawlik, M | 1 |
| Pawlik, WW | 2 |
| Kurilo, AE | 1 |
| V'iuchnova, ES | 1 |
| Shchekina, MI | 1 |
| Atherton, JC | 4 |
| Treichel, HC | 2 |
| Ravic, M | 1 |
| Sargýn, M | 1 |
| Uygur-Bayramicli, O | 1 |
| Sargýn, H | 1 |
| Orbay, E | 1 |
| Yavuzer, D | 1 |
| Yayla, A | 1 |
| Marzio, L | 4 |
| Cellini, L | 6 |
| Angelucci, D | 2 |
| Kuwayama, H | 5 |
| Fukuda, Y | 13 |
| Takemoto, T | 2 |
| Kimura, K | 13 |
| Shimoyama, T | 14 |
| Shimizu, K | 2 |
| Kobayashi, S | 3 |
| Miyamoto, M | 3 |
| Haruma, K | 13 |
| Yoshihara, M | 8 |
| Sumioka, M | 2 |
| Kamada, T | 6 |
| Masuda, H | 2 |
| Nishisaka, T | 2 |
| Tanaka, S | 5 |
| Chayama, K | 5 |
| Kirchner, T | 3 |
| Kist, M | 2 |
| Leodolter, A | 7 |
| Peitz, U | 12 |
| Strobel, S | 2 |
| Bohuschke, M | 1 |
| Hammoud, F | 2 |
| Kim, JG | 3 |
| El-Serag, HB | 1 |
| Huang, JJ | 2 |
| Martín De Argila, C | 21 |
| López Sanromán, A | 1 |
| Hernández Ranz, F | 2 |
| García Plaza, A | 11 |
| Gomollón, F | 10 |
| Domínguez-Muñoz, JE | 1 |
| Borda, F | 1 |
| Miño, G | 1 |
| Jiménez, I | 3 |
| Vázquez, MA | 1 |
| Santolaria, S | 3 |
| Gallego, S | 1 |
| Iglesias, J | 1 |
| Pastor, G | 1 |
| Hervás, A | 1 |
| Menchise, A | 1 |
| de Nucci, C | 1 |
| Balzano, A | 3 |
| Hiyama, T | 2 |
| Sarnelli, G | 1 |
| Grasso, R | 1 |
| Verde, C | 1 |
| Bottiglieri, ME | 1 |
| Nardone, G | 3 |
| Budillon, G | 1 |
| Cuomo, R | 1 |
| Veldhuyzen Van Zanten, S | 8 |
| Machado, S | 1 |
| Lee, J | 3 |
| Unge, P | 11 |
| Ekström, P | 2 |
| Hellblom, M | 3 |
| Ohlin, B | 2 |
| Stubberöd, A | 4 |
| Kihira, K | 9 |
| Yube, T | 1 |
| Yoshida, Y | 11 |
| Roghani, HS | 1 |
| Massarrat, S | 4 |
| Shirekhoda, M | 1 |
| Butorab, Z | 1 |
| Mario, FD | 1 |
| Dal Bo, N | 6 |
| Aragona, G | 3 |
| Moussa, AM | 2 |
| Iori, V | 3 |
| Cavestro, GM | 3 |
| Pilotto, A | 13 |
| Leandro, G | 11 |
| Franceschi, M | 12 |
| Rugge, M | 4 |
| Franze, A | 3 |
| Miyazawa, M | 2 |
| Nagahashi, S | 3 |
| Sato, M | 1 |
| Bessho, M | 1 |
| Nagata, H | 2 |
| Ishii, H | 9 |
| Wong, SH | 1 |
| Leung, SY | 3 |
| Yuen, ST | 4 |
| Wright, NA | 1 |
| Lorenzetti, R | 3 |
| Marignani, M | 3 |
| Angeletti, S | 2 |
| Reddy, R | 2 |
| Sapone, A | 1 |
| Trespidi, S | 1 |
| Cantelli-Forti, G | 1 |
| Biagi, GL | 1 |
| Paolini, M | 1 |
| Uang, YS | 1 |
| van Zanten, SJ | 2 |
| Kolesnikow, T | 1 |
| Leung, V | 1 |
| O'Rourke, JL | 2 |
| Lee, A | 3 |
| Sasaki, A | 2 |
| Manabe, N | 1 |
| Udd, M | 1 |
| Miettinen, P | 3 |
| Palmu, A | 1 |
| Julkunen, R | 2 |
| Ford, A | 1 |
| Moayyedi, P | 17 |
| Wheeldon, TU | 2 |
| Hoang, TT | 2 |
| Phung, DC | 1 |
| Björkman, A | 1 |
| Granström, M | 3 |
| Sörberg, M | 4 |
| Enjoji, A | 1 |
| Fujimoto, C | 1 |
| Yamakawa, M | 1 |
| Hirakata, Y | 1 |
| Shimada, S | 1 |
| Lauritsen, K | 3 |
| Junghard, O | 3 |
| Glise, H | 1 |
| Lai, YC | 1 |
| Huang, SH | 2 |
| Wu, CH | 3 |
| Chen, TK | 3 |
| Lee, CL | 3 |
| Matsukura, N | 2 |
| Tajiri, T | 1 |
| Kato, S | 6 |
| Togashi, A | 1 |
| Masuda, G | 1 |
| Fujita, I | 1 |
| Tokunaga, A | 1 |
| Yamada, N | 1 |
| Hata, J | 1 |
| Kusunoki, H | 2 |
| Osipenko, MF | 1 |
| Pankova, LIu | 1 |
| Bikbulatova, EA | 1 |
| Orziev, ZM | 2 |
| Nurbaev, FE | 2 |
| Rakhimova, GSh | 2 |
| Kamiya, T | 1 |
| Kobayashi, Y | 1 |
| Misu, N | 1 |
| Hirako, M | 1 |
| Adachi, H | 2 |
| Nagao, T | 1 |
| Shikano, M | 1 |
| Matsuhisa, E | 1 |
| Ando, T | 3 |
| Kimura, G | 1 |
| Asaumi, N | 3 |
| Masuda, K | 1 |
| Yoshida, C | 3 |
| Kiguchi, T | 1 |
| Niiya, M | 3 |
| Niiya, K | 3 |
| Tanimoto, M | 3 |
| Rukhliada, NV | 1 |
| Nazarov, VE | 1 |
| Ermolaev, IA | 1 |
| Uthaisaengsook, W | 1 |
| Dore, MP | 6 |
| Marras, L | 2 |
| Maragkoudakis, E | 1 |
| Nieddu, S | 2 |
| Manca, A | 3 |
| Realdi, G | 5 |
| Miehlke, S | 13 |
| Kirsch, C | 4 |
| Schneider-Brachert, W | 3 |
| Haferland, C | 2 |
| Neumeyer, M | 2 |
| Bästlein, E | 5 |
| Papke, J | 1 |
| Jacobs, E | 2 |
| Vieth, M | 5 |
| Lehn, N | 15 |
| Bayerdörffer, E | 29 |
| de Boer, SY | 2 |
| v d Meeberg, PC | 1 |
| Siem, H | 1 |
| de Boer, WA | 17 |
| Glasbrenner, B | 4 |
| Wiedeck, H | 1 |
| Eberhardt, H | 1 |
| Brinkmann, A | 1 |
| MOssner, J | 1 |
| Layer, P | 2 |
| Demleitner, K | 1 |
| Fuchs, W | 3 |
| Vallve, M | 2 |
| Piglionica, D | 1 |
| Wang, WH | 4 |
| Chan, AO | 6 |
| Hui, CK | 3 |
| Sjölund, M | 1 |
| Wreiber, K | 2 |
| Andersson, DI | 1 |
| Blaser, MJ | 2 |
| Engstrand, L | 4 |
| Fedorak, RN | 1 |
| Lambert, J | 2 |
| Cohen, L | 1 |
| Vanjaka, A | 1 |
| Liu, CC | 1 |
| Chan, CC | 2 |
| Tu, TC | 2 |
| Liao, CC | 1 |
| Lara, LF | 1 |
| Cisneros, G | 1 |
| Gurney, M | 1 |
| Van Ness, M | 1 |
| Jarjoura, D | 1 |
| Moauro, B | 1 |
| Polen, A | 1 |
| Rutecki, G | 1 |
| Whittier, F | 1 |
| Karateev, AE | 1 |
| Murav'ev, IuV | 1 |
| Radenska-Lopovok, SG | 1 |
| Nasonova, VA | 1 |
| Masaoka, T | 3 |
| Nomura, S | 2 |
| Kurabayashi, K | 1 |
| Minegishi, Y | 1 |
| Choi, BK | 1 |
| Yang, SY | 1 |
| Park, ET | 1 |
| Jang, YS | 1 |
| Lee, YJ | 2 |
| Seol, SY | 1 |
| Chung, JM | 2 |
| Chiba, N | 6 |
| Barkun, A | 2 |
| Fallone, C | 1 |
| Farley, A | 5 |
| Cockeram, A | 3 |
| Dallaire, C | 2 |
| Simms, L | 1 |
| Nicholls, B | 1 |
| Lamouliatte, H | 9 |
| Bretagne, JF | 1 |
| Courillon-Mallet, A | 1 |
| De Korwin, JD | 2 |
| Fauchère, JL | 2 |
| Labigne, A | 1 |
| Fléjou, JF | 4 |
| Ebert, S | 1 |
| Buchner, M | 1 |
| Festa, V | 6 |
| Barberani, F | 1 |
| Andriulli, A | 7 |
| Neri, M | 3 |
| Milano, A | 1 |
| Laterza, F | 2 |
| Di Bonaventura, G | 1 |
| Piccolomini, R | 1 |
| Caldarella, MP | 1 |
| Balatsinou, C | 1 |
| Lapenna, D | 1 |
| Cuccurullo, F | 2 |
| Chu, KM | 6 |
| Hui, WM | 5 |
| Kwok, KF | 1 |
| Hu, HC | 1 |
| Chan, OO | 1 |
| Chang, FY | 6 |
| Lu, CL | 3 |
| Chen, CY | 3 |
| Luo, JC | 2 |
| Jium, KL | 1 |
| Lee, SD | 6 |
| Berwert, L | 1 |
| Kaeser, P | 1 |
| Livio, F | 1 |
| Vollenweider, P | 1 |
| Waeber, G | 1 |
| Soto, G | 1 |
| Bautista, CT | 1 |
| Roth, DE | 1 |
| Gilman, RH | 1 |
| Velapatiño, B | 1 |
| Ogura, M | 1 |
| Dailide, G | 1 |
| Razuri, M | 1 |
| Meza, R | 1 |
| Katz, U | 1 |
| Monath, TP | 2 |
| Taylor, DN | 1 |
| Shibakura, M | 2 |
| Watanabe, K | 9 |
| Kositchaiwat, C | 1 |
| Ovartlarnporn, B | 1 |
| Kachintorn, U | 2 |
| Atisook, K | 1 |
| Romero-Gómez, M | 1 |
| Martínez-Delgado, C | 1 |
| Hergueta, P | 1 |
| Navarro, JM | 1 |
| Garrido-Serrano, A | 1 |
| Santos, O | 1 |
| Montojo, C | 1 |
| Borody, TJ | 7 |
| Ashman, O | 1 |
| Di Mario, F | 12 |
| Cavallaro, L | 1 |
| Comparato, G | 1 |
| Watanabe, Y | 2 |
| Kachi, M | 1 |
| Wambura, C | 2 |
| Marchetti, F | 2 |
| Gerarduzzi, T | 1 |
| Ventura, A | 1 |
| Sukhareva, GV | 1 |
| Tsaregorodtseva, TM | 1 |
| Trubitsina, IE | 1 |
| Serova, TI | 1 |
| Goncharenko, LS | 1 |
| Dolgova, NIu | 1 |
| Zarudnaia, SI | 1 |
| Kuz'mina, OS | 1 |
| Lopatina, IN | 1 |
| Manannikov, IV | 1 |
| Melik-Ogandzhanian, NB | 1 |
| Appelman-Eszczuk, S | 1 |
| Bochenek, WJ | 2 |
| Peters, S | 1 |
| Fraga, PD | 2 |
| Wang, W | 1 |
| Mack, ME | 2 |
| Davis, KD | 1 |
| Ishiki, K | 2 |
| Nagahara, Y | 2 |
| Shiratori, Y | 2 |
| Füessl, HS | 2 |
| Sugimoto, M | 9 |
| Mansia, C | 1 |
| Nelis, GF | 4 |
| Klinkenberg-Knol, EC | 16 |
| Snel, P | 5 |
| Goldfain, D | 2 |
| Kolkman, JJ | 2 |
| Festen, HP | 7 |
| Dent, J | 4 |
| Zeitoun, P | 2 |
| Havu, N | 5 |
| Lamm, M | 2 |
| Walan, A | 4 |
| Goebeler-Kolve, ME | 1 |
| Fakheri, H | 2 |
| Merat, S | 2 |
| Hosseini, V | 1 |
| Malekzadeh, R | 4 |
| Shimatani, T | 3 |
| Inoue, M | 4 |
| Kuroiwa, T | 3 |
| Horikawa, Y | 1 |
| Ojetti, V | 5 |
| Migneco, A | 1 |
| Zocco, MA | 4 |
| Nista, EC | 4 |
| Gasbarrini, G | 20 |
| Lee, SB | 1 |
| Park, SJ | 1 |
| Ryu, JK | 1 |
| Lee, JK | 1 |
| Bae, JS | 1 |
| Jung, HS | 3 |
| Park, SM | 1 |
| Vithayasai, N | 1 |
| Isakov, VA | 4 |
| Simanenkov, VI | 1 |
| Kononov, AV | 1 |
| Abdulkhakov, RA | 1 |
| Zakharova, NV | 2 |
| Predvechnaia, IK | 1 |
| Chen, JS | 2 |
| Zheng, TT | 1 |
| Feng, RE | 1 |
| Fong, DY | 1 |
| Ho, J | 4 |
| Ching, CK | 3 |
| Wu, JC | 6 |
| Chan, FK | 10 |
| Ching, JY | 4 |
| Leung, WK | 10 |
| Hui, Y | 3 |
| Leong, R | 1 |
| Chung, SC | 15 |
| Sung, JJ | 17 |
| Johnstone, I | 1 |
| Cannizzaro, O | 5 |
| Martino, A | 1 |
| Fedeli, P | 2 |
| Lecca, PG | 1 |
| di Caro, S | 2 |
| Cesaro, P | 1 |
| Branca, G | 3 |
| González Carro, P | 3 |
| Legaz Huidobro, ML | 3 |
| Pérez Roldán, F | 3 |
| Esteban López Jamar, JM | 1 |
| Valenzuela Gámez, JC | 1 |
| Ponte Tellechea, A | 1 |
| Ruiz Carrillo, F | 3 |
| Pedraza Martín, C | 2 |
| Díaz de Rojas, F | 2 |
| Sáez Bravo, JM | 2 |
| van Grieken, NC | 2 |
| Meijer, GA | 2 |
| Kale, I | 1 |
| Offerhaus, GJ | 2 |
| Baak, JP | 2 |
| Hamaguchi, K | 1 |
| Ogawa, K | 3 |
| Katsube, T | 2 |
| Konno, S | 1 |
| Aiba, M | 1 |
| Marangi, S | 2 |
| Burattini, O | 2 |
| Berloco, P | 1 |
| Russo, F | 2 |
| Barone, M | 1 |
| Di Leo, A | 4 |
| Minenna, MF | 2 |
| Stoppino, V | 6 |
| Francavilla, A | 3 |
| Saltanova, SD | 1 |
| Tkach, OS | 1 |
| Escalera Temprado, T | 1 |
| Banzo Marraco, J | 1 |
| Abós Olivares, MD | 1 |
| Olave Rubio, MT | 1 |
| Prats Rivera, E | 1 |
| García López, F | 1 |
| Razola Alba, P | 1 |
| Yang, KC | 2 |
| Wang, GM | 1 |
| Chen, TJ | 1 |
| Lee, SC | 3 |
| Veldhuyzen Van Zanten, SJ | 7 |
| Escobedo, S | 2 |
| Grace, E | 2 |
| Armstrong, D | 9 |
| He, XX | 1 |
| Zhao, YH | 1 |
| Hao, YT | 1 |
| Gumurdulu, Y | 1 |
| Serin, E | 1 |
| Ozer, B | 1 |
| Kayaselcuk, F | 1 |
| Ozsahin, K | 1 |
| Cosar, AM | 1 |
| Gursoy, M | 1 |
| Gur, G | 2 |
| Yilmaz, U | 2 |
| Boyacioglu, S | 2 |
| Guo, CY | 1 |
| Wu, YB | 1 |
| Liu, HL | 1 |
| Wu, JY | 1 |
| Zhong, MZ | 1 |
| Helander, HF | 1 |
| Poorkhalkali, N | 1 |
| Xiao, F | 5 |
| El-Omar, EM | 2 |
| Rabkin, CS | 2 |
| Sugimura, H | 3 |
| Romano, M | 3 |
| Marmo, R | 1 |
| Cuomo, A | 1 |
| De Simone, T | 2 |
| Mucherino, C | 1 |
| Iovene, MR | 3 |
| Montella, F | 3 |
| Tufano, MA | 2 |
| Del Vecchio Blanco, C | 2 |
| Raps, S | 1 |
| Plein, K | 2 |
| Hotz Dagger, J | 1 |
| Gillen, D | 6 |
| Wirz, AA | 3 |
| Kornienko, EA | 2 |
| Klochko, OG | 1 |
| Chaudhary, A | 1 |
| Ahuja, V | 4 |
| Bal, CS | 2 |
| Das, B | 2 |
| Pandey, RM | 1 |
| Sharma, MP | 7 |
| Candelli, M | 5 |
| Rigante, D | 1 |
| Marietti, G | 1 |
| Crea, F | 1 |
| Schiavino, A | 1 |
| Pignataro, G | 1 |
| Petrucci, S | 1 |
| Mizuki, A | 1 |
| Tatemichi, M | 1 |
| Nishiya, H | 1 |
| Fukui, K | 1 |
| Hayashi, T | 1 |
| Tsukada, N | 1 |
| Birkenfeld, S | 1 |
| Shevah, O | 2 |
| Levine, A | 3 |
| Epstein, J | 1 |
| Boaz, M | 2 |
| Avni, Y | 2 |
| Inami, N | 1 |
| Kanazawa, S | 1 |
| Martínek, J | 2 |
| Pantoflícková, D | 2 |
| Hucl, T | 1 |
| Benes, M | 1 |
| Dorta, G | 5 |
| Lukás, M | 1 |
| Spicák, J | 1 |
| Della Valle, N | 2 |
| Amoruso, A | 2 |
| Muscatiello, N | 1 |
| Amarapurkar, D | 1 |
| Makesar, M | 1 |
| Amarapurkar, A | 1 |
| Das, HS | 1 |
| Sarna, S | 1 |
| Valtonen, V | 1 |
| Osborn, JF | 1 |
| Laheij, RJ | 3 |
| Hermsen, JT | 1 |
| Jansen, JB | 6 |
| Horrevorts, AM | 1 |
| Rongen, RJ | 1 |
| Van Rossum, LG | 1 |
| Witteman, E | 1 |
| de Koning, RW | 1 |
| Gribajcević, M | 3 |
| Vanis, N | 2 |
| Mesihović, R | 1 |
| Cameron, EAB | 1 |
| Powell, KU | 5 |
| Baldwin, L | 1 |
| Jones, P | 1 |
| Bell, GD | 8 |
| Williams, SGJ | 1 |
| Bhatia, V | 1 |
| Bal, C | 2 |
| Iijima, K | 3 |
| Sekine, H | 4 |
| Koike, T | 1 |
| Imatani, A | 1 |
| Ohara, S | 3 |
| Shimosegawa, T | 3 |
| Ingegnoli, A | 1 |
| Cavallaro, LG | 1 |
| Ulu, O | 1 |
| Aydin, O | 1 |
| Camdeviren, H | 1 |
| Sharara, AI | 4 |
| Chaar, HF | 2 |
| Racoubian, E | 1 |
| Moukhachen, O | 2 |
| Barada, KA | 1 |
| Mourad, FH | 1 |
| Araj, GF | 3 |
| Saribas, S | 1 |
| Kocazeybek, B | 1 |
| Aslan, M | 1 |
| Altun, S | 1 |
| Seyhun, Y | 1 |
| Öner, YA | 1 |
| Memisoglu, N | 1 |
| Namiot, Z | 4 |
| Namiot, DB | 3 |
| Kemona, A | 3 |
| Stasiewicz, J | 2 |
| Singh, G | 1 |
| Pietrini, L | 1 |
| Winn, S | 3 |
| Monno, R | 2 |
| Phuncarg, DC | 1 |
| Nilsson, LE | 1 |
| Lane, E | 1 |
| Lobetti, R | 1 |
| Burroughs, R | 1 |
| Sakabe, H | 1 |
| Yagi, Y | 1 |
| Kakinoki, R | 1 |
| Yoshikawa, K | 1 |
| Inoue, T | 2 |
| Fujiyama, Y | 1 |
| Giral, A | 2 |
| Ozdogan, O | 2 |
| Celikel, CA | 2 |
| Tozun, N | 4 |
| Ulusoy, NB | 2 |
| Kalayci, C | 2 |
| Lanza, F | 2 |
| Schwartz, H | 3 |
| Barth, J | 2 |
| Shabat-Sehayek, V | 1 |
| Aeed, H | 1 |
| Wu, CJ | 1 |
| Hsu, PI | 2 |
| Lo, GH | 2 |
| Lo, CC | 2 |
| Lin, CK | 2 |
| Shie, CB | 1 |
| Peng, NJ | 2 |
| Tseng, HH | 2 |
| Jou, HS | 1 |
| Tsai, PM | 1 |
| Chen, A | 1 |
| Chen, JL | 1 |
| Lai, KH | 2 |
| Yukselen, V | 1 |
| Yasa, MH | 1 |
| Karaoglu, AO | 1 |
| Belson, G | 1 |
| Abudayyeh, S | 1 |
| Chen, XX | 1 |
| Ou, BY | 1 |
| Wu, XY | 1 |
| Zhou, XL | 1 |
| Tang, HF | 1 |
| Qü, YP | 1 |
| Shang, SQ | 1 |
| Farrell, S | 1 |
| Milliken, I | 1 |
| Doherty, GM | 1 |
| Murphy, JL | 1 |
| Wootton, SA | 1 |
| McCallion, WA | 1 |
| Marinello, D | 1 |
| Lerro, P | 2 |
| Kuvidi, M | 1 |
| Ferzetti, A | 1 |
| Cucchiara, S | 1 |
| Franco, MT | 1 |
| Romano, C | 2 |
| Strisciuglio, P | 1 |
| Pensabene, L | 1 |
| Tindberg, Y | 1 |
| Casswall, TH | 2 |
| Blennow, M | 1 |
| Bengtsson, C | 1 |
| Nada, T | 1 |
| Nobata, K | 2 |
| Tsuzuki, T | 2 |
| Minami, M | 2 |
| Ina, K | 2 |
| Iinuma, Y | 1 |
| Ichiyama, S | 1 |
| Ohta, M | 1 |
| El-Omar, E | 4 |
| Kusugami, K | 2 |
| Goto, H | 3 |
| SuzukiKurabayashi, HK | 1 |
| Kamiya, AG | 1 |
| Kondo, Y | 2 |
| Joh, T | 3 |
| Sasaki, M | 2 |
| Oshima, T | 2 |
| Itoh, K | 2 |
| Tanida, S | 2 |
| Kataoka, H | 3 |
| Ohara, H | 3 |
| Nomura, T | 1 |
| Itoh, M | 4 |
| Muramatsu, A | 2 |
| Okajima, T | 1 |
| Ohtani, M | 3 |
| Dojo, M | 3 |
| Yamazaki, Y | 3 |
| Kuriyama, M | 4 |
| Wit, NJ | 1 |
| Boer, WA | 1 |
| Geldof, H | 1 |
| Hazelhoff, B | 1 |
| Bergmans, P | 1 |
| Tytgat, GN | 19 |
| Smout, AJ | 3 |
| Lin, SR | 4 |
| To, KF | 4 |
| Ng, EK | 6 |
| Lau, JY | 7 |
| Ozturk, Y | 1 |
| Buyukgebiz, B | 1 |
| Ozer, E | 1 |
| Arslan, N | 1 |
| Bekem, O | 1 |
| Hizli, S | 1 |
| Ashorn, M | 3 |
| Rägö, T | 1 |
| Kokkonen, J | 1 |
| Ruuska, T | 2 |
| Rautelin, H | 3 |
| Karikoski, R | 1 |
| Ghazzawi, IM | 1 |
| Obeidat, WA | 1 |
| Zuriekat, FA | 1 |
| Sivri, B | 2 |
| Simsek, I | 1 |
| Hulagu, S | 1 |
| Kadayifci, A | 6 |
| Akarsu, M | 1 |
| Uraz, S | 1 |
| Savas, MC | 2 |
| Koruk, M | 1 |
| Bozbas, A | 1 |
| Wallace, RA | 1 |
| Schluter, PJ | 1 |
| Webb, PM | 1 |
| Bosques-Padilla, FJ | 1 |
| Garza-González, E | 1 |
| Calderón-Lozano, IE | 1 |
| Reed-SanRoman, G | 1 |
| de Ariño Suárez, M | 1 |
| Valdovinos-Díaz, MA | 1 |
| Orozco-Gámiz, A | 1 |
| Blancas-Valencia, JM | 1 |
| Tamayo-de la Cuesta, JL | 1 |
| Güliter, S | 2 |
| Kandilci, U | 1 |
| Ebara, S | 1 |
| Montserrat, A | 2 |
| Güell, M | 1 |
| Gené, E | 4 |
| Schwab, M | 2 |
| Schaeffeler, E | 1 |
| Klotz, U | 8 |
| Treiber, G | 11 |
| Galović, A | 1 |
| Belosić Halle, Z | 1 |
| Park, SC | 1 |
| Chun, HJ | 2 |
| Jung, SW | 1 |
| Keum, B | 1 |
| Han, WS | 1 |
| Choung, RS | 1 |
| Kim, YS | 3 |
| Jeen, YT | 1 |
| Lee, HS | 1 |
| Um, SH | 1 |
| Choi, JH | 1 |
| Kim, CD | 1 |
| Ryu, HS | 1 |
| Hyun, JH | 1 |
| Miyajima, H | 2 |
| Ogata, M | 1 |
| Ohtsuka, E | 1 |
| Saburi, Y | 1 |
| Janssen, MJ | 1 |
| Serpa, J | 1 |
| Lunet, N | 1 |
| Mendes, N | 1 |
| Barros, H | 1 |
| David, L | 1 |
| Kanamori, H | 2 |
| Yamato, H | 2 |
| Ehira, N | 2 |
| Miura, T | 1 |
| Kawamura, T | 2 |
| Obara, S | 2 |
| Tanaka, J | 3 |
| Imamura, M | 2 |
| Masauzi, N | 2 |
| Horn, J | 1 |
| Robinson, M | 2 |
| Longoa, MG | 1 |
| Scarcelli, C | 1 |
| Orsitto, G | 1 |
| Perri, FC | 1 |
| D'Ambrosio, LP | 1 |
| Farinati, F | 1 |
| Cardin, R | 1 |
| Russo, VM | 1 |
| Busatto, G | 1 |
| Franco, M | 1 |
| Falda, A | 1 |
| Mescoli, C | 1 |
| Befrits, R | 2 |
| Sjöstedt, S | 5 |
| Tour, R | 1 |
| Leijonmarck, CE | 1 |
| Hedenborg, L | 1 |
| Backman, M | 1 |
| Asfeldt, AM | 1 |
| Løchen, ML | 1 |
| Straume, B | 1 |
| Steigen, SE | 1 |
| Florholmen, J | 1 |
| Paulssen, EJ | 1 |
| Cao, X | 1 |
| Tsukamoto, T | 1 |
| Nozaki, K | 2 |
| Shimizu, N | 3 |
| Mizoshita, T | 1 |
| Kumagai, T | 2 |
| Kaminishi, M | 3 |
| Tatematsu, M | 1 |
| Fukuda, S | 5 |
| Mikami, T | 2 |
| Fukushi, M | 2 |
| Munakata, A | 5 |
| Vasil'ev, IuB | 1 |
| Kashimura, K | 1 |
| Miura, M | 1 |
| Ootsu, S | 1 |
| Konno, M | 3 |
| Maisawa, S | 1 |
| Tajiri, H | 1 |
| Yoshimura, N | 1 |
| Shimizu, T | 5 |
| Toyoda, S | 1 |
| Nakayama, Y | 1 |
| Iinuma, K | 3 |
| Buzás, GM | 1 |
| Metz, DC | 3 |
| Cremonini, F | 4 |
| Cazzato, IA | 1 |
| Franceschi, F | 2 |
| Kato, A | 1 |
| Kato, H | 2 |
| Hirashima, N | 1 |
| Sakamoto, T | 1 |
| Nukaya, H | 1 |
| Ito, K | 1 |
| Matsunaga, S | 1 |
| Kondo, H | 3 |
| Tanaka, Y | 2 |
| Sakakibara, K | 1 |
| Miwa, H | 14 |
| Kawabe, M | 1 |
| Kurosawa, A | 5 |
| Hojo, M | 3 |
| Terai, T | 1 |
| Miyazaki, A | 2 |
| Sato, N | 16 |
| Bak-Romaniszyn, L | 1 |
| Wojtuń, S | 1 |
| Gil, J | 2 |
| Płaneta-Małecka, I | 1 |
| Elizalde, JI | 3 |
| Pérez-Pujol, S | 1 |
| Heras, M | 1 |
| Sionis, A | 1 |
| Casanovas, N | 1 |
| Martorell, T | 1 |
| Lozano, M | 1 |
| González, J | 1 |
| Escolar, G | 1 |
| Sanz, G | 1 |
| Piqué, JM | 5 |
| Hu, PJ | 2 |
| Huang, JQ | 1 |
| Wu, SM | 2 |
| Li, CJ | 1 |
| Cui, Y | 1 |
| Hirschowitz, BI | 3 |
| Simmons, J | 2 |
| Mohnen, J | 2 |
| Arkkila, PE | 1 |
| Seppälä, K | 1 |
| Kosunen, TU | 2 |
| Mäkinen, J | 1 |
| Kunicki, PK | 1 |
| Sobieszczańska-Małek, M | 1 |
| Malfatti, F | 3 |
| Giannini, E | 2 |
| Emanuela, T | 1 |
| Polegato, S | 2 |
| Podestà, E | 1 |
| Fumagalli, A | 2 |
| Cotelessa, T | 1 |
| Chiarbonello, B | 2 |
| Bellotti, M | 1 |
| Botta, F | 3 |
| Milazzo, S | 1 |
| Testa, R | 5 |
| Kao, AW | 1 |
| Cheng, HC | 1 |
| Hunag, SF | 1 |
| Chen, TW | 1 |
| Lu, CC | 1 |
| Tanaka, A | 3 |
| Imase, K | 1 |
| Sugano, H | 1 |
| Kai, A | 1 |
| Ishida, H | 3 |
| Itoh, T | 2 |
| Marko, D | 1 |
| Ozawa, K | 1 |
| Ohyauchi, M | 1 |
| Minoura, T | 1 |
| Maruta, F | 1 |
| Sugiyama, A | 2 |
| Ishizone, S | 1 |
| Miyagawa, S | 1 |
| Ota, H | 3 |
| Katsuyama, T | 5 |
| de Silva, HA | 1 |
| Hewavisenthi, J | 1 |
| Pathmeswaran, A | 1 |
| Dassanayake, AS | 1 |
| Navaratne, NM | 1 |
| Peiris, R | 1 |
| de Silva, HJ | 1 |
| Bishop, AE | 2 |
| Polak, JM | 2 |
| Romanska, HM | 1 |
| Rowland, A | 2 |
| Thompson, M | 3 |
| Morris, P | 3 |
| Schaefer-Preuss, S | 1 |
| Luehmann, R | 1 |
| McCaldin, B | 3 |
| Mana, F | 1 |
| Van Laer, W | 1 |
| Van Laere, W | 1 |
| Bossuyt, A | 1 |
| Urbain, D | 1 |
| Shintani, S | 1 |
| Hori, K | 1 |
| Tomita, T | 2 |
| Matsumoto, T | 6 |
| Magistà, AM | 2 |
| Castellaneta, S | 1 |
| Miniello, VL | 2 |
| Lionetti, E | 2 |
| Ros, P | 1 |
| Rigillo, N | 1 |
| Francavilla, R | 2 |
| de Mascarel, A | 6 |
| Ruskone-Fourmestraux, A | 2 |
| Lavergne-Slove, A | 2 |
| Dubus, P | 1 |
| Merlio, JP | 1 |
| Chang, CC | 1 |
| Chen, SH | 1 |
| Lien, GS | 1 |
| Lou, HY | 1 |
| Hsieh, CR | 1 |
| Fang, CL | 1 |
| Pan, S | 1 |
| Lu, RH | 1 |
| Feng, LY | 1 |
| Yao, XX | 1 |
| Jiang, SL | 1 |
| Gadzhieva, MG | 1 |
| Koivisto, TT | 1 |
| Rautelin, HI | 1 |
| Voutilainen, ME | 1 |
| Heikkinen, MT | 1 |
| Koskenpato, JP | 1 |
| Färkkilä, MA | 1 |
| Moretzsohn, LD | 1 |
| Vieira, WL | 1 |
| Gallo, MA | 1 |
| Cindr, JM | 1 |
| Cerqueira, MC | 1 |
| Vitiello, L | 1 |
| Ribeiro, ML | 2 |
| Mendonça, S | 1 |
| Pedrazzoli-Júnior, J | 1 |
| Ohnita, K | 1 |
| Wen, CY | 1 |
| Wang, HH | 1 |
| Chou, JW | 1 |
| Liao, KF | 1 |
| Lin, ZY | 1 |
| Lai, HC | 1 |
| Hsu, CH | 1 |
| Chen, CB | 1 |
| Amini, M | 1 |
| Khedmat, H | 1 |
| Yari, F | 1 |
| Ruiz García, A | 1 |
| Gordillo López, FJ | 1 |
| Hermosa Hernán, JC | 1 |
| Arranz Martínez, E | 1 |
| Villares Rodríguez, JE | 1 |
| Morozov, SV | 1 |
| Tsodikova, OM | 1 |
| Tereshchenko, SG | 1 |
| Gushchin, AE | 1 |
| Shipulin, GA | 1 |
| Stasi, R | 1 |
| Rossi, Z | 1 |
| Stipa, E | 1 |
| Amadori, S | 1 |
| Newland, AC | 1 |
| Provan, D | 1 |
| Calleja, JL | 1 |
| Suarez, M | 1 |
| De Tejada, AH | 1 |
| Navarro, A | 1 |
| Pieramico, O | 2 |
| Giardullo, N | 2 |
| Bergman, MP | 1 |
| Faller, G | 1 |
| Aar, A | 1 |
| Lakhai, W | 1 |
| Vandenbroucke-Grauls, CM | 2 |
| Appelmelk, BJ | 1 |
| Babic, Z | 1 |
| Nesanovic, M | 1 |
| Lucijanic-Mlinac, M | 1 |
| Stajcar, V | 1 |
| Jacobs, A | 1 |
| Sun, WH | 1 |
| Ou, XL | 1 |
| Cao, DZ | 1 |
| Yu, Q | 1 |
| Hu, JM | 1 |
| Zhu, F | 1 |
| Sun, YL | 1 |
| Fu, XL | 1 |
| Su, H | 1 |
| Filik, L | 1 |
| Yolcu, OF | 1 |
| Odemiş, B | 1 |
| Ulker, A | 1 |
| Saşmaz, N | 1 |
| Ozden, A | 1 |
| Sahin, B | 1 |
| Viiala, CH | 1 |
| Windsor, HM | 1 |
| Marshall, BJ | 1 |
| Kim, SH | 1 |
| Sung, IK | 1 |
| Keum, DK | 1 |
| Gedik, GK | 1 |
| Karaduman, A | 1 |
| Caner, B | 1 |
| Faber, J | 1 |
| Bar-Meir, M | 1 |
| Rudensky, B | 1 |
| Schlesinger, Y | 1 |
| Rachman, E | 1 |
| Benenson, S | 1 |
| Sirota, G | 1 |
| Stankiewic, H | 1 |
| Halle, D | 1 |
| Wilschanski, M | 1 |
| Karel'skaia, IA | 1 |
| Ignat'ev, VK | 1 |
| Theil, AL | 2 |
| Somm, G | 1 |
| Cartell, A | 2 |
| Rivero, LF | 2 |
| Scarpignato, C | 1 |
| Kubota, K | 2 |
| Takeshita, Y | 1 |
| Ueda, T | 1 |
| Imamura, K | 1 |
| Hiki, N | 1 |
| Yamaguchi, H | 3 |
| Shimoyama, S | 1 |
| MaFune, K | 1 |
| Tanabe, H | 2 |
| Hara, H | 1 |
| Ohtubo, C | 1 |
| Miyokawa, N | 1 |
| Sano, H | 2 |
| Hershko, C | 1 |
| Hoffbrand, AV | 1 |
| Keret, D | 1 |
| Souroujon, M | 1 |
| Maschler, I | 1 |
| Monselise, Y | 1 |
| Lahad, A | 1 |
| Zhang, ST | 1 |
| Yu, ZL | 1 |
| Shao, Y | 1 |
| Tsuji, S | 3 |
| Fujiwara, Y | 4 |
| Nebiki, H | 2 |
| Chono, S | 1 |
| Uno, H | 1 |
| Kitada, K | 1 |
| Satoh, H | 1 |
| Nakagawa, K | 3 |
| Kobayashi, K | 4 |
| Watanabe, T | 5 |
| Oshitani, N | 2 |
| Arakawa, T | 8 |
| Cheung, KL | 1 |
| Ho, VY | 1 |
| García-Altés, A | 1 |
| Rota, R | 1 |
| Barenys, M | 1 |
| Abad, A | 1 |
| Pons, JM | 1 |
| Si, JM | 2 |
| Cao, Q | 1 |
| Wu, JG | 1 |
| Catalán, M | 1 |
| Bernabucci, V | 1 |
| Cavina, M | 1 |
| Sagehashi, Y | 1 |
| Nakamura, A | 3 |
| Kodaira, M | 1 |
| Kenmotsu, K | 1 |
| Nagano, M | 1 |
| Egashira, T | 1 |
| Ueda, K | 1 |
| Yoneyama, M | 1 |
| Hishida, A | 3 |
| Hashimoto, T | 3 |
| Furuta, K | 1 |
| Ishihara, S | 5 |
| Hattori, S | 2 |
| Gawrońska-Szklarz, B | 1 |
| Wrześniewska, J | 1 |
| Starzyńska, T | 1 |
| Pawlik, A | 1 |
| Safranow, K | 1 |
| Ferenc, K | 1 |
| Droździk, M | 1 |
| Okiyama, Y | 1 |
| Matsuzawa, K | 1 |
| Hidaka, E | 1 |
| Sano, K | 1 |
| Akamatsu, T | 5 |
| Rammer, M | 1 |
| Kirchgatterer, A | 1 |
| Höbling, W | 1 |
| Knoflach, P | 1 |
| Pace, F | 3 |
| Annese, V | 2 |
| Prada, A | 2 |
| Zambelli, A | 1 |
| Casalini, S | 1 |
| Nardini, P | 1 |
| Bianchi Porro, G | 17 |
| Beinborn, M | 1 |
| Nagamatsu, S | 1 |
| Raghunath, AS | 1 |
| McLoughlin, RC | 1 |
| Giannini, EG | 3 |
| Testa, E | 1 |
| Mamone, M | 3 |
| Kanbay, M | 1 |
| Yücel, M | 1 |
| Jury, J | 1 |
| Gee, LC | 1 |
| Delaney, KH | 1 |
| Perdue, MH | 1 |
| Bonner, RA | 1 |
| Biswal, N | 1 |
| Ananathakrishnan, N | 1 |
| Srinivasan, S | 3 |
| Nalini, P | 1 |
| Mathai, B | 1 |
| Umehara, S | 1 |
| Mori, A | 1 |
| Ogura, N | 1 |
| Pellegrini, M | 1 |
| Urso, R | 1 |
| Giorgi, G | 1 |
| Bayeli, PF | 1 |
| Marzocca, G | 1 |
| Cerretani, D | 1 |
| Bjarnason, IT | 2 |
| Charlett, A | 1 |
| Dobbs, RJ | 1 |
| Dobbs, SM | 1 |
| Ibrahim, MA | 1 |
| Kerwin, RW | 1 |
| Mahler, RF | 1 |
| Oxlade, NL | 1 |
| Peterson, DW | 1 |
| Plant, JM | 1 |
| Price, AB | 1 |
| Weller, C | 1 |
| Ogasawara, N | 1 |
| Okada, N | 1 |
| Nakao, H | 1 |
| Sobue, S | 1 |
| Chen, YH | 1 |
| Wang, WM | 2 |
| Li, HY | 1 |
| Salih, BA | 1 |
| Abasiyanik, MF | 1 |
| Saribasak, H | 1 |
| Huten, O | 1 |
| Sander, E | 1 |
| Ahlawat, S | 1 |
| Haddad, N | 1 |
| Kanber, Y | 1 |
| Cohen, P | 2 |
| Ozdemirli, M | 1 |
| Benjamin, S | 1 |
| Horvat, D | 2 |
| Vcev, A | 8 |
| Soldo, I | 1 |
| Timarac, J | 1 |
| Dmitrović, B | 5 |
| Misević, T | 1 |
| Ivezić, Z | 1 |
| Kraljik, N | 1 |
| Kim, SS | 1 |
| Meitner, P | 1 |
| Konkin, TA | 1 |
| Cho, YS | 1 |
| Resnick, MB | 1 |
| Domínguez-Muñoz, A | 1 |
| Domínguez-Martín, A | 1 |
| Henry, EB | 1 |
| Carswell, A | 2 |
| Wirz, A | 3 |
| Fyffe, V | 1 |
| Chen, LT | 2 |
| Lin, JT | 2 |
| Tai, JJ | 1 |
| Wang, HP | 1 |
| Kuo, SH | 1 |
| Jan, CM | 2 |
| Wang, TE | 1 |
| Wu, CW | 1 |
| Chen, CL | 2 |
| Su, IJ | 3 |
| Whang-Peng, J | 1 |
| Cheng, AL | 2 |
| Wani, S | 1 |
| Sampliner, RE | 1 |
| Weston, AP | 1 |
| Mathur, S | 1 |
| Hall, M | 1 |
| Higbee, A | 1 |
| Sharma, P | 1 |
| Mizuno, T | 1 |
| Watanabe, O | 1 |
| Ishiguro, K | 1 |
| Nishiwaki, T | 1 |
| Shimada, M | 1 |
| Magalhães, AF | 2 |
| Carvalhaes, A | 1 |
| Natan-Eisig, J | 1 |
| Paraíso-Ferraz, JG | 1 |
| Trevisan, M | 2 |
| Zaterkaad, S | 1 |
| Kikuchi, R | 1 |
| Arai, D | 1 |
| Fukuchi, K | 1 |
| Gomi, K | 1 |
| Gessner, BD | 1 |
| Bruce, MG | 1 |
| Parkinson, AJ | 1 |
| Gold, BD | 1 |
| Muth, PT | 1 |
| Dunaway, E | 1 |
| Baggett, HC | 1 |
| Nijevitch, AA | 1 |
| Sataev, VU | 1 |
| Khasanov, RSh | 1 |
| Al Khashash, R | 1 |
| Tuygunov, MM | 1 |
| Sakai, G | 1 |
| Hibi, T | 3 |
| Uygun, A | 2 |
| Yeşilova, Z | 1 |
| Ateş, Y | 2 |
| Karslioğlu, Y | 1 |
| Ciğerim, M | 1 |
| Bağci, S | 1 |
| Dağalp, K | 2 |
| Keleş, H | 1 |
| Ozkurt, ZN | 1 |
| Cengiz, DU | 1 |
| Kolukisa, E | 1 |
| Wong, J | 3 |
| Castellaneta, SP | 1 |
| Boscarelli, G | 1 |
| Piscitelli, D | 1 |
| Cavallo, L | 1 |
| Declich, P | 2 |
| Tavani, E | 2 |
| Ferrara, A | 1 |
| Caruso, S | 1 |
| Bellone, S | 2 |
| Krishna, M | 1 |
| Lalmuanpuii, J | 1 |
| Gurbuz, AK | 1 |
| Ozel, AM | 1 |
| Ozturk, R | 1 |
| Yildirim, S | 1 |
| Yazgan, Y | 1 |
| Demirturk, L | 1 |
| Lim, PW | 1 |
| Goh, KL | 10 |
| Nishiyama, M | 1 |
| Maeda, K | 4 |
| Aoyagi, K | 2 |
| Sakisaka, S | 1 |
| Jho, T | 1 |
| Koizuka, H | 1 |
| Nakmura, A | 1 |
| Okazaki, K | 1 |
| Mori, S | 1 |
| Tahashi, K | 1 |
| Takagi, Y | 2 |
| Okudaira, K | 1 |
| Takeda, H | 9 |
| Yanaka, A | 2 |
| Fujishiro, M | 3 |
| Omata, M | 3 |
| Oka, M | 2 |
| Hiratsuka, T | 1 |
| Tamura, K | 4 |
| Hiratsuka, H | 1 |
| Suzuki, T | 3 |
| Bray, R | 1 |
| Ichinose, M | 1 |
| Nakagawa, S | 2 |
| Nakagawa, M | 2 |
| Hikichi, T | 1 |
| Irisawa, A | 1 |
| Abe, C | 1 |
| Obara, K | 1 |
| Hamasaki, N | 1 |
| Tanigawa, T | 1 |
| Sasaki, E | 1 |
| Ishii, E | 1 |
| Tezuka, Y | 1 |
| Nagaoka, T | 1 |
| Kadota, S | 1 |
| Schaeverbeke, T | 1 |
| Broutet, N | 3 |
| Zerbib, F | 2 |
| Combe, B | 1 |
| Bertin, P | 1 |
| Perié, F | 2 |
| Joubert-Collin, M | 3 |
| Santi, ML | 2 |
| Campos, A | 1 |
| Chavez, A | 1 |
| Guerrero, L | 1 |
| Mieno, H | 1 |
| Nakamura, M | 1 |
| Tazuma, S | 2 |
| Barros, SG | 1 |
| Polanczyk, CA | 1 |
| Fritscher, LG | 1 |
| Asano, M | 1 |
| Taniwaki, H | 1 |
| Tsuji, D | 1 |
| Troiani, L | 1 |
| Stella, F | 1 |
| Mierzwa, M | 1 |
| Peng, JZ | 1 |
| Cheung, HK | 1 |
| Kwong, YL | 1 |
| Rashid, A | 1 |
| Saccà, SC | 1 |
| Pascotto, A | 1 |
| Venturino, GM | 1 |
| Prigione, G | 1 |
| Mastromarino, A | 1 |
| Baldi, F | 1 |
| Brusati, C | 1 |
| Rebora, A | 1 |
| Kim, MS | 1 |
| Jung, HK | 1 |
| Choi, JY | 1 |
| Na, YJ | 2 |
| Pyun, GW | 1 |
| Ryu, JH | 1 |
| Moon, IH | 1 |
| Jo, MS | 1 |
| Confino-Cohen, R | 1 |
| Goldberg, A | 1 |
| Madisch, A | 3 |
| Neuber, F | 1 |
| Morgner, A | 5 |
| Kuhlisch, E | 2 |
| Rappel, S | 1 |
| Seitz, G | 1 |
| Pang, G | 1 |
| Wettstein, AR | 1 |
| Clancy, R | 1 |
| Herdman, K | 1 |
| Surace, R | 1 |
| Llorente, R | 1 |
| Ng, C | 1 |
| Benito, LM | 2 |
| López-Rivas, L | 1 |
| Pabón, M | 1 |
| Olivares, D | 2 |
| Abe, T | 2 |
| Onoda, N | 1 |
| Katsuragi, K | 1 |
| Sawada, T | 1 |
| Mino, A | 1 |
| Ohira, M | 1 |
| Ishikawa, T | 1 |
| Wakasa, K | 1 |
| Hirakawa, K | 4 |
| Lundell, L | 3 |
| Myrvold, HE | 2 |
| Wallin, L | 1 |
| Levander, K | 2 |
| Hatlebakk, JG | 3 |
| Liedman, B | 3 |
| Malm, A | 1 |
| Postavnyĭ, VE | 1 |
| Butorov, IV | 2 |
| Osoianu, IuP | 2 |
| Butorov, SI | 2 |
| Maksimov, VV | 2 |
| Walshe, V | 1 |
| Bennett, K | 1 |
| Keeling, PW | 1 |
| Barry, M | 1 |
| Agustí-Escasany, A | 1 |
| Vallano-Ferraz, A | 1 |
| Kubo, N | 1 |
| Kochi, S | 1 |
| Ariyama, I | 2 |
| Murata, M | 1 |
| Furusyo, N | 2 |
| Hayashi, J | 2 |
| Aladağ, M | 1 |
| Kantarçeken, B | 1 |
| Karincaoğlu, M | 1 |
| Sertkaya, A | 1 |
| Cikim, K | 1 |
| Harputluoğlu, MM | 1 |
| Demirel, U | 1 |
| Alan, H | 1 |
| Ateş, F | 1 |
| Yildirim, B | 1 |
| Hilmioğlu, F | 2 |
| Luna, M | 1 |
| Gómez, B | 1 |
| Herrerías, JM | 1 |
| Monés, J | 3 |
| Pregun, I | 1 |
| Herszényi, L | 2 |
| Juhász, M | 1 |
| Miheller, P | 1 |
| Tulassay, Z | 4 |
| Wang, ZW | 1 |
| Ning, JW | 1 |
| Wang, QY | 1 |
| Chen, JY | 1 |
| Li, YM | 1 |
| Bahremand, S | 1 |
| Nematollahi, LR | 1 |
| Fourutan, H | 1 |
| Tirgari, F | 1 |
| Nouripour, S | 1 |
| Mir, E | 1 |
| Aghakhani, S | 1 |
| Lule, GN | 1 |
| You, JH | 1 |
| Lau, W | 1 |
| Lee, IY | 1 |
| Yung, M | 1 |
| Lee, KK | 1 |
| Centanni, M | 1 |
| Gargano, L | 1 |
| Canettieri, G | 1 |
| Viceconti, N | 1 |
| Franchi, A | 1 |
| Delle Fave, G | 5 |
| Annibale, B | 6 |
| Kikuchi, S | 2 |
| Tominaga, S | 1 |
| Mandekou-Lefaki, I | 1 |
| Delli, FS | 1 |
| Kountouras, I | 1 |
| Athanasiou, E | 1 |
| Mattheou-Vakali, G | 1 |
| Tan, HJ | 1 |
| Rizal, AM | 1 |
| Rosmadi, MY | 1 |
| Tran, TT | 2 |
| Quandalle, P | 2 |
| Huo, XH | 1 |
| Chu, JK | 1 |
| Yang, XF | 1 |
| Zhang, LJ | 1 |
| Ma, JC | 1 |
| Yu, J | 1 |
| Díte, P | 5 |
| Kunovská, M | 1 |
| Pulgretová, D | 1 |
| Woznica, V | 1 |
| Petrtýl, J | 1 |
| Hůlek, P | 1 |
| Pásková, J | 1 |
| Dostalík, Z | 1 |
| Novotný, I | 1 |
| Procházka, V | 1 |
| Hegyi, P | 1 |
| Zelenková, J | 2 |
| Samek, M | 1 |
| Králová, Z | 1 |
| Vyhnálek, P | 1 |
| Matejovic, F | 1 |
| Weinberg, J | 1 |
| Kyzeková, J | 1 |
| Castro Fernández, M | 3 |
| García Díaz, E | 1 |
| Larraona, JL | 1 |
| Rodríguez Hornillo, MC | 1 |
| Lamas Rojas, E | 1 |
| Núñez Hospital, D | 1 |
| Pallarés Querol, M | 1 |
| Jarbol, DE | 2 |
| Kragstrup, J | 2 |
| Stovring, H | 1 |
| Havelund, T | 2 |
| Schaffalitzky de Muckadell, OB | 3 |
| Bytzer, P | 4 |
| Ji, KY | 1 |
| Lu, R | 1 |
| Sun, DF | 1 |
| Hansky, K | 1 |
| Jin, ML | 2 |
| Chang, YS | 3 |
| Xu, GW | 3 |
| Padol, S | 1 |
| Thabane, M | 1 |
| Padol, IT | 1 |
| Hunt, RH | 8 |
| Mousavi, S | 1 |
| Toussy, J | 1 |
| Yaghmaie, S | 1 |
| Zahmatkesh, M | 1 |
| Aoun, E | 1 |
| Abdul-Baki, H | 1 |
| Kanj, SS | 1 |
| Gon, S | 1 |
| Irie, Y | 1 |
| Takahashi, M | 5 |
| Sayan, O | 1 |
| Akyol Erikci, A | 1 |
| Ozturk, A | 1 |
| Komoto, M | 1 |
| Nakata, B | 1 |
| Takashima, T | 2 |
| Rokkas, T | 4 |
| Sechopoulos, P | 1 |
| Robotis, J | 1 |
| Pistiolas, D | 1 |
| Mirbagheri, SA | 1 |
| Hasibi, M | 1 |
| Abouzari, M | 1 |
| Rashidi, A | 1 |
| Aristoteli, LP | 1 |
| Danon, S | 1 |
| Larsson, H | 1 |
| Mellgard, B | 1 |
| Mitchell, H | 1 |
| Dietrich, JW | 1 |
| Boehm, BO | 1 |
| Bech, M | 1 |
| Kawakami, E | 1 |
| Machado, RS | 1 |
| Ogata, SK | 1 |
| Langner, M | 1 |
| Fukushima, E | 1 |
| Carelli, AP | 1 |
| Bonucci, VC | 1 |
| Patricio, FR | 1 |
| Wang, YQ | 1 |
| Amagase, H | 1 |
| Zagari, RM | 2 |
| Bianchi-Porro, G | 1 |
| Roda, E | 3 |
| Khayat, O | 1 |
| Kilani, A | 1 |
| Chedly-Debbiche, A | 1 |
| Zeddini, A | 1 |
| Gargouri, D | 1 |
| Kharrat, J | 1 |
| Souissi, A | 1 |
| Ghorbel, AJ | 1 |
| Ben Ayed, M | 1 |
| Ben Khelifa, H | 1 |
| Sohn, YH | 1 |
| Lee, WS | 1 |
| Park, CH | 1 |
| Joo, YE | 1 |
| Kim, HS | 2 |
| Choi, SK | 1 |
| Rew, JS | 2 |
| Kim, SJ | 1 |
| Sancar, M | 1 |
| Izzettin, FV | 1 |
| Apikoglu-Rabus, S | 1 |
| Dulger, G | 1 |
| Emami, MH | 1 |
| Saberfiroozi, MM | 1 |
| Taghavi, AR | 1 |
| Bagheri-Lankarani, K | 1 |
| Dehbashi, N | 2 |
| Fattahi, MR | 1 |
| Alizadeh, M | 1 |
| Kaviani, MJ | 1 |
| Bahri-Najafi, R | 1 |
| Geramizadeh, B | 1 |
| Esmaeili, A | 1 |
| Paoluzi, P | 1 |
| Iacopini, F | 1 |
| Crispino, P | 1 |
| Nardi, F | 1 |
| Bella, A | 1 |
| Rivera, M | 1 |
| Rossi, P | 1 |
| Gurnari, M | 1 |
| Caracciolo, F | 1 |
| Zippi, M | 1 |
| Pica, R | 1 |
| Ikuma, M | 1 |
| Yilmaz, S | 1 |
| Bayan, K | 1 |
| Dursun, M | 1 |
| Canoruç, F | 1 |
| Kilinç, N | 1 |
| Tüzün, Y | 1 |
| Daniş, R | 1 |
| Ertem, M | 1 |
| Maekawa, T | 1 |
| Chouno, S | 1 |
| Tomono, N | 1 |
| Orino, A | 1 |
| Tanimura, H | 3 |
| Asahina, K | 1 |
| Matsuura, N | 1 |
| Endo, M | 1 |
| Hirano, M | 1 |
| Sakamoto, C | 2 |
| Inomoto, T | 1 |
| Choi, J | 1 |
| Jang, JY | 1 |
| Kim, JS | 3 |
| Park, HY | 1 |
| Choe, YH | 1 |
| Kim, KM | 1 |
| Bontemps, P | 1 |
| Van Biervliet, S | 1 |
| Alliet, P | 1 |
| Lauvau, D | 1 |
| Vandenhoven, G | 1 |
| Kim, BG | 2 |
| Ye, BD | 1 |
| Lee, KH | 2 |
| Kim, BW | 1 |
| Kim, SG | 2 |
| Kim, SW | 1 |
| Kim, SK | 1 |
| Kim, JJ | 1 |
| Kim, HY | 1 |
| Park, JJ | 1 |
| Park, CY | 1 |
| Baik, GH | 1 |
| Hahm, KB | 2 |
| Hong, SJ | 1 |
| Bucki, R | 2 |
| Gotebiewska, M | 1 |
| Omazzi, B | 1 |
| Gozzini, C | 1 |
| Bortoli, A | 4 |
| Tziomalos, K | 1 |
| Chatzimavroudis, G | 1 |
| Vasiliadis, T | 1 |
| Katsinelos, T | 1 |
| Pilpilidis, I | 1 |
| Triantafillidis, I | 1 |
| Paroutoglou, G | 1 |
| Papaziogas, B | 1 |
| Duggan, AE | 1 |
| Shcherbakov, P | 1 |
| Urruzuno, P | 1 |
| Gottrand, F | 3 |
| Gómez, MJ | 1 |
| Ravelli, A | 1 |
| Gandullia, P | 1 |
| Roma, E | 1 |
| De Giacomo, C | 1 |
| Canani, RB | 1 |
| Rutigliano, V | 1 |
| Pehlivanoglu, E | 1 |
| Roggero, P | 1 |
| Celinska-Cedro, D | 1 |
| Drumm, B | 2 |
| Casswall, T | 1 |
| Arvanitakis, SN | 1 |
| Tsai, SH | 1 |
| Chu, SJ | 1 |
| Wu, CP | 1 |
| Keshavarz, AA | 1 |
| Bashiri, H | 1 |
| Rahbar, M | 1 |
| Tepes, B | 2 |
| Khalil, T | 1 |
| Dorchy, H | 1 |
| Melot, C | 1 |
| Moriwaki, M | 1 |
| Volodin, DV | 1 |
| Ivanova, OI | 1 |
| Burdina, EG | 1 |
| Belousov, IuB | 1 |
| Karpov, OI | 1 |
| Belousov, DIu | 1 |
| Beketov, AS | 1 |
| Subei, IM | 1 |
| Cardona, HJ | 1 |
| Bachelet, E | 1 |
| Useche, E | 1 |
| Arigbabu, A | 1 |
| Hammour, AA | 1 |
| Miller, T | 1 |
| Shmuely, H | 1 |
| Yahav, J | 1 |
| Samra, Z | 1 |
| Chodick, G | 1 |
| Koren, R | 1 |
| Ofek, I | 1 |
| Neefjes, VM | 1 |
| Heijboer, H | 1 |
| Tamminga, RY | 1 |
| Mikinori, K | 1 |
| Takei, K | 1 |
| Itoi, T | 1 |
| Aoki, T | 1 |
| Watanebe, K | 1 |
| Matsumoto, Y | 1 |
| Rimbara, E | 1 |
| Noguchi, N | 1 |
| Sasatsu, M | 1 |
| Malinovskaia, NK | 1 |
| Rapoport, SI | 1 |
| Zhernakova, NI | 1 |
| Rybnikova, SN | 1 |
| Postnikova, LI | 1 |
| Parkhomenko, IE | 1 |
| Riquelme, A | 1 |
| Soza, A | 1 |
| Pedreros, C | 1 |
| Bustamante, A | 1 |
| Valenzuela, F | 1 |
| Otarola, F | 1 |
| Abbott, E | 1 |
| Arellano, M | 1 |
| Medina, B | 1 |
| Pattillo, A | 1 |
| Greig, D | 1 |
| Arrese, M | 1 |
| Rollan, A | 2 |
| Czerwionka-Szaflarska, M | 1 |
| Brazowski, J | 1 |
| Chung, SJ | 1 |
| Navarro-Jarabo, JM | 1 |
| Fernández, N | 1 |
| Sousa, FL | 1 |
| Cabrera, E | 1 |
| Ramírez, LM | 1 |
| Rivera, R | 1 |
| Ubiña, E | 1 |
| Vera, F | 1 |
| Méndez, I | 1 |
| Rivas-Ruiz, F | 1 |
| Moreno, JL | 1 |
| Perea-Milla, E | 1 |
| Li, XB | 1 |
| Chen, XY | 1 |
| Liu, WZ | 2 |
| Hong, L | 1 |
| Zhao, Y | 1 |
| Han, Y | 2 |
| Guo, W | 1 |
| Li, X | 1 |
| Fan, D | 1 |
| Jakobsson, H | 1 |
| Fall, K | 1 |
| Fjelstad, B | 1 |
| Thong-Ngam, D | 1 |
| Koussoulas, V | 1 |
| Vassiliou, S | 1 |
| Spyridaki, E | 1 |
| Demonakou, M | 1 |
| Vaki, I | 1 |
| Barbatzas, C | 1 |
| Giamarellou, H | 1 |
| Giamarellos-Bourboulis, EJ | 1 |
| Huisman, AM | 1 |
| Vonkeman, HE | 1 |
| Kadir, SW | 1 |
| van Tulder, MW | 1 |
| Kubben, FJ | 1 |
| Sier, CF | 1 |
| Schram, MT | 1 |
| Witte, AM | 1 |
| Veenendaal, RA | 3 |
| van Duijn, W | 1 |
| Verheijen, JH | 1 |
| Hanemaaijer, R | 1 |
| Lamers, CB | 8 |
| Verspaget, HW | 2 |
| Magen, E | 1 |
| Mishal, J | 1 |
| Schlesinger, M | 1 |
| Scharf, S | 1 |
| Pfeiffer, RM | 1 |
| Ortiz, V | 1 |
| Niño, P | 1 |
| Carneros, JA | 1 |
| García-Durán, F | 1 |
| O'Callaghan, E | 1 |
| Valer, MP | 1 |
| Hazazi, R | 1 |
| Waked, A | 1 |
| Lederfein, T | 1 |
| Achiel, K | 1 |
| Ford, AC | 1 |
| Forman, D | 2 |
| Nathan, J | 2 |
| Crocombe, WD | 1 |
| Axon, AT | 21 |
| Page, RL | 1 |
| Ferguson, D | 1 |
| Cantu, M | 1 |
| Maróstica, M | 1 |
| Arçari, DP | 1 |
| Bartchewsky, W | 1 |
| Pedrazzoli, J | 6 |
| Hoehr, NF | 1 |
| Gambero, A | 1 |
| Jimenez-Alonso, I | 2 |
| Choi, HS | 1 |
| Hwang, SJ | 1 |
| Park, JS | 1 |
| Shehada, S | 1 |
| Srugo, I | 1 |
| Shaoul, R | 1 |
| Nasseri-Moghaddam, S | 1 |
| Razjouyan, H | 1 |
| Alimohamadi, SM | 1 |
| Mamarabadi, M | 1 |
| Ghotbi, MH | 1 |
| Mostajabi, P | 1 |
| Sohrabpour, AA | 1 |
| Sotoudeh, M | 1 |
| Abedi, B | 1 |
| Mofid, A | 1 |
| Nouraie, M | 1 |
| Tofangchiha, S | 1 |
| Kori, M | 1 |
| Cohen, S | 1 |
| Givony, S | 1 |
| Sokolovskaia-Ziv, N | 1 |
| Melzer, E | 2 |
| Granot, E | 1 |
| Roblin, X | 1 |
| Rostami, N | 1 |
| Keshtkar-Jahromi, M | 2 |
| Rahnavardi, M | 1 |
| Esfahani, FS | 1 |
| Serhal, L | 1 |
| Bergeret, M | 4 |
| Spyckerelle, C | 2 |
| Dupont, C | 5 |
| Tzathas, C | 1 |
| Triantafyllou, K | 2 |
| Mallas, E | 1 |
| Ladas, SD | 4 |
| Jung, JM | 1 |
| Shim, KN | 1 |
| Oh, HJ | 1 |
| Jung, SA | 1 |
| Yoo, K | 1 |
| Chen, SJ | 1 |
| Wang, LJ | 1 |
| Zhu, Q | 1 |
| Cai, JT | 1 |
| Chen, T | 1 |
| Cavanna, L | 1 |
| Pagani, R | 1 |
| Seghini, P | 1 |
| Zangrandi, A | 1 |
| Paties, C | 1 |
| Castellanos Monedero, JJ | 1 |
| Villafáñez García, MC | 1 |
| Roncero García-Escribano, O | 1 |
| Radziejewska, I | 1 |
| Borzym-Kluczyk, M | 1 |
| Kisiel, DG | 1 |
| Wosek, J | 1 |
| Gindzieński, A | 1 |
| Lee, CW | 1 |
| Rickman, B | 1 |
| Ge, Z | 1 |
| Wang, TC | 1 |
| Fox, JG | 2 |
| Hansen, JM | 2 |
| Wildner-Christensen, M | 1 |
| Hallas, J | 1 |
| Yadav, MK | 1 |
| Rishi, JP | 1 |
| Nijawan, S | 1 |
| Robles-Jara, C | 1 |
| Robles-Medranda, C | 1 |
| Moncayo, M | 1 |
| Landivar, B | 1 |
| Parrales, J | 1 |
| Avunduk, C | 1 |
| Navab, F | 1 |
| Hampf, F | 1 |
| Coughlin, B | 1 |
| Andrews, P | 2 |
| Fracchia, G | 1 |
| Brandl, S | 1 |
| Shortis, NP | 2 |
| Bae, H | 1 |
| Tillenburg, B | 10 |
| Köhl, H | 2 |
| Becker, T | 5 |
| Börsch, G | 29 |
| Domschke, W | 6 |
| Dettmer, A | 2 |
| Fenner, T | 1 |
| Gregor, M | 1 |
| Hesse, P | 1 |
| Holtmann, G | 3 |
| van Husen, N | 1 |
| Miederer, SE | 1 |
| Schentke, KU | 1 |
| Schütz, E | 1 |
| Schepp, W | 2 |
| Bokemeyer, B | 1 |
| Hoffenberg, P | 1 |
| Reyes, V | 1 |
| Contreras, L | 1 |
| Giglio, M | 1 |
| Ossa, P | 1 |
| Weitz, JC | 1 |
| Folwaczny, C | 1 |
| Jhala, NC | 1 |
| McFarland, MM | 1 |
| Brightman, SA | 1 |
| Morale, B | 1 |
| Rubin, W | 1 |
| Atkinson, BF | 1 |
| Reinauer, S | 2 |
| Megahed, M | 1 |
| Goerz, G | 2 |
| Ruzicka, T | 2 |
| Borchard, F | 2 |
| Susanto, F | 2 |
| Reinauer, H | 2 |
| Shimada, T | 1 |
| Ogura, K | 2 |
| Higashi, T | 1 |
| Mukuda, T | 1 |
| Imaizumi, T | 1 |
| Tatsumi, T | 1 |
| Miura, N | 1 |
| Miyajima, K | 1 |
| Noguchi, M | 1 |
| Hisano, K | 1 |
| Ochiai, T | 1 |
| Fujita, N | 2 |
| Kobayashi, T | 2 |
| Yabana, T | 2 |
| Kurokawa, I | 1 |
| Yachi, A | 1 |
| Katoh, M | 1 |
| Kudoh, M | 1 |
| Kagaya, H | 8 |
| Katagiri, M | 4 |
| Nakagawa, T | 1 |
| Yoneshima, M | 1 |
| Yamamoto, M | 1 |
| Tsujino, D | 1 |
| Murai, S | 1 |
| Saito, N | 1 |
| Kokubun, N | 1 |
| Kajiwara, M | 2 |
| Takimoto, T | 6 |
| Ido, K | 4 |
| Taniguchi, Y | 7 |
| Saifuku, K | 7 |
| Nakata, H | 1 |
| Itoh, H | 1 |
| Nishioka, S | 1 |
| Mizuki, I | 1 |
| Akagi, T | 1 |
| Ohkawa, K | 1 |
| Aisawa, T | 1 |
| Sakata, Y | 1 |
| Shirai, T | 2 |
| Takagi, A | 2 |
| Kurumada, T | 2 |
| Ohta, U | 1 |
| Kobayashi, H | 1 |
| Harasawa, S | 2 |
| Miwa, T | 2 |
| Yamamoto, I | 3 |
| Okui, M | 2 |
| Tonokatsu, Y | 2 |
| Ohashi, T | 1 |
| Sakata, J | 1 |
| Haraguchi, Y | 1 |
| Eto, T | 1 |
| Murakami, M | 5 |
| Saita, H | 4 |
| Takahashi, Y | 4 |
| Kusaka, S | 1 |
| Asagoe, K | 1 |
| Dekigai, H | 1 |
| Matsumoto, M | 1 |
| Seki, M | 2 |
| Maeda, S | 2 |
| Ogoshi, K | 1 |
| Kato, T | 5 |
| Sakagawa, T | 1 |
| Gummett, PA | 4 |
| Logan, RP | 4 |
| Ashworth, HM | 1 |
| Baron, JH | 6 |
| Misiewicz, JJ | 9 |
| Yousfi, MM | 4 |
| al-Assi, MT | 4 |
| Cole, RA | 5 |
| Genta, RM | 9 |
| Katelaris, PH | 4 |
| Patchett, SE | 1 |
| Zhang, ZW | 1 |
| Domizio, P | 1 |
| Farthing, MJ | 1 |
| Kreiss, C | 1 |
| Nos, P | 1 |
| Jaspersen, D | 4 |
| Körner, T | 1 |
| Schorr, W | 1 |
| Brennenstuhl, M | 1 |
| Hammar, CH | 2 |
| Cahill, RJ | 1 |
| Xia, H | 1 |
| Kilgallen, C | 1 |
| Beattie, S | 3 |
| Hamilton, H | 2 |
| Keller, IJ | 1 |
| van der Hulst, RW | 8 |
| Mannes, GA | 7 |
| Sommer, A | 5 |
| Höchter, W | 5 |
| Weingart, J | 5 |
| Hatz, R | 6 |
| Ruckdeschel, G | 4 |
| Dirschedl, P | 2 |
| Uyterlinde, AM | 1 |
| Peña, AS | 1 |
| Hazenberg, HJ | 1 |
| Karttunen, TJ | 1 |
| Stein, C | 2 |
| Neil, G | 7 |
| Graham, KS | 1 |
| Malaty, H | 2 |
| Neil, GA | 3 |
| Saberi-Firoozi, M | 1 |
| Zare, S | 1 |
| Fattahi, M | 1 |
| Javan, A | 1 |
| Etaati, H | 1 |
| Leung, VK | 4 |
| Ling, TK | 10 |
| Suen, R | 4 |
| Cheng, AF | 7 |
| Li, AK | 6 |
| Ozmen, MM | 1 |
| Johnson, CD | 1 |
| Choné, L | 1 |
| Grignon, Y | 1 |
| Bigard, MA | 3 |
| Jorias, I | 2 |
| Leverkus, F | 2 |
| Sollböhmer, M | 3 |
| Bertrams, J | 5 |
| Kohli, Y | 1 |
| Ito, S | 3 |
| Hirai, M | 1 |
| Lazzaroni, M | 8 |
| Maconi, G | 10 |
| Bargiggia, S | 6 |
| Minguzzi, M | 1 |
| Mela, GS | 6 |
| Celle, G | 6 |
| Getz, HD | 1 |
| Heldwein, W | 2 |
| Klann, H | 3 |
| Simon, T | 3 |
| Schmitt, W | 2 |
| Viver, JM | 2 |
| Espinós, JC | 2 |
| Coll, I | 1 |
| Tresserra, F | 1 |
| Garau, J | 2 |
| Reed, PI | 1 |
| Park, KN | 1 |
| Hahm, JS | 1 |
| Verdú, EF | 7 |
| Fraser, R | 1 |
| Viani, F | 2 |
| Idström, JP | 10 |
| Cederberg, C | 4 |
| Louw, JA | 5 |
| Lucke, W | 1 |
| Jaskiewicz, K | 2 |
| Lastovica, AJ | 1 |
| Winter, TA | 1 |
| Marks, IN | 4 |
| Hudson, N | 2 |
| Brydon, WG | 1 |
| Eastwood, MA | 1 |
| Ferguson, A | 3 |
| Palmer, KR | 1 |
| Burridge, SM | 3 |
| Bowden, AF | 1 |
| Atoyebi, W | 1 |
| Bolton, GH | 1 |
| Jones, PH | 2 |
| Brown, C | 2 |
| Jaup, BH | 3 |
| Norrby, A | 2 |
| Burette, A | 2 |
| Glupczynski, Y | 1 |
| Neubauer, A | 8 |
| Rudolph, B | 3 |
| Thiede, C | 6 |
| Eidt, S | 3 |
| Bajador, E | 1 |
| Klotz, O | 1 |
| Harris, A | 4 |
| Bätz, CH | 1 |
| Alvarez Baleriola, I | 6 |
| Redondo, C | 6 |
| De Rafael, L | 4 |
| Yung, MY | 8 |
| Li, MK | 1 |
| Humfeld, S | 1 |
| Wagner, S | 2 |
| Beil, W | 1 |
| Mai, UE | 1 |
| Bokemeyer, C | 1 |
| Meyer, HJ | 1 |
| Manns, MP | 1 |
| Driessen, WM | 6 |
| Adamek, RJ | 15 |
| Freitag, M | 2 |
| Opferkuch, W | 9 |
| Rühl, GH | 13 |
| Wegener, M | 9 |
| Trespi, E | 3 |
| Broglia, F | 1 |
| Villani, L | 4 |
| Luinetti, O | 3 |
| Solcia, E | 7 |
| Karjoo, M | 1 |
| Kane, R | 1 |
| Rune, SJ | 2 |
| Kirk, GE | 2 |
| Hawkey, CK | 1 |
| Spiller, RC | 7 |
| Dominguez, HL | 1 |
| Freston, JW | 2 |
| Goddard, A | 1 |
| Logan, R | 1 |
| Vetvik, K | 1 |
| Schrumpf, E | 1 |
| Mowinckel, P | 1 |
| Aase, S | 1 |
| Andersen, KJ | 1 |
| tho Pesch, S | 1 |
| Müller, W | 1 |
| Peters, U | 1 |
| Parasakthi, N | 7 |
| Simsek, H | 2 |
| Arslan, M | 1 |
| Tatar, G | 2 |
| Archimandritis, A | 6 |
| Balatsos, V | 3 |
| Delis, V | 3 |
| Mentis, A | 3 |
| Kastanas, K | 1 |
| Scandalis, N | 1 |
| Szymanski, C | 4 |
| Pfaffenbach, B | 5 |
| Ricken, D | 2 |
| Montalban, C | 1 |
| Manzanal, A | 1 |
| Bellas, C | 1 |
| Domian, C | 1 |
| de Boer, W | 1 |
| Driessen, W | 1 |
| Jansz, A | 1 |
| Tytgat, G | 2 |
| Berndt, H | 1 |
| Hosking, SW | 3 |
| Termini, R | 3 |
| Goddard, AF | 3 |
| Florent, C | 1 |
| Ohtaki, T | 1 |
| Kudo, M | 5 |
| Kimura, T | 1 |
| Meguro, T | 1 |
| Horita, S | 1 |
| Gad, A | 1 |
| Peh, SC | 6 |
| Wong, NW | 3 |
| Tan, KK | 2 |
| Lo, YL | 5 |
| Chuah, SY | 3 |
| Azian, M | 2 |
| Ong, KK | 2 |
| Penston, JG | 2 |
| Susi, D | 1 |
| Di Iorio, P | 1 |
| Seccia, G | 1 |
| Mezzetti, A | 1 |
| Karita, M | 1 |
| Morshed, MG | 1 |
| Ouchi, K | 1 |
| Okita, K | 1 |
| Jablonowski, H | 1 |
| Hengels, KJ | 1 |
| Kraemer, N | 1 |
| Geis, G | 1 |
| Strohmeyer, G | 1 |
| Boldorini, R | 1 |
| Perego, M | 3 |
| Alvisi, C | 2 |
| Allocati, N | 3 |
| Di Campli, E | 4 |
| Dainelli, B | 2 |
| Floch, MH | 1 |
| Groisman, GM | 1 |
| George, J | 1 |
| Berman, D | 1 |
| Harpaz, N | 1 |
| Zala, G | 4 |
| Wirth, HP | 5 |
| Bauer, S | 1 |
| Wüst, J | 4 |
| Flury, R | 6 |
| Meyenberger, C | 4 |
| Ammann, R | 3 |
| Giezendanner, S | 2 |
| Netchvolodoff, CV | 1 |
| Fraser, AG | 3 |
| Arens, MJ | 1 |
| Schaufelberger, HD | 1 |
| Greaves, RR | 1 |
| Mendelson, GM | 1 |
| Walker, MM | 4 |
| Thomas, PH | 1 |
| Lööf, L | 1 |
| Maniatis, AG | 1 |
| Brazer, SR | 1 |
| Ritter, MM | 1 |
| Brooks, W | 1 |
| Marchi, M | 1 |
| Vacondio, R | 1 |
| Bagnulo, A | 1 |
| Mengoli, M | 1 |
| Pallone, F | 2 |
| Luzza, F | 2 |
| Marcheggiano, A | 3 |
| Biancone, L | 1 |
| Torsoli, A | 1 |
| Capurso, L | 1 |
| Misra, SC | 1 |
| Dasarathy, S | 1 |
| McCarthy, CJ | 1 |
| Collins, R | 2 |
| Sandro Mela, G | 1 |
| Imoto, I | 2 |
| Suzuki, S | 3 |
| Bowden, AN | 1 |
| Rameh, B | 1 |
| Bolton, G | 2 |
| Purser, K | 2 |
| Harrison, G | 3 |
| Gant, PW | 3 |
| Murai, M | 1 |
| Tanaka, M | 2 |
| Nelis, F | 2 |
| Jankiewicz, E | 1 |
| Ferch, N | 1 |
| Carroll, M | 1 |
| Kimura, S | 1 |
| Fukuda, T | 2 |
| Raedsch, R | 1 |
| Soucková, A | 1 |
| Drábek, J | 1 |
| Hanika, J | 1 |
| Vejvalka, J | 1 |
| Zeman, V | 1 |
| Tucci, A | 2 |
| Corinaldesi, R | 1 |
| Stanghellini, V | 1 |
| Paparo, GF | 2 |
| Gasperoni, S | 1 |
| Biasco, G | 2 |
| Varoli, O | 2 |
| Ricci-Maccarini, M | 1 |
| Barbara, L | 1 |
| Xia, HX | 2 |
| Gyenes, E | 4 |
| Dallera, F | 1 |
| Gendarini, A | 1 |
| Scanzi, G | 1 |
| Lamberts, R | 2 |
| Creutzfeldt, W | 3 |
| Strüber, HG | 1 |
| Brunner, G | 2 |
| Karim, QN | 2 |
| Justesen, T | 2 |
| Jensen, TG | 1 |
| Eriksen, J | 2 |
| Thomsen, OO | 1 |
| Scheibel, J | 1 |
| Bonnevie, O | 2 |
| Bremmelgaard, A | 1 |
| Vilien, M | 2 |
| Ramírez Ramos, A | 1 |
| Mur Villacampa, M | 1 |
| Sáinz Samitier, R | 1 |
| Chey, WD | 8 |
| Spybrook, M | 1 |
| Carpenter, S | 1 |
| Nostrant, TT | 2 |
| Elta, GH | 3 |
| Scheiman, JM | 4 |
| Thijs, JC | 4 |
| van Zwet, AA | 3 |
| Moolenaar, W | 1 |
| Wolfhagen, MJ | 1 |
| ten Bokkel Huinink, J | 1 |
| Cadiot, G | 1 |
| Vissuzaine, C | 1 |
| Pospai, D | 2 |
| Ruszniewski, P | 1 |
| Potet, F | 1 |
| Mignon, M | 2 |
| Khulusi, S | 1 |
| Badve, S | 1 |
| Patel, P | 1 |
| Lloyd, R | 1 |
| Marrero, JM | 1 |
| Finlayson, C | 1 |
| Mendall, MA | 1 |
| Northfield, TC | 1 |
| Sahay, P | 1 |
| Tompkins, DS | 6 |
| Deltenre, M | 4 |
| Jonas, C | 3 |
| van Gossum, M | 1 |
| Buset, M | 1 |
| Otero, J | 3 |
| De Koster, E | 3 |
| Uemura, N | 4 |
| Okamoto, S | 4 |
| Mukai, T | 4 |
| Yamaguchi, S | 4 |
| Kaji, M | 1 |
| Hrruma, K | 1 |
| Sumii, K | 7 |
| Kajiyama, G | 6 |
| Diehl, HG | 1 |
| Nesje, LB | 1 |
| Hausken, T | 1 |
| Bang, CJ | 1 |
| Berstad, A | 2 |
| Bate, CM | 2 |
| Tildesley, G | 3 |
| Kerr, GD | 3 |
| Green, JR | 1 |
| Emmas, CE | 1 |
| Taylor, MD | 2 |
| Tursi, A | 11 |
| Montalto, M | 7 |
| Papa, A | 11 |
| Vecchio, FM | 1 |
| Renzi, C | 1 |
| Verzí, A | 1 |
| Armuzzi, A | 6 |
| Pretolani, S | 1 |
| Lorenzetti, M | 1 |
| Marchetti, P | 1 |
| Volpe, L | 1 |
| Navalesi, R | 1 |
| Dalenback, J | 1 |
| Schütze, K | 2 |
| Hentschel, E | 3 |
| Fennerty, MB | 6 |
| Bertoni, G | 2 |
| Sassatelli, R | 1 |
| Nigrisoli, E | 1 |
| Tansini, P | 1 |
| Bianchi, G | 1 |
| Della Casa, G | 1 |
| Bagni, A | 1 |
| Bedogni, G | 2 |
| Grassi, SA | 1 |
| Cassaro, M | 1 |
| Donisi, PM | 1 |
| Vianello, F | 1 |
| Kusstatscher, S | 1 |
| Salandin, S | 1 |
| Grasso, GA | 1 |
| Ferrana, M | 1 |
| Battaglia, G | 2 |
| Davis, S | 1 |
| Dammann, HG | 3 |
| García, M | 2 |
| Oksüzöğlu, G | 1 |
| Blomgren, K | 1 |
| Alván, G | 1 |
| Mur, M | 2 |
| Sainz, S | 1 |
| Ceña, G | 2 |
| Martín, C | 1 |
| Sainz, R | 2 |
| Artan, R | 1 |
| Gelen, T | 1 |
| Cesana, B | 3 |
| Fedeli, G | 9 |
| Figueroa, G | 1 |
| Acuña, R | 1 |
| Troncoso, M | 1 |
| Portell, DP | 1 |
| Toledo, MS | 1 |
| Albornoz, V | 1 |
| Vigneaux, J | 1 |
| Alkan, S | 1 |
| Karcher, DS | 1 |
| Newman, MA | 1 |
| Schwery, S | 1 |
| Goebell, H | 1 |
| Lambert, JR | 2 |
| Keller, JJ | 4 |
| Rauws, EA | 6 |
| Dresner, D | 1 |
| Peterson, R | 2 |
| Duntemann, T | 2 |
| Lawson, JM | 2 |
| Leung, KP | 1 |
| Yung, RW | 1 |
| Lai, CL | 4 |
| Jönsson, B | 2 |
| Carlsson, J | 1 |
| Rudbäck, A | 1 |
| Zeijlon, L | 7 |
| Caselli, M | 4 |
| Ruina, M | 4 |
| Fabbri, P | 1 |
| Balhous, W | 1 |
| Alvisi, V | 2 |
| Perkins, SE | 1 |
| Yan, LL | 1 |
| Shen, Z | 1 |
| Hayward, A | 1 |
| Murphy, JC | 1 |
| Carrère, MO | 1 |
| Auquier, P | 1 |
| Poynard, T | 1 |
| Sambuc, R | 1 |
| Weel, JF | 3 |
| Verheul, SB | 1 |
| ten Kate, FJ | 3 |
| van der Ende, A | 5 |
| Dankert, J | 5 |
| Dalla Libera, M | 1 |
| Pazzi, P | 2 |
| Carli, G | 1 |
| Gamberini, S | 2 |
| Scagliarini, R | 2 |
| Merighi, A | 1 |
| Gullini, S | 2 |
| Parente, F | 5 |
| Colombo, E | 4 |
| Rosengren, H | 1 |
| Polson, RJ | 1 |
| Caucheteur, B | 1 |
| Masulli, M | 1 |
| Di Bartolomeo, S | 1 |
| Markham, A | 2 |
| McTavish, D | 1 |
| Keerl, R | 1 |
| Weber, R | 2 |
| Huppmann, A | 1 |
| Draf, W | 2 |
| Santander, C | 2 |
| Grávalos, RG | 2 |
| Gómez-Cedenilla, A | 1 |
| Cantero, J | 1 |
| Stermer, E | 1 |
| Levy, N | 1 |
| Sobhani, I | 1 |
| Bado, A | 1 |
| Cherifi, Y | 1 |
| Moizo, L | 1 |
| Laigneau, JP | 1 |
| Sito, E | 1 |
| Kwiecień, N | 1 |
| Jedynak, M | 1 |
| Gabryelewicz, A | 2 |
| Cozzoli, A | 1 |
| Denis, P | 1 |
| Roesch, W | 1 |
| Anderson, PE | 1 |
| Blum, RA | 1 |
| Bolle, KH | 2 |
| Meining, A | 8 |
| Repucci, AH | 1 |
| Jansz, AR | 1 |
| Elamine, I | 1 |
| Chaussade, S | 1 |
| Garcia, F | 1 |
| Trujillo, M | 4 |
| Estrada, R | 4 |
| Weldon, MJ | 1 |
| Broadbent, A | 1 |
| Chambers, S | 2 |
| Mistry, R | 1 |
| Ranganath, L | 1 |
| Gould, SR | 2 |
| Dickey, W | 1 |
| Kenny, BD | 1 |
| McConnell, JB | 1 |
| Veneto, G | 2 |
| Cuoco, L | 6 |
| Trua, F | 1 |
| Pommerien, W | 2 |
| Braun, M | 1 |
| Wrangstadh, M | 8 |
| Londong, W | 2 |
| Schultze, V | 1 |
| Braden, B | 1 |
| Lembcke, B | 1 |
| van Etten, RJ | 6 |
| Schade, RW | 2 |
| Ouwehand, ME | 2 |
| Schneeberger, PM | 7 |
| Pollak, PT | 2 |
| Kapoor, H | 1 |
| Yeung, PK | 1 |
| Navaratnam, P | 2 |
| Rahman, NA | 1 |
| Phull, PS | 1 |
| Griffiths, AE | 1 |
| Halliday, D | 1 |
| Jacyna, MR | 1 |
| Maes, B | 1 |
| Geypens, B | 1 |
| Ghoos, Y | 2 |
| Hiele, M | 1 |
| Rutgeerts, P | 2 |
| Tokushima, H | 2 |
| Tamura, H | 2 |
| Matsumura, O | 2 |
| Murakawa, M | 2 |
| Itakura, Y | 1 |
| Itoyama, S | 2 |
| Mitarai, T | 2 |
| Isoda, K | 2 |
| Goenka, MK | 1 |
| Das, K | 1 |
| Nijhawan, R | 1 |
| Kocbhar, R | 1 |
| Cullen, DJ | 1 |
| Martin, JL | 1 |
| Richardson, PD | 1 |
| Lai, JY | 3 |
| Geuskens, LM | 1 |
| Genta, R | 1 |
| Evans, DG | 1 |
| Clarridge, JE | 1 |
| Olson, CA | 3 |
| Edmonds, AL | 1 |
| Siepman, N | 5 |
| Nagahata, Y | 1 |
| Kawakita, N | 1 |
| Azumi, Y | 1 |
| Numata, N | 1 |
| Yano, M | 1 |
| Saitoh, Y | 1 |
| Dhar, A | 3 |
| Gupta, VK | 2 |
| Carling, L | 1 |
| Wetterhus, S | 1 |
| Wingren, PE | 1 |
| Anker-Hansen, O | 1 |
| Lundegårdh, G | 1 |
| Thorhallsson, E | 1 |
| Hackelsberger, A | 1 |
| Bohmeyer, J | 1 |
| Heller, A | 1 |
| Hartig, C | 1 |
| Wetenberger-Treumann, M | 1 |
| Huchzermeyer, H | 1 |
| Otte, HG | 1 |
| Stadler, R | 1 |
| Thor, P | 1 |
| Lorens, K | 1 |
| Tabor, S | 1 |
| Herman, R | 1 |
| Konturek, JW | 2 |
| Imbesi, V | 5 |
| Montrone, F | 1 |
| Caruso, I | 1 |
| Bercík, P | 4 |
| Sukegawa, M | 4 |
| Koshiyama, T | 1 |
| Nishikawa, K | 5 |
| Hokari, K | 5 |
| Spadaccini, A | 2 |
| De Fanis, C | 2 |
| Sciampa, G | 2 |
| Masciulli, V | 1 |
| Pantaleone, U | 2 |
| Di Virgilio, M | 2 |
| Magnarini, C | 1 |
| Pizzicannella, G | 1 |
| Behler, EM | 1 |
| Crause, I | 1 |
| Bonagura, AF | 1 |
| Dabezies, MA | 1 |
| Muñoz, N | 1 |
| Vivas, J | 1 |
| Buiatti, E | 1 |
| Kato, I | 1 |
| Oliver, W | 1 |
| Pérez, T | 1 |
| Plebani, M | 1 |
| Basso, D | 1 |
| Scrigner, M | 1 |
| Toma, A | 1 |
| Samloff, IM | 1 |
| Komorowski, RA | 1 |
| Hogan, WJ | 1 |
| Chausow, DD | 1 |
| Alder, JD | 1 |
| Ewing, PJ | 1 |
| Mitten, MJ | 1 |
| Oleksijew, A | 1 |
| Tanaka, SK | 3 |
| Moreno, JA | 1 |
| Carpintero, P | 1 |
| Hermida, C | 1 |
| Lara, S | 1 |
| García Grávalos, R | 2 |
| Ishino, Y | 2 |
| Yamamoto, H | 2 |
| Tsujiai, T | 1 |
| Nishizono, A | 1 |
| Nagai, J | 1 |
| Tokieda, M | 2 |
| Kodama, R | 2 |
| Kubota, T | 3 |
| Reynaert, H | 1 |
| Fernandes, E | 1 |
| Bourgain, C | 1 |
| Smekens, L | 1 |
| Devis, G | 1 |
| Rubin, CE | 1 |
| Aller, R | 3 |
| Petersen, KU | 1 |
| Malfertheimer, P | 1 |
| Gimeno, L | 2 |
| Valdepérez, J | 2 |
| Yus, C | 2 |
| Marzo, J | 1 |
| Pérez-Caballero, MC | 1 |
| Pryce, DI | 1 |
| Gabe, SM | 1 |
| Langworthy, H | 5 |
| Moshkowitz, M | 3 |
| Konikoff, FM | 2 |
| Peled, Y | 1 |
| Brill, S | 3 |
| Hallak, A | 1 |
| Tiomny, E | 1 |
| Santo, M | 1 |
| Bujanover, Y | 2 |
| Gilat, T | 1 |
| Soffiati, G | 3 |
| Scagnelli, M | 2 |
| Bozzola, L | 5 |
| Valerio, G | 5 |
| Fukanaga, K | 1 |
| Lux, G | 1 |
| Weber, HC | 1 |
| Venzon, DJ | 1 |
| Jensen, RT | 1 |
| Tham, TC | 1 |
| Collins, JS | 1 |
| Molloy, C | 1 |
| Sloan, JM | 1 |
| Bamford, KB | 1 |
| Watson, RG | 1 |
| Tacke, W | 1 |
| Konrad, H | 1 |
| Kaneko, E | 7 |
| Arai, H | 3 |
| Sekine, S | 1 |
| Hirose, H | 1 |
| Shortridge, VD | 1 |
| Stone, GG | 2 |
| Flamm, RK | 2 |
| Beyer, J | 2 |
| Versalovic, J | 1 |
| Graham, DW | 1 |
| Pérez García, JI | 1 |
| Bock, H | 3 |
| Mares, A | 1 |
| Veneto, GM | 1 |
| Stark, CA | 1 |
| Adamsson, I | 5 |
| Edlund, C | 4 |
| Sjösted, S | 1 |
| Seensalu, R | 5 |
| Wikström, B | 3 |
| Nord, CE | 5 |
| Paar, D | 1 |
| Terjung, B | 1 |
| Sauerbruch, T | 1 |
| Seko, A | 1 |
| Amano, K | 2 |
| Shimizu, H | 2 |
| Goto, A | 1 |
| Sugie, S | 1 |
| Yoshimi, N | 1 |
| Moriwaki, H | 1 |
| Muto, Y | 1 |
| Wang, XM | 1 |
| Nishifuku, K | 1 |
| Kidaira, K | 1 |
| Sato, K | 8 |
| Sohara, H | 1 |
| Kawada, H | 1 |
| Sánchez, I | 1 |
| Trevisani, L | 3 |
| Sartori, S | 3 |
| Luzzi, I | 2 |
| Gaudenzi, P | 1 |
| Jonkers, D | 2 |
| Houben, P | 1 |
| Stobberingh, E | 1 |
| Stockbrügger, R | 1 |
| Walker, S | 2 |
| Dohil, R | 1 |
| Israel, DM | 1 |
| Hassall, E | 1 |
| Lerang, F | 3 |
| Moum, B | 3 |
| Haug, JB | 3 |
| Tolås, P | 3 |
| Breder, O | 1 |
| Aubert, E | 2 |
| Søberg, T | 2 |
| Flaaten, B | 1 |
| Farup, P | 1 |
| Berge, T | 3 |
| Eissele, R | 2 |
| Simon, B | 3 |
| Weismüller, J | 1 |
| Lütke, A | 1 |
| Vautier, G | 1 |
| Scott, BB | 2 |
| van Unnik, AJ | 1 |
| Erah, PO | 1 |
| Barrett, DA | 1 |
| Shaw, PN | 1 |
| Crowe, JP | 1 |
| Beattie, AD | 1 |
| Thompson, RP | 2 |
| Smith, PM | 1 |
| Hollanders, FD | 1 |
| Lynch, DA | 1 |
| Dixon, MF | 6 |
| Birrell, H | 1 |
| Gillon, KR | 2 |
| Chalmers, DM | 2 |
| Ritter, M | 2 |
| Müller, S | 1 |
| Neubauer, B | 2 |
| Seifert, E | 5 |
| Otto, P | 1 |
| Kung, NN | 1 |
| Yuen, NW | 1 |
| Ng, PW | 1 |
| Wong, KC | 1 |
| Chung, EC | 1 |
| Lim, BH | 1 |
| Choi, CH | 1 |
| Li, TH | 1 |
| Ma, HC | 1 |
| Kwok, SP | 1 |
| Lee, YT | 6 |
| Chan, LY | 1 |
| Woods, M | 1 |
| DelValle, J | 2 |
| Sumazaki, R | 1 |
| Ahmed, T | 1 |
| Matsubara, T | 1 |
| Hori, T | 1 |
| Nakahara, A | 3 |
| Takita, H | 1 |
| Hazell, SL | 2 |
| Daskalopoulous, G | 1 |
| Massey, D | 1 |
| Gotoh, A | 3 |
| Kawakami, Y | 3 |
| Akahane, T | 1 |
| Kiyosawa, K | 2 |
| Rodrigo Sáez, L | 1 |
| Fernández Cadenas, F | 1 |
| Lomo Montero, J | 1 |
| García Calero, C | 1 |
| García Saavedra, L | 1 |
| Müller, P | 2 |
| Martin, J | 1 |
| Boyle, S | 1 |
| Jacyna, M | 1 |
| Delpre, G | 1 |
| Livni, E | 1 |
| Verdú, E | 4 |
| Ragnhildstveit, E | 1 |
| Hauge, T | 1 |
| Henriksen, M | 1 |
| Efskind, PS | 1 |
| Nicolaysen, K | 1 |
| Odegaard, A | 1 |
| Smith, JG | 1 |
| Kong, L | 1 |
| Abruzzo, GK | 1 |
| Gill, CJ | 1 |
| Flattery, AM | 1 |
| Scott, PM | 1 |
| Silver, L | 1 |
| Kropp, H | 1 |
| Bartizal, K | 1 |
| Thijs, WJ | 1 |
| Van der Wouden, EJ | 2 |
| Kooy, A | 2 |
| Ström, M | 1 |
| Jönsson, KA | 1 |
| Spinzi, G | 1 |
| Lesinigo, E | 1 |
| Venturelli, R | 3 |
| Terruzzi, V | 1 |
| Imperiali, G | 1 |
| Minoli, G | 3 |
| Hele, C | 1 |
| Peterson, WL | 1 |
| D'Ambra, G | 2 |
| Iannoni, C | 1 |
| Paoletti, M | 2 |
| Anania, MC | 1 |
| Sherman, PM | 1 |
| Nakao, K | 1 |
| Ikemura, N | 1 |
| Shibata, T | 1 |
| Takaji, S | 1 |
| Taguchi, Y | 1 |
| Misaki, M | 1 |
| Yamauchi, K | 1 |
| Yamazaki, N | 1 |
| Abraira, V | 3 |
| Damianos, AJ | 1 |
| McGarrity, TJ | 1 |
| Ebell, MH | 1 |
| Warbasse, L | 1 |
| Brenner, C | 1 |
| Lo, WC | 1 |
| Lin, HJ | 2 |
| Wang, K | 1 |
| Perng, CL | 3 |
| Bordi, C | 3 |
| Malagnino, F | 1 |
| Mancino, C | 1 |
| Takeyama, J | 1 |
| Ebina, K | 1 |
| Naganuma, H | 1 |
| Götz, JM | 1 |
| Thio, JL | 1 |
| Biemond, I | 2 |
| Vuković, D | 2 |
| Ivandić, A | 6 |
| Vceva, A | 7 |
| Kovacić, D | 1 |
| Volaric, M | 1 |
| Paulini, D | 1 |
| Mićunović, N | 2 |
| Mihaljević, S | 3 |
| Dekker, FW | 1 |
| Kruizinga, SP | 1 |
| Kim, MJ | 1 |
| Michener, R | 1 |
| Triadafilopoulos, G | 1 |
| Schweigart, U | 1 |
| Franck, H | 1 |
| Becker, K | 1 |
| Beker, JA | 1 |
| Dekker, CP | 1 |
| Klör, HU | 2 |
| Jönsson, A | 1 |
| Breuer, T | 1 |
| Gurer, IE | 1 |
| Graham, DP | 2 |
| Lim, AG | 1 |
| Walker, C | 1 |
| Rattan, A | 1 |
| Kayser, S | 1 |
| Zbinden, R | 1 |
| Fried, M | 2 |
| Fleischmann, R | 1 |
| Demharter, R | 1 |
| Barnert, J | 1 |
| Füger, K | 1 |
| Wienbeck, M | 1 |
| Busch, R | 1 |
| Iida, M | 1 |
| Shimizu, M | 1 |
| Hoffman, JS | 1 |
| Diana, F | 3 |
| Pugliano, F | 3 |
| Attili, AF | 5 |
| Mashiba, H | 3 |
| Taniyama, K | 3 |
| Sasaki, N | 3 |
| Hanna, G | 1 |
| Daskalopoulos, G | 1 |
| Pohle, T | 3 |
| Hilker, E | 1 |
| Rudnicka, L | 1 |
| Bobrzyński, A | 3 |
| Hirakawa, T | 1 |
| Tari, A | 1 |
| Hamada, M | 1 |
| Kamiyasu, T | 1 |
| Kishimoto, S | 1 |
| Walsh, JH | 2 |
| Tan, WC | 1 |
| Hogan, J | 1 |
| Purkayastha, SK | 1 |
| Lombard, M | 1 |
| Krasner, N | 1 |
| Kobler, E | 1 |
| Werth, B | 1 |
| Wüst, W | 1 |
| Reinhart, WH | 1 |
| Shortridge, D | 1 |
| Ghoneim, AT | 1 |
| Ammon, S | 4 |
| Oomoto, Y | 1 |
| Alpen, B | 2 |
| Wündisch, T | 2 |
| Ehninger, G | 3 |
| Wright, DH | 1 |
| Fisher, L | 1 |
| Barnett, JL | 1 |
| Nostrant, T | 1 |
| Hasler, WL | 1 |
| Sackmann, M | 1 |
| Schulz, H | 1 |
| Kraemer, W | 1 |
| Boersch, G | 1 |
| Rohde, P | 1 |
| Bayerdoerffer, E | 1 |
| Chien, CH | 1 |
| Lin, XZ | 4 |
| Schauwecker, P | 2 |
| Wehlen, G | 1 |
| Dorlars, D | 1 |
| Kohler, B | 1 |
| Maier, M | 1 |
| Frantz, JE | 1 |
| Baker, A | 1 |
| Cottrill, MR | 1 |
| McKinnon, C | 1 |
| Mason, I | 1 |
| Chesters, SA | 1 |
| Slatcher, G | 1 |
| Copeman, MB | 1 |
| Turbitt, ML | 1 |
| Valente, C | 1 |
| Hoffman, J | 4 |
| Wurzer, H | 2 |
| Stamler, D | 1 |
| Archambault, A | 2 |
| Skandalis, N | 3 |
| Fedorak, R | 1 |
| Mora, P | 1 |
| Zuberi, BF | 1 |
| Lal, S | 1 |
| Sheikh, RM | 1 |
| Cooper, J | 1 |
| Buckley, MJ | 2 |
| Hyde, DM | 1 |
| Keane, CT | 1 |
| Dobrucali, A | 1 |
| Tuncer, M | 2 |
| Eralp, YT | 1 |
| Goksel, S | 1 |
| Altin, M | 1 |
| Dinc, I | 1 |
| Sangaletti, O | 2 |
| Vago, L | 3 |
| Kawasaki, M | 1 |
| Hizawa, K | 2 |
| Fujishima, M | 1 |
| de Argila, CM | 3 |
| Riff, DS | 1 |
| Kidd, S | 2 |
| Rose, P | 4 |
| Haber, M | 4 |
| Weissfeld, A | 4 |
| Harford, W | 1 |
| Arora, A | 1 |
| Graham, D | 1 |
| Krause, R | 2 |
| Sahba, B | 2 |
| Jaup, BK | 1 |
| Shanahan, K | 1 |
| Rambow, A | 1 |
| von Fritsch, E | 1 |
| Spiller, R | 3 |
| Bradette, M | 2 |
| van de Wouw, BA | 2 |
| Srinivasan, R | 1 |
| Minocha, A | 1 |
| Pipkin, GA | 1 |
| Dixon, JS | 1 |
| Williamson, R | 2 |
| Wood, JR | 1 |
| Tan, AC | 1 |
| den Hartog, G | 1 |
| Meijer, JW | 1 |
| Thies, JE | 1 |
| de Vries, RA | 1 |
| Mulder, CJ | 2 |
| Loane, J | 1 |
| Bindel, H | 1 |
| Bhutta, AS | 1 |
| Cunnane, K | 2 |
| Matsunaga, K | 1 |
| Oofukuji, M | 1 |
| Syukuwa, S | 1 |
| Osabe, M | 1 |
| Takeno, Y | 1 |
| Gedliczka, O | 2 |
| Konturek, S | 2 |
| Budzyński, A | 2 |
| Suchower, LJ | 1 |
| Ronca, PD | 1 |
| Skoglund, ML | 1 |
| Zanetti, MV | 1 |
| Innerhofer, M | 1 |
| Katsoulis, S | 1 |
| Fölsch, UR | 2 |
| Shimoi, K | 2 |
| Horiuchi, T | 2 |
| Fujiki, K | 3 |
| Takashimizu, I | 3 |
| Sandvei, PK | 1 |
| Pozzato, P | 5 |
| Laszewicz, W | 1 |
| Dzieniszewski, J | 1 |
| Ciok, J | 1 |
| Marlicz, K | 1 |
| Bielecki, D | 1 |
| Popiela, T | 1 |
| Legutko, J | 1 |
| Knapik, Z | 1 |
| Poniewierka, E | 1 |
| Ilunga, KO | 1 |
| Schep, G | 1 |
| Sidorov, J | 1 |
| Matisko, A | 1 |
| Jewell, D | 1 |
| Esteve, M | 1 |
| Fernández-Bañares, F | 1 |
| Lite, J | 1 |
| Quintana, S | 1 |
| Salas, A | 1 |
| Levi, S | 2 |
| Cooper, BT | 3 |
| Piper, D | 2 |
| Berstad, AE | 1 |
| Maartmann-Moe, H | 1 |
| Brandtzaeg, P | 1 |
| Franko, TG | 1 |
| Richter, JE | 1 |
| Grossi, L | 3 |
| Diodoro, MG | 1 |
| Tzivras, M | 2 |
| Souyioultzis, S | 2 |
| Kanellopoulou, E | 1 |
| Manika, Z | 2 |
| Davaris, P | 2 |
| Takac, B | 6 |
| Gardasanić, J | 1 |
| Horonitz, M | 1 |
| Karner, I | 2 |
| Price, J | 1 |
| Hamilton, W | 1 |
| Ohtsu, T | 1 |
| Boku, N | 1 |
| Mori, M | 4 |
| Miyayama, A | 1 |
| Iwai, N | 1 |
| Tsunematsu, N | 1 |
| Oonuki, M | 1 |
| Seelis, RE | 1 |
| Dohmen, W | 1 |
| Sagar, M | 2 |
| Lindberg, G | 2 |
| Huber, F | 1 |
| Fischer, G | 1 |
| Nagasawa, Y | 1 |
| Tatsuta, M | 1 |
| Iishi, H | 1 |
| Ishiguro, S | 1 |
| Boixeda de Miquel, D | 3 |
| Pérez Mota, A | 1 |
| Alberdi, JM | 1 |
| Pita, L | 1 |
| Galán, JL | 1 |
| García Benito, MD | 1 |
| Crespo, L | 1 |
| Blanco, MA | 1 |
| Güemes, C | 1 |
| Villalgordo, C | 1 |
| Carnicero, JA | 1 |
| Beckford, C | 1 |
| Pérez Muñoz, C | 1 |
| Fernández Velázquez, J | 1 |
| Casanova, A | 1 |
| Kusuhara, H | 1 |
| Matsuyuki, H | 1 |
| Hisadome, M | 1 |
| Ikeda, Y | 2 |
| Dubois, A | 1 |
| Fiala, N | 1 |
| Heman-Ackah, LM | 1 |
| Perez-Perez, GI | 2 |
| Kubo, M | 1 |
| Goto, M | 2 |
| Tanabe, J | 1 |
| Asai, A | 1 |
| Ito, T | 1 |
| Paramsothy, M | 1 |
| Bux, S | 1 |
| Lee, KJ | 1 |
| Cho, SW | 1 |
| Yim, H | 1 |
| Joo, HJ | 1 |
| Pilato, FP | 1 |
| Damilano, I | 1 |
| Verdianelli, G | 2 |
| Abbasciano, V | 2 |
| Berquist, WE | 1 |
| Matsukawa, Y | 2 |
| Nishinarita, S | 2 |
| Kaneko, M | 1 |
| Takei, M | 1 |
| Horie, T | 1 |
| Kawamura, F | 2 |
| Arakawa, Y | 2 |
| Kurosaka, H | 1 |
| Moreno, L | 2 |
| Leri, O | 1 |
| Perinelli, P | 1 |
| Mastropasqua, M | 1 |
| Tubili, S | 1 |
| Losi, T | 1 |
| Homan, A | 1 |
| Roorda, P | 1 |
| el-Nujumi, A | 5 |
| Williams, C | 3 |
| Ardill, JE | 3 |
| Oien, K | 1 |
| Suchower, L | 4 |
| Johnson, E | 2 |
| Ronca, P | 2 |
| Forbes, GM | 1 |
| Collins, BJ | 1 |
| McCullough, CA | 1 |
| Coombs, GW | 1 |
| Robins, PD | 1 |
| Glaser, J | 1 |
| Hein, J | 1 |
| Daikeler, R | 1 |
| Weithofer, G | 1 |
| Schmidt, M | 1 |
| Schneider, E | 1 |
| Lindsetmo, RO | 1 |
| Johnsen, R | 1 |
| Revhaug, A | 1 |
| Comet, R | 3 |
| Navarro, M | 2 |
| García, N | 5 |
| Sanfeliu, I | 2 |
| Lanas Arbeloa, A | 1 |
| Serrano Aulló, MT | 1 |
| Carnicer, J | 1 |
| Konar, A | 1 |
| Das, AS | 1 |
| De, PK | 1 |
| Roy, A | 1 |
| Mazumder, DN | 1 |
| Sonnenberg, A | 3 |
| Schwartz, JS | 2 |
| Cutler, AF | 1 |
| Bloom, BS | 1 |
| Hibi, K | 1 |
| Imaizumi, H | 2 |
| Ohida, M | 2 |
| Okabe, H | 1 |
| Okayasu, I | 1 |
| Schmitz, JM | 1 |
| Alexandridis, T | 1 |
| McLoughlin, R | 1 |
| Kelly, S | 1 |
| Laundon, J | 1 |
| Freston, J | 1 |
| Malizia, T | 2 |
| Tejada, M | 1 |
| Favini, P | 1 |
| Pizzarelli, G | 1 |
| Campa, M | 2 |
| Senesi, S | 2 |
| Cloud, ML | 1 |
| Enas, N | 1 |
| Bassion, S | 1 |
| Yu, Z | 1 |
| Lü, B | 1 |
| Chen, Z | 1 |
| Bei, L | 1 |
| Thamer, M | 1 |
| Ray, NF | 1 |
| Henderson, SC | 1 |
| Rinehart, CS | 1 |
| Sherman, CR | 1 |
| Ferguson, JH | 1 |
| Takashima, M | 7 |
| Ragunathan, PL | 2 |
| Mapstone, N | 2 |
| Tsuneoka, H | 1 |
| Takaba, M | 1 |
| Nagatomi, Y | 1 |
| Mori, K | 1 |
| Honda, T | 1 |
| Benhamou, PH | 3 |
| Barbet, JP | 1 |
| Gendrel, D | 2 |
| Dasani, BM | 1 |
| Sigal, SH | 1 |
| Lieber, CS | 1 |
| Nobre-Leitão, C | 1 |
| Lage, P | 1 |
| Cravo, M | 1 |
| Cabeçadas, J | 1 |
| Chaves, P | 1 |
| Alberto-Santos, A | 1 |
| Correia, J | 1 |
| Soares, J | 1 |
| Costa-Mira, F | 1 |
| Poli, L | 1 |
| Bocus, P | 1 |
| Togliani, T | 1 |
| Mazzoni, C | 1 |
| Orcioni, GF | 1 |
| Agosti, R | 1 |
| Grigioni, WF | 1 |
| Sottili, S | 2 |
| Caletti, G | 1 |
| Katsorida, M | 1 |
| Ducóns, JA | 4 |
| Fuentes, J | 3 |
| García, S | 3 |
| Vera, J | 2 |
| Ikezawa, K | 2 |
| Kashimura, H | 2 |
| Mahmudul, H | 1 |
| Matsuzaki, Y | 1 |
| Mutoh, H | 3 |
| Tanaka, N | 2 |
| Ohkura, R | 8 |
| Murai, T | 6 |
| Yamada, T | 6 |
| Ogihara, T | 2 |
| Watanabe, S | 5 |
| Calvet Calvo, X | 1 |
| Sakaguchi, AA | 1 |
| Macri, G | 1 |
| Milani, S | 1 |
| Surrenti, E | 2 |
| Passaleva, MT | 1 |
| Salvadori, G | 1 |
| Surrenti, C | 2 |
| Campo, R | 5 |
| Brullet, E | 5 |
| Cucino, C | 2 |
| Manzionna, G | 2 |
| Reif, S | 2 |
| Ringel, Y | 1 |
| Arber, N | 2 |
| Halpern, Z | 2 |
| Diehl, KL | 1 |
| Kind, M | 1 |
| Arps, H | 1 |
| Brieva, L | 1 |
| Ara, JR | 1 |
| Bertol, V | 1 |
| Canellas, A | 1 |
| del Agua, C | 1 |
| Murray, LS | 2 |
| Dickson, A | 3 |
| Kelman, AW | 1 |
| Hilditch, TE | 2 |
| Spinzi, GC | 2 |
| Bierti, L | 1 |
| Fertitta, AM | 1 |
| Lanzi, GL | 1 |
| Zagari, M | 3 |
| Fossi, S | 4 |
| Ricciardiello, L | 3 |
| Alampi, G | 2 |
| Nicolini, G | 4 |
| Simoni, P | 1 |
| Roda, A | 1 |
| Kovac, D | 2 |
| Cheah, PL | 1 |
| Chin, SC | 1 |
| Siem, TH | 1 |
| Tan, TG | 1 |
| Oudkerk Pool, M | 1 |
| Van Kleef, WA | 1 |
| Geraedts, AA | 1 |
| Timmerman, RJ | 1 |
| Crobach, LF | 1 |
| Nicolai, JJ | 1 |
| Wolff, AA | 1 |
| Van Der Laan, J | 1 |
| Sanfélix Genovés, J | 1 |
| Pereiró Berenguer, I | 1 |
| Jimeno Bernard, R | 1 |
| García Tell, G | 1 |
| Navarro Pérez, J | 1 |
| Bonet Pla, A | 1 |
| Ballester Belenguer, J | 1 |
| Clemente, R | 3 |
| Quitadamo, M | 5 |
| Conoscitore, P | 1 |
| Niro, G | 1 |
| van Rensburg, CJ | 3 |
| Hanslo, D | 1 |
| Grundlings, HD | 1 |
| Girdwood, AH | 1 |
| Carvalho, AF | 1 |
| Fiorelli, LA | 1 |
| Jorge, VN | 1 |
| Da Silva, CM | 2 |
| De Nucci, G | 3 |
| Ferraz, JG | 4 |
| Groves, FD | 1 |
| Heinrich, JP | 1 |
| Hu, J | 1 |
| Mark, SD | 1 |
| Senouci, L | 1 |
| Petrillo, M | 1 |
| David, FL | 1 |
| Mendes, FD | 2 |
| Muscara, MN | 1 |
| Moreno, H | 1 |
| Hwang, C | 1 |
| Riachi, G | 1 |
| Thibault, P | 1 |
| Morton, D | 1 |
| Slater, DN | 1 |
| Perry, MJ | 2 |
| Cherian, P | 2 |
| Jones, RB | 1 |
| Brookes, A | 1 |
| Coremans, A | 1 |
| Hashimoto, Y | 1 |
| Weilert, F | 1 |
| Smith, AC | 1 |
| Stokes, PL | 1 |
| Blandizzi, C | 1 |
| Gherardi, G | 1 |
| Marveggio, C | 1 |
| Natale, G | 1 |
| Tacca, MD | 1 |
| Schenk, BE | 4 |
| Jansen, EH | 1 |
| Ellenrieder, V | 2 |
| Fensterer, H | 1 |
| Waurick, M | 1 |
| Adler, G | 2 |
| Piana, A | 2 |
| Carta, M | 3 |
| Atzei, A | 2 |
| Are, BM | 2 |
| Mura, I | 2 |
| Massarelli, G | 2 |
| Maida, A | 2 |
| Sepulveda, AR | 1 |
| Améndola, R | 1 |
| Roldán, CD | 1 |
| Morgade, L | 1 |
| Solagna, A | 1 |
| Lineado, A | 1 |
| Musi, AO | 1 |
| Valero, J | 1 |
| Zerbo, O | 1 |
| Kogan, Z | 1 |
| Ferro, FE | 1 |
| Schenone, L | 1 |
| Corti, R | 1 |
| Cecchi, R | 1 |
| Torelli, E | 1 |
| Sou, Y | 2 |
| Kaitani, K | 1 |
| Nishio, K | 1 |
| Tanahashi, T | 1 |
| Kodama, T | 1 |
| Sawai, N | 1 |
| Tatsumi, Y | 1 |
| Kashima, K | 1 |
| Higashi, Y | 1 |
| Sasaki, Y | 1 |
| Richardson, S | 1 |
| Duchateau, A | 1 |
| Colin, R | 2 |
| Cortot, A | 1 |
| Matarese, V | 1 |
| Rizzo, C | 1 |
| Kiel, G | 1 |
| Korman, MG | 1 |
| Bolin, TD | 1 |
| Nicholson, FB | 1 |
| Engelman, JL | 1 |
| Berretti, D | 3 |
| De Luca, L | 3 |
| Choi, HK | 1 |
| Tuen, HH | 1 |
| Law, SY | 1 |
| Branicki, FJ | 2 |
| Cayla, R | 1 |
| Forestier, S | 1 |
| Siu, LK | 1 |
| Sung, JY | 1 |
| Ling, JM | 1 |
| De Mas, CR | 1 |
| Huang, WH | 1 |
| Ho, AS | 1 |
| Shyu, RY | 2 |
| Lee, MM | 1 |
| Hsu, CT | 2 |
| Sato, F | 1 |
| Ando, K | 2 |
| Ito, H | 1 |
| Harihara, S | 1 |
| Kuroki, T | 2 |
| Knigge, K | 1 |
| Szczepanski, L | 1 |
| Filipowicz-Sosnowska, A | 1 |
| Lanas, A | 2 |
| Wason, CM | 1 |
| Lee, JM | 2 |
| Doermann, HP | 1 |
| Moola, S | 1 |
| Kotze, D | 1 |
| Bethke, TD | 1 |
| Stack, WA | 1 |
| Knifton, A | 1 |
| Thirlwell, D | 1 |
| Cockayne, A | 1 |
| Jenkins, D | 1 |
| Meier, E | 1 |
| Okada, M | 2 |
| Oki, K | 1 |
| Shirotani, T | 1 |
| Seo, M | 2 |
| Okabe, N | 2 |
| Nishimura, H | 2 |
| Ohkuma, K | 2 |
| Langtry, HD | 2 |
| Wilde, MI | 1 |
| Alfvén, G | 1 |
| Drapinski, M | 1 |
| Bergström, M | 1 |
| Dahlström, KA | 1 |
| Kirstein, FW | 2 |
| Epple, HJ | 2 |
| Bojarski, C | 2 |
| Victor, L | 1 |
| Fromm, M | 2 |
| Riecken, EO | 2 |
| Schulzke, JD | 2 |
| Russo, L | 1 |
| Silla, M | 1 |
| Pizzicanella, G | 1 |
| Frantz, J | 1 |
| Connors, A | 1 |
| Tybring, G | 1 |
| Dahl, ML | 1 |
| Bertilsson, L | 1 |
| Valsecchi, R | 1 |
| Pigatto, P | 1 |
| Reyes, E | 1 |
| Sakurazawa, T | 1 |
| Ariake, K | 1 |
| Ishii, K | 1 |
| Kumagai, J | 2 |
| Tanizawa, T | 2 |
| Barrera Linares, F | 1 |
| Gomollón García, F | 1 |
| Caballero Herráez, P | 1 |
| Valdepérez Torrubia, JJ | 1 |
| Ritsuno, H | 1 |
| Ohnuma, K | 1 |
| Peifer-Weiss, A | 1 |
| Ramos, F | 1 |
| García Arata, I | 2 |
| Meineche-Schmidt, V | 1 |
| Paré, P | 2 |
| Duckworth, M | 1 |
| Räisänen, P | 1 |
| Pap, A | 2 |
| Kordecki, H | 1 |
| Schmid, V | 1 |
| Hasselgren, G | 3 |
| Kirdeikis, P | 1 |
| Röhss, K | 1 |
| Yamagata, R | 1 |
| Yoshimura, T | 1 |
| Haga, Y | 1 |
| McColl, K | 1 |
| Murray, L | 1 |
| Kelman, A | 2 |
| Penny, C | 1 |
| Knill-Jones, R | 1 |
| Hilditch, T | 1 |
| Theodórs, A | 1 |
| Sundin, M | 2 |
| Friedman, LS | 1 |
| Kamata, T | 1 |
| Kosuge, K | 2 |
| Kawasaki, T | 1 |
| Suzuki, J | 1 |
| Kobayasi, I | 1 |
| Fujita, T | 1 |
| Dattilo, M | 1 |
| Kitahora, T | 2 |
| Kozawa, H | 1 |
| Yamada, Y | 2 |
| Kamisawa, T | 1 |
| Momma, K | 1 |
| Chan, HL | 3 |
| Lai, AC | 1 |
| Severens, JL | 1 |
| Van de Lisdonk, EH | 1 |
| Verbeek, AL | 1 |
| Galvani, F | 1 |
| Stoll, R | 1 |
| Heep, M | 2 |
| Martín Mir, ML | 1 |
| Val, J | 1 |
| Simón, MA | 3 |
| Baena Díez, JM | 3 |
| Sancho Perpiñán, A | 1 |
| López Mompó, C | 2 |
| Rams Rams, F | 2 |
| Jiménez Navarrete, S | 1 |
| Comet Jaumet, D | 1 |
| Hartmann, M | 1 |
| Lühmann, R | 2 |
| Wiesel, P | 1 |
| Garrido, A | 1 |
| Lepe, JA | 1 |
| Guerrero, FJ | 1 |
| Palomo, S | 1 |
| Rué, M | 1 |
| Qvigstad, G | 1 |
| Arnestad, JS | 1 |
| Brenna, E | 1 |
| Waldum, HL | 2 |
| Stimac, T | 1 |
| Pezerović, D | 3 |
| Blazanović, A | 1 |
| Yakabi, K | 1 |
| Tsuda, K | 1 |
| Hoshika, Y | 1 |
| Tomono, H | 1 |
| Saito, S | 3 |
| Sakurai, K | 1 |
| Takahashi, H | 1 |
| Yamaguchi, Y | 1 |
| Kirihara, K | 1 |
| Kojima, T | 1 |
| Fujita, R | 1 |
| Kato, K | 3 |
| Hoshiya, S | 2 |
| Iwasaki, A | 2 |
| Sugano, Y | 2 |
| Ko, K | 1 |
| Waki, S | 1 |
| Kouda, K | 1 |
| Tada, U | 1 |
| Wada, T | 1 |
| Ooishi, M | 1 |
| Yoda, Y | 1 |
| Kawamura, N | 1 |
| Ooizumi, H | 1 |
| Saitou, M | 1 |
| Kumakura, Y | 1 |
| Sugano, K | 7 |
| Kanayama, S | 1 |
| Harase, I | 1 |
| Okuda, J | 1 |
| Ida, K | 1 |
| Nakai, H | 1 |
| Keto, Y | 3 |
| Okabe, S | 3 |
| Nilsson, F | 1 |
| Walder, M | 1 |
| Schultz-Süchting, F | 1 |
| Stallmach, T | 2 |
| Braegger, CP | 2 |
| Vásconez, C | 1 |
| Llach, J | 1 |
| Ginès, A | 1 |
| de la Rosa, C | 1 |
| Fernández, RM | 1 |
| Mas, A | 1 |
| Santamaría, J | 1 |
| Bordas, JM | 1 |
| Terés, J | 1 |
| Koop, H | 3 |
| Udvardy, M | 1 |
| Pérez Páramo, M | 1 |
| Albillos Martínez, A | 1 |
| Ortiz Berrocal, J | 1 |
| Neithercut, WD | 1 |
| Henry, A | 1 |
| Batey, RG | 1 |
| García-Romero, E | 1 |
| del Val, A | 1 |
| Garrigues, V | 1 |
| Cuquerella, J | 1 |
| Higón, MD | 1 |
| Barrachina, M | 1 |
| Pons, V | 1 |
| Bixquert, M | 1 |
| Janssens, J | 1 |
| Rácz, I | 1 |
| Torgano, G | 1 |
| Cosentini, R | 1 |
| Mandelli, C | 1 |
| Perondi, R | 1 |
| Blasi, F | 1 |
| Bertinieri, G | 1 |
| Tien, TV | 1 |
| Ceriani, G | 1 |
| Tarsia, P | 1 |
| Arosio, C | 1 |
| Ranzi, ML | 1 |
| Navuluri, R | 1 |
| Yue, S | 1 |
| Tirén, U | 1 |
| Sandstedt, B | 1 |
| Finkel, Y | 1 |
| Zanten, SJ | 2 |
| Leddin, D | 1 |
| Lau, GK | 3 |
| Shi, Y | 1 |
| Zhang, DZ | 2 |
| Xu, WW | 1 |
| Stålhammar, NO | 1 |
| Craig, AM | 1 |
| Davey, P | 1 |
| Malek, M | 1 |
| Murray, F | 1 |
| Grimaz, S | 1 |
| Damiani, D | 1 |
| Brosolo, P | 1 |
| Skert, C | 1 |
| Geromin, A | 1 |
| de Pretis, G | 1 |
| Lee, CK | 1 |
| Soike, K | 1 |
| Hill, J | 1 |
| Georgakopoulos, K | 1 |
| Tibbitts, T | 1 |
| Ingrassia, J | 1 |
| Gray, H | 1 |
| Boden, J | 1 |
| Kleanthous, H | 1 |
| Giannasca, P | 1 |
| Ermak, T | 1 |
| Weltzin, R | 1 |
| Blanchard, J | 1 |
| Eskes, SA | 1 |
| Cheybani, K | 1 |
| Yeramian, P | 1 |
| Smith, S | 1 |
| Chen, W | 2 |
| Shu, D | 1 |
| Wilson, IR | 1 |
| Tie, A | 1 |
| Chadwick, VS | 1 |
| Suzuki, K | 3 |
| Hassan, M | 1 |
| Sawahata, T | 1 |
| Neville, PM | 2 |
| Everett, S | 1 |
| Tompkins, D | 1 |
| Mapstone, NP | 1 |
| Breslin, NP | 1 |
| Hyde, DK | 1 |
| Bisso, G | 2 |
| Pivari, M | 2 |
| Luca, S | 1 |
| Terranova, R | 1 |
| Michalos, A | 1 |
| Dawson, BK | 1 |
| Chodash, HB | 1 |
| Wustlich, S | 1 |
| Brehler, R | 1 |
| Luger, TA | 1 |
| Foerster, E | 1 |
| Addolorato, G | 1 |
| Gasbarrini, GB | 1 |
| Yamamoto, T | 2 |
| Matsumoto, J | 1 |
| Shiota, K | 1 |
| Kitajima, S | 1 |
| Imaizumi, M | 1 |
| Arima, T | 1 |
| Zhao, XJ | 1 |
| Kimura, M | 3 |
| Nishimoto, M | 1 |
| Schnyder, B | 1 |
| Helbling, A | 1 |
| Pichler, WJ | 1 |
| Wiesel, PH | 1 |
| Brassart, D | 1 |
| Herranz, M | 1 |
| Felley, C | 1 |
| Porta, N | 1 |
| Rouvet, M | 1 |
| Abdul Aal, GM | 1 |
| Dajani, AI | 2 |
| Nounou, M | 1 |
| Awad, S | 2 |
| Abdul Rasheed, Z | 2 |
| Gautam, S | 2 |
| Ukabam, S | 2 |
| Nayal, S | 2 |
| Nounou, MA | 1 |
| Abdul Aal, G | 1 |
| Pauly, MP | 1 |
| Levenson, SD | 1 |
| Fortunato, A | 1 |
| Rassu, M | 3 |
| Meli, S | 1 |
| Jacoby, EB | 1 |
| Porter, KB | 1 |
| Madridejos Mora, R | 1 |
| Hamlet, A | 1 |
| Stage, L | 1 |
| Lönroth, H | 1 |
| Cahlin, C | 1 |
| Nyström, C | 1 |
| Pettersson, A | 2 |
| Bhasin, DK | 2 |
| Sharma, BC | 2 |
| Sinha, SK | 1 |
| Ray, P | 2 |
| Behrens, R | 1 |
| Lang, T | 1 |
| Keller, KM | 1 |
| Bindl, L | 1 |
| Becker, M | 1 |
| Rodeck, B | 1 |
| Küster, P | 1 |
| Wündisch, GF | 1 |
| Bamford, JT | 1 |
| Tilden, RL | 1 |
| Blankush, JL | 1 |
| Gangeness, DE | 1 |
| Lombardo, L | 2 |
| Masoero, G | 1 |
| Della Monica, P | 1 |
| Pera, A | 1 |
| Cain, C | 1 |
| Schubert, ML | 1 |
| Trautmann, M | 1 |
| Riediger, C | 1 |
| Möricke, A | 1 |
| Vogt, K | 1 |
| Bohr, U | 1 |
| Cugia, L | 1 |
| Nie, Y | 1 |
| Wu, H | 1 |
| Sha, W | 1 |
| Dai, S | 1 |
| Diete, U | 2 |
| Misiuna, P | 1 |
| Treichel, H | 1 |
| Ujszászy, L | 1 |
| Hirai, S | 2 |
| Kawashima, M | 1 |
| Takata, T | 1 |
| Ferrero, M | 2 |
| López-Lorente, M | 1 |
| Cubells, M | 1 |
| Barè, M | 1 |
| Gálvez, E | 1 |
| Molina, E | 1 |
| Sieg, A | 1 |
| Sellinger, M | 1 |
| Schlauch, D | 1 |
| Hörner, M | 1 |
| Grimley, CE | 1 |
| Penny, A | 1 |
| O'sullivan, M | 1 |
| Shebani, M | 1 |
| Lismore, JR | 1 |
| Cross, R | 1 |
| Illing, RC | 1 |
| Loft, DE | 1 |
| Houben, MH | 1 |
| Hensen, EF | 1 |
| Hulst, RW | 1 |
| Hoff, BW | 1 |
| Ende, AV | 1 |
| Kate, FJ | 1 |
| Peters, FT | 1 |
| Ganesh, S | 1 |
| Sluiter, WJ | 1 |
| Kleibeuker, JH | 1 |
| Realpe, JL | 2 |
| DeLany, JP | 1 |
| Steinbach, G | 1 |
| Ford, R | 1 |
| Glober, G | 1 |
| Sample, D | 1 |
| Hagemeister, FB | 1 |
| Lynch, PM | 1 |
| McLaughlin, PW | 1 |
| Rodriguez, MA | 1 |
| Romaguera, JE | 1 |
| Sarris, AH | 1 |
| Younes, A | 1 |
| Luthra, R | 1 |
| Manning, JT | 1 |
| Johnson, CM | 1 |
| Lahoti, S | 1 |
| Shen, Y | 1 |
| Lee, JE | 1 |
| Winn, RJ | 1 |
| Cabanillas, FF | 1 |
| Pedersen, SA | 1 |
| Thor, K | 1 |
| Andersson, A | 1 |
| Hattlebakk, J | 1 |
| Janatuinen, E | 1 |
| Nyström, P | 1 |
| Schmid, CH | 1 |
| Whiting, G | 1 |
| Cory, D | 1 |
| Ross, SD | 1 |
| Chalmers, TC | 1 |
| Grimm, KJ | 1 |
| Owen, RJ | 3 |
| Slater, ER | 1 |
| Gibson, J | 1 |
| Lorenz, E | 1 |
| López Gosp, D | 1 |
| Hernández Chafes, FJ | 1 |
| Barrera Aguilera, N | 1 |
| Ali', A | 1 |
| Landi, F | 1 |
| Acciardi, C | 1 |
| Dong, Q | 1 |
| Sasakii, M | 1 |
| Seno, K | 1 |
| Tsuchida, K | 1 |
| Kurokawa, T | 1 |
| Romãozinho, JM | 1 |
| French, PC | 1 |
| Roberts, PM | 1 |
| Gschwantler, M | 2 |
| Hirschl, AM | 2 |
| Pasching, E | 2 |
| Wimmer, M | 1 |
| Klimpfinger, M | 1 |
| Oberhuber, G | 2 |
| Brandstätter, G | 1 |
| Weiss, W | 1 |
| Sercombe, JC | 1 |
| Lawson, AJ | 1 |
| Slater, E | 1 |
| Catanzaro, R | 3 |
| Cipolla, R | 3 |
| Nuciforo, G | 2 |
| Komoto, K | 1 |
| Mihara, M | 2 |
| Tahara, K | 2 |
| Kawamura, Y | 4 |
| Werdmuller, BF | 1 |
| van der Putten, AB | 1 |
| Balk, AG | 1 |
| Loffeld, RJ | 1 |
| Zwimpfer, J | 1 |
| Campo, C | 1 |
| Ohtsuka, T | 1 |
| Yamakage, A | 1 |
| Yamazaki, S | 1 |
| Rodríguez Téllez, M | 1 |
| Valenzuela Barranco, M | 1 |
| Caballero Plasencia, A | 1 |
| Martín Ruiz, J | 1 |
| López-Andrade, A | 1 |
| Carmona Soria, I | 1 |
| Herrerías Gutiérrez, J | 1 |
| Boeck, W | 1 |
| Richter, C | 1 |
| Marre, R | 1 |
| Axon, A | 3 |
| Nieves Rincón, M | 1 |
| Jesús Higes, M | 1 |
| Angeles Arpa, M | 1 |
| Erdil, A | 1 |
| Cetin, C | 1 |
| Gulsen, M | 1 |
| Karaeren, N | 1 |
| Germano, MP | 1 |
| Frigerio, P | 1 |
| De Paolis, PL | 1 |
| Ballard, ED | 1 |
| Coyle, WJ | 1 |
| Sedlack, RE | 1 |
| Murphy, M | 1 |
| Fischer, DR | 1 |
| Nussbaum, MS | 1 |
| Pritts, TA | 1 |
| Gilinsky, NH | 1 |
| Weesner, RE | 1 |
| Martin, SP | 1 |
| Giannella, RA | 1 |
| Kanamoto, K | 1 |
| Yao, T | 2 |
| Suekane, H | 1 |
| Yano, Y | 2 |
| Kashiwagi, S | 2 |
| Chen, SY | 1 |
| Wang, JY | 1 |
| Zhang, SS | 1 |
| Gonzalez Cueto, D | 1 |
| Bruno, S | 1 |
| Bustos Fernandez, LM | 1 |
| Narbaitz, M | 1 |
| de Grauw, WJ | 1 |
| Melnichouk, S | 1 |
| Friendship, RM | 1 |
| Dewey, CE | 1 |
| Bildfell, R | 1 |
| Connor, SJ | 1 |
| Seow, F | 1 |
| Ngu, MC | 1 |
| Carpio, D | 2 |
| Hammett, DC | 1 |
| Evans, MF | 1 |
| Greenberg, PD | 1 |
| Cello, JP | 1 |
| Lundquist, P | 1 |
| Tennvall, GR | 1 |
| Norinder, A | 1 |
| Adeyemi, EO | 1 |
| Danial, MF | 1 |
| Helal, T | 1 |
| Benedict, S | 1 |
| Abdulle, AM | 1 |
| Tseng, GY | 1 |
| Hsieh, YH | 1 |
| Lee, FY | 1 |
| Samoyeau, R | 2 |
| Madsen, LG | 2 |
| Taskiran, M | 2 |
| Madsen, JL | 1 |
| Mach, T | 1 |
| Zahradnik-Bilska, J | 1 |
| de Luis, DA | 2 |
| Garcia Avello, A | 1 |
| Lasuncion, MA | 1 |
| de la Calle, H | 2 |
| Tanigawara, Y | 2 |
| Shirakawa, K | 2 |
| Komada, F | 1 |
| Salentijn, GJ | 1 |
| Dias, MG | 1 |
| Franco, JM | 1 |
| Magalhães, LC | 1 |
| Mendes, GS | 1 |
| De Castro, LP | 1 |
| Toppa, NH | 1 |
| Cabral, MM | 1 |
| Salles, PG | 1 |
| Lonovics, J | 1 |
| Domján, L | 1 |
| Kisfalvi, I | 1 |
| Burman, CF | 2 |
| Martino, G | 1 |
| García Cabezudo, J | 1 |
| Feldman, M | 1 |
| Cryer, B | 1 |
| Sammer, D | 1 |
| Lee, E | 1 |
| Spechler, SJ | 1 |
| Raderer, M | 1 |
| Pfeffel, F | 1 |
| Pohl, G | 1 |
| Mannhalter, C | 1 |
| Valencak, J | 1 |
| Chott, A | 1 |
| Liatsos, C | 2 |
| Karameris, A | 2 |
| Petridou, E | 1 |
| Lazaris, A | 1 |
| Antoniades, D | 1 |
| Kalafatis, E | 1 |
| Ishizuka, J | 2 |
| Komatsu, Y | 4 |
| Toyota, J | 1 |
| Kodama, F | 1 |
| Yoshinaga, T | 1 |
| Sekikawa, A | 1 |
| Nakazawa, T | 1 |
| Shio, S | 1 |
| Kohigashi, K | 1 |
| Gotoda, T | 1 |
| Saito, D | 1 |
| Ono, H | 1 |
| Oda, I | 1 |
| García Pérez, A | 1 |
| Valverde de La Osa, J | 1 |
| Giménez Samper, M | 1 |
| Alonso García, I | 1 |
| Ng, WW | 1 |
| Lam, CP | 1 |
| Chau, WK | 1 |
| Fen-Yau Li, A | 1 |
| Huang, CC | 2 |
| Lugannani, C | 1 |
| Strickland, C | 1 |
| Ninomiya, H | 1 |
| Shingaki, M | 1 |
| Hu, YB | 1 |
| Dillon, J | 1 |
| Wyatt, JI | 1 |
| Braun, W | 1 |
| Van Oijen, AH | 1 |
| Mao, HV | 1 |
| Lak, BV | 1 |
| Long, T | 1 |
| Chung, NQ | 1 |
| Thang, DM | 1 |
| Hop, TV | 1 |
| Chien, NN | 1 |
| Hoan, PQ | 1 |
| Henley, KS | 1 |
| Connor, BA | 1 |
| Stone, CD | 1 |
| Ivanikov, IO | 1 |
| Khomeriki, NM | 1 |
| Kudriavtseva, LV | 1 |
| Moreira Vicente, V | 1 |
| Giancaspero, R | 1 |
| Fuster, F | 1 |
| Acevedo, C | 1 |
| Figueroa, C | 1 |
| Hola, K | 1 |
| Schulz, M | 1 |
| Duarte, I | 1 |
| Anderson, SY | 2 |
| Qian, SC | 1 |
| Huang, NX | 1 |
| Manan, C | 1 |
| Lesmana, L | 1 |
| Carpio, RE | 1 |
| Perez, JY | 1 |
| Fock, KM | 4 |
| Phornphutkul, K | 1 |
| Kullavanijaya, P | 3 |
| Chelvam, P | 1 |
| Lim, SG | 1 |
| Marshall, CP | 1 |
| Claessens, AA | 1 |
| Heerdink, ER | 1 |
| van Eijk, JT | 1 |
| Leufkens, HG | 1 |
| Meddi, P | 2 |
| Moscatelli, R | 1 |
| Miyabayashi, H | 1 |
| Furihata, K | 1 |
| Ueno, I | 1 |
| Taskin, V | 1 |
| Gurer, I | 1 |
| Ozyilkan, E | 1 |
| Sare, M | 1 |
| von Kleist, DH | 1 |
| Nouhan, N | 1 |
| Plaisier, AP | 1 |
| Lam, YH | 1 |
| Chan, AC | 1 |
| Lee, DW | 1 |
| Law, BK | 1 |
| Lau, WY | 2 |
| Suleymanlar, I | 1 |
| Tugrul Sezer, M | 1 |
| Ertugrul, C | 1 |
| Sarikaya, M | 1 |
| Fevzi Ersoy, F | 1 |
| Isitan, F | 1 |
| Yakupoglu, G | 1 |
| Suleymanlar, G | 1 |
| Remacha, B | 1 |
| Aydin, A | 2 |
| Ersöz, G | 1 |
| Tekesin, O | 1 |
| Akçiçek, E | 1 |
| Tuncyürek, M | 1 |
| Szlachcic, A | 1 |
| Sliwowski, Z | 1 |
| Karczewska, E | 1 |
| Pytko-Polonczyk, J | 1 |
| Georgopoulos, SD | 2 |
| Karatapanis, S | 2 |
| Spiliadi, C | 2 |
| Artikis, V | 2 |
| Raptis, SA | 3 |
| Ohta, K | 1 |
| Takei, Y | 2 |
| Shamaly, H | 1 |
| Berkowitz, D | 1 |
| Rosenthal, E | 1 |
| Naveh, Y | 1 |
| Schweeger, I | 1 |
| Fitscha, P | 1 |
| Sinzinger, H | 1 |
| Luman, W | 2 |
| Ling, KL | 2 |
| Ng, HS | 3 |
| Gomes, BS | 1 |
| Kearney, DJ | 2 |
| Brousal, A | 1 |
| Mitchell, B | 1 |
| Prichard, P | 1 |
| Lloyd, D | 1 |
| Frame, MH | 1 |
| Romàn, J | 1 |
| Tracci, D | 1 |
| Lehmann, FS | 1 |
| Drewe, J | 2 |
| Terracciano, L | 2 |
| Beglinger, C | 4 |
| Nishira, T | 1 |
| Boni, F | 1 |
| Ballardini, G | 1 |
| Begum, S | 2 |
| Endo, H | 3 |
| Kawamata, H | 2 |
| Shashidhar, H | 1 |
| Peters, J | 1 |
| Lin, CH | 1 |
| Rabah, R | 1 |
| Thomas, R | 1 |
| Tolia, V | 1 |
| Markert, M | 1 |
| Luckers, AE | 1 |
| Viergever, PP | 1 |
| Pitocco, D | 1 |
| Silveri, NG | 2 |
| Pola, P | 3 |
| Ghirlanda, G | 1 |
| Bisson, S | 1 |
| Vernet Vernet, M | 1 |
| Roca Figueras, G | 1 |
| Jovell Fernández, E | 1 |
| Iglesias Rodríguez, M | 1 |
| Ureña Tapia, MM | 1 |
| Roca Fusalba, A | 1 |
| Yoshinaga, M | 2 |
| Ohtani, A | 2 |
| Tsuruta, S | 1 |
| Higashi, E | 1 |
| Harada, N | 2 |
| Nawata, H | 2 |
| Yoshida, N | 2 |
| Yoshikawa, T | 1 |
| Kassai, K | 1 |
| Kondo, M | 1 |
| Suto, H | 2 |
| Ito, Y | 2 |
| Miyaji, H | 1 |
| Gonlachanvit, S | 1 |
| Kladchareon, N | 1 |
| Agrawal, NM | 1 |
| Safdi, MA | 1 |
| Lukasik, NL | 1 |
| Nakajima, A | 1 |
| Matsuhashi, N | 1 |
| Yazaki, Y | 1 |
| Oka, T | 1 |
| Kaushik, SP | 1 |
| Vu, C | 1 |
| Sugg, J | 1 |
| Vargas, J | 2 |
| Grande, L | 2 |
| Otero, MA | 1 |
| Bernal, S | 1 |
| Baños, F | 1 |
| Madridejos, R | 1 |
| Cabezas, C | 1 |
| Burrull, M | 1 |
| Lafuente, C | 1 |
| Morera, R | 1 |
| Ohning, GV | 1 |
| Kovacs, TO | 1 |
| Sytnik, B | 1 |
| Lionetti, R | 1 |
| Ripani, C | 1 |
| Tomaselli, G | 1 |
| Feltbower, R | 3 |
| Crocombe, W | 3 |
| Mason, S | 3 |
| Atha, P | 1 |
| Brown, J | 3 |
| Dowell, AC | 2 |
| Richards, ID | 2 |
| Michopoulos, S | 1 |
| Tsibouris, P | 1 |
| Bouzakis, H | 1 |
| Balta, A | 1 |
| Vougadiotis, J | 1 |
| Kralios, N | 1 |
| Kwon, DH | 2 |
| Adamthwaite, D | 1 |
| Midolo, P | 1 |
| Davidson, G | 1 |
| Kees, F | 1 |
| Pathak, CM | 1 |
| Iida, N | 1 |
| Jakić-Razumović, J | 1 |
| Tentor, D | 1 |
| Kusec, V | 1 |
| Cuzić, S | 1 |
| Brkić, T | 1 |
| Vukobrat-Bijedić, Z | 1 |
| Lacević, N | 1 |
| Bratović, I | 1 |
| Gogov, B | 1 |
| Radović, S | 1 |
| Taguchi, H | 1 |
| Osaki, T | 1 |
| Kamiya, S | 1 |
| Saito, K | 1 |
| Arai, K | 1 |
| Kobayashi, R | 1 |
| Ohki, I | 1 |
| Niigaki, M | 2 |
| Kaji, T | 2 |
| Kawamura, A | 4 |
| Sato, H | 4 |
| Okuyama, T | 2 |
| Watanabe, M | 6 |
| van Herwaarden, MA | 1 |
| Samsom, M | 1 |
| Wang, RT | 1 |
| Yeung, CK | 1 |
| Chao, W | 1 |
| Muraoka, S | 1 |
| Imai, T | 1 |
| Mason, J | 2 |
| Miwi, H | 1 |
| Ohtaka, K | 2 |
| Minowa, T | 1 |
| Einecke, D | 1 |
| Mowat, C | 1 |
| Hossack, M | 1 |
| Gilmour, D | 1 |
| Preston, T | 1 |
| Uchida, Y | 1 |
| Hurenkamp, GJ | 1 |
| Grundmeijer, HG | 1 |
| Germanà, B | 2 |
| Marin, R | 2 |
| Kawakami, S | 1 |
| Fukazawa, K | 1 |
| Miyoshi, E | 1 |
| Kitadai, Y | 3 |
| Hattori, N | 1 |
| Wittayalertpanya, S | 1 |
| Wannachai, N | 1 |
| Thongnopnua, P | 1 |
| Salaka, U | 1 |
| Pasalić, G | 1 |
| Daudén, E | 1 |
| García-Díez, A | 1 |
| Garuz, R | 1 |
| Barrera, F | 1 |
| Malo, J | 1 |
| Tirado, M | 1 |
| Castellote, J | 1 |
| Porta, F | 1 |
| Lee, TH | 1 |
| Frevel, M | 1 |
| Daake, H | 1 |
| Janisch, HD | 1 |
| Kellner, HU | 1 |
| Krezdorn, HG | 1 |
| Tanneberger, D | 1 |
| Wack, R | 1 |
| Cattoli, G | 1 |
| Bart, A | 1 |
| Klaver, PS | 1 |
| Robijn, RJ | 1 |
| Beumer, HJ | 1 |
| van Vugt, R | 1 |
| Pot, RG | 1 |
| van der Gaag, I | 1 |
| Kusters, JG | 1 |
| Battaglia, F | 1 |
| Benedetti, E | 1 |
| Bottona, E | 1 |
| Caroli, A | 1 |
| Costan-Biedo, F | 1 |
| De Bastiani, R | 1 |
| Andrea Grassi, S | 1 |
| Madia, D | 1 |
| Marcon, V | 1 |
| Monica, F | 1 |
| Olivieri, P | 1 |
| Orzes, N | 1 |
| Ronzani, G | 1 |
| Saggioro, A | 1 |
| Tafner, G | 1 |
| Buzás György, M | 1 |
| Székely, E | 1 |
| Illyés, G | 1 |
| Széles, I | 1 |
| Weinstein, WM | 1 |
| Martínez Delgado, C | 1 |
| Otero Fernández, MA | 1 |
| Testoni, PA | 2 |
| Bagnolo, F | 1 |
| Sanz, JM | 1 |
| Flores, S | 1 |
| Opazo, H | 1 |
| Valderrama, D | 1 |
| Aguilera, R | 1 |
| Marchese, A | 1 |
| Valderrama, S | 1 |
| Pirozzi, G | 1 |
| Santarelli, L | 2 |
| Arancio, F | 1 |
| Yamamoto, S | 1 |
| Matsumura, N | 1 |
| Makristathis, A | 1 |
| Barousch, W | 1 |
| Binder, C | 1 |
| Kuderna, C | 1 |
| Apfalter, P | 1 |
| Rotter, ML | 1 |
| Goh, K | 1 |
| Cheah, P | 1 |
| Ranjeev, C | 1 |
| Rosmawati, M | 1 |
| Tan, Y | 1 |
| Chin, S | 1 |
| Frank, F | 1 |
| Stricker, T | 1 |
| Romagnoli, P | 2 |
| Fasoli, A | 1 |
| Risso, D | 1 |
| Lantieri, PB | 1 |
| Bezborodnyĭ, SD | 2 |
| Okai, T | 1 |
| Ohtsubo, K | 1 |
| Sakai, J | 1 |
| Watanabe, H | 1 |
| Motoo, Y | 1 |
| Kawashima, A | 1 |
| Sawabu, N | 1 |
| Herr, H | 1 |
| You, CH | 1 |
| Abid, S | 1 |
| Abbas, Z | 1 |
| Van Rensburg, C | 1 |
| Chen, PC | 1 |
| Schneider, H | 1 |
| Simjee, AE | 1 |
| Hamid, SS | 1 |
| Seebaran, A | 1 |
| Destefano, M | 1 |
| Vitale, LM | 1 |
| Idda, M | 1 |
| Casu, M | 1 |
| Aalykke, C | 1 |
| Rune, S | 2 |
| Weywadt, L | 1 |
| Gjørup, T | 1 |
| Bekker, C | 1 |
| Kromann-Andersen, H | 1 |
| Kjaergaard, J | 1 |
| Rask-Madsen, J | 1 |
| Hansen, J | 1 |
| Vyberg, M | 1 |
| Teglbjaerg, PS | 1 |
| Perrucci, V | 1 |
| Morra, I | 1 |
| Gaido, F | 1 |
| Ansaldi, N | 1 |
| Oki, Y | 1 |
| Jungnickel, PW | 1 |
| Isler, M | 1 |
| Fujiwara, T | 1 |
| Hamazaki, K | 1 |
| Murashima, N | 1 |
| Akura, Y | 1 |
| Nishisita, C | 1 |
| Umekawa, Y | 1 |
| Göthe, L | 1 |
| Calabrese, C | 1 |
| Di Febo, G | 1 |
| Areni, A | 1 |
| Scialpi, C | 1 |
| Morikawa, T | 1 |
| Nishiyama, T | 1 |
| Toracchio, S | 1 |
| Cappello, G | 1 |
| Malatesta, MG | 1 |
| Ferri, A | 1 |
| Ciccaglione, AF | 1 |
| Tincani, E | 1 |
| Silingardi, M | 1 |
| Ghirarduzzi, A | 1 |
| Iori, I | 1 |
| Nakahara, T | 1 |
| Inuzuka, S | 1 |
| Akagi, K | 1 |
| Iaquinto, G | 1 |
| Piccirillo, MM | 1 |
| Lioniello, M | 1 |
| García Lareo, M | 1 |
| Rosario Hernández Ibáñez, M | 1 |
| Teruel Gila, J | 1 |
| Sicilia, B | 1 |
| Sierra, E | 1 |
| Lago, A | 1 |
| Villar, M | 1 |
| Furlan, F | 1 |
| Sgarro, C | 1 |
| Bartolozzi, F | 3 |
| Canducci, F | 2 |
| Anti, M | 1 |
| De Lorenzo , A | 1 |
| Cheng, JS | 1 |
| Chan, HH | 1 |
| Ku, MK | 1 |
| Chien, EJ | 1 |
| Hsu, PN | 1 |
| Fanti, L | 1 |
| Ieri, R | 1 |
| Mezzi, G | 1 |
| Passaretti, S | 1 |
| Guslandi, M | 1 |
| Lanas, AI | 1 |
| Lavergne, A | 1 |
| Aegerter, PH | 1 |
| Palazzo, L | 1 |
| Molina, T | 1 |
| Rambaud, JL | 1 |
| De Lorenzo, A | 1 |
| Bardhan, K | 2 |
| Gromark, P | 1 |
| Odman, B | 1 |
| Sörngård, H | 1 |
| Wason, C | 1 |
| Peacock, R | 1 |
| Roberts, P | 1 |
| Cordero, JM | 1 |
| Caballero, C | 1 |
| Cantón, R | 1 |
| Nomura, H | 1 |
| Miyake, K | 2 |
| Villani, MR | 3 |
| Caruso, N | 1 |
| Bergoli, ML | 1 |
| Khatibian, M | 1 |
| Fazel, A | 1 |
| Alizadeh, BZ | 1 |
| Satoh, R | 1 |
| Watari, J | 1 |
| Shibata, N | 1 |
| Satoh, T | 1 |
| Kohgo, Y | 1 |
| Miki, H | 1 |
| Harada, H | 1 |
| Yamanoi, Y | 1 |
| Uraoka, T | 1 |
| Sotozono, M | 1 |
| Ohmori, M | 1 |
| Lee, DK | 1 |
| Kim, KH | 1 |
| Jeong, YS | 1 |
| Seo, JI | 1 |
| Baik, SK | 1 |
| Kwon, SO | 1 |
| Cho, MY | 1 |
| Sugitani, M | 1 |
| Nagata, T | 1 |
| Ishii, Y | 1 |
| Komuro, S | 1 |
| Yanai, M | 1 |
| Nemoto, N | 1 |
| Russo, A | 2 |
| Eishi, Y | 1 |
| Yokoyama, T | 1 |
| Qureshi, H | 1 |
| Mehdi, I | 1 |
| Alam, E | 1 |
| Lutgen, N | 1 |
| Delforge, M | 1 |
| Bastens, B | 1 |
| Demoulin, JC | 1 |
| Fontaine, F | 1 |
| Gillard, V | 1 |
| Gerard, A | 1 |
| Khor, CJ | 1 |
| Ng, TM | 2 |
| Teo, EK | 1 |
| Sim, CS | 1 |
| Tan, AL | 1 |
| Ng, A | 1 |
| Yoshida, H | 3 |
| Ohmi, N | 1 |
| Higuchi, S | 1 |
| Rathi, P | 1 |
| Sawant, P | 1 |
| Gopanpallikar, A | 1 |
| Suen, BY | 1 |
| Lai, MS | 1 |
| Law, NM | 1 |
| Lim, CC | 1 |
| Marais, A | 1 |
| Salamon, R | 1 |
| Müller-Hermelink, H | 1 |
| Schetelig, J | 1 |
| Saeed, MA | 1 |
| Avidan, B | 1 |
| Keller, N | 1 |
| Bar-Meir, S | 1 |
| Chathadi, KV | 1 |
| Montague, J | 1 |
| Ahmed, F | 1 |
| Murthy, U | 1 |
| Street, ME | 1 |
| Caruana, P | 1 |
| Caffarelli, C | 1 |
| Magliani, W | 1 |
| Fornaroli, F | 1 |
| Carratù, R | 1 |
| Iuliano, D | 1 |
| Ferraraccio, F | 1 |
| Esposito, P | 1 |
| Russo, MI | 1 |
| Abbate, G | 1 |
| Tankovic, J | 2 |
| Lamarque, D | 2 |
| Lascols, C | 2 |
| Soussy, CJ | 2 |
| Chen, JD | 1 |
| Parolisi, S | 1 |
| Shifflett, J | 1 |
| Peura, DA | 1 |
| McCallum, RW | 1 |
| Fändriks, L | 1 |
| von Bothmer, C | 1 |
| Aneman, A | 1 |
| Olbe, L | 1 |
| Barrowclough, S | 1 |
| Shahin, WA | 1 |
| Abdel-Baset, EZ | 1 |
| Nassar, AK | 1 |
| Atta, MM | 1 |
| Kabil, SM | 1 |
| Murray, JA | 1 |
| Shimamoto, F | 1 |
| Lüth, S | 1 |
| Teyssen, S | 1 |
| Kölbel, CB | 1 |
| Singer, MV | 1 |
| Fischer, H | 1 |
| Huber, V | 1 |
| Boknik, P | 1 |
| Luess, H | 1 |
| Neumann, J | 1 |
| Schmitz, W | 1 |
| Della Libera, E | 1 |
| Rohr, MR | 1 |
| Moraes, M | 1 |
| Siqueira, ES | 1 |
| Ferrari, AP | 2 |
| Horai, Y | 1 |
| Furuie, H | 1 |
| Matsuguma, K | 1 |
| Irie, S | 1 |
| Koga, Y | 1 |
| Nagahama, T | 1 |
| Matsui, T | 1 |
| Urae, A | 1 |
| Meier, R | 1 |
| Wettstein, A | 1 |
| Geiser, HR | 1 |
| Bardou, M | 1 |
| Gołebiewska, M | 1 |
| Zimmermann, AE | 1 |
| Walters, JK | 1 |
| Katona, BG | 1 |
| Souney, PE | 1 |
| Levine, D | 1 |
| Giglio, A | 1 |
| Ciliberto, E | 1 |
| Belmonte, A | 1 |
| Cavaliere, C | 1 |
| Saccà, N | 1 |
| Frandina, C | 1 |
| Trimboli, V | 1 |
| Schwizer, W | 1 |
| Thumshirn, M | 1 |
| Guldenschuh, I | 1 |
| Menne, D | 1 |
| Cathomas, G | 1 |
| Romanska, H | 1 |
| Schneider, A | 1 |
| Fischer, R | 2 |
| Ng, W | 1 |
| Niro, GA | 1 |
| Krizman, I | 1 |
| Gorensek, M | 1 |
| Gubina, M | 1 |
| Orel, I | 1 |
| Meyer, JM | 1 |
| Silliman, NP | 1 |
| Dixon, CA | 1 |
| Siepman, NY | 1 |
| Sugg, JE | 1 |
| Hopkins, RJ | 1 |
| Ohara, T | 2 |
| Goshi, S | 1 |
| Taneike, I | 1 |
| Tamura, Y | 1 |
| Zhang, HM | 1 |
| Phillips, RH | 1 |
| Whitehead, MW | 1 |
| Doig, LA | 1 |
| Sieniawska, CE | 1 |
| Delves, HT | 1 |
| Powell, JJ | 1 |
| Bateson, MC | 1 |
| Yamaji, Y | 1 |
| Kawabe, T | 1 |
| Okamoto, M | 1 |
| Toyoda, H | 1 |
| Yamaguchi, M | 1 |
| Mukai, K | 1 |
| Sawa, H | 1 |
| Kawamura, K | 1 |
| Shiku, H | 1 |
| Koçak, N | 1 |
| Saltik, IN | 1 |
| Ozen, H | 1 |
| Yüce, A | 1 |
| Gürakan, F | 1 |
| Wang, YL | 2 |
| Chan, KL | 1 |
| Zhou, H | 1 |
| Ng, DK | 1 |
| Tam, PK | 1 |
| Heinrich, J | 1 |
| Yang, CS | 1 |
| Ell, C | 1 |
| Schoerner, C | 1 |
| Solbach, W | 1 |
| Ridl, W | 1 |
| Moser, W | 1 |
| Jacobson, BC | 1 |
| Mäkipernaa, A | 1 |
| Maga, T | 1 |
| Torigoe, T | 1 |
| Nasu, J | 1 |
| Hall, L | 1 |
| Eccles, M | 1 |
| Barton, R | 1 |
| Steen, N | 1 |
| Campbell, M | 1 |
| Oncel, M | 1 |
| Kurt, N | 1 |
| Walsh, M | 1 |
| Ishimura, N | 1 |
| Behrendt, J | 1 |
| Wenzel, C | 1 |
| Panagou, E | 1 |
| Lau, CF | 1 |
| Hui, PK | 1 |
| Fung, TT | 1 |
| Tung, SY | 1 |
| Lam, KM | 1 |
| Calafatti, SA | 3 |
| Ortiz, RA | 3 |
| Deguer, M | 3 |
| Martinez, M | 1 |
| Cicconi, V | 1 |
| Carloni, E | 1 |
| Nocente, R | 1 |
| Manna, R | 1 |
| Servidei, S | 1 |
| Bentivoglio, AR | 1 |
| Avcu, N | 1 |
| Avcu, F | 1 |
| Beyan, C | 1 |
| Ural, AU | 1 |
| Kaptan , K | 1 |
| Ozyurt, M | 1 |
| Nevruz, O | 1 |
| Yalçin, A | 1 |
| Hotz, J | 1 |
| Hsu, CC | 1 |
| Chen, JJ | 1 |
| Hu, TH | 1 |
| Lu, SN | 1 |
| Changchien, CS | 1 |
| Froehlich, F | 1 |
| Gonvers, JJ | 1 |
| Wietlisbach, V | 1 |
| Burnand, B | 1 |
| Hildebrand, P | 2 |
| Schneider, C | 1 |
| Saraga, E | 1 |
| Vader, JP | 1 |
| Sazhin, VP | 1 |
| Fedorov, AV | 1 |
| Grigor'ev, PIa | 1 |
| Iakovenko, EP | 1 |
| Talanova, EV | 1 |
| Vermeer, IT | 1 |
| Engels, LG | 1 |
| Pachen, DM | 1 |
| Dallinga, JW | 1 |
| Kleinjans, JC | 1 |
| van Maanen, JM | 1 |
| Wongkusoltham, P | 1 |
| Phaosawadi, K | 1 |
| Sánchez, A | 1 |
| Iriondo, C | 1 |
| Muñoz, C | 1 |
| Baranskaia, EK | 1 |
| Di Vita, G | 1 |
| Patti, R | 1 |
| Aragona, F | 1 |
| Leo, P | 1 |
| Montalto, G | 1 |
| Magaret, N | 1 |
| Burm, M | 1 |
| Faigel, D | 1 |
| Kelly, C | 1 |
| Peterson, W | 1 |
| Bühling, A | 1 |
| Radun, D | 1 |
| Müller, WA | 1 |
| Saito, M | 1 |
| Miyagishima, T | 1 |
| Hige, S | 1 |
| Wang, CS | 1 |
| Kuo, CF | 1 |
| Antonova, PV | 1 |
| Kume, K | 1 |
| Hirakoba, M | 1 |
| Yoshikawa, I | 1 |
| Otsuki, M | 1 |
| Fendrick, AM | 1 |
| Lahaie, R | 1 |
| Fallone, CA | 1 |
| Ponich, T | 1 |
| Oravec, M | 1 |
| Whitsitt, P | 1 |
| Marcon, N | 1 |
| Bailey, R | 1 |
| Dumont, A | 1 |
| Desrochers, S | 1 |
| Bechi, P | 1 |
| Bacci, S | 1 |
| Cianchi, F | 1 |
| Amorosi, A | 2 |
| Nesi, G | 1 |
| Dei, R | 1 |
| Ribeiro, JM | 1 |
| Lucas, M | 1 |
| Palhano, MJ | 1 |
| Victorino, RM | 1 |
| Sekigawa, K | 1 |
| Hashimoto, N | 1 |
| Shirato, R | 1 |
| Chahine, C | 1 |
| Chedid, M | 1 |
| Ho, B | 1 |
| Bardhan, P | 1 |
| Rossi, L | 1 |
| Parvin, S | 1 |
| Rahman, A | 1 |
| Arefin, MS | 1 |
| Ahmad, MM | 1 |
| Glatz-Krieger, K | 1 |
| Bauerfeind, P | 1 |
| Gyr, N | 1 |
| Khan, AK | 1 |
| Timm, S | 1 |
| Sailer, M | 1 |
| Fuchs, KH | 1 |
| Bardhan, C | 1 |
| Young, L | 1 |
| Brown, L | 1 |
| Ebata, M | 2 |
| Ikeda, S | 1 |
| Tamamuro, T | 1 |
| Hamashima, C | 1 |
| Laurent, J | 1 |
| Geboes, K | 1 |
| Dekker, W | 1 |
| Nusteling, K | 1 |
| Salam, I | 1 |
| Durai, D | 1 |
| Murphy, JK | 1 |
| Sundaram, B | 1 |
| Mayr-Kanhäuser, S | 1 |
| Kränke, B | 1 |
| Kaddu, S | 1 |
| Müllegger, RR | 1 |
| Weiss, MM | 1 |
| Pierantozzi, M | 1 |
| Pietroiusti, A | 1 |
| Galante, A | 1 |
| Sancesario, G | 1 |
| Lunardi, G | 1 |
| Fedele, E | 1 |
| Giacomini, P | 1 |
| Stanzione, P | 1 |
| Chiang, IP | 1 |
| Liu, SM | 1 |
| Guimber, D | 1 |
| Mougenot, JF | 1 |
| Tounian, P | 1 |
| Lenaerts, C | 1 |
| Roquelaure, B | 1 |
| Lachaux, A | 1 |
| Morali, A | 1 |
| Maurage, C | 1 |
| Husson, MO | 2 |
| Loginov, AS | 1 |
| Reshetnyak, VI | 1 |
| Dudik, TV | 1 |
| Vostroknutova, GN | 1 |
| Il'chenko, AA | 1 |
| Kaprel'yants, AS | 1 |
| Misawa, H | 1 |
| Kusano, Y | 1 |
| Esaki, M | 1 |
| Kurahara, K | 1 |
| Sharma, VK | 1 |
| Sahai, AV | 1 |
| Corder, FA | 1 |
| Li, KF | 1 |
| Lau, P | 1 |
| Kryszewski, A | 1 |
| Kleczkowski, D | 1 |
| Rudzinski, J | 1 |
| Bartuzi, Z | 1 |
| Larkö, A | 1 |
| Rieder, G | 2 |
| Samuelson, LC | 2 |
| Röbbecke, J | 1 |
| Dias, FE | 1 |
| Bento, AP | 1 |
| Pereira, AA | 1 |
| Piovesana, H | 1 |
| Lerner, F | 1 |
| Starostin, BD | 1 |
| Carswell, CI | 1 |
| Goa, KL | 1 |
| Saito, T | 1 |
| Sanduleanu, S | 1 |
| de Bruïne, A | 1 |
| Hameeteman, W | 1 |
| Stockbrügger, RW | 1 |
| Chen, TS | 1 |
| Kang, LJ | 1 |
| Kurbel, S | 1 |
| Ostojić, R | 1 |
| Barbir, A | 1 |
| Hovat, D | 1 |
| Wittig, J | 1 |
| Kwok, T | 1 |
| Chan, CS | 1 |
| Hui, E | 1 |
| Woo, J | 1 |
| Koçkar, C | 1 |
| Oztürk, M | 1 |
| Bavbek, N | 1 |
| Antos, D | 1 |
| Läuter, J | 1 |
| Lee, CH | 1 |
| Kim, CW | 1 |
| Kim, CY | 1 |
| Gremse, DA | 1 |
| Kikuta, T | 1 |
| Ota, A | 1 |
| Tsuji, H | 1 |
| Hino, R | 1 |
| Messerer, P | 1 |
| Ott, MG | 1 |
| Zober, A | 1 |
| Sakurane, M | 1 |
| Shiotani, A | 1 |
| Furukawa, F | 1 |
| Sotoudehmanesh, R | 1 |
| Vahedi, H | 1 |
| Dariani, NE | 1 |
| Asgari, AA | 1 |
| Khan, Z | 1 |
| Nair, P | 1 |
| O'Shea, C | 1 |
| Spiers, N | 1 |
| Playford, RJ | 1 |
| Wicks, AC | 1 |
| Jarque, I | 1 |
| Andreu, R | 1 |
| Llopis, I | 1 |
| De la Rubia, J | 1 |
| Gomis, F | 1 |
| Senent, L | 1 |
| Jiménez, C | 1 |
| Martín, G | 1 |
| Martínez, JA | 1 |
| Sanz, GF | 1 |
| Sanz, MA | 1 |
| Hahne, W | 1 |
| Di Pietro, C | 1 |
| Morelli, P | 1 |
| Choi, KW | 1 |
| Ahn, DS | 1 |
| Yang, US | 1 |
| Lee, SI | 1 |
| Rhee, JC | 1 |
| Hong, WS | 1 |
| Hungin, AP | 1 |
| Jones, R | 1 |
| Park, MJ | 1 |
| Su, J | 1 |
| Lai, CH | 1 |
| Yang, CC | 1 |
| Wang, WC | 1 |
| Sulliga, M | 1 |
| Wolle, K | 1 |
| Von Arnim, U | 1 |
| Kahl, S | 1 |
| Levy, M | 1 |
| Copie-Bergman, C | 1 |
| Traulle, C | 1 |
| Brousse, N | 1 |
| Hemery, F | 1 |
| Gaulard, P | 1 |
| Narayani, RI | 1 |
| Burton, MP | 1 |
| Young, GS | 1 |
| Kokkola, A | 1 |
| Härkönen, M | 1 |
| Haapiainen, R | 1 |
| Puolakkainen, P | 1 |
| Lupascu, A | 1 |
| Wong, SK | 1 |
| Sainaghi, M | 1 |
| Anderloni, A | 1 |
| Duffett, S | 1 |
| Drummond, M | 1 |
| Morillas, JD | 1 |
| Elizalde, I | 1 |
| Castiella, A | 1 |
| Ros, E | 1 |
| Suetsugu, H | 1 |
| Moriyama, N | 1 |
| Kazumori, H | 1 |
| Barbier, C | 1 |
| Odaka, T | 1 |
| Yamaguchi, T | 1 |
| Koyama, H | 1 |
| Saisho, H | 1 |
| Nomura, F | 1 |
| Ciancio, G | 1 |
| Nuti, M | 1 |
| Orsini, B | 1 |
| Iovi, F | 1 |
| Ortolani, M | 1 |
| Palomba, A | 1 |
| Ilani, SM | 1 |
| Bown, RL | 1 |
| Yin, Y | 1 |
| Baena, JM | 1 |
| López, C | 1 |
| Hidalgo, A | 1 |
| Rams, F | 1 |
| Jiménez, S | 1 |
| Hernández, MR | 1 |
| Ferguson, RA | 1 |
| Fu, HY | 1 |
| Ishitobi, H | 1 |
| Mitsuno, Y | 1 |
| Miyatani, H | 1 |
| Tokuyama, T | 1 |
| Hirakawa, R | 1 |
| Sawada, A | 1 |
| Chiba, T | 1 |
| Yoshino, J | 1 |
| Kawata, H | 1 |
| Kato, C | 1 |
| Kanke, K | 1 |
| Suga, M | 1 |
| Takata, H | 1 |
| Koizumi, K | 1 |
| Kiriyama, Y | 1 |
| Wermeille, J | 1 |
| Cunningham, M | 1 |
| Dederding, JP | 1 |
| Girard, L | 1 |
| Baumann, R | 1 |
| Zelger, G | 1 |
| Buri, P | 1 |
| Metry, JM | 1 |
| Sitavanc, R | 1 |
| Gallaz, L | 1 |
| Merki, H | 1 |
| Godin, N | 1 |
| Scott, LJ | 1 |
| Dunn, CJ | 1 |
| Mallarkey, G | 1 |
| Sharpe, M | 1 |
| Tomita, K | 1 |
| Mele, R | 1 |
| Wedi, B | 1 |
| Kapp, A | 1 |
| Dhir, V | 1 |
| Corazzi, A | 1 |
| Souza, JM | 1 |
| De Souza, CA | 1 |
| Marchioretto, MA | 1 |
| Bernasconi, G | 1 |
| Noguchi, K | 1 |
| Nagura, H | 1 |
| Azagra, R | 1 |
| López, T | 1 |
| Cubells, MJ | 1 |
| Gościmski, A | 1 |
| Matras, J | 1 |
| Wallner, G | 1 |
| Shimodaira, K | 1 |
| Kaneko, T | 1 |
| Ishida, K | 1 |
| Ikeno, T | 1 |
| Knippig, C | 1 |
| Arand, F | 1 |
| Nilius, M | 1 |
| Klein, U | 1 |
| Abe, K | 1 |
| Oshima, N | 1 |
| Kawashima, K | 1 |
| Hamamoto, N | 1 |
| Moritani, M | 1 |
| Mak, R | 1 |
| Kawauchi, H | 1 |
| Meneghelli, UG | 1 |
| Boaventura, S | 1 |
| Moraes-Filho, JP | 1 |
| Leitão, O | 1 |
| Almeida, JR | 1 |
| Haddad, MT | 1 |
| Tolentino, M | 1 |
| Jorge, JL | 1 |
| Silva, E | 1 |
| Maguilnik, I | 1 |
| Ozdemir, A | 1 |
| Mas, MR | 1 |
| Sahin, S | 1 |
| Sağlamkaya, U | 1 |
| Ateşkan, U | 1 |
| Bickley, J | 1 |
| Hegarty, BT | 1 |
| Pikkarainen, P | 1 |
| Tjivras, M | 1 |
| Kapsalas, D | 1 |
| Kyriaki, D | 1 |
| Alevizou, V | 1 |
| Fertakis, A | 1 |
| Cheng, A | 1 |
| Leung, JW | 1 |
| Ebert, R | 1 |
| Bertschinger, P | 1 |
| Brunner, J | 1 |
| Lammer, F | 1 |
| Jost, R | 1 |
| Häcki, WH | 1 |
| Sherman, P | 1 |
| Shames, B | 1 |
| Loo, V | 1 |
| Matlow, A | 1 |
| Penner, J | 1 |
| Birkholz, S | 1 |
| Spencer, G | 1 |
| Brooks, S | 1 |
| Prosser, S | 1 |
| Nujumi, AM | 1 |
| Dorrian, CA | 1 |
| Macdonald, AM | 1 |
| Fullarton, GM | 1 |
| Harwood, J | 1 |
| Mainguet, P | 1 |
| Jouret, A | 1 |
| Haot, J | 1 |
| D'Adda, T | 1 |
| Langenberg, W | 1 |
| Bosma, A | 1 |
| Mangiameli, A | 1 |
| Inserra, G | 1 |
| Monello, S | 1 |
| Sofia, M | 1 |
| Rizzo, G | 1 |
| Ayoubi Khajekini, M | 1 |
| Blasi, A | 1 |
| Cariani, G | 2 |
| Vandelli, A | 2 |
| Santini, D | 2 |
| Caselli, A | 1 |
| Fontana, G | 2 |
| Varrentrapp, M | 1 |
| Lange, P | 1 |
| Müller, MJ | 1 |
| Schorn, T | 1 |
| Soudah, B | 1 |
| Bär, W | 1 |
| Gebel, M | 1 |
| Daw, MA | 1 |
| Deegan, P | 1 |
| Leen, E | 1 |
| Stumpf, M | 1 |
| Stöckmann, F | 1 |
| Di Girolamo, A | 1 |
| Scialabba, A | 1 |
| Pisciotta, G | 1 |
| Weil, J | 1 |
| Powell, K | 1 |
| Morden, A | 1 |
| Trowell, JE | 1 |
| Aversa, GP | 1 |
| Lok, AS | 1 |
| Ng, MM | 1 |
| Bethke, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Helicobacter Pylori Resistance. A Study of Morbidity, Immunological and Clinical Phenotypes[NCT05019586] | 185 participants (Actual) | Observational | 2010-04-15 | Completed | |||
| Effectiveness of Rifabutin Triple Therapy for First-line and Rescue Treatment of Helicobacter Pylori Infection[NCT04652284] | Phase 3 | 300 participants (Anticipated) | Interventional | 2021-05-01 | Not yet recruiting | ||
| A Randomized Double Blind Active Comparator Controlled Phase III Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection[NCT03198507] | Phase 3 | 455 participants (Actual) | Interventional | 2017-06-18 | Completed | ||
| Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication[NCT03650543] | Phase 4 | 133 participants (Actual) | Interventional | 2012-09-10 | Completed | ||
| Reinfection After Eradication of Helicobacter Pylori Infection in Adult :A National Multicentre Study[NCT02674802] | 3,500 participants (Anticipated) | Observational | 2015-12-31 | Recruiting | |||
| Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice[NCT01273441] | Phase 4 | 338 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication[NCT02547038] | 352 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012] | 51 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
| Does Eradication of H-pylori in Pregnant Patients With Iron Deficiency Anemia Have an Effect on Iron Replacement Therapy?[NCT03347513] | Phase 4 | 150 participants (Anticipated) | Interventional | 2017-11-25 | Recruiting | ||
| Usefulness of Antimicrobial Susceptibility in the Eradication of Helicobacter Pylori[NCT01486082] | 1 participants (Anticipated) | Observational | 2011-02-28 | Recruiting | |||
| Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial[NCT04039412] | Phase 4 | 330 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
| Effects of Different Omeprazole Dosing on Gastric pH in Non- Variceal Upper Gastrointestinal Bleeding: A Randomized Prospective Study[NCT03980496] | Phase 4 | 50 participants (Actual) | Interventional | 2010-09-09 | Completed | ||
| A Randomised, Double-blind, Parallel-group, Placebo Controlled Study of Esomeprazole i.v. (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour) Administered for 72 Hours to Assess Prevention of Rebleeding in Subjects That Have Under[NCT00251979] | Phase 3 | 1,312 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial[NCT02541864] | 330 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)[NCT02359435] | 440 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| "Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple Hybrid and Concomitant Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance"[NCT01464060] | Phase 4 | 400 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| Comparison Between Ten Days Sequential Treatment (With Metronidazole or Tetracycline) and Ten Days Standard Triple Therapy of Helicobacter Pylori[NCT01573975] | Phase 4 | 345 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Prospective, Randomized Controlled Trial Comparing Amoxicillin and Metronidazole Based Bismuth-containing Quadruple Therapy With Amoxicillin and Clarithromycin Based Quadruple Therapy for First-line Helicobacter Pylori Eradication[NCT02175901] | Phase 4 | 215 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Efficacy and Safety of Quadruple Therapy by Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given X 10 Days With Omeprazole in Eradication of Helicobacter Pylori: A Comparison to Omeprazole, Amoxicillin and Clarithromycin Given X 7 Days[NCT00669955] | Phase 3 | 440 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Tailored Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Randomized Trial[NCT02635191] | Phase 4 | 200 participants (Anticipated) | Interventional | 2014-03-31 | Recruiting | ||
| Dyspeptic Symptoms Evolution After Eradication of Helicobacter Pylori in Patients With Different Endoscopic Findings: a Randomized Double-blind Placebo-controlled Clinical Trial With 12 Months of Follow-up[NCT00404534] | Phase 3 | 407 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Prospective Randomized Trial of Levofloxacin-amoxicillin Triple Therapy vs. Levofloxacin-tetracycline Quadruple Therapy in Second-line Helicobacter Pylori Treatment[NCT02978157] | 102 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Personalized Treatment for Refractory H Pylori Infection[NCT02547025] | 126 participants (Actual) | Interventional | 2012-08-01 | Completed | |||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| Comparative Recurrence Rate Investigation of Esomeprazole Versus Lansoprazole in Triple-Combination Therapy to Eradicate Helicobacter Pylori Infection Among Pediatrics: Multicentre, Randomized, and Controlled Trials[NCT05861687] | Phase 2/Phase 3 | 51 participants (Actual) | Interventional | 2021-08-01 | Completed | ||
| High Eradication Rates of Helicobacter Pylori With a New Sequential Treatment[NCT00132171] | Phase 3 | 1,000 participants | Interventional | 2001-01-31 | Completed | ||
| A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Stra[NCT02959255] | Phase 4 | 364 participants (Actual) | Interventional | 2017-01-30 | Completed | ||
| Rifaximin Associated With Classic Triple Therapy (Inhibitor of Proton Pump, Amoxicillin and Clarithromycin) for the Eradication of Helicobacter Pylori Infection[NCT03124199] | Phase 3 | 40 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| European Registry on the Management of Helicobacter Pylori Infection[NCT02328131] | 10,000 participants (Anticipated) | Observational | 2013-06-30 | Recruiting | |||
| the Effect of Daily Use of Proton Pump Inhibitors for One Month on Renal Function[NCT03910647] | Phase 2 | 200 participants (Anticipated) | Interventional | 2019-12-31 | Not yet recruiting | ||
| Randomized, Controlled, Multicenter Phase III Study for the Efficacy and Tolerability of Triple Therapy With Esomeprazole, Moxifloxacin and Amoxicillin for Rescue Therapy of Helicobacter Pylori Infection[NCT00455806] | Phase 3 | 132 participants | Interventional | 2007-01-31 | Recruiting | ||
| Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain[NCT00365976] | Phase 4 | 58 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Bismuth Quadruple Therapy in Helicobacter Pylori Rescue Therapy: A Multicenter Randomized Non-Inferiority Trial of Different Tetracycline Doses and Frequencies.[NCT05802888] | Phase 4 | 260 participants (Anticipated) | Interventional | 2023-03-12 | Recruiting | ||
| Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment: A Multicenter Randomized Clinical Trial of Different Tetracycline Doses and Frequencies.[NCT05431075] | Phase 4 | 407 participants (Anticipated) | Interventional | 2022-07-31 | Not yet recruiting | ||
| Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy: A Multicenter Randomized Non-Inferiority Trial of Different Tetracycline Doses and Frequencies.[NCT05432115] | Phase 4 | 407 participants (Anticipated) | Interventional | 2022-06-25 | Recruiting | ||
| Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors[NCT00204373] | Phase 4 | 72 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B[NCT02759393] | Phase 4 | 200 participants (Anticipated) | Interventional | 2015-10-31 | Enrolling by invitation | ||
| Sequential Therapy Versus Triple Therapy for Helicobacter Pylori Eradication: a Placebo-controlled Trial[NCT00403364] | Phase 2/Phase 3 | 300 participants | Interventional | 2003-07-31 | Completed | ||
| Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori[NCT00149084] | Phase 3 | 296 participants | Interventional | 2003-04-30 | Recruiting | ||
| Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features in a Primary Care Setting: A Pragmatic, Randomized, Single Blind Study[NCT04028466] | Phase 4 | 82 participants (Actual) | Interventional | 2019-05-26 | Terminated (stopped due to Budget for the study was withdrawn and discontinued) | ||
| Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial[NCT01269788] | Phase 2/Phase 3 | 144 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of Mucosa-associated Lymphoid Tissue Type of The Stomach[NCT00201422] | 70 participants (Actual) | Interventional | 1996-06-30 | Completed | |||
| Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection[NCT00656968] | Phase 4 | 232 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Treatment of Low-Grade Gastric Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type Stages IE & II1E (HELYX-Study)[NCT00154440] | Phase 3 | 200 participants | Interventional | 2001-11-30 | Recruiting | ||
| Premedication With Simethicone and N-acetylcysteine in Improving Mucosal Visibility During Upper Endoscopy - a Prospective Double-blinded Randomized Controlled Trial[NCT02357303] | Phase 4 | 300 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis[NCT01524757] | 48 participants (Anticipated) | Interventional | 2012-03-31 | Not yet recruiting | |||
| Open Label, Randomized, Single Site Clinical Trial To Compare The Safety Of Herbal Melanin Extracted From Nigella Sativa Seeds Vs Standard Of Care Treatment In Treating Gastritis Patients[NCT03428568] | Phase 2 | 132 participants (Anticipated) | Interventional | 2018-03-31 | Not yet recruiting | ||
| Phase IV Study Comparing Helicobacter Pylori Empiric Eradication With Test-Guided Treatment in Patients With Peptic Ulcer Bleeding[NCT00687336] | Phase 4 | 178 participants (Anticipated) | Interventional | 2008-03-31 | Recruiting | ||
| Helicobacter Pylori Eradication and Motor Fluctuations in Parkinson's Disease[NCT00664209] | Phase 3 | 64 participants (Actual) | Interventional | 2008-01-31 | Terminated (stopped due to Prevalence of H Pylori in the study population was much lower than anticipated) | ||
| Efficacy and Safety of Black Seed Oil With Vonoprazan Based Triple Therapy in Treatment of Helicobacter Pylori[NCT05957432] | Phase 2 | 90 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Eradication of H. pylori confirmed via 13C Urea Breath Test (UBT) testing. Subjects with negative test results (eradication of H. pylori) were considered treatment successes. Subjects who tested positive for H. pylori infection (no eradication) were considered treatment failures. (NCT03198507)
Timeframe: 43-71 days after initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| RHB-105 | 191 |
| Active Comparator | 131 |
"A pre-specified responder analysis of eradication of H. pylori confirmed via 13C Urea Breath Test (UBT) was performed in the PK population.~The PK population was generated based on the measurement of plasma concentrations of amoxicillin, omeprazole, rifabutin, and the rifabutin metabolite 25-O-desacetyl-rifabutin (on Day 13). It included those subjects in the FAS who had demonstrable presence of any component of investigational drug at Visit 3 or had no levels detected >250 hours after the last dose. For all subjects, the reason for exclusion from the PKP was the absence of any pharmacokinetic component of study drug at Visit 3 within 250 hours of the last reported dose. Two hundred fifty hours was selected to account for approximately 10 times the terminal half-life of rifabutin." (NCT03198507)
Timeframe: 43-71 days after initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| RHB-105 | 187 |
| Active Comparator | 119 |
The number of participants that presented treatment emergent adverse events (TEAE) during the study overall, TEAEs related to study drug and severe TEAEs. (NCT03198507)
Timeframe: After first dose of study drug until 28 days following last dose.
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| No. of subjects with any TEAE | No. of subjects with any study drug related TEAE | No. of subjects with any severe TEAE | |
| Active Comparator | 72 | 44 | 4 |
| RHB-105 | 83 | 47 | 4 |
"The primary endpoint was summarized within subgroups formed by the presence of H. pylori susceptibility and resistance to amoxicillin, clarithromycin, metronidazole, and rifabutin from H. pylori cultures from samples obtained prior to initiating study treatment (i.e. baseline).~A participant is considered a responder when H. pylori is eradicated after treatment as confirmed via 13C Urea Breath Test (UBT). A participant is considered a non-responder when H. pylori is not eradicated after treatment." (NCT03198507)
Timeframe: 43-71 days after initiation of treatment
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rifabutin resistant72525830 | Rifabutin resistant72525831 | Rifabutin Susceptible72525830 | Rifabutin Susceptible72525831 | Amoxicillin Resistant72525830 | Amoxicillin Resistant72525831 | Amoxicillin Susceptible72525830 | Amoxicillin Susceptible72525831 | Clarithromycin Resistant72525831 | Clarithromycin Resistant72525830 | Clarithromycin Susceptible72525831 | Clarithromycin Susceptible72525830 | Metronidazole Resistant72525830 | Metronidazole Resistant72525831 | Metronidazole Susceptible72525830 | Metronidazole Susceptible72525831 | |||||||||||||||||
| Responder | Non-responder | |||||||||||||||||||||||||||||||
| RHB-105 | 0 | |||||||||||||||||||||||||||||||
| Active Comparator | 0 | |||||||||||||||||||||||||||||||
| RHB-105 | 147 | |||||||||||||||||||||||||||||||
| Active Comparator | 99 | |||||||||||||||||||||||||||||||
| RHB-105 | 27 | |||||||||||||||||||||||||||||||
| Active Comparator | 72 | |||||||||||||||||||||||||||||||
| RHB-105 | 9 | |||||||||||||||||||||||||||||||
| Active Comparator | 4 | |||||||||||||||||||||||||||||||
| Active Comparator | 5 | |||||||||||||||||||||||||||||||
| RHB-105 | 138 | |||||||||||||||||||||||||||||||
| Active Comparator | 95 | |||||||||||||||||||||||||||||||
| Active Comparator | 67 | |||||||||||||||||||||||||||||||
| RHB-105 | 21 | |||||||||||||||||||||||||||||||
| Active Comparator | 22 | |||||||||||||||||||||||||||||||
| RHB-105 | 4 | |||||||||||||||||||||||||||||||
| Active Comparator | 13 | |||||||||||||||||||||||||||||||
| RHB-105 | 126 | |||||||||||||||||||||||||||||||
| Active Comparator | 77 | |||||||||||||||||||||||||||||||
| RHB-105 | 23 | |||||||||||||||||||||||||||||||
| Active Comparator | 59 | |||||||||||||||||||||||||||||||
| RHB-105 | 57 | |||||||||||||||||||||||||||||||
| Active Comparator | 45 | |||||||||||||||||||||||||||||||
| RHB-105 | 14 | |||||||||||||||||||||||||||||||
| Active Comparator | 34 | |||||||||||||||||||||||||||||||
| RHB-105 | 90 | |||||||||||||||||||||||||||||||
| Active Comparator | 53 | |||||||||||||||||||||||||||||||
| RHB-105 | 13 | |||||||||||||||||||||||||||||||
| Active Comparator | 38 | |||||||||||||||||||||||||||||||
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (Number of Participants With Complete Eradication of Helicobacter Pylori) (NCT02547038)
Timeframe: sixth week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 169 |
| (Panto+Amox+Clar+Metr)+(Panto+Amox) | 170 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02547012)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo+Tetra | 13 |
| Esomeprazole+Amox+Levo | 21 |
Questionnaire to measure the number of Participants with Treatment-Emergent Adverse Events (NCT04039412)
Timeframe: 10-14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 49 |
| (2) Hybrid Regimen | 58 |
| (3) Levofloxacin Quadruple Regimen | 44 |
Measuring the curative rate of each regimen by a fecal antigen test (NCT04039412)
Timeframe: 40-44 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 102 |
| (2) Hybrid Regimen | 101 |
| (3) Levofloxacin Quadruple Regimen | 91 |
Questionnaire to evaluate the compliance with each treatment regimen (NCT04039412)
Timeframe: 10-14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 109 |
| (2) Hybrid Regimen | 107 |
| (3) Levofloxacin Quadruple Regimen | 108 |
(NCT00251979)
Timeframe: Within 30 days
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 29 |
| Placebo | 53 |
(NCT00251979)
Timeframe: Within 7 days
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 27 |
| Placebo | 50 |
(NCT00251979)
Timeframe: Within 72 hours
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 22 |
| Placebo | 40 |
(NCT00251979)
Timeframe: Within 30 days
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 2 |
| Placebo | 3 |
(NCT00251979)
Timeframe: Within 30 days
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 3 |
| Placebo | 8 |
(NCT00251979)
Timeframe: Within 72 hours
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 1 |
| Placebo | 0 |
(NCT00251979)
Timeframe: within 30 days
| Intervention | blood units (Number) |
|---|---|
| Esomeprazole | 589 |
| Placebo | 935 |
(NCT00251979)
Timeframe: Within 72 hours
| Intervention | blood units (Number) |
|---|---|
| Esomeprazole | 492 |
| Placebo | 738 |
(NCT00251979)
Timeframe: Within 30 days
| Intervention | days (Number) |
|---|---|
| Esomeprazole | 284 |
| Placebo | 500 |
(NCT00251979)
Timeframe: Within 30 days
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 24 |
| Placebo | 45 |
(NCT00251979)
Timeframe: Within 72 hours
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 16 |
| Placebo | 32 |
(NCT00251979)
Timeframe: Within 30 days
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 10 |
| Placebo | 21 |
(NCT00251979)
Timeframe: Within 72 hours
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole | 5 |
| Placebo | 9 |
Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests are conducted to assess H. pylori status. (NCT02541864)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 154 |
| Hybrid Therapy | 154 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02359435)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Reverse Hybrid Therapy | 206 |
| Standard Triple Therapy | 191 |
Eradication rates in subset of patients infected with a bacterial strain confirmed as resistant to clarithromycin at baseline. Resistance to clarithromycin defined as Minimum Inhibitory Concentration (MIC) of 1 ug/ml and above (NCT00669955)
Timeframe: Measured at baseline
| Intervention | participants (Number) |
|---|---|
| Quadruple Therapy (OBMT) 10 Days | 30 |
| Triple Therapy (OAC) 7 Days | 2 |
Eradication rates in the subset of patients with peptic ulcer (current or past history) at baseline are reported based on the per protocol population. Eradication must be confirmed at week 6 and week 10 by a negative Urea Breath Test conducted within the allocated windows. (NCT00669955)
Timeframe: Week 6 and week 10 follow-up visits
| Intervention | Participants (Number) |
|---|---|
| Quadruple Therapy (OBMT) 10 Days | 18 |
| Triple Therapy (OAC) 7 Days | 15 |
H. pylori Eradication defined as a negative C13-UBT (urea breath test) result at both Week 6 and Week 10 follow-up visits. (NCT00669955)
Timeframe: Week 6 and week 10 follow-up visits
| Intervention | Participants (Number) |
|---|---|
| Quadruple Therapy (OBMT) 10 Days | 166 |
| Triple Therapy (OAC) 7 Days | 112 |
Eradication rates in subset of patients infected with a bacterial strain confirmed as resistant to metronidazole at baseline. Resistance to metronidazole defined as Minimum Inhibitory Concentration (MIC) above 8 ug/ml (NCT00669955)
Timeframe: Measured at baseline
| Intervention | participants (Number) |
|---|---|
| Quadruple Therapy (OBMT) 10 Days | 38 |
| Triple Therapy (OAC) 7 Days | 28 |
"A treatment-emergent adverse event is defined as an event not present prior to exposure to the study medication or any event already present that worsens in either intensity or frequency following exposure to study medication up to 30 days after study discontinuation.~All safety analysis based on the safety population." (NCT00669955)
Timeframe: at the end of treatment (day 8-14), week 6 and wek 10 follow-up visits.
| Intervention | Participants (Number) |
|---|---|
| Quadruple Therapy (OBMT) 10 Days | 101 |
| Triple Therapy (OAC) 7 Days | 112 |
Tolerability of OBMT with respect to plasma bismuth concentrations: number of patients with bismuth concentrations above the toxic level (50 ug per liter) (NCT00669955)
Timeframe: Baseline (both arms), end of treatment (Day 11-14) and end of study (Day 70) OBMT arm only
| Intervention | participants (Number) |
|---|---|
| Quadruple Therapy (OBMT) 10 Days | 0 |
Overall compliance: number of capsules dispensed - number of capsules returned/Number of prescribed capsules X 100. Percentages based on safety population (NCT00669955)
Timeframe: At the end of the treatment phase (days 8-14)
| Intervention | participants (Mean) |
|---|---|
| Quadruple Therapy (OBMT) 10 Days | 97.58 |
| Triple Therapy (OAC) 7 Days | 97.47 |
Number of participants with negative H pylori status in follow-up tests as a measure of successful eradication (NCT02978157)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo | 36 |
| Esomeprazole+Bismuth+Tetra+Levo | 49 |
Percentage of patients that has comply with treatment, considered as intake of more than 90% of study drugs in patients who attended the post-treatment visit. (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 100 |
Percentage of Participants with H.Pylori Infection Eradication confirmed with urea breath test at least 4 weeks after the end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 61 |
Patients with side effects present during treatment and in the 4 weeks after end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| with diarrhea | with metallic taste | headache | nausea | abdominal pain | |
| Rifaximin | 13 | 9 | 5 | 5 | 1 |
The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe. (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 6.45 | 6.38 | 4.54 | 4.14 | 2.62 |
| Placebo | 7.10 | 6.57 | 5.53 | 5.07 | 6.21 |
The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0-28: 0-7 (no clinical insomnia), 8-14 (subthreshold insomnia), 15-21 (insomnia of moderate severity), and 22-28 (severe insomnia). (NCT00365976)
Timeframe: Prenaprosyn Baseline, Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Prenaprosyn Baseline | Postnaprosyn baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 18.85 | 18.00 | 11.28 | 10.61 | 8.38 |
| Placebo | 20.26 | 16.78 | 12.85 | 12.74 | 13.75 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | minutes (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 38.28 | 22.36 | 17.50 | 15.28 |
| Placebo | 34.11 | 27.00 | 23.10 | 19.91 |
Nightly total sleep time was averaged from diary entries. (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, week 2, week 4
| Intervention | Minutes (Mean) | |||
|---|---|---|---|---|
| postnaprosyn baseline | week 1 | week 2 | Week 4 | |
| Eszopiclone | 316.96 | 403.47 | 421.97 | 411.97 |
| Placebo | 380.45 | 375.56 | 382.11 | 388.96 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | awakenings (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 2.29 | 1.31 | 1.35 | 1.33 |
| Placebo | 2.08 | 1.98 | 2.13 | 2.34 |
Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain) (NCT00365976)
Timeframe: postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 4.02 | 3.54 | 3.30 | 3.08 |
| Placebo | 3.90 | 3.82 | 4.01 | 3.80 |
"The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 yes-no items assessing potential disabilities.~Scores range from 0 (no disability) to 24 (severe disability)." (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 12.27 | 9.97 | 9.10 | 7.63 | 6.59 |
| Placebo | 11.33 | 10.30 | 9.05 | 9.32 | 7.94 |
Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep (NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 4.52 | 5.99 | 6.18 | 6.38 |
| Placebo | 4.44 | 4.90 | 5.33 | 5.29 |
Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, Week 2, Week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 48.51 | 40.72 | 34.70 | 31.69 |
| Placebo | 53.79 | 51.99 | 51.25 | 51.60 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | minutes (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 91.51 | 49.34 | 37.07 | 36.74 |
| Placebo | 81.43 | 76.71 | 81.32 | 76.18 |
number of participants with control of gastric acid production (NCT00204373)
Timeframe: up to 240 months from study enrollment
| Intervention | participants (Number) |
|---|---|
| Single Group | 72 |
The median survival from the time of diagnosis (NCT00204373)
Timeframe: survival or up to 240 months
| Intervention | years (Median) |
|---|---|
| Single Group | 6.6 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT00656968)
Timeframe: one month after finishing study drugs
| Intervention | participants (Number) |
|---|---|
| Concomitant Therapy (A) | 92 |
| Sequential Therapy (B) | 95 |
Good drug compliance is defined as taking equal to or more than 80% of eradication medicines (NCT00656968)
Timeframe: one month after finishing test therapy
| Intervention | participants (Number) |
|---|---|
| Concomitant Therapy (A) | 106 |
| Sequential Therapy (B) | 104 |
Side effects profile (NCT00664209)
Timeframe: 2 months
| Intervention | participants (Number) |
|---|---|
| Active | 0 |
267 reviews available for omeprazole and Infections, Helicobacter
| Article | Year |
|---|---|
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
Topics: Animals; Anti-Ulcer Agents; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Humans; | 2007 |
Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2023 |
Gastric MALT lymphoma and Helicobacter pylori.
Topics: Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Resistance, Multiple, Bacterial; Drug Ther | 2019 |
[The role of Helicobacter pylori in occurrence of the digestive system pathologic processes].
Topics: Anti-Bacterial Agents; Digestive System Diseases; Drug Therapy, Combination; Gastric Mucosa; Helicob | 2014 |
Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and Helicobacter pylori infection.
Topics: Esomeprazole; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Omepraz | 2015 |
Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.
Topics: Adult; Anti-Ulcer Agents; Duodenal Ulcer; Esomeprazole; Gastroesophageal Reflux; Helicobacter Infect | 2008 |
What is new in the management of Helicobacter pylori?
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infecti | 2008 |
Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Administration Schedule; Esomeprazole; Helicobacter In | 2008 |
Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration | 2009 |
Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Contr | 2008 |
Effect of proton pump inhibitors on vitamins and iron.
Topics: Absorption; Ascorbic Acid; Biological Availability; Gastric Juice; Helicobacter Infections; Helicoba | 2009 |
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
Pylera for the eradication of Helicobacter pylori infection.
Topics: Administration, Oral; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Capsules; Drug Ad | 2009 |
[Ulcer disease: challenging problems of etiology, pathogenesis, differential treatment].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Antioxidants; Disease Management; Drug Resistance, Multipl | 2012 |
Esomeprazole magnesium (Nexium).
Topics: Anti-Ulcer Agents; Esomeprazole; Esophagitis; Gastroesophageal Reflux; Helicobacter Infections; Huma | 2001 |
Esomeprazole: a clinical review.
Topics: Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Esomepraz | 2002 |
[Treatment of NSAID-associated gastric ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2002 |
[Reflux esophagitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Esophagitis, Peptic; Gastritis, Atrophic; | 2002 |
[Eradication therapy of Helicobacter pylori for elderly patients in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; | 2002 |
[Several points that should be noticed during PPI treatment for peptic ulcers in elderly patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Drug Interactions; Helicobacter In | 2002 |
Motion--Helicobacter pylori worsens GERD: arguments for the motion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials a | 2002 |
Motion--Helicobacter pylori causes or worsens GERD: arguments against the motion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Enzyme Inhibit | 2002 |
[Helicobacter pylori induced gastritis: recent topics on eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combinati | 2002 |
Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2003 |
What's new: proton pump inhibitors and pediatrics.
Topics: Child; Dyspepsia; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Ome | 2003 |
Review of esomeprazole in the treatment of acid disorders.
Topics: Anti-Ulcer Agents; Dose-Response Relationship, Drug; Esomeprazole; Esophagitis, Peptic; Gastric Acid | 2003 |
[New triple therapy for Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Hel | 2003 |
[Tailor-made medicine in Helicobacter pylori eradication therapy].
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Helicobacter Infections; Helicobacter pylor | 2003 |
Extragastric mucosa-associated lymphoid tissue lymphoma showing the regression by Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Aged; Amoxicillin; Clarithromycin; Drug The | 2003 |
Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Helicobacter Infections; | 2003 |
Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2003 |
[Guidelines in the management of Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Gas | 2003 |
Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Drug The | 2003 |
Helicobacter pylori infection in patients with liver cirrhosis: facts and fictions.
Topics: Ammonia; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; | 2003 |
How can the current strategies for Helicobacter pylori eradication therapy be improved?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2003 |
Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; D | 2003 |
Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Apoptosis; Chemistry, Clinical; Clari | 2003 |
Proton pump inhibitors in children: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Drug Interactions; Esophagitis, P | 2003 |
[The treatment of Helicobacter pylori infection in upper gastrointestinal disorders].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Dyspepsia; Gastritis; Gastrointes | 2003 |
Epigastric pain in dyspepsia and reflux disease.
Topics: Abdominal Pain; Anti-Ulcer Agents; Drug Therapy, Combination; Dyspepsia; Gastroesophageal Reflux; He | 2003 |
[Clarithromycin--standard component of anti-Helicobacter therapy].
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter; Helicobacter Infecti | 2003 |
[Eradication effect of lansoprazole-based triple therapy against H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2004 |
Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Benzimidazoles; Drug Therapy, Combin | 2004 |
Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; H | 2004 |
Understanding NSAID-PPI-COX-2 interrelationships.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzimida | 2004 |
Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2004 |
Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastric Ac | 2004 |
[Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Female; | 2004 |
[Proton pump inhibitors as the basis of anti-helicobacter therapeutic schemes].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Fe | 2004 |
Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Benzimidazoles; D | 2004 |
[Evaluation of the efficacy of an Helicobacter pylori eradication treatment for idiopathic thrombocytopenic purpura patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Infective Agents; Clarithromycin; D | 2004 |
[Peptic ulcer disease etiology, diagnosis and treatment].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Child; Gastroscopy; Helicobacter | 2004 |
Helicobacter heilmannii infection in a child after successful eradication of Helicobacter pylori: case report and review of literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chil | 2005 |
[Diagnosis of and therapy for peptic ulcer].
Topics: Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clarithromycin; Drug Therap | 2005 |
Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Famotidine; Gastroesophageal Reflux; H | 2005 |
Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastric Acid; Gastroesop | 2005 |
Cost-effectiveness of a 'score and scope' strategy for the management of dyspepsia.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Cost-Benefit Analysis; Decision Trees; Diagn | 2005 |
Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clin | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Review article: the long-term use of proton-pump inhibitors.
Topics: Age Factors; Enzyme Inhibitors; Gastritis, Atrophic; Gastroesophageal Reflux; Helicobacter Infection | 2005 |
[Eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2005 |
Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Benzimidazoles; Helicobacte | 2005 |
CYP2C19 genotype and the PPIs--focus on rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Aryl Hydrocar | 2005 |
[Guidelines in the management of H. pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 2005 |
[Establishment of 2nd line treatment regimen for H. pylori infection--future prospect for the application for national health insurance system in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Drug Therapy, Combination; Hel | 2005 |
[Cap polyposis and Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Cla | 2005 |
[Recent topics on important drugs for H. pylori eradication: Omeprazole].
Topics: Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Drug Therapy, Combin | 2005 |
[Recent topics on important drugs for H. pylori eradication: Lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Drug Therapy, Combination; | 2005 |
[Recent topics on important drugs for H. pylori eradication: Rabeprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Benzi | 2005 |
[Recent topics on important drugs for H. pylori eradication: Pantoprazole sodium].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Benzimidazoles; Drug Therapy, Combin | 2005 |
[Quality of ulcer healing and rebamipide].
Topics: Alanine; Amoxicillin; Animals; Anti-Ulcer Agents; Antioxidants; Cytokines; Drug Therapy, Combination | 2005 |
[Concomitant dosing of a H2 receptor antagonist (H2RA) with a triple therapy increases the cure rate of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; | 2005 |
[Triple therapy for eradication of Helicobacter pylori in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Re | 2005 |
[Adverse effects of Helicobacter pylori eradication and its prevention].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 2005 |
[Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Re | 2005 |
[Second-line eradication therapy for H. pylori infection--PPI+AMPC+MNZ triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Drug Resistance, Bacterial; Dr | 2005 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydrox | 2005 |
[Comparison between one-week and two-week regimens of new triple therapy in H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Enzyme | 2005 |
[Investigation about 3rd line eradication of H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ampicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxy | 2005 |
[Helicobacter pylori eradication therapy for children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents | 2005 |
[Eradication therapy for the remnant stomach infected with Helicobacter pylori ].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; En | 2005 |
[Eradication of Helicobacter pylori in patients with end-stage renal disease undergoing dialysis treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dialysi | 2005 |
[Gastroduodenal erosions observed after Helicobacter pylori eradication].
Topics: Adult; Amoxicillin; Clarithromycin; Duodenitis; Helicobacter Infections; Helicobacter pylori; Histam | 2005 |
[Influence of cytochrome P450 2C19 genetic polymorphism on H. pylori eradication therapy].
Topics: Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 | 2005 |
[Cytochrome P450 2C19 genotype -based second line therapy with amoxicillin and lansoprazole after failure of initial helicobacter pylori eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydrox | 2005 |
[Is the successful eradication of Helicobacter pylori sufficient for the healing of peptic ulcer?].
Topics: Antacids; Anti-Ulcer Agents; Drug Administration Schedule; Helicobacter Infections; Helicobacter pyl | 2006 |
Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cardiova | 2006 |
A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribution; Dose-Response Relationship, Drug; | 2006 |
The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2006 |
[Proton pump inhibitors in developmental period medicine].
Topics: Adult; Age Factors; Anti-Ulcer Agents; Child; Drug Interactions; Duodenitis; Enzyme Inhibitors; Esom | 2007 |
CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Biotransf | 2007 |
High grade B-cell gastric lymphoma with complete pathologic remission after eradication of Helicobacter pylori infection: report of a case and review of the literature.
Topics: Adult; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter | 2008 |
Pylera plus omeprazole: quadruple treatment for Helicobacter pylori.
Topics: Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Capsules; Drug Therapy, Combination; He | 2008 |
[Functional dyspepsia: approaches to Helicobacter pylori eradication therapy].
Topics: Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyspepsia; Gastritis | 1995 |
[Lansoprazol].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Controlled Clinical Trials as Topic; Duo | 1995 |
The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice?
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Resistan | 1995 |
[How to use proton pump inhibitors and histamine H2 antagonists in the therapy of peptic ulcer].
Topics: Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Omeprazol | 1995 |
Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole shown in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Cells, Cultured; Chemotherapy, Adjuvant; Duodenal | 1995 |
Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole in clinical studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Chemotherapy, Adj | 1995 |
The potential value of lansoprazole in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter | 1995 |
Helicobacter pylori: the place of the new macrolides in the eradication of the bacteria in peptic ulcer disease.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combinatio | 1995 |
[Helicobacter pylori eradication therapy with omeprazole and amoxicillin: current status].
Topics: Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Helicobacter Infections; Helicobacter p | 1994 |
The role of omeprazole and antibiotic combinations in the eradication of Helicobacter pylori--an update.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter | 1994 |
Treatment strategies for symptom resolution, healing, and Helicobacter pylori eradication in duodenal ulcer patients.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; | 1994 |
[Controversies and trends in ulcer therapy. 2: Prevention of recurrence].
Topics: Adult; Aged; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylor | 1993 |
Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastritis; Gastroesophag | 1993 |
Omeprazole, Helicobacter pylori, and gastritis.
Topics: Amoxicillin; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicoba | 1994 |
Hp and pH--the relevance of gastric acid to the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Drug Therapy, Combination; Gastric Acid; Gastric Mucosa; Gastrins; Helicobacter Infecti | 1994 |
[How to eradicate Helicobacter pylori?].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combina | 1994 |
Antibacterial therapy of Helicobacter pylori-associated peptic ulcer disease: a new strategy. The Swedes go for it.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Inf | 1994 |
Helicobacter pylori in peptic ulcer disease.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Hel | 1994 |
[Helicobacter pylori therapy with omeprazole and clarithromycin: current status].
Topics: Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Ome | 1994 |
Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence.
Topics: Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infecti | 1994 |
Review article: Helicobacter pylori eradication--understandable caution but no excuse for inertia.
Topics: Anti-Bacterial Agents; Attitude of Health Personnel; Clinical Trials as Topic; Drug Administration S | 1994 |
The role of acid inhibition in the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Depression, Chemical; Drug Administration Schedule; Drug Therapy, Combination; Gastric | 1994 |
The role of Helicobacter pylori in peptic ulcer disease.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helic | 1994 |
Emerging strategies for managing peptic ulcer disease.
Topics: Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Depression, Chemical; Drug Therapy, Combinatio | 1994 |
Refractory peptic lesions. Therapeutic strategies for ulcers and reflux esophagitis that resist standard regimens.
Topics: Anti-Ulcer Agents; Chronic Disease; Clinical Protocols; Combined Modality Therapy; Drug Therapy, Com | 1993 |
Gastric acid secretion and intragastric acidity: measurement in health and disease.
Topics: Duodenal Ulcer; Female; Gastric Acid; Gastric Acidity Determination; Gastroesophageal Reflux; Helico | 1993 |
Acid pump blockers: what are their current therapeutic roles?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Gastroesophageal Reflux; | 1993 |
[Current therapy of Helicobacter pylori infection].
Topics: Amoxicillin; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Helicobacter Infe | 1994 |
Effect of lansoprazole on Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Drug Therapy, Combination; Dyspepsia; Helicoba | 1993 |
[Activity of Lansoprazole (new proton pump inhibitor) against Helicobacter pylori and its therapeutic efficacy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Helicobacter Infections; Helicobacter pylori; Humans; Lanso | 1993 |
Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment.
Topics: Amoxicillin; Bismuth; Cimetidine; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter | 1993 |
[Treatment of Helicobacter pylori infection: current status].
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Sch | 1995 |
Review article: the development of atrophic gastritis--Helicobacter pylori and the effects of acid suppressive therapy.
Topics: Animals; Anti-Ulcer Agents; Follow-Up Studies; Gastric Juice; Gastritis, Atrophic; Helicobacter Infe | 1995 |
[Omeprazole and amoxycillin in the eradicating treatment of Helicobacter pylori].
Topics: Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pyl | 1995 |
The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Cost-Benef | 1996 |
Triple therapy and Helicobacter pylori.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; | 1996 |
Helicobacter pylori eradication: the best long-term prophylaxis for ulcer bleeding recurrence?
Topics: Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; | 1995 |
[Reconsider management of Helicobacter pylori infections. Time to go over to the triple therapy].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials as Topic; Drug Therapy, Combination; Helic | 1996 |
[Are proton pump inhibitors superior to H2 receptor antagonists within the scope of H. pylori eradication therapy? Meta analysis of current parallel group comparisons].
Topics: Anti-Ulcer Agents; Enzyme Inhibitors; Gastric Acidity Determination; Helicobacter Infections; Helico | 1996 |
[Treatment of Helicobacter pylori infection].
Topics: Adolescent; Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Drug Therapy, | 1996 |
Review of Helicobacter pylori eradication regimens.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combin | 1996 |
Eradication of Helicobacter pylori: omeprazole in combination with antibiotics.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter I | 1996 |
[How to eradicate Helicobacter pylori in 1995? Critical review of available treatments].
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Thera | 1996 |
Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter In | 1996 |
Strategies for Helicobacter pylori eradication in 1995: a review of international and Belgian experience.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Belgium; Clarithromycin; Drug Therapy, Combin | 1996 |
Cost-effectiveness of H. pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Helicobacter | 1996 |
Lansoprazole and omeprazole in the treatment of acid peptic disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Drug Interacti | 1996 |
[Helicobacter pylori eradication: triple therapy versus dual therapy].
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Com | 1996 |
A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Dyspepsia; H | 1996 |
Helicobacter pylori infection. The importance of eradication in patients with gastric disease.
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter | 1996 |
Triple therapy as a cure for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimi | 1996 |
Efficacy of clarithromycin in eradicating Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibito | 1996 |
Eradication of Helicobacter pylori: an objective assessment of current therapies.
Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Hel | 1997 |
[What is the current therapeutic role of omeprazole in gastroduodenal ulcer disease?].
Topics: Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; | 1997 |
[Helicobacter pylori eradication: modified triple therapy with lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter | 1996 |
The role of antisecretory drugs in the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Syner | 1997 |
The role of antisecretory drugs in the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Syner | 1997 |
The role of antisecretory drugs in the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Syner | 1997 |
The role of antisecretory drugs in the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Syner | 1997 |
Helicobacter pylori: new developments and treatments.
Topics: Algorithms; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Hel | 1997 |
Treatment strategies for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combin | 1997 |
[Diagnosis and treatment of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Bacteriological Techniques; Clarithromycin; Dr | 1997 |
Treatment of Helicobacter pylori infection: a review of the world literature.
Topics: Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Micro | 1996 |
Clarithromycin dual therapy regimens for eradication of Helicobacter pylori: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; C | 1997 |
Therapy of H. pylori infection.
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Clarithromycin; | 1997 |
Proton-pump inhibitors for gastric acid-related disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Gastric Acid; Helicobacter | 1998 |
Rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 1998 |
Amoxycillin dual therapy against Helicobacter pylori--the final nail in the coffin?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Clinical Trials as Topic; Dru | 1997 |
Should Helicobacter pylori be eradicated before starting long-term proton pump inhibitors?
Topics: Anti-Ulcer Agents; Atrophy; Gastric Acid; Gastric Mucosa; Gastritis; Gastroesophageal Reflux; Helico | 1997 |
Is the sensitivity to gastric acid inhibition Helicobacter pylori status-dependent?
Topics: Enzyme Inhibitors; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagoni | 1998 |
[Gastric lesion caused by NSAID and inflammation due to Helicobacter pylori. Is there potentiation or attenuation?].
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials a | 1998 |
Current regimens for treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Antitrichomonal Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infecti | 1998 |
[Treatment of Helicobacter pylori infections].
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Thera | 1998 |
[Peptic ulcer due to Helicobacter pylori].
Topics: Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Gastric Acid; Gastric Mucosa; Helicobacter Infect | 1998 |
The impact of Helicobacter pylori eradication on peptic ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer | 1998 |
Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1998 |
Proton pump inhibitors.
Topics: Anti-Ulcer Agents; Drug Therapy, Combination; Enzyme Inhibitors; Gastroesophageal Reflux; H(+)-K(+)- | 1998 |
Different management for Helicobacter pylori positive and negative patients with gastro-oesophageal reflux disease?
Topics: Anti-Ulcer Agents; Barrett Esophagus; Duodenal Ulcer; Gastroesophageal Reflux; Helicobacter Infectio | 1998 |
Clinical relevance of resistant strains of Helicobacter pylori: a review of current data.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combinatio | 1998 |
Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Gastroesophageal Reflux; Helico | 1998 |
Eradication therapies for Helicobacter pylori.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combi | 1998 |
[Omeprazole plus 2 antibiotics for the eradication of H. pylori, are 5 days of treatment sufficient?].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 1998 |
[Role of pantoprazole in the eradicating treatment of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromy | 1998 |
Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 1998 |
Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Gastric Acid; Gastroesophagea | 1999 |
[History of the treatment of Helicobacter pylori and clinical efficacy].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Therapy, Combinati | 1999 |
[The role and significance of acid suppressive drugs in the eradication of H. pylori].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Depression, Chemical; Drug Therapy, Combination; Gastric A | 1999 |
[In a view of international consensus conference for the treatment of H. pylori infection].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Congresses as Topic; Drug Therapy, Combination; Europe; He | 1999 |
[Importance of drug selection and the use of sensitivity tests for the eradication therapy for Helicobacter pylori].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; | 1999 |
[The treatment strategy of H. pylori infection and the new triple therapy].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials as Topic; Drug Therapy, Combination; Helic | 1999 |
[Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1999 |
[Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials a | 1999 |
[Effect of the eradication of Helicobacter pylori on peptic ulcer healing].
Topics: Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Histological Te | 1999 |
[Effects of Helicobacter pylori eradication therapy on the healing process of peptic ulcers].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Helico | 1999 |
[Antibiotic resistance of Helicobacter pylori in Malmö. Therapeutic success in spite of antibiotic resistance].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, | 1999 |
[The breath test with labeled urea for the diagnosis of Helicobacter pylori infection].
Topics: Anti-Ulcer Agents; Bacterial Proteins; Breath Tests; Carbon Dioxide; Carbon Isotopes; Carbon Radiois | 1998 |
Gastro-oesophageal reflux and Helicobacter pylori.
Topics: Adenocarcinoma; Anti-Ulcer Agents; Barrett Esophagus; Diagnosis, Differential; Esophageal Neoplasms; | 1998 |
Antibiotic treatment of Helicobacter pylori infection.
Topics: Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Gastrointestinal Di | 1999 |
Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management.
Topics: Barrett Esophagus; Gastritis, Atrophic; Gastroesophageal Reflux; Helicobacter Infections; Helicobact | 1999 |
[Lansoprazole: a review of its role in Helicobacter pylori eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 1999 |
[Omeprazole and gastric protection].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials as Topic; Helicobacter I | 1999 |
Omeprazole plus antibiotics in the eradication of Helicobacter pylori infection: a meta-regression analysis of randomized, controlled trials.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Data Collection; Drug Therapy, Combination; Helicobacter I | 1999 |
[Mechanism of proton pump inhibitors in the treatment of Holicobacter pylori-associated ulcers].
Topics: Anti-Ulcer Agents; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inh | 1997 |
Review article: the pharmacology of rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimid | 1999 |
[Gastric solitary plasmacytoma associated with +Helicobacter pylori infection].
Topics: Adolescent; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Gastric Mucosa; Helicobacter I | 1999 |
Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 1999 |
Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroi | 1999 |
[Indications and use of omeprazole in esophago-gastro-duodenal diseases].
Topics: Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Esophageal Diseases; Esophagitis; Gastritis; | 1999 |
Microbial ecology and treatment of Helicobacter pylori infections: review.
Topics: Adenocarcinoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; | 2000 |
Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
Topics: Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome | 2000 |
Helicobacter pylori and idiopathic chronic urticaria.
Topics: Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Carbo | 2000 |
[Menetrier's disease. Another Helicobacter pylori associated disease?].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Female; Gastric Mucosa; Helicoba | 2000 |
Proton pump inhibitors and H. pylori infection: why the concern?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Enzyme Inhibitors; Gastritis, Atrophic; | 1999 |
Pantoprazole: a new proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2000 |
Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials as Topic; Enzyme Inhibit | 2001 |
[Recent guidelines for the management of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enz | 2001 |
[Selection of antibiotics and planning of eradication for H. pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Administr | 2001 |
[A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; | 2001 |
[Long-term results of conservative management of reflux esophagitis].
Topics: Age Factors; Anti-Ulcer Agents; Diet; Drug Therapy, Combination; Esophagitis, Peptic; Helicobacter I | 2001 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child | 2001 |
A review of omeprazole use in the treatment of acid-related disorders in children.
Topics: Administration, Oral; Adolescent; Adult; Anti-Ulcer Agents; Biological Availability; Child; Child, P | 2001 |
Helicobacter pylori and early duodenal ulcer status post-treatment: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clinical | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
[Pariet in current patterns of eradication of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Administration Sche | 2001 |
[Progress in study for mechanism of gastric mucosal injury].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion Molecules; Cytokines; Gastric Mucosa | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 2001 |
[Pharmacological study on the pathological changes of the gastric mucosa in Helicobacter pylori-infected Mongolian gerbils].
Topics: Adenocarcinoma; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer | 2001 |
Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infection | 2001 |
Rabeprazole: an update of its use in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2001 |
Changes in gastric mucosa and luminal environment during acid-suppressive therapy: a review in depth.
Topics: Anti-Ulcer Agents; Enterochromaffin-like Cells; Fundoplication; Gastric Mucosa; Gastritis, Atrophic; | 2001 |
[Progress of tailor-made treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylas | 2002 |
Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Esophagitis, | 2001 |
[Duodenal ulcer].
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; | 2002 |
Review article: rabeprazole-based therapy in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2002 |
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report.
Topics: Adult; Anti-Ulcer Agents; Child; Duodenal Ulcer; Germany; Helicobacter Infections; Helicobacter pylo | 2002 |
Problems associated with the clinical use of proton pump inhibitors.
Topics: Animals; Anti-Ulcer Agents; Carcinoid Tumor; Gastric Acid; Gastritis, Atrophic; Helicobacter Infecti | 2001 |
An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Digestive System Diseases; Duodenal Ulcer; Dyspepsia; Enzym | 2002 |
Combined analysis of the ORCHID and OCAY studies: does eradication of Helicobacter pylori lead to sustained improvement in functional dyspepsia symptoms?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind M | 2002 |
[The outline of medical treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Clari | 2002 |
[Guidelines for the management of Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Hel | 2002 |
[Guidelines of Helicobacter pylori eradication in children].
Topics: Amoxicillin; Breath Tests; Child; Clarithromycin; Drug Therapy, Combination; Europe; Gastroscopy; He | 2002 |
[New triple therapy for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Clinical Trials as Topic; Drug | 2002 |
[Dual therapy for Helicobacter pylori resistance to anti microbial agents].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Clinical Trial | 2002 |
[Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Bismuth; Clarithromycin; Drug | 2002 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2002 |
[Effect of PPI/AM re-treatment regimen for the patients with Helicobacter pylori infection after failure of first line eradication therapy by PPI/AC regimens].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enz | 2002 |
[Second line treatment regimen of PPI + AMPC + MNZ for patients with clarithromycin-resistant Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Clinical Trial | 2002 |
[Minocycline-containing eradication therapy for patients with clarithromycin-resistant Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clarithromycin; Drug Administration Schedul | 2002 |
[Ecabet sodium (ECA) + PPI + AMPC therapy for clarithromycin-resistant Helicobacter pylori infections].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; | 2002 |
[Eradication therapy for clarithromycin-resistant and metronidazole-resistant Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Administration Schedule; | 2002 |
[Adverse effects of H. pylori eradication therapy and its measure].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Clarithromycin; Diarrhea; Drug Therap | 2002 |
[Acute mucosal lesion of the upper-gastrointestinal tract observed after H. pylori-eradication].
Topics: Acute Disease; Amoxicillin; Clarithromycin; Esophagitis, Peptic; Gastric Acid; Gastric Mucosa; Helic | 2002 |
[H. pylori eradication therapy and natural history of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enz | 2002 |
[Continuation of acid suppression therapy after H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Benzimidazoles; Clinical Trials as Topic; Enzyme | 2002 |
[Intractable ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differe | 2002 |
[Prophylaxis against non-steroidal anti-inflammatory drug-associated ulcers and erosions].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygena | 2002 |
[Peptic ulcer in the elderly].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; | 2002 |
[Proton pump inhibitors: Omeprazole].
Topics: Amoxicillin; Clarithromycin; Clinical Trials as Topic; Depression, Chemical; Drug Therapy, Combinati | 2002 |
[Proton pump inhibitors: Rabeprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Depression, Ch | 2002 |
[Proton pump inhibitors: Efficacy of lansoprazole in eradicating Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Depression, Chemical; Drug The | 2002 |
[Amoxicillin (AMPC)].
Topics: Amoxicillin; Animals; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Heli | 2002 |
[Sucralfate].
Topics: Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Gastric Ac | 2002 |
[Plaunotol].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diterpenes; | 2002 |
[Sofalcone].
Topics: Amoxicillin; Anti-Ulcer Agents; Chalcone; Chalcones; Clarithromycin; Drug Resistance, Bacterial; Dru | 2002 |
[Ecabet sodium].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Animals; Anti-Ulcer Agents; Diterpe | 2002 |
[Polaprezinc].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Ulcer Agents; Carnosine; Clarith | 2002 |
[Non-ulcer dyspepsia and H. pylori].
Topics: Amoxicillin; Clarithromycin; Dyspepsia; Gastric Acid; Gastric Emptying; Helicobacter Infections; Hel | 2002 |
[Cause and prevention of nocturnal gastric acid breakthrough].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rh | 2002 |
[Helicobacter heilmannii-associated gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Clarithromycin; Drug Therapy, Combina | 2002 |
[Practice guidelines for diagnosis and treatment of Helicobacter pylori infections and their application in clinical practice].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Hel | 2002 |
Helicobacter pylori infection in skin diseases: a critical appraisal.
Topics: Amoxicillin; Clarithromycin; Clinical Trials as Topic; Comorbidity; Drug Therapy, Combination; Femal | 2002 |
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2002 |
Review article: esomeprazole in the treatment of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibito | 2002 |
Helicobacter pylori, peptic ulcer disease and inhibition of gastric acid secretion.
Topics: Amoxicillin; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Gastric Acid; Gast | 1992 |
[Omeprazole].
Topics: Esophagitis, Peptic; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer | 1992 |
[Proton pump blockade and Helicobacter pylori: status of current knowledge and clinical importance].
Topics: Amoxicillin; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer; Proton | 1992 |
[Gastropathies with nodules and enlarged folds].
Topics: Adult; Crohn Disease; Gastritis, Hypertrophic; Helicobacter Infections; Helicobacter pylori; Humans; | 1992 |
999 trials available for omeprazole and Infections, Helicobacter
| Article | Year |
|---|---|
Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; He | 2021 |
[A prospective randomized comparative study of the efficacy and safety of a two-week bismuth-based quadrotherapy of
Topics: Amoxicillin; Anti-Bacterial Agents; Bifidobacterium longum; Bismuth; Clarithromycin; Drug Therapy, C | 2021 |
Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study.
Topics: Amoxicillin; Anti-Ulcer Agents; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Duodenal Ulcer; | 2022 |
Comparative Study on Effect of Rabeprazole Versus Omeprazole in Acid-peptic Disorder with Helicobacter pylori Infection.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Cross-Sectional Studies; Drug Therapy, Combin | 2020 |
Efficacy of Omeprazole, Tetracycline, and 4 Times Daily Dosing of Amoxicillin in Helicobacter pylori Eradication in Limited Resource Area in Bhutan: A Prospective Randomized Trial (BHUTAN Study).
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bhutan; Developing Countries; Female; F | 2020 |
Rifabutin-Based Triple Therapy (RHB-105) for
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Double-Blind Method; Drug Therapy, Comb | 2020 |
Rifabutin-Based Triple Therapy (RHB-105) for
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Double-Blind Method; Drug Therapy, Comb | 2020 |
Rifabutin-Based Triple Therapy (RHB-105) for
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Double-Blind Method; Drug Therapy, Comb | 2020 |
Rifabutin-Based Triple Therapy (RHB-105) for
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Double-Blind Method; Drug Therapy, Comb | 2020 |
Positive Effect of Helicobacter pylori Treatment on Outcome of Patients With Chronic Spontaneous Urticaria.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Chronic Urticaria; Clarithromycin; Double-Blind Met | 2021 |
Comparing the Efficacy of Sequential and Standard Quadruple Therapy for Eradication of H. Pylori Infection.
Topics: Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections | 2020 |
Effect of treatment failure on the CagA EPIYA motif in
Topics: Adult; Amino Acid Motifs; Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Protein | 2017 |
Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial.
Topics: Adult; Amoxicillin; Carnosine; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicob | 2017 |
Dietary PUFA Increase Apoptosis in Stomach of Patients with Dyspeptic Symptoms and Infected with H. pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Apoptosis; Caspase 3; Clarithromycin; Dietary Fats, | 2017 |
Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; | 2017 |
Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; C | 2017 |
New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese pro
Topics: Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Capsules; China; Cla | 2018 |
Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial.
Topics: Adult; Amoxicillin; Bismuth; Breath Tests; China; Drug Administration Schedule; Drug Therapy, Combin | 2018 |
Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; He | 2018 |
Efficacy of Helicobacter pylori eradication regimens in Rwanda: a randomized controlled trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Ciprofloxacin; Clarithromycin; Disease Eradication; Doxyc | 2018 |
Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicoba | 2019 |
Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study.
Topics: Adult; Alanine; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administ | 2018 |
Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dru | 2018 |
Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first-line triple therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combinat | 2019 |
H. pylori eradication with antibiotic treatment causes changes in glucose homeostasis related to modifications in the gut microbiota.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Gastrointestinal Microbiome; Gluc | 2019 |
Potential roles of Helicobacter pylori treatment, body mass index and waist circumference in the causation of erosive esophagitis: a randomized clinical trial (HEROES-GERD).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 2020 |
[Use of the immunopotentiator N-acetyl-glucosamine-N-acetylmuramyl dipeptide during triple anti-Helicobacter pylori therapy].
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Adult; Amoxicillin; Anti-Bacterial Agents | 2012 |
Penbactam for Helicobacter pylori eradication: a randomised comparison of quadruple and triple treatment schedules in an Iranian population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Analysis of Variance; Anti-Bact | 2013 |
Twice a day quadruple therapy for the first-line treatment of Helicobacter pylori in an area with a high prevalence of background antibiotic resistance.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistance, Bacterial; Female; Gastritis; Heli | 2013 |
Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 2014 |
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinat | 2013 |
Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; | 2013 |
Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; | 2013 |
Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; | 2013 |
Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; | 2013 |
Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Clarithromycin; Drug The | 2013 |
Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Asian People; Child; Child, Preschool; China; Clarit | 2013 |
Expression comparison of azithromycin and clarithromycin in triple-therapy regimens for eradication of Helicobacter pylori in hemodialysis patients.
Topics: Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Azithromycin; Breath Tests; Chi-Square Dist | 2014 |
Effect of clopidogrel with or without omeprazole in patients with carotid artery stenting.
Topics: Angiography; Aspirin; Breath Tests; Carotid Arteries; Carotid Stenosis; Clopidogrel; Drug Interactio | 2013 |
The efficacy of levofloxacin-based triple therapy for first-line helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infection | 2013 |
[Clinical effect of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori infection in children].
Topics: Amoxicillin; Child; Child, Preschool; Clarithromycin; Combined Modality Therapy; Drug Therapy, Combi | 2014 |
Modified sequential Helicobacter pylori eradication therapy using high dose omeprazole and amoxicillin in the initial phase in the extensive metaboliser Turkish patients for CYP2C19 polymorphism is ineffective.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochr | 2014 |
Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Female; Follow | 2014 |
Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Drug Combinations; Drug Resista | 2014 |
Helicobacter pylori eradication in renal recipient: triple or quadruple therapy?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Breath Tests; Drug Therapy, Combination; | 2014 |
Efficacy and safety of 1-week Helicobacter pylori eradication therapy and 7-week rebamipide treatment after endoscopic submucosal dissection of early gastric cancer in comparison with 8-week PPI standard treatment: a randomized, controlled, prospective, m
Topics: Aged; Alanine; Anti-Bacterial Agents; Clarithromycin; Dissection; Early Detection of Cancer; Female; | 2015 |
Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Resistance, Bact | 2014 |
Replacement of clarithromycin with azithromycin in triple therapy regimens for the eradication of Helicobacter pylori: A randomized clinical trial.
Topics: Amoxicillin; Azithromycin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infection | 2014 |
Low dose furazolidone for eradication of H- pylori instead of clarithromycin: a clinical trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Breath T | 2014 |
Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2015 |
A randomized-controlled study to compare the efficacy of sequential therapy with standard triple therapy for Helicobacter pylori eradication in an Irish population.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Breath Tests; Clarithromycin | 2015 |
Phytomedicine-based and Quadruple Therapies in Helicobacter pylori Infection: A Comparative, Randomized Trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Com | 2015 |
Helicobacter pylori, cyclooxygenase-2 and evolution of gastric lesions: results from an intervention trial in China.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Celecoxib; China; Clarithromycin; Cyclooxygenase 2; Cyclo | 2015 |
Impact of creatinine clearance on Helicobacter pylori eradication rate in patients with peptic ulcer disease.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Creatinine; Drug Therapy, C | 2015 |
[Effect of Yiqi Huoxue Qingre Huashi Recipe on the Eradication Rate of Hp in Peptic Ulcer Patients].
Topics: Breath Tests; Drug Therapy, Combination; Drugs, Chinese Herbal; Gastric Mucosa; Helicobacter Infecti | 2015 |
Helicobacter pylori eradication effect on patients with functional dyspepsia symptoms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, | 2016 |
A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Administr | 2016 |
Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: A randomized prospective study.
Topics: Adult; Aged; Aged, 80 and over; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Adm | 2016 |
High efficacy of gemifloxacin-containing therapy in Helicobacter Pylori eradication: A pilot empirical second-line rescue therapy.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Therapy, Combinati | 2016 |
Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori-related chronic gastritis: a prospective randomized study in China.
Topics: Adult; China; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastritis; Helicobact | 2017 |
Prevalence of A2143G mutation of H. pylori-23S rRNA in Chinese subjects with and without clarithromycin use history.
Topics: Adult; Amoxicillin; China; Clarithromycin; DNA Mutational Analysis; DNA, Bacterial; Double-Blind Met | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
Efficacy of a new therapeutic regimen versus two routinely prescribed treatments for eradication of Helicobacter pylori: a randomized, double-blind study of doxycycline, co-amoxiclav, and omeprazole in Iranian patients.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blin | 2009 |
A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Clarithromycin; Esomeprazol | 2009 |
Helicobacter pylori eradication in patients on long-term treatment with NSAIDs reduces the severity of gastritis: a randomized controlled trial.
Topics: Aged; Amoxicillin; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents | 2009 |
Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Dr | 2008 |
Efficacy of the standard quadruple therapy versus triple therapies containing proton pump inhibitor plus amoxicillin and clarithromycin or amoxicillin-clavulanic acid and metronidazole for Helicobacter pylori eradication in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Child; Child, Preschool; Clarithromyci | 2009 |
Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Asian People; Dietary Supplements; Dos | 2009 |
Effect of Helicobacter pylori eradication on ulcer recurrence after simple closure of perforated duodenal ulcer.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ul | 2009 |
[Interleukin-1beta gene polymorphism as a predictor of eradication treatment efficacy in gastric and duodenal ulcer associated with Helicobacter pylori].
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Endoscopy, | 2008 |
Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 2009 |
Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Drug Administration Sc | 2009 |
Randomized, double-blind, placebo-controlled trial: effect of lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Combined M | 2009 |
The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Asian People; Clarithromycin; Double-Blind Method; | 2009 |
The efficacy of Helicobacter pylori eradication regimen with and without vitamin C supplementation.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2009 |
[Effect of CYP2C19 gene polymorphism on eradication treatment efficacy of Helicobacter pylori infection].
Topics: Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Breath Tests; Clarithromycin; Cohort Studies; Cyt | 2009 |
A placebo-controlled trial of 10-day bismuth-based quadruple therapy to eradicate Helicobacter pylori infection; a pilot study for the large Linqu County trial.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Te | 2010 |
[Anti-Helicobacter pylori treatment in patients with idiopathic thrombocytopenic purpura].
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infectio | 2009 |
Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; C | 2010 |
A randomized controlled trial: efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Breath Tests; Female; Helicobacter Infections; Humans; Ira | 2010 |
Effect of eradication of Helicobacter pylori and iron supplementation on the iron status of children with iron deficiency.
Topics: Adolescent; Amoxicillin; Anemia, Iron-Deficiency; Child; Clarithromycin; Drug Therapy, Combination; | 2010 |
Investigation of the anti-inflammatory effect of Curcuma longa in Helicobacter pylori-infected patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Load; | 2010 |
High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Colony Count, Microbial | 2010 |
Eradication of Helicobacter spp. by using medicated diet in mice deficient in functional natural killer cells and complement factor D.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Antigens, CD1; Clarithromycin; Complement Factor D; Dru | 2010 |
Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co | 2010 |
Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Bismuth; Clarithromycin; Double-Blind Method; Female; Helicobacter Infecti | 2010 |
Effect of eradication of Helicobacter pylori in children with chronic immune thrombocytopenia: a prospective, controlled, multicenter study.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Blood Platelets; Child; Chronic D | 2011 |
Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance.
Topics: Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Comb | 2010 |
The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2010 |
Clarithromycin-based triple therapy for Helicobacter pylori treatment in peptic ulcer patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Brazil; Clarithromycin; Drug Therapy, | 2010 |
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromyc | 2011 |
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromyc | 2011 |
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromyc | 2011 |
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromyc | 2011 |
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromyc | 2011 |
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromyc | 2011 |
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromyc | 2011 |
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromyc | 2011 |
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromyc | 2011 |
Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; C | 2011 |
Sequential therapy compared with standard triple therapy for Helicobacter pylori eradication in children: a double-blind, randomized, controlled trial.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Double-Bli | 2011 |
Helicobacter pylori chronic gastritis in children: to eradicate or not to eradicate?
Topics: Adolescent; Aluminum Hydroxide; Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Child; C | 2011 |
Furazolidone, amoxicillin and omeprazole with or without bismuth for eradication of Helicobacter pylori in peptic ulcer disease.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents | 2011 |
High eradication rates of Helicobacter pylori infection following sequential therapy: the Israeli experience treating naïve patients.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; | 2011 |
Sequential therapy versus standard triple drug therapy for eradication of Helicobacter pylori in patients with perforated duodenal ulcer following simple closure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; C | 2011 |
Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diarrhea; Double-Blind Method; Drug | 2011 |
Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Child; Child, Presc | 2011 |
Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Child; Child, Presc | 2011 |
Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Child; Child, Presc | 2011 |
Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Child; Child, Presc | 2011 |
Healing effects of rebamipide and omeprazole in Helicobacter pylori-positive gastric ulcer patients after eradication therapy: a randomized double-blind, multinational, multi-institutional comparative study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2011 |
Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Drug Administration Schedule; Drug Therapy, Combin | 2012 |
Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; D | 2011 |
Effect of Helicobacter pylori eradication therapy in iron deficiency anaemia of pregnancy - a pilot study.
Topics: Adolescent; Adult; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Clarithromycin; Dise | 2011 |
Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Celecoxib; Clarithromycin; Cyclooxygenase 2 Inhibitors; D | 2012 |
[Effect of anti-Helicobacter pylori on the prognosis in patients with acute cerebral infarction].
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; C-Reactive Protein; Cerebral Infarction; Female; Fibrinoge | 2011 |
A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2011 |
Correlation between creatinine clearance and Helicobacter pylori infection eradication with sequential and triple therapeutic regimens: A randomised clinical trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Antibodies, Bacterial; Ciprofloxacin; Creatinine; Dose-Response | 2011 |
Helicobacter pylori eradication in functional dyspepsia: HEROES trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind M | 2011 |
Effects of melatonin and tryptophan on healing of gastric and duodenal ulcers with Helicobacter pylori infection in humans.
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Gastric | 2011 |
Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Ascorbic Acid; China; Confounding Factors, Epidemio | 2012 |
Clarithromycin versus metronidazole in first-line Helicobacter pylori eradication. Prospective randomized study of 85 Tunisian adults.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Female; Helico | 2012 |
Yellow brain culinary-medicinal mushroom, Tremella mesenterica Ritz.:Fr. (higher Basidiomycetes), is subjectively but not objectively effective for eradication of Helicobacter pylori: a prospective controlled trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Basidiomycota; Drug Therapy, Comb | 2012 |
Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combin | 2012 |
Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combin | 2012 |
Lycopene an adjunctive therapy for Helicobacter pylori eradication: a quasi-control trial.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antioxidants; Bismuth; | 2012 |
[Ilaprazole based bismuth-containing quadruple regimen for the first-line treatment of Helicobacter pylori infection: a multicenter, randomized, controlled clinical study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; China; Drug The | 2012 |
[A 10-day sequential therapy for eradication of Helicobacter pylori infection in children].
Topics: Administration, Oral; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Test | 2012 |
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 2002 |
Genotyping of Helicobacter pylori in paraffin-embedded gastric biopsy specimens: relation to histological parameters and effects on therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Outer Membrane Proteins; Bacteria | 2002 |
One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration S | 2002 |
Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistance, Bacterial; Drug Therap | 2002 |
Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2002 |
Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial.
Topics: Adult; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clarithromycin; Dicl | 2002 |
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2002 |
Helicobacter pylori and different topographic types of gastritis: treatment response after successful eradication therapy in functional dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Breath Tests; Chronic Disease; Drug T | 2002 |
Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Bifidobacterium; Clarithromycin; Combin | 2002 |
Influence of Helicobacter pylori eradication therapy on the occurrence of gastrointestinal events in patients treated with conventional nonsteroidal antiinflammatory drugs combined with omeprazole.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Confidence Intervals; D | 2002 |
Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 2002 |
Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2002 |
[Fromilid (clarithromycin) in eradication patients in patients with duodenal ulcer associated with Helicobacter pylori (comparison of two treatment variations)].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Duodenal | 2002 |
[Fromilide (clarithromycin) in eradication of Helicobacter pylori in patients with duodenal ulcer].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Com | 2002 |
Azithromycin in a triple therapy for H.pylori eradication in active duodenal ulcer.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug T | 2002 |
Eradication rate of Helicobacter pylori in a Mexican population at high risk for gastric cancer and use of serology to assess cure.
Topics: Adenocarcinoma; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; | 2002 |
Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; | 2002 |
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Ascorbic Acid; D | 2002 |
The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance; Drug Therapy, Combi | 2002 |
[Comparison of pantoprazole and omeprazole-based triple therapy regimens in the treatment of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti | 2002 |
Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug | 2002 |
Seven-day triple therapy with omeprazole, amoxycillin and clarithromycin for Helicobacter pylori infection in haemodialysis patients.
Topics: Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dr | 2002 |
Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: a double blind randomised trial with a six month follow up.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combination; Dyspeps | 2003 |
Eradication therapy with rabeprazole versus omeprazole in the treatment of active duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clar | 2002 |
The effects of nocturnal acid breakthrough on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
Oxidative stress in gastric mucosa of asymptomatic humans infected with Helicobacter pylori: effect of bacterial eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biomarkers; Biopsy; Catalase; Clarithr | 2002 |
Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Ag | 2003 |
Comparison of three triple regimens with omeprazole or ranitidine bismuth citrate for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female | 2002 |
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alanine; Anti-Ulcer Agents; Breath Tests; False Nega | 2003 |
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Dose-Respon | 2003 |
[New triple therapy for Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Hel | 2003 |
Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; | 2003 |
Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Cro | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
Omeprazole plus azithromycin and either amoxicillin or tinidazole for eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Azithromycin; Dose-Response Relationship, Drug; Drug Administration Schedu | 2003 |
Impact of long-term ranitidine and pantoprazole on accuracy of [13C]urea breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzimidazoles; Breath Tests; Dose-Response Relations | 2003 |
Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Capsules; | 2003 |
Clinical and pathological implications of IgG antibody responses to Helicobacter pylori and its virulence factors in non-ulcer dyspepsia.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Antibodies, Bacterial; Double-Blind | 2003 |
Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2003 |
[Esomeprazole in treating duodenal ulcer in various modes of anti-Helicobacter therapy].
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazole; Fe | 2003 |
Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Be | 2003 |
Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial.
Topics: Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combin | 2003 |
Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Be | 2003 |
Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Drug The | 2003 |
The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2003 |
Validation of the 13c-urea breath test for the initial diagnosis of helicobacter pylori infection and to confirm eradication after treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Carbon Isotopes; Clarith | 2003 |
Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment.
Topics: Adult; Anti-Ulcer Agents; Dyspepsia; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; H | 2003 |
One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin | 2003 |
Do Japanese and Swedish peptic ulcer patients respond differently to Helicobacter pylori eradication therapies and what are their histological features?
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Asian People; Clarithromycin; Dr | 2003 |
Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Drug The | 2003 |
Rabeprazole in a one-week eradication therapy of Helicobacter pylori: comparison of different dosages.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal A | 2003 |
Effect of short-term treatment with regular or high doses of omeprazole on the detection of Helicobacter pylori in bleeding peptic ulcer patients.
Topics: Anti-Ulcer Agents; Diagnostic Techniques, Digestive System; Dose-Response Relationship, Drug; Double | 2003 |
Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 2003 |
High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia?
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Female; Health Status; Heartburn; He | 2003 |
Density of Helicobacter pylori may affect the efficacy of eradication therapy and ulcer healing in patients with active duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2003 |
Helicobacter pylori eradication therapy for the remnant stomach after gastrectomy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-I | 2003 |
The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Met | 2003 |
Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Te | 2003 |
A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Re | 2003 |
Comparison of four-day and seven-day pantoprazole-based quadruple therapy as a routine treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Ag | 2003 |
Influence of Helicobacter pylori infection and omeprazole treatment on gastric regional CO2.
Topics: Adult; Carbon Dioxide; Enzyme Inhibitors; Female; Gastric Mucosa; Helicobacter Infections; Humans; M | 2003 |
Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2003 |
Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Antacids; Anti-Ulcer Agents; Benz | 2003 |
Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Clarithromycin; Dose-Response Relations | 2003 |
Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study.
Topics: Adult; Aged; Antacids; Anti-Ulcer Agents; Breath Tests; Carbolines; Clarithromycin; Drug Therapy, Co | 2003 |
One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; B | 2003 |
[Efficacy of antihelicobacter therapy in NSAID-induced gastropathies].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Female; Helicobacter Infections; Humans; | 2003 |
[A prospective study on rabeprazole-based triple therapy for Helicobacter pylori eradication in patients with peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2003 |
A randomized trial comparing seven-day ranitidine bismuth citrate and clarithromycin dual therapy to seven-day omeprazole, clarithromycin and amoxicillin triple therapy for the eradication of Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug A | 2003 |
Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dr | 2003 |
Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance; Drug Therapy | 2003 |
Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2003 |
Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bac | 2003 |
Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2003 |
Influence of anti-ulcer drugs used in Japan on the result of (13)C-urea breath test for the diagnosis of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Breath Tests; Carbon Radioisotope | 2003 |
Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Three-day intravenous triple therapy is not effective for the eradication of Helicobacter pylori infection in patients with bleeding gastro-duodenal ulcer.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Clavulanic Acids; Double-Blin | 2003 |
Use of bovine lactoferrin for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitric | 2003 |
[Therapeutic effect of gastrozolum in stomach ulcers].
Topics: Administration, Oral; Adolescent; Adult; Aged; Dosage Forms; Drug Administration Schedule; Enzyme In | 2003 |
Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2003 |
Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylas | 2003 |
Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Ag | 2003 |
Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Disease Progression; Double- | 2004 |
Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Therapy, Co | 2004 |
Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, C | 2004 |
Beta-lactamase inhibitor enhances Helicobacter pylori eradication rate.
Topics: Amoxicillin-Potassium Clavulanate Combination; beta-Lactamase Inhibitors; beta-Lactamases; Clarithro | 2004 |
[Results of an open multicenter study of the efficiency of one-week anti-helicobacter therapy using omeprazole, clarithromycin, and amoxicillin in patients with duodenal peptic ulcer].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug | 2003 |
[Treatment of Helicobacter pylori infection--results and experiences with an Internet-based collaboration trial].
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Fe | 2003 |
Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Anti-Ulcer Agents; Chin | 2004 |
Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Anti-Ulcer Agents; Chin | 2004 |
Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Anti-Ulcer Agents; Chin | 2004 |
Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Anti-Ulcer Agents; Chin | 2004 |
Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial.
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Chi-Square Distribution; Clarithromycin; Double-Blind Method; | 2004 |
Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial.
Topics: Adenocarcinoma; Adult; Anti-Ulcer Agents; Double-Blind Method; Female; Gastritis; Helicobacter Infec | 2004 |
High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infect | 2004 |
[Efficacy of Helicobacter pylori eradication in non-ulcer dyspepsia].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combin | 2004 |
Quantitative assessment of gastric antrum atrophy shows restitution to normal histology after Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Atrophy; Biopsy; Endoscopy, Gastrointestinal; Gastric Muco | 2004 |
Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
[Efficacy of anti-Helicobacter therapy in children with ulcer-like functional dyspepsia].
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Thera | 2003 |
Empirical Helicobacter pylori "rescue" therapy after failure of two eradication treatments.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Drug Therapy, Combinatio | 2004 |
Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2003 |
Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithrom | 2004 |
[Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hyd | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulce | 2004 |
Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective A | 2004 |
Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost Savings; Cost-Ben | 2003 |
[Eradication effect of lansoprazole-based triple therapy against H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2004 |
[Comparative efficacy of proton pump inhibitors in children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; | 2003 |
Rank order of success favors longer duration of imidazole-based therapy for Helicobacter pylori in duodenal ulcer disease: a randomized pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2004 |
Absence of nocturnal acid breakthrough in Helicobacter pylori-positive subjects treated with twice-daily omeprazole.
Topics: Adult; Breath Tests; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; | 2004 |
Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benz | 2004 |
Helicobacter pylori eradication: efficacy of conventional therapy in India.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Clarithromycin; Double-Blin | 2004 |
Does the 'test-and-treat' strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Dyspepsia; Endoscopy, Gastrointestinal | 2004 |
Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection.
Topics: Administration, Oral; Adult; Aged; Aluminum Hydroxide; Antacids; Breath Tests; Dose-Response Relatio | 2004 |
Empirical treatment followed by a test-and-treat strategy is more cost-effective in comparison with prompt endoscopy or radiography in patients with dyspeptic symptoms: a randomized trial in a primary care setting.
Topics: Adult; Anti-Ulcer Agents; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylo | 2004 |
[Clinical effectiveness of omeprazole, azithromycin and amoxicillin in ulcer healing and eradication of Helicobacter pylori infection].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Therapy, Combinatio | 2003 |
Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2004 |
Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2004 |
Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2004 |
The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; D | 2004 |
Effect of Helicobacter pylori eradication on anti-thrombotic dose aspirin-induced gastroduodenal mucosal injury.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer | 2004 |
Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Esomeprazole; Female; Follow-Up Stud | 2004 |
Seven-day therapy for Helicobacter pylori in the United States.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles | 2004 |
Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; B | 2004 |
Comparison of cetraxate-based and pantoprazole-based triple therapies in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2004 |
In treatment of active duodenal ulcer and Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2003 |
Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Ant | 2004 |
[Long-term therapeutic effect of triple therapy consisted of omeperazole, clarithromycin and amoxycillin in children with Helicobacter pylori infection and approach to re-treatment after failure of the treatment].
Topics: Adolescent; Amoxicillin; Anti-Ulcer Agents; Child; Child, Preschool; Clarithromycin; Drug Therapy, C | 2004 |
Total family unit Helicobacter pylori eradication and pediatric re-infection rates.
Topics: Adolescent; Amoxicillin; Breath Tests; Child; Child, Preschool; Clarithromycin; Community-Acquired I | 2004 |
Dual vs. triple therapy for childhood Helicobacter pylori gastritis: a double-blind randomized multicentre trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Breath Tests; Child; Double-Blind | 2004 |
Helicobacter pylori eradication in children and adolescents by a once daily 6-day treatment with or without a proton pump inhibitor in a double-blind randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Azithromycin; Breath Tests; Child; Doubl | 2004 |
Helicobacter pylori eradication decreases blood neutrophil and monocyte counts.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Gastritis; | 2004 |
Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Female; Gas | 2004 |
Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication.
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Disease Progression; Drug Therapy, Combination | 2004 |
Symptomatic response to Helicobacter pylori eradication in children with recurrent abdominal pain: double blind randomized placebo-controlled trial.
Topics: Abdominal Pain; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Double | 2004 |
The efficacy, safety and tolerability of pantoprazole-based one-week triple therapy in H. pylori eradication and duodenal ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2004 |
The effect of Helicobacter pylori eradication on gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu | 2004 |
Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dose-Re | 2004 |
[Effects of different triple therapies on duodenal ulcer-associated Helicobacter pylori infection and a one-year follow-up study].
Topics: Amoxicillin; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; H | 2004 |
Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Chronic Disease; | 2004 |
The influence of pretreatment on cure rates of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth | 2004 |
Lewis and Secretor status and Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Helicobacte | 2004 |
Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ben | 2004 |
Differential effects of Helicobacter pylori eradication on oxidative DNA damage at the gastroesophageal junction and at the gastric antrum.
Topics: Anti-Ulcer Agents; DNA Adducts; DNA Damage; Esophageal Diseases; Esophagogastric Junction; Female; G | 2004 |
Long-term effects of eradication of Helicobacter pylori on relapse and histology in gastric ulcer patients: a two-year follow-up study.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combination; Endoscopy, | 2004 |
Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Ba | 2004 |
Effects of Helicobacter pylori eradication on platelet activation and disease recurrence in patients with acute coronary syndromes.
Topics: Acute Disease; Amoxicillin; Antigens, CD; Coronary Disease; Female; Helicobacter Infections; Helicob | 2004 |
Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis | 2005 |
Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agent | 2005 |
Effects of the association of lansoprazole, clarithromycin and metronidazole for helicobacter Pylori eradication therapy, measured by the 13C Aminopyrine breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Aminopyrine; Breath Tests; Carbon | 2005 |
Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Chi-Squ | 2005 |
Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Chi-Squ | 2005 |
Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Chi-Squ | 2005 |
Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Chi-Squ | 2005 |
Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clari | 2005 |
Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clari | 2005 |
Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clari | 2005 |
Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clari | 2005 |
Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clari | 2005 |
Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clari | 2005 |
Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clari | 2005 |
Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clari | 2005 |
Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clari | 2005 |
Comparison of one week and two weeks of triple therapy for the eradication of Helicobacter pylori in a Sri Lankan population: a randomised, controlled study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Analysis of Variance; Clarithromycin; Confidence Inte | 2004 |
Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2005 |
Effects of killing Helicobacter pylori quadruple therapy on peptic ulcer: a randomized double-blind clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2005 |
First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Cl | 2005 |
Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2005 |
One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2005 |
Eradication rate of Helicobacter pylori in dyspeptic patients.
Topics: Analysis of Variance; Anti-Bacterial Agents; Breath Tests; Ciprofloxacin; Drug Therapy, Combination; | 2005 |
[Effect of the Helicobacter pylori eradication in patients with functional dyspepsia: randomised placebo-controlled trial].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Confidence Intervals; | 2005 |
[Esomeprasol and rabeprasol effects on esophageal acidification in patients with gastroesophageal reflux disease, intensively metabolizing inhibitors of proton pump].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenoscopy; Esophagosc | 2005 |
Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy.
Topics: Adult; Aged; Analysis of Variance; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 2005 |
Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 2005 |
Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Biopsy; Dis | 2005 |
Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Asian People; Clarithromycin | 2005 |
Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Chi-Square Dist | 2005 |
Effect of high-dose aspirin on Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aspirin; Chronic Disease; Clarithromyc | 2005 |
Treatment regimens for Helicobacter pylori infection in children: is in vitro susceptibility testing helpful?
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Child; Child, Presc | 2005 |
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug | 2005 |
Efficacy of triple therapy plus cetraxate for the Helicobacter pylori eradication in partial gastrectomy patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Drug | 2005 |
[The clinical applications of rabeprazole either alone or combined with anti-Helicobacter pylori agents in peptic ulcer patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 2005 |
Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Famotidine; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacte | 2005 |
Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2005 |
Quality of gastric ulcer healing evaluated by endoscopic ultrasonography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2005 |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles; Clari | 2005 |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles; Clari | 2005 |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles; Clari | 2005 |
High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles; Clari | 2005 |
Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Comorbidity; Cross-Over Studies; D | 2005 |
Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance o
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Benzimidazoles; Dose-Re | 2005 |
Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aminopyrine; Anti-Bacterial Agents; Anti-Infective Ag | 2005 |
Does eradication of Helicobacter pylori infection help normalize serum lipid and CRP levels?
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; C-Reactive Protein; Clarithromycin; Drug Therapy, Combina | 2005 |
Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
Is a long-term ranitidine-based triple therapy against Helicobacter pylori only a heritage of the past? A prospective, randomized clinicopharmacological study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Chromatogr | 2005 |
Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-b
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Clarithromycin; Double-Blind | 2005 |
[Comparison of esomeprazole- and omeprazole-based triple therapy regimens for duodenal ulcer with Helicobacter pylori infection].
Topics: Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Co | 2005 |
A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2005 |
The results of Helicobacter pylori eradication on repeated bleeding in patients with stomach ulcer.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Administration Sc | 2005 |
Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Esomeprazole; | 2005 |
Proton pump inhibitors reduce the bioavailability of dietary vitamin C.
Topics: Ascorbic Acid; Biological Availability; Enzyme Inhibitors; Female; Gastric Acid; Helicobacter Infect | 2005 |
Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett | 2005 |
Long-term follow-up after eradication of Helicobacter pylori with omeprazole, clarithromycin, and tinidazole (OCT regimen) in a Japanese population.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, Combina | 2005 |
A randomized trial of triple therapy for pediatric Helicobacter pylori infection and risk factors for treatment failure in a population with a high prevalence of infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2005 |
Helicobacter pylori eradication in childhood after failure of initial treatment: advantage of quadruple therapy with nifuratel to furazolidone.
Topics: Adolescent; Amoxicillin; Antacids; Anti-Bacterial Agents; Child; Drug Therapy, Combination; Female; | 2005 |
Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2005 |
Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal | 2005 |
Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal | 2005 |
Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal | 2005 |
Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal | 2005 |
Effect of N-acetyl cysteine on Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetylcysteine; Anti-Bacterial Agents; Clarithromycin; Drug | 2005 |
[H. pylori eradication package set (Lansap)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Packaging; Drug Therapy, | 2005 |
[PPI plus bismuth-based quintuple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug | 2005 |
[Cetraxate hydrochloride (Neuer) induces the effectiveness of new triple therapy in H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2005 |
Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2005 |
A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Antitrichomon | 2006 |
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Be | 2006 |
Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2006 |
Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2006 |
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infec | 2006 |
Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Cadherins; Chronic Disease; Clarithromycin; D | 2006 |
Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co | 2006 |
Third-line rescue therapy with levofloxacin after two H. pylori treatment failures.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, C | 2006 |
Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2006 |
Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial.
Topics: Aged; Anti-Ulcer Agents; Atrophy; Enteroendocrine Cells; Female; Gastric Acid; Gastric Mucosa; Gastr | 2006 |
[Lipid peroxidation and antioxidant system in treatment dynamics of patients with chronic gastritis].
Topics: Adult; Aged; alpha-Tocopherol; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Antioxidants; | 2005 |
[Comparison of the effectiveness of tri- and quadricomponent eradication therapy in patients with peptic ulcer].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administrat | 2005 |
Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and chronic gastritis in the elderly. A randomized, multicenter, eight-month study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents | 2006 |
Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2006 |
Evaluation of triple and quadruple Helicobacter pylori eradication therapies in Iranian children: a randomized clinical trial.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Child; Child, Preschool; Clar | 2006 |
Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis.
Topics: Adult; Aged; Anti-Ulcer Agents; Chronic Disease; Gastric Acid; Gastritis; Goiter; Helicobacter Infec | 2006 |
Design and planned analyses of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2006 |
Role of Helicobacter pylori virulence factor and genotypes in non-ulcer dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Clar | 2006 |
Efficacy of one-day quadruple therapy for H pylori infection in Chinese patients.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; As | 2006 |
[Double blind randomized multicentre study of a seven-day eradication regime of Helicobacter pylori by omeprazole, clarithromycin and ornidazole vs. omeprazole, clarithromycin and metronidazole].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Meth | 2002 |
Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Denmark; Drug Therapy, Combinat | 2006 |
Eradication of H pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective A | 2006 |
Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal A | 2006 |
Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cros | 2006 |
Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions.
Topics: Adult; Amoxicillin; Ascorbic Acid; China; Disease Progression; Double-Blind Method; Drug Therapy, Co | 2006 |
Azithromycin in one week quadruple therapy for H pylori eradication in Iran.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agent | 2006 |
Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Bacterial Protei | 2006 |
Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co | 2006 |
Economic evaluation of empirical antisecretory therapy versus Helicobacter pylori test for management of dyspepsia: a randomized trial in primary care.
Topics: Adult; Anti-Ulcer Agents; Cost-Benefit Analysis; Dyspepsia; Endoscopy, Gastrointestinal; Female; Hel | 2006 |
Furazolidone-based triple therapy for H pylori gastritis in children.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Child; Child, Preschool | 2006 |
A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; China; Cholesterol; Cholesterol, HDL; Cholest | 2006 |
Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Bl | 2007 |
Pharmacoeconomic comparison of Helicobacter pylori eradication regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Infective Agents; Clar | 2006 |
Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial.
Topics: Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Dopamine Agents; | 2006 |
2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study.
Topics: Administration, Oral; Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Administration Schedu | 2006 |
Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.
Topics: Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C1 | 2006 |
Does adding misoprostol to standard intravenous proton pump inhibitor protocol improve the outcome of aspirin/NSAID-induced upper gastrointestinal bleeding?: a randomized prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2007 |
Efficacy and safety of Helicobacter pylori eradication therapy with omeprazole, amoxicillin and high- and low-dose clarithromycin in Japanese patients: a randomised, double-blind, multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochro | 2006 |
Improvement of the eradication rate of Helicobacter pylori gastritis in children is by adjunction of omeprazole to a dual antibiotherapy.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Child; Child, Presc | 2007 |
Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug | 2007 |
Oral health status and oral hygiene practices of patients with peptic ulcer and how these affect Helicobacter pylori eradication from the stomach.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2007 |
Omeprazole-based triple therapy with low-versus high-dose of clarithromycin plus amoxicillin for H pylori eradication in Iranian population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; C | 2007 |
Acid-suppressive effects of various regimens of omeprazole in Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers: which regimen has the strongest effect?
Topics: Adult; Antibodies, Bacterial; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CY | 2007 |
[Age and eradication treatment of duodenal ulcer].
Topics: Adolescent; Adult; Age Factors; Aged; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Combinations; | 2007 |
One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; | 2007 |
Effect of cranberry juice on eradication of Helicobacter pylori in patients treated with antibiotics and a proton pump inhibitor.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Beverages; Clarithromycin; Double-Blind Method; Fem | 2007 |
H. pylori infection in childhood chronic immune thrombocytopenic purpura.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool; Chronic Disease; Cla | 2007 |
Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarb | 2007 |
Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Chile; Clarithromycin; Drug Administration Schedule; Drug | 2007 |
Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combinat | 2007 |
Reversal of migraine symptoms by Helicobacter pylori eradication therapy in patients with hepatitis-B-related liver cirrhosis.
Topics: Adult; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobact | 2007 |
Evidence for the role of gastric mucosa at the secretion of soluble triggering receptor expressed on myeloid cells (strem-1) in peptic ulcer disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Clarithromycin; | 2007 |
Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents | 2007 |
Eradication of Helicobacter pylori infection favourably affects altered gastric mucosal MMP-9 levels.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Therapy, Combina | 2007 |
Eradication of Helicobacter pylori infection equally improves chronic urticaria with positive and negative autologous serum skin test.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Autoantibodies; Chronic Disease; Clari | 2007 |
Garlic, vitamin, and antibiotic treatment for Helicobacter pylori: a randomized factorial controlled trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Garlic; Helicobacter Infections; Helicobacter pylori; Hum | 2007 |
Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Endosco | 2008 |
Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use.
Topics: Adult; Alkylating Agents; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost-Benefit Ana | 2007 |
Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients.
Topics: Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Breath Tests; Drug Therapy, Combina | 2008 |
Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug | 2007 |
Effect of eradication of Helicobacter pylori on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: a controlled trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Combined M | 2008 |
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Co | 2008 |
Effect of Helicobacter pylori eradication and antisecretory maintenance therapy on peptic ulcer recurrence in cirrhotic patients: a prospective, cohort 2-year follow-up study.
Topics: Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Cohort Studies; Endoscopy; Follow-Up Studies; Greece | 2008 |
[Role of anti-secretory treatment in addition to Helicobacter pylori eradication triple therapy in the treatment of peptic ulcer].
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter Inf | 2008 |
The effect of Helicobacter pylori eradication treatment on the MUC 1 and Lewis antigens level in human gastric juice: a preliminary study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Epithelial Cells; Female; Gastric Juice; Gastric Mucosa; | 2008 |
Effect of a community screening for Helicobacter pylori: a 5-Yr follow-up study.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Community Health Services; Cost-Benefit Analy | 2008 |
Is a 7-day Helicobater pylori treatment enough for eradication and inactivation of gastric inflammatory activity?
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Dose-Response | 2008 |
Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori.
Topics: Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Famotidine; F | 1995 |
Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Female; | 1995 |
[Comparison of 2 treatment schemes to eradicate Helicobacter pylori].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Dyspepsia; Endosco | 1995 |
[Antibacterial treatment of gastric ulcers associated with Helicobacter pylori without acid suppression].
Topics: Aluminum Hydroxide; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Combinations; | 1995 |
The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 1995 |
Clinical efficacy of lansoprazole-amoxicillin treatment in eradicating Helicobacter pylori: evaluation by the polymerase chain reaction method.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Base Sequence; Drug | 1995 |
Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Famotidine; Female; Fibroblast Growth Fa | 1995 |
Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; | 1995 |
Clinical efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Drug Administration | 1995 |
13C-UBT using an infrared spectrometer for detection of Helicobacter pylori and for monitoring the effects of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Breath Tests; Carbon Dioxide; Carbon Iso | 1995 |
Efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 1995 |
Efficacy of lansoprazole and amoxicillin in eradicating Helicobacter pylori: evaluation using 13C-UBT and Monoclonal H. pylori antibody testing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Antibodies, Bacterial; Anti | 1995 |
Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; D | 1995 |
Eradication of Helicobacter pylori with lansoprazole, amoxicillin, and plaunotol in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Dr | 1995 |
Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Amoxicillin; Anti-Bacterial Agents; Anti- | 1995 |
Effect of lansoprazole on peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Female; Helicobacter Inf | 1995 |
Therapeutic effects of lansoprazole on peptic ulcers in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Anti-Ulce | 1995 |
Peptic ulcer therapy with lansoprazole and Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Helicobacter Infections; | 1995 |
Eradication of Helicobacter pylori with lansoprazole and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Clarithromycin; | 1995 |
A randomized prospective comparison of clarithromycin versus amoxycillin in combination with omeprazole for eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Dizziness; Drug Therapy, Combination; Female; | 1995 |
[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 1995 |
Omeprazole-amoxycillin therapy for eradication of Helicobacter pylori in duodenal ulcer bleeding: preliminary results of a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Colony Count, Microbial; Drug Therapy, Combination; Duo | 1995 |
Effect of eradication of Helicobacter pylori infection on gastric epithelial cell proliferation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cell Division; Clarithromyc | 1995 |
Two-year follow-up of duodenal ulcer patients treated with omeprazole and amoxicillin.
Topics: Amoxicillin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow | 1995 |
Treatment of Helicobacter pylori infection with omeprazole-amoxicillin combination therapy versus ranitidine/sodium bicarbonate-amoxicillin.
Topics: Amoxicillin; Biopsy; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastric Mucosa | 1995 |
Limited efficacy of omeprazole-based dual and triple therapy for Helicobacter pylori: a randomized trial employing "optimal" dosing.
Topics: Adult; Amoxicillin; Breath Tests; Drug Administration Schedule; Drug Therapy, Combination; Female; F | 1995 |
Variability with omeprazole-amoxicillin combinations for treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Biopsy; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastric | 1995 |
Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized
Topics: Adult; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer | 1995 |
Triple therapy with sucralfate, tetracycline, and metronidazole for Helicobacter pylori-associated duodenal ulcers.
Topics: Adult; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Hel | 1995 |
Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinatio | 1995 |
Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duode | 1995 |
Lansoprazole treatment of Helicobacter pylori-positive peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulce | 1995 |
Proton pump inhibitors for Helicobacter pylori eradication in patients with peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Biopsy; Endoscopy, Digestive Syst | 1995 |
Efficacy of omeprazole combined with antibiotics for Helicobacter pylori eradication and duodenal ulcer recurrence.
Topics: Adult; Aged; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Fo | 1995 |
Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers.
Topics: Adolescent; Adult; Aged; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer | 1995 |
Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study.
Topics: Antacids; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Hel | 1995 |
The ECP-IM intervention study.
Topics: Ascorbic Acid; Clarithromycin; Double-Blind Method; Drug Combinations; Europe; Female; Helicobacter | 1994 |
Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Com | 1994 |
Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole.
Topics: Adult; Breath Tests; Cross-Over Studies; Double-Blind Method; Female; Gastric Acidity Determination; | 1995 |
Successful Helicobacter pylori eradication incorporating a one-week antibiotic regimen.
Topics: Adult; Amoxicillin; Drug Synergism; Drug Therapy, Combination; Female; Helicobacter Infections; Heli | 1995 |
Rapid eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Chi-Square Distribution; Cost-Benefit Analysis; Drug Interactions; Drug Sy | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Intravenous omeprazole/amoxicillin and omeprazole pretreatment in Helicobacter pylori-positive acute peptide ulcer bleeding. A pilot study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Breath Tests; Carb | 1994 |
Distinct profiles of gastritis in dyspepsia subgroups. Their different clinical responses to gastritis healing after Helicobacter pylori eradication.
Topics: Adult; Age Factors; Amoxicillin; Chronic Disease; Drug Therapy, Combination; Dyspepsia; Female; Gast | 1994 |
[Helicobacter pylori eradication therapy with omeprazole and amoxicillin: current status].
Topics: Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Helicobacter Infections; Helicobacter p | 1994 |
Amoxycillin capsules with omeprazole for the eradication of Helicobacter pylori. Assessment of the importance of antibiotic dose timing in relation to meals.
Topics: Adolescent; Adult; Aged; Amoxicillin; Drug Administration Schedule; Duodenal Ulcer; Eating; Female; | 1994 |
One-week low-dose triple therapy for the eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 1995 |
Effects of omeprazole and eradication of Helicobacter pylori on gastric and duodenal mucosal enzyme activities and DNA in duodenal ulcer patients.
Topics: Antacids; Biopsy; Bismuth; DNA; Drug Therapy, Combination; Duodenal Ulcer; Duodenum; Female; Gastric | 1994 |
Primary and acquired resistance to clarithromycin among Helicobacter pylori strains in Malaysia.
Topics: Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Famotidine; Helicobacter Infe | 1995 |
Low dose clarithromycin plus omeprazole eradicates Helicobacter pylori in duodenal ulcer disease.
Topics: Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Duodenitis; Helicobacter Infections; Heli | 1995 |
Triple therapy eradicated H. pylori equally in patients pretreated with omeprazole or ranitidine. A 12-month follow-up.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Chi-Square Distribution; Confidence Intervals; Drug Ther | 1995 |
Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success.
Topics: Adult; Aged; Amoxicillin; Analysis of Variance; Clinical Trials as Topic; Drug Therapy, Combination; | 1994 |
[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Benzimidazoles; Biopsy; Clarithrom | 1995 |
High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease.
Topics: Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer | 1995 |
Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection.
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hel | 1995 |
Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial.
Topics: Adult; Aged; Antacids; Biopsy; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer | 1994 |
Duodenal ulcer healing drugs.
Topics: Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori | 1994 |
Causal role of Helicobacter pylori in peptic ulcer relapse.
Topics: Aged; Amoxicillin; Bismuth; Chi-Square Distribution; Drug Therapy, Combination; Gastric Mucosa; Heli | 1994 |
Omeprazole 40 mg o.m. combined with amoxycillin alone or with amoxycillin and metronidazole in the eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; | 1994 |
Roxithromycin in the eradication of Helicobacter pylori.
Topics: Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; | 1994 |
[24-hour gastric pH profile with 2 x 20 mg and 2 x 40 mg omeprazole in patients with Helicobacter pylori-associated gastroduodenal ulcer disease].
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastric Acidity | 1994 |
Omeprazole, bismuth and clarithromycin in the sequential treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Bismuth; Clarithromycin; Drug Administration Schedule; Female; Gastritis; Helicobacter | 1994 |
Bismuth-free triple therapy for eradicating Helicobacter pylori and reducing the gastric ulcer recurrence rate.
Topics: Amoxicillin; Anti-Ulcer Agents; Diterpenes; Drug Therapy, Combination; Fatty Alcohols; Female; Gastr | 1994 |
Medium- and high-dose omeprazole plus amoxicillin for eradication of Helicobacter pylori in duodenal ulcer disease.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Female; Heli | 1994 |
Short report: omeprazole-tetracycline combinations are inadequate as therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Dose-Response Relationship, Drug; Drug Therapy, Combination | 1994 |
Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients.
Topics: Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mucosa; Gastrit | 1994 |
[Eradication of metronidazole-resistant Helicobacter pylori: is omeprazole/amoxicillin a therapeutic alternative?].
Topics: Adult; Aged; Amoxicillin; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Co | 1994 |
[Omeprazole/amoxicillin: improved eradication of Helicobacter pylori in smokers because of N-acetylcysteine].
Topics: Acetylcysteine; Adult; Aged; Amoxicillin; Drug Therapy, Combination; Female; Gastric Mucosa; Helicob | 1994 |
[Omeprazole/amoxicillin: impaired eradication of Helicobacter pylori in smoking but not in premedication with omeprazole].
Topics: Adult; Aged; Amoxicillin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter p | 1994 |
Medium- or high-dose omeprazole plus amoxicillin eradicates Helicobacter pylori in gastric ulcer disease.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Drug Therapy, Combination; Female; Helicobacter Infecti | 1994 |
[Omeprazole modified antibiotic therapy of Helicobacter pylori infection: can clarithromycin be replaced by roxithromycin?].
Topics: Adult; Aged; Aged, 80 and over; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Female; Helico | 1994 |
Lansoprazole and Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; | 1993 |
Omeprazole versus famotidine in the healing and relapse of duodenal ulcer.
Topics: Absenteeism; Adult; Analgesics; Antacids; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; H | 1993 |
Helicobacter pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens.
Topics: Aged; Amoxicillin; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combinati | 1993 |
Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Breath Tests; Drug Administration | 1994 |
One-year follow-up of duodenal ulcers after 1-wk triple therapy for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Follow-Up Studi | 1994 |
Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin.
Topics: Adolescent; Adult; Aged; Amoxicillin; Drug Administration Schedule; Drug Therapy, Combination; Duode | 1993 |
Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study.
Topics: Adult; Aged; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; | 1993 |
Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Drug Administration Schedule; Drug Therapy, Combination | 1993 |
Prevention of duodenal ulcer recurrence with penicillin. A double-blind, placebo-controlled trial.
Topics: Double-Blind Method; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; M | 1993 |
Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized, controlled study of efficacy and side effects.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Colloids; Drug Therapy, Combination; Female; Helico | 1996 |
Cure of Helicobacter pylori infection: role of duration of treatment with omeprazole and amoxicillin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Gastric Mucosa; | 1996 |
[Ulcer healing through the elimination of Helicobacter pylori: is a week of therapy enough?].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug The | 1996 |
Pathogenesis of gastric metaplasia of the human duodenum: role of Helicobacter pylori, gastric acid, and ulceration.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Du | 1996 |
Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Resistance, Micr | 1995 |
Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Therapy, Combina | 1995 |
Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithro | 1995 |
Effect of Helicobacter pylori eradication on the healing and recurrence of peptic ulcer: combination therapy with low-dose omeprazole and clarithromycin.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Therapy, Combination; | 1995 |
Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Amoxicillin; Anti-Ulcer Agents; Capsu | 1995 |
Addition of metronidazole to omeprazole/amoxycillin dual therapy increases the rate of Helicobacter pylori eradication: a double-blind, randomized trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; An | 1995 |
Prevention and treatment of low-grade B-cell primary gastric lymphoma by anti-H. pylori therapy.
Topics: Adolescent; Adult; Aged; Amoxicillin; Antitrichomonal Agents; Drug Therapy, Combination; Female; Hel | 1995 |
Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cohort Studies; Esophagitis, Peptic; | 1996 |
Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Duodenal Ulcer; Dy | 1996 |
Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer.
Topics: Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Female; Gastric Acid; Gastric Acidity Determination; | 1996 |
Dual therapy versus triple therapy for Helicobacter pylori-associated duodenal ulcers.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribut | 1996 |
Low eradication rates of Helicobacter pylori with omeprazole plus amoxycillin combination in a Turkish population.
Topics: Amoxicillin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicob | 1996 |
Omeprazole coupled with two antibiotics for Helicobacter pylori eradication and prevention of ulcer recurrence.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Com | 1996 |
The use of azithromycin in short-term low-dose triple therapies for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Therapy, Combination; Heli | 1996 |
Low H. pylori reinfection rate after triple therapy in Chilean duodenal ulcer patients.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Chile; Drug Therapy, Combination; | 1996 |
Efficacy of ciprofloxacin in the eradication of Helicobacter pylori.
Topics: Adult; Aged; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Ciprofloxacin; Double-Blin | 1996 |
Effects of permanent eradication or transient clearance of Helicobacter pylori on histology of gastric mucosa using omeprazole with or without antibiotics.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Drug Therapy, Co | 1996 |
Treatment of Helicobacter pylori infection with low or high dose omeprazole combined with amoxycillin and the effect of early retreatment.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combinat | 1996 |
Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Antitrichomonal Agents; Dru | 1996 |
Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 1996 |
One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1996 |
Prolonged treatment with omeprazole does not improve the eradication rate of Helicobacter pylori infection--a short report [corrected].
Topics: Adult; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Duodenal Ulcer; Duodenoscopy; Female; Fo | 1995 |
Cure of gastric ulcer disease after cure of Helicobacter pylori infection--German Gastric Ulcer Study.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Biopsy; Bismuth; Drug Administration Schedule; Drug The | 1996 |
Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single-centre study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Ant | 1995 |
Omeprazole-amoxycillin versus omeprazole-amoxycillin-clarithromycin in the eradication of Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Combinations; Drug Thera | 1996 |
Prospective evaluation of the macrolide antibiotic dirithromycin for the treatment of Helicobacter pylori.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Drug Combinations; Eryth | 1996 |
Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1996 |
A seven-day Helicobacter pylori treatment regimen using clarithromycin, omeprazole and tripotassium dicitrato bismuthate.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, C | 1996 |
Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, | 1996 |
Pharmacokinetic and pharmacodynamic interactions between omeprazole and amoxycillin in Helicobacter pylori-positive healthy subjects.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Area Under Curve; Breath Tests; Cross- | 1996 |
Dose-response of omeprazole combined with amoxycillin on duodenal ulcer healing and eradication of Helicobacter pylori.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; | 1996 |
The effects of omeprazole 20 and 40 mg twice daily on intragastric acidity in duodenal ulcer patients.
Topics: Adult; Circadian Rhythm; Cross-Over Studies; Duodenal Ulcer; Enzyme Inhibitors; Female; Gastric Acid | 1996 |
4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; | 1996 |
Helicobacter pylori eradication with short-term therapy leads to duodenal ulcer healing without the need for continued acid suppression therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 1996 |
One week treatment for Helicobacter pylori infection: a randomised study of quadruple therapy versus triple therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, C | 1995 |
Only four days of quadruple therapy can effectively cure Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Th | 1995 |
[Eradication of Helicobacter pylori in patients with end-stage renal disease undergoing dialysis treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Age | 1996 |
Helicobacter pylori eradication--evaluation of triple therapy containing omeprazole.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ul | 1996 |
One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administrat | 1996 |
Enhanced eradication of Helicobacter pylori by pre- versus post-prandial amoxycillin suspension with omeprazole: implications for antibiotic delivery.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Eating; Female; Helicobacter Infec | 1996 |
Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Gastroscopy; Helic | 1996 |
Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Heli | 1996 |
Omeprazole and clarithromycin with and without metronidazole for the eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cohort Studies; Drug Administration Schedu | 1996 |
Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Dyspep | 1996 |
Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy.
Topics: Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Drug Therapy, Co | 1996 |
Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Ulcer | 1996 |
Omeprazole versus ranitidine: short-term triple-therapy in patients with Helicobacter pylori-positive duodenal ulcers.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Chi-Square Distributi | 1996 |
One-week therapy for Helicobacter pylori. A randomized trial of two treatment regimens.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Fe | 1996 |
Chemoprevention trial on precancerous lesions of the stomach in Venezuela: summary of study design and baseline data.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anticarcinogenic Agents; Antioxidants; Clarithromyc | 1996 |
Therapeutic options after failed Helicobacter pylori eradication therapy.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinat | 1996 |
A liquid chromatography assay for the study of serum and gastric juice metronidazole concentrations in the treatment of Helicobacter pylori.
Topics: Antitrichomonal Agents; Chromatography, High Pressure Liquid; Drug Interactions; Gastric Juice; Heli | 1996 |
Significant increase in eradication rates of Helicobacter pylori infection with two consecutive dual therapies (omeprazole and amoxycillin or omeprazole and clarithromycin). A randomized study in 450 Spanish patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cross-Over Studies; Dr | 1996 |
Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer A | 1996 |
Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Azithromyc | 1996 |
Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clar | 1996 |
High-dose proton pump inhibitor plus amoxycillin for the treatment or retreatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Dose-Response | 1996 |
One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Admin | 1996 |
Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer | 1996 |
Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Sc | 1996 |
Randomised controlled trial of ranitidine versus omeprazole in combination with antibiotics for eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistanc | 1996 |
Reinfection and duodenal ulcer relapse in south-east Asian patients following successful Helicobacter pylori eradication: results of a 2-year follow-up.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-U | 1996 |
Molecular typing of Helicobacter pylori isolates from a multicenter U.S. clinical trial by ureC restriction fragment length polymorphism.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Bacterial Typing | 1997 |
Evaluation of the efficacy and tolerability of four different therapeutic regimens for the Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co | 1996 |
Effects of omeprazole and amoxycillin on the human oral and gastrointestinal microflora in patients with Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; beta-Lactamases; Biopsy; Dental Plaq | 1996 |
Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; A | 1997 |
Omeprazole, amoxicillin and bismuth for peptic ulcer healing and Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Drug Interactions; Drug Therapy, Combination; Female; Helicob | 1997 |
Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance?
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromyci | 1997 |
One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combina | 1997 |
Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 1997 |
One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1997 |
Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Female; Follow-Up Studies; Helicobacter | 1997 |
Is the polymerase chain reaction or cure of Helicobacter pylori infection of help in the differential diagnosis of early gastric mucosa-associated lymphatic tissue lymphoma?
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Cross-Over Studies; Diagnosis, Diffe | 1997 |
Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
Topics: Activities of Daily Living; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Adm | 1997 |
Lansoprazole and amoxycillin: observations on the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Double-Bli | 1997 |
Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1997 |
A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, | 1997 |
One-week triple therapy with omeprazole, amoxycillin and tinidazole for Helicobacter pylori infection: the significance of imidazole resistance.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistance, Microbial; Drug Therap | 1997 |
Immediate repeat course of amoxycillin, metronidazole and omeprazole to eradicate Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Femal | 1997 |
Randomized study comparing omeprazole plus amoxycillin versus omeprazole plus clarithromycin for eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug | 1997 |
An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Gastriti | 1997 |
Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients?
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Fe | 1997 |
Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; | 1997 |
Omeprazole-based dual and triple regimens for Helicobacter pylori eradication in children.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Biopsy; Child; C | 1997 |
Another therapeutic schedule in eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti | 1997 |
Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients.
Topics: Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Fema | 1997 |
Eradication of H. pylori in a developing country: comparison of lansoprazole versus omeprazole with norfloxacin, in a dual-therapy study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug | 1997 |
[Comparative effect of lansoprazole/amoxicillin with omeprazole/amoxicillin for the eradication of Helicobacter pylori in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 1997 |
Eradication of Helicobacter pylori in peptic ulcer disease with amoxycillin, 2.0 g, and omeprazole, 80 or 120 mg: a prospective randomized trial.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Biopsy; Dose-Response Relationship, Drug; Drug Therapy, | 1997 |
Influence of a proton pump inhibitor-based therapy on Helicobacter pylori strain selection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Gastric Muc | 1997 |
Helicobacter pylori eradication--comparison of three drug regimens and symptomatic assessment in duodenitis and antral gastritis.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; | 1997 |
PCR-RFLP typing of ureC from Helicobacter pylori isolated from gastric biopsies during a European multi-country clinical trial.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Clarithromycin; D | 1997 |
Age-dependent eradication of Helicobacter pylori with dual therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Age Factors; Aged; Amoxicillin; Anti-Ulc | 1997 |
Gastric corpus IL-8 concentration and neutrophil infiltration in duodenal ulcer patients.
Topics: Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Enzyme Inhibitors; Female; Gastritis; Helicobacter I | 1997 |
Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 1997 |
Cure with omeprazole plus amoxicillin versus long-term ranitidine therapy in Helicobacter pylori-associated peptic ulcer bleeding.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Drug Administration Schedule; Drug T | 1997 |
A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibit | 1997 |
Two omeprazole-based Helicobacter pylori eradication regimens for the treatment of duodenal ulcer disease in general practice.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Double-Blind Method; Drug Therapy, Combination; Duodenal | 1997 |
The management of failed dual or triple therapy for Helicobacter pylori eradication.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Fe | 1997 |
Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; | 1997 |
Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Canada; Clarithromycin; Double-Blind Method; Drug Resista | 1997 |
Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Com | 1997 |
Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 1997 |
Triple therapy with lansoprazole, clarithromycin, and amoxicillin for the cure of Helicobacter pylori infection: a short report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Com | 1996 |
Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diar | 1996 |
Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: a short report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Clarithromycin; Diarrhea; Drug Administration | 1996 |
Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Clarithromycin; Drug Therapy | 1996 |
Quadruple therapy: the golden bullet or a drug too far?
Topics: Antacids; Drug Therapy, Combination; Enzyme Inhibitors; Famotidine; Helicobacter Infections; Helicob | 1996 |
Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug The | 1996 |
Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Administration Schedule; D | 1996 |
Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Bacterial Protein | 1996 |
No additional value of bismuth subcitrate to combination omeprazole/amoxicillin therapy in the eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Atrophy; Biopsy; Data Interpreta | 1997 |
One week triple therapy for Helicobacter pylori: does high-dose clarithromycin confer additional benefit?
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Cl | 1997 |
[Hormonal changes and secretion and stomach mucosal microstructure in the course of H. pylori in patients with duodenal ulcer].
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Epidermal Growth Factor; Gastric Juice; Gas | 1997 |
[Endocrine and exocrine gastric mucosal secretion in the course of H. pylori eradication in patients with non-ulcer dyspepsia].
Topics: Amoxicillin; Bismuth; Dyspepsia; Epidermal Growth Factor; Gastric Juice; Gastric Mucosa; Gastrins; H | 1997 |
Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Female; Helicobacte | 1997 |
The efficacy and safety of one-week triple therapy with lansoprazole, clarithromycin, and metronidazole for the treatment of Helicobacter pylori infection in Japanese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1997 |
Omeprazole-based dual and triple therapy for the treatment of Helicobacter pylori infection in peptic ulcer disease: a randomized trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duod | 1997 |
Highly effective second-line anti-Helicobacter pylori therapy in patients with previously failed metronidazole-based therapy.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithr | 1997 |
Multicenter evaluation of dual-therapy (omeprazol and amoxycillin) for Helicobacter pylori-associated duodenal and gastric ulcer (two years of the observation).
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Administration Schedule; Drug Synergis | 1997 |
Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Ag | 1998 |
Adding once-daily omeprazole 20 mg to metronidazole/amoxicillin treatment for Helicobacter pylori gastritis: a randomized, double-blind trial showing the importance of metronidazole resistance.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Chronic Disease; C | 1998 |
Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Data Interpr | 1998 |
One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 1997 |
One-week therapy with omeprazole, clarithromycin and metronidazole or ornidazole, followed by 3 weeks' treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomona | 1997 |
[Omeprazole and azithromycin with and without metronidazole in the eradication of Helicobacter pylori in duodenal ulcer disease].
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Therapy, Combination; Duodenal U | 1997 |
Double-blind trial of omeprazole and amoxicillin in the cure of Helicobacter pylori infection in gastric ulcer patients. The Ulcer Study Group, Germany.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Dru | 1998 |
Prevention of gastric ulcer recurrence with tetraprenylacetone.
Topics: Adult; Aged; Anti-Ulcer Agents; Diterpenes; Drug Therapy, Combination; Female; Gastric Mucosa; Helic | 1998 |
Helicobacter pylori, efficacy of the new triple therapy in six and twelve-day schedules.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; | 1997 |
Does Helicobacter pylori eradication depend on the period of amoxicillin treatment? A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Diterpenes; D | 1998 |
Augmented eradication rates of Helicobacter pylori by new combination therapy with lansoprazole, amoxicillin, and rebamipide.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Alanine; Amoxicillin; Anti-Infective Agents; A | 1998 |
Dual therapy with high or low doses of omeprazole does not achieve an acceptable rate of Helicobacter pylori eradication in duodenal ulcer patients. A multicentre randomized long-term detailed study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Dose-Response Relationship | 1997 |
A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 1998 |
Lansoprazole elevates the ratio of serum pepsinogen I v.s. pepsinogen II.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Helicobacter Infections; He | 1997 |
[new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinat | 1998 |
[Effects of the triple therapy in the eradication of Helicobacter pylori: comparison of 3 different antibiotics].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Clarithromycin; Da | 1997 |
Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment.
Topics: Adult; Alginates; Aluminum Hydroxide; Amoxicillin; Antacids; Anti-Ulcer Agents; Drug Combinations; D | 1998 |
Accuracy of CLOtest after Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulc | 1998 |
Short duration therapy for Helicobacter pylori in Western Australia: the impact of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1998 |
Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug The | 1998 |
Lansoprazole, amoxicillin, and clarithromycin triple therapy in vagotomized patients with dyspeptic complaints. A randomized, double-blind, placebo-controlled, clinical study without pretreatment diagnostic upper endoscopy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug The | 1998 |
A prospective randomized study of amoxycillin and omeprazole with and without metronidazole in the eradication treatment of Helicobacter pylori.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Female; Heli | 1998 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double | 1998 |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1998 |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; | 1998 |
Four-day lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Drug Administration Sch | 1998 |
Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
One-week proton pump inhibitor-based triple therapy eradicates residual Helicobacter pylori after failed dual therapy.
Topics: Adult; Ampicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microb | 1998 |
Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Dose-Respo | 1998 |
[Clarithromycin combined short-term triple therapies for eradication of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithrom | 1996 |
[Omeprazole, clarithromycin and amoxicillin therapy for Helicobacter pylori infection].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Clarithromycin; Drug | 1996 |
[Reflux esophagitis; is the preventive eradication of Helicobacter pylori needed in patients on omeprazole?].
Topics: Enzyme Inhibitors; Esophagitis, Peptic; Female; Gastritis, Atrophic; Gastroesophageal Reflux; Helico | 1998 |
Miconazole gel increases the cure rate of Helicobacter pylori infection when added to lansoprazole and amoxicillin in a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, | 1998 |
Amount of Helicobacter pylori in gastric mucus during anti-H. pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combin | 1998 |
Helicobacter pylori eradication in the healing and recurrence of benign gastric ulcer: a two-year, double-blind, placebo controlled study.
Topics: Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter | 1997 |
Eradication of Helicobacter pylori reduces the rate of duodenal ulcer rebleeding: a long-term follow-up study.
Topics: Adult; Amoxicillin; Antacids; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; | 1998 |
Two-day quadruple therapy for cure of Helicobacter pylori infection: a comparative, randomized trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Fema | 1998 |
Effects of Helicobacter pylori eradication on gastric function indices in functional dyspepsia. A prospective controlled study.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dyspepsi | 1998 |
One-week triple therapy with omeprazole, clarithromycin, and nitroimidazole for Helicobacter pylori infection in children and adolescents.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Administrat | 1998 |
Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 1998 |
Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Bli | 1998 |
Omeprazole, azithromycin and either amoxycillin or metronidazole in eradication of Helicobacter pylori in duodenal ulcer patients.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; | 1998 |
Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection?
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug | 1997 |
Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Metho | 1997 |
[Helicobacter pylori: 6-day triple therapy in duodenal ulcer].
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; He | 1998 |
Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Admin | 1998 |
Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Addition of bismuth subnitrate to omeprazole plus amoxycillin improves eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up S | 1998 |
Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Ascorbic Acid; China; Double-Blind Method; Drug Therapy, Comb | 1998 |
Spiramycin as an alternative to amoxicillin treatment associated with lansoprazole/metronidazole for Helicobacter pylori infection in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool | 1998 |
Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duode | 1998 |
Acid suppression by omeprazole does not affect orally administered metronidazole bioavailability and metabolism in healthy male volunteers.
Topics: Administration, Oral; Adult; Anti-Ulcer Agents; Antitrichomonal Agents; Biological Availability; Cro | 1998 |
US double-blind, controlled trials of omeprazole and amoxycillin for treatment of Helicobacter pylori.
Topics: Administration, Oral; Adult; Amoxicillin; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Doubl | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, D | 1998 |
Two-day 'weekend' lansoprazole-quadruple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1998 |
[Eradication therapies for Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection.
Topics: Aged; Anti-Ulcer Agents; Area Under Curve; Gastric Emptying; Gastrins; Gastroesophageal Reflux; Heli | 1998 |
Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1998 |
Amoxycillin resistance is one reason for failure of amoxycillin-omeprazole treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter Infecti | 1998 |
Factors influencing Helicobacter pylori eradication with 2 week combination therapy of lansoprazole and amoxycillin: intragastric distribution of colonization and gastric mucosal atrophy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Administration Sch | 1998 |
Factors influencing corpus argyrophil cell density and hyperplasia in reflux esophagitis patients treated with antisecretory drugs and controls.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cell Count; Cross-Sectional Studies; Enterochroma | 1998 |
Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 1998 |
One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromy | 1998 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Female; Gas | 1998 |
Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1998 |
Cure of H. pylori infection using a 7-day triple therapy combining pantoprazole with two antibiotics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1998 |
A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin | 1998 |
Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin | 1998 |
Evaluation of a selective transport medium for gastric biopsy specimens to be cultured for Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; China; Clarithromycin; C | 1998 |
New one-week, low-dose triple therapy for the treatment of duodenal ulcer with Helicobacter pylori infection.
Topics: Adult; Aged; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infecti | 1998 |
Effects of rebamipide in combination with lansoprazole and amoxicillin on Helicobacter pylori-infected gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alanine; Amoxicillin; Anti-Ulcer Agents; Diterpenes; | 1998 |
Effect of rebamipide on Helicobacter pylori infection in patients with peptic ulcer.
Topics: Adult; Aged; Alanine; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Fem | 1998 |
The value of different detection methods of Helicobacter pylori during treatment.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Bacteriological Techniques; Biopsy; Drug Administration | 1998 |
Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Cl | 1998 |
Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1998 |
Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1998 |
Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromy | 1998 |
A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Dyspe | 1998 |
Dual versus triple therapy: comparison of five antibiotic regimens for eradication of Helicobacter pylori in a prospective, randomized study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Dose-Response | 1998 |
Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Clarithromycin; | 1998 |
Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Dr | 1998 |
Chronic urticaria and Helicobacter pylori.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Blood Donors; Breath Tests; | 1998 |
Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; | 1998 |
Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
[Omeprazole plus 2 antibiotics for the eradication of H. pylori, are 5 days of treatment sufficient?].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 1998 |
Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies).
Topics: Adenosine Triphosphatases; Adult; Anti-Ulcer Agents; Chi-Square Distribution; Confidence Intervals; | 1998 |
Optimization of acid suppression for patients with peptic ulcer bleeding: an intragastric pH-metry study with omeprazole.
Topics: Adult; Duodenal Ulcer; Enzyme Inhibitors; Female; Gastric Acid; Helicobacter Infections; Helicobacte | 1998 |
Can the C-14 urea breath test replace follow-up endoscopic biopsies in patients treated for Helicobacter pylori infection?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Br | 1998 |
Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combin | 1998 |
Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Doub | 1998 |
Preliminary study on a novel quadruple eradication therapy with a mucoprotective drug, sofalcone, for Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chalcone; Chalcones; | 1998 |
Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Therapy, Combination; | 1998 |
Randomized controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: a cost-effectiveness analysis.
Topics: Adult; Cost-Benefit Analysis; Dyspepsia; Endoscopy; Female; Helicobacter Infections; Humans; Male; M | 1998 |
Evaluation of a new ultrashort triple therapy for Helicobacter pylori disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Azithromycin; Female; Helic | 1998 |
Eradication of Helicobacter pylori with lansoprazole, roxithromycin and metronidazole--an open pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Drug Resistance, Microbial; Femal | 1998 |
[Effectiveness of the eradication of Helicobacter pylori by treatment with omeprazol, amoxicillin, and clarithromycin according to dosage and administration schedule].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administrat | 1998 |
[Previous treatment with omeprazole and H. pylori: does it diminish the eradication efficacy of the "new" triple therapies of one week's duration?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1998 |
[Treatment with omeprazole, clarithromycin and amoxicillin for one week. Their efficacy and tolerance in eradicating Helicobacter pylori in primary care].
Topics: Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacte | 1998 |
Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection.
Topics: Adult; Antacids; Anti-Ulcer Agents; Cross-Over Studies; Double-Blind Method; Electrocardiography; Fe | 1999 |
The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug Resistance, Microbial; | 1999 |
Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients.
Topics: Adult; Aged; Chromogranin A; Chromogranins; Drug Tolerance; Esophagitis; Female; Gastric Acid; Gastr | 1998 |
Omeprazole, azithromycin and amoxicillin or amoxicillin plus clavulanic acid in eradication of Helicobacter pylori in duodenal ulcer disease.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Clavulanic Acid; Drug Th | 1998 |
[Recurrence rate of H. pylori after successful eradication and second eradication therapy after initial failure of treatment].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Follow-Up Studies; Helico | 1999 |
[Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H. pylori eradication in peptic ulcer disease].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Cost-Benefit Analysis; Drug Evaluation; Drug Therapy | 1999 |
[Four kinds of new triple therapy regiments for Helicobacter pylori eradication in patients with peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin | 1999 |
[A comparative study; one week treatment versus two weeks treatment with lansoprazol, amoxycillin and clarythromycin for the eradication of Helicobacter pylori in patient with gastric and duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Admini | 1999 |
[Triple therapy regimens involving H2 blockaders for therapy of Helicobacter pylori infections].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1999 |
Enhancing compliance not a prerequisite for effective eradication of Helicobacter pylori: the HelP Study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, | 1999 |
[Treatment with omeprazole, clarithromycin and amoxicillin over 6 days in patients with Helicobacter pylori-infected duodenal ulcer].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug | 1999 |
Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; D | 1999 |
Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Chlamydia Infections; Chlamydophila pneumoniae; Chronic Di | 1999 |
Helicobacter pylori gastritis in children: efficacy of 2 weeks of treatment with clarithromycin, amoxicillin and omeprazole.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool; Clarithr | 1999 |
The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy.
Topics: Acute Disease; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-B | 1999 |
Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, Combina | 1999 |
Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; | 1999 |
The cost effectiveness of Helicobacter pylori eradication versus maintenance and episodic treatment in duodenal ulcer patients in Sweden.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Cost-Benefit Analysis; Decision Trees; Duodenal Ulcer; Hel | 1995 |
The effect of antibiotic therapy on bleeding from duodenal ulcer.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, | 1999 |
Once-daily therapy for H. pylori infection: a randomized comparison of four regimens.
Topics: Adult; Amoxicillin; Azithromycin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combin | 1999 |
Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1999 |
Rapid elimination of Helicobacter pylori and reduction of histocompatibility leucocyte antigen-DR expression 12 h after a single dose of omeprazole, amoxycillin and metronidazole triple therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Drug Therapy, Combination; Female; Ga | 1999 |
Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Carnosine; | 1999 |
The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1999 |
Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; C | 1999 |
[Antral biopsy is sufficient to confirm Helicobacter pylori eradication with the "new" one-week long triple treatments].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Administration S | 1999 |
Head-to-head comparison of 1-week triple regimens combining ranitidine or omeprazole with two antibiotics to eradicate Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobact | 1999 |
Eradication of Helicobacter pylori with a Chinese herbal medicine without emergence of resistant colonies.
Topics: Amoxicillin; Anti-Ulcer Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Chines | 1999 |
Helicobacter pylori-positive functional dyspepsia in elderly patients: comparison of two treatments.
Topics: Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; D | 1999 |
Helicobacter pylori as a possible bacterial focus of chronic urticaria.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Drug Therapy, Combination; Female; Gastritis | 1999 |
Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 1999 |
CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.
Topics: Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome | 1999 |
Chronic idiopathic urticaria: natural course and association with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Chronic Disease; Cros | 1999 |
Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans.
Topics: Adolescent; Adult; Aged; Antibodies, Bacterial; Bacterial Adhesion; Breath Tests; Colony Count, Micr | 1999 |
Resolution of gastritis induced by Helicobacter pylori 4-5 weeks after successful eradication of infection using a triple therapy regimen of pantoprazole, amoxycillin and clarithromycin for one week.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Biopsy; Cla | 1999 |
One-week triple regime therapy consisting of pantoprazole, amoxicillin and clarithromycin for cure of Helicobacter pylori-associated upper gastrointestinal diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimid | 1999 |
Antibiotic therapy of Helicobacter pylori infection reduces healthcare expenditures related to duodenal ulcer.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Costs; Drug Therapy, | 1999 |
High dose omeprazole plus amoxicillin and azithromycin in eradication of Helicobacter pylori in duodenal ulcers.
Topics: Adult; Aged; Amoxicillin; Azithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duo | 1999 |
Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Antibodies, Bacterial | 1999 |
A novel tablet-based 13C urea breath test for Helicobacter pylori with enhanced performance during acid suppression therapy.
Topics: Anti-Ulcer Agents; Breath Tests; Carbon Isotopes; Dyspepsia; Female; Helicobacter Infections; Helico | 1999 |
The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive older patients with dyspepsia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribution; Clarithr | 1999 |
"Reappearance" of Helicobacter pylori after eradication: implications on duodenal ulcer recurrence: a prospective 6 year study.
Topics: Adolescent; Adult; Aged; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicob | 1999 |
Helicobacter pylori eradication: comparison of three treatment regimens in India.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug | 1999 |
Dual versus triple therapy of Helicobacter pylori infection: results of a multicentre trial.
Topics: Adolescent; Amoxicillin; Anti-Ulcer Agents; Child; Child, Preschool; Clarithromycin; Drug Therapy, C | 1999 |
Effect of treatment of Helicobacter pylori infection on rosacea.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Enzyme Inhibitors; Female; Helico | 1999 |
Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and azithromycin: failure of a "promising" association.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Do | 1999 |
Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Double-Blind Method; Enzyme In | 1999 |
H. pylori and nonulcer dyspepsia: not guilty as charged.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Dyspepsi | 1999 |
Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Doxycycline; Drug Resistance, | 1999 |
Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 1999 |
The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Female; Helicobacter Infections; Helicobacter p | 1999 |
Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Clarithromycin; D | 1999 |
Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial.
Topics: Adult; Aged; Amoxicillin; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Huma | 1999 |
Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 1999 |
Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 1999 |
Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug | 1999 |
The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy.
Topics: Adult; Aged; Barrett Esophagus; Double-Blind Method; Esophagus; Female; Gastroesophageal Reflux; Hel | 1999 |
Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; C | 1999 |
Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Atrophy; Esophagitis; Female; Gastric Mucosa; Gastrins; | 1999 |
[Is lack of stomach carcinoma prevention by Helicobacter pylori eradication unethical?].
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Et | 1999 |
The therapeutic effect of proton pump inhibitors on Helicobacter pylori-positive gastric ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Famotidine; Female; Helicob | 1999 |
Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clari | 1999 |
Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Combinations; Drug Resis | 1999 |
The effect of omeprazole dosing on the isolation of Helicobacter pylori from gastric aspirates.
Topics: Adult; Anti-Ulcer Agents; Breath Tests; Culture Media; Double-Blind Method; Enzyme-Linked Immunosorb | 1999 |
Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1999 |
Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinat | 1999 |
Morphometric estimation of acid output in duodenal ulcer associated with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 1999 |
Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 1999 |
The OAC and OMC options.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Res | 1999 |
Resistance of Helicobacter pylori to antibiotics: the main limitation of current proton-pump inhibitor triple therapy.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme | 1999 |
Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithro | 1999 |
Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Cla | 1999 |
Use of omeprazole in the management of giant duodenal ulcer: results of a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Biopsy; Duodenal Ulcer; Female; Gastroscopy; Heli | 1999 |
Assessment of decisions in the treatment of Helicobacter pylori-related duodenal ulcer: a cost-effectiveness study.
Topics: Adolescent; Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; China; Cimetidine; Cost-Be | 1999 |
Helicobacter treatment with quadruple therapy in primary health care for patients with a history of ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combinati | 1999 |
Evaluation of lansoprazole (an H+/K+-ATPase inhibitor) and azithromycin (an antibiotic) for control of gastric ulceration in swine during periods of feed deprivation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animal Feed; Animals; Anti-Bacterial Agents; Anti-Ulcer Age | 1999 |
The effect of dosing with omeprazole on the accuracy of the 13C-urea breath test in Helicobacter pylori-infected subjects.
Topics: Adult; Anti-Ulcer Agents; Breath Tests; Carbon Radioisotopes; False Negative Reactions; Female; Heli | 1999 |
Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administ | 1999 |
Functional (non-ulcer) dyspepsia and Helicobacter pylori infection. To treat or not to treat?
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combin | 1999 |
Lack of effect of treatment for Helicobacter pylori on symptoms of nonulcer dyspepsia.
Topics: Adult; Antibodies, Bacterial; Blotting, Western; Dyspepsia; Enzyme Inhibitors; Female; Helicobacter | 1999 |
Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co | 1999 |
Cost effectiveness of Helicobacter pylori eradication therapies in patients with duodenal ulcer. An analysis of triple therapy versus two dual therapy alternatives.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 1999 |
The outcome of a 2-week treatment of Helicobacter pylori-positive duodenal ulcer with omeprazole-based antibiotic regimen in a region with high metronidazole resistance rate.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Biopsy; Clarithromycin; Contraindications; Dr | 1999 |
Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1999 |
[Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication].
Topics: Adult; Amoxicillin; Bismuth; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Duodenal Ul | 1999 |
Improvement in lipid and haemostasis patterns after Helicobacter pylori infection eradication in type 1 diabetic patients.
Topics: Adult; Amoxicillin; Analysis of Variance; Body Mass Index; Breath Tests; Cholesterol; Clarithromycin | 1999 |
Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Brazil; Clarithromycin; Drug Therapy, C | 1999 |
Efficacy of two different dosage regimens of omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Breath Tests; Drug Resistance; | 1999 |
Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Re | 1999 |
Pantoprazole suppresses Helicobacter pylori without affecting cure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Drug Thera | 1999 |
Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1999 |
Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1999 |
Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection: results of a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug | 1999 |
Does eradication of Helicobacter pylori alone heal duodenal ulcers?
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Duodenal Ulcer; Female; Helicobac | 2000 |
Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 2000 |
Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2000 |
Bismuth-based quadruple therapy for Helicobacter pylori - a single triple capsule plus lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti- | 2000 |
Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Enzyme Inhibitors; H | 2000 |
Omeprazole or ranitidine bismuth citrate triple therapy to treat Helicobacter pylori infection: a randomized, controlled trial in Vietnamese patients with duodenal ulcer.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Bismuth; Duoden | 2000 |
[Losek therapy of duodenal ulcer in contamination with different strains of Helicobacter pylori].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Duodenal Ulcer; Enzyme In | 1999 |
Furazolidone combination therapies for Helicobacter pylori infection in the United States.
Topics: Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Fu | 2000 |
Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2000 |
Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Asia, Southeastern; | 2000 |
Omeprazole once or twice daily with clarithromycin and metronidazole for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Female; Heli | 2000 |
Helicobacter pylori eradication with dual and low-dose triple therapy in patients with liver cirrhosis.
Topics: Amoxicillin; Drug Administration Schedule; Female; Helicobacter Infections; Helicobacter pylori; Hum | 1999 |
Influence of oral Helicobacter pylori on the success of eradication therapy against gastric Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Clarithromy | 2000 |
Effect of Helicobacter pylori eradication on peptic ulcer disease complicated with outlet obstruction.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, | 2000 |
Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Anti-Bacterial Agents; Anti-Ul | 2000 |
Four-day, twice daily, quadruple therapy with amoxicillin, clarithromycin, tinidazole and omeprazole to cure Helicobacter pylori infection: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diarrhea; Drug A | 2000 |
Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 2000 |
Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; D | 2000 |
Response to triple treatment with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori infections in continuous ambulatory peritoneal dialysis patients.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co | 1999 |
Garlic oil and Helicobacter pylori infection.
Topics: Adult; Allyl Compounds; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Disulfides; Dyspe | 2000 |
[The MACH2 Study: value of inhibiting gastric acid secretion in eradication of Helicobacter pylori with a one week triple therapy protocol].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, Drug; Double-Blind Metho | 2000 |
Helicobacter pylori and its eradication in rosacea.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dy | 1999 |
Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2000 |
Efficacy of bismuth-based triple therapy in children with abdominal pain and Helicobacter pylori gastritis.
Topics: Abdominal Pain; Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool | 2000 |
One week triple therapy for Helicobacter pylori associated duodenal ulcer disease.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichom | 1999 |
Once-daily Helicobacter pylori treatment to family members of gastric cancer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Clarithromycin; Dose-Response Rel | 2000 |
Effect of gastric acid suppression on 13C-urea breath test: comparison of ranitidine with omeprazole.
Topics: Anti-Ulcer Agents; Breath Tests; Depression, Chemical; Enzyme Inhibitors; False Negative Reactions; | 2000 |
Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2000 |
Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Met | 2000 |
Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 2000 |
A prospective trial of lansoprazole triple therapy for pediatric Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Biop | 2000 |
Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Case-Control Studies; Clarithrom | 2000 |
Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Bism | 2000 |
Patients with dyspepsia benefit from eradication of Helicobacter pylori if other organic causes for dyspepsia were carefully ruled out.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Diagnosis, Differential; Dose- | 2000 |
Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromy | 2000 |
Eradication of Helicobacter pylori with lansoprazole based triple therapy in peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antitrichomona | 2000 |
Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2000 |
One-week therapy with pantoprazole versus ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2000 |
Helicobacter pylori eradication with lansoprazole, amoxycillin and clarithromycin: testing an ideal regimen in a multicultural south east Asian population and examining factors potentially influencing eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; China; Clarithromycin; Drug | 2000 |
Endoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Double-Blind Method; | 2000 |
[Effectiveness of omeprazole, clarithromycin and amoxycillin therapy to eradicate Helicobacter pylori in patients with active peptic ulcer. Preliminary results of GENPY study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; C | 2000 |
Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Anti-Ulcer A | 2000 |
A new highly effective short-term therapy schedule for Helicobacter pylori eradication.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitricho | 2000 |
The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clari | 2000 |
Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; | 2000 |
Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study.
Topics: Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Drug Admi | 2000 |
Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance; Drug T | 2000 |
Comparison of seven and fourteen days of lansoprazole, clarithromycin, and amoxicillin therapy for eradication of Helicobacter pylori: a report from India.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2000 |
Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidaz | 2000 |
[Effect of pantoprazole, amoxicillin and metronidazole treatment on the level of H. pylori eradication and the histological image of antral gastritis in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
Effect of Helicobacter pylori eradication on malignant transformation of gastric adenoma.
Topics: Adenoma; Aged; Aged, 80 and over; Amoxicillin; Carcinoma; Cell Transformation, Neoplastic; Clarithro | 2000 |
Efficacy of sucralfate for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2000 |
Helicobacter pylori eradication increases nocturnal acid breakthrough.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Gastric Acid; Helic | 2000 |
Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Endoscopy; Female; Gastric | 2000 |
[Treatment of Helicobacter pylori infection with lansoprazole 30 mg or 60 mg combined with two antibiotics for duodenal ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group.
Topics: Adult; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; | 2000 |
Comparison of the efficacy of 400mg and 800mg of clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection in a Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 2000 |
Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin | 2000 |
Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Aging; Amoxicillin; Anti-Bacterial Agent | 2000 |
Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2000 |
Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Met | 2000 |
Effect of omeprazole on gastric mucosa and serum levels of amoxicillin in patients with non-ulcer dyspepsia.
Topics: Adult; Amoxicillin; Drug Interactions; Dyspepsia; Enzyme Inhibitors; Female; Gastric Mucosa; Helicob | 2000 |
[Cost-effectiveness analysis of 2 strategies of Helicobacter pylori eradication: results of a prospective and randomized study in primary care].
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost-Benef | 2000 |
[Combination of ranitidine and bismuth citrate plus 2 antibiotics in the eradication of Helicobacter pylori].
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Bli | 2000 |
Eradication of Helicobacter pylori with pantoprazole and two antibiotics: a comparison of two short-term regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
Cure of Helicobacter pylori-positive active duodenal ulcer patients: a double-blind, multicentre, 12-month study comparing a two-week dual vs a one-week triple therapy. GISU (Interdisciplinary Group for Ulcer Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Aged; Aged, 80 and over; Amoxicillin; | 2000 |
[Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; C | 2000 |
Intravenous eradication therapy for bleeding gastroduodenal ulcer associated with Helicobacter pylori infection.
Topics: Adult; Aged; Ampicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Fem | 2000 |
Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group.
Topics: Adolescent; Adult; Aged; Algorithms; Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Female; Foll | 2000 |
Five-day triple therapy in Helicobacter pylori-positive duodenal ulcer: an eighteen-month follow-up.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2000 |
In dyspeptic patients without gastric phase III of the migrating motor complex, Helicobacter pylori eradication produces no short-term changes in interdigestive motility pattern.
Topics: Administration, Oral; Adult; Analysis of Variance; Biopsy, Needle; Breath Tests; Clarithromycin; Dru | 2000 |
Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Clarithromycin; Drug Resistance, Microb | 2000 |
[Triple therapy of short-term with azithromycin, amoxycillin and omeprazole for the eradication of Helicobacter pylori].
Topics: Amoxicillin; Anti-Ulcer Agents; Azithromycin; Drug Administration Schedule; Drug Therapy, Combinatio | 2000 |
Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromy | 2000 |
Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2000 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan.
Topics: Anti-Ulcer Agents; Enzyme Inhibitors; Famotidine; Gastric Mucosa; Gastritis; Gastroscopy; Helicobact | 2000 |
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aminopyrine; Anti-Ulcer Agents; Benzimidazoles | 2000 |
Does the depth of gastric ulceration influence a modified dual therapy with amoxicillin and lansoprazole for Helicobacter pylori-associated gastric ulcer?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Drug | 2000 |
Relationship between Helicobacter pylori and rosacea: it may be a myth.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Cohort Studies | 2000 |
High-dose ecabet sodium improves the eradication rate of helicobacter pylori in dual therapy with lansoprazole and amoxicillin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Dit | 2000 |
Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 2000 |
Pretreatment antimicrobial-susceptibility testing in the eradication of H. pylori infection.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Case-Control Studies; Female; Helicobacter Infectio | 2000 |
Eradication of Helicobacter pylori compared with long-term acid suppression in duodenal ulcer disease. A randomized trial with 2-year follow-up. The Danish Ulcer Study Group.
Topics: Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Female; Follow-Up Studies; Gast | 2000 |
One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease.
Topics: Adult; Aged; Amoxicillin; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal U | 2000 |
Pantoprazole, azithromycin and tinidazole: short duration triple therapy for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Azithromycin; Benzimidazoles; Drug Therapy, Co | 2000 |
5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Clarithromycin; D | 2000 |
Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infe | 2000 |
Accuracy of the stool antigen test in the diagnosis of Helicobacter pylori infection before treatment and in patients on omeprazole therapy.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Bacterial; Breath Tests; Enzyme Inhibitors; Feces; Female; | 2001 |
Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, | 2000 |
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazo | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 2001 |
Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies | 2001 |
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 2001 |
The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Presch | 2000 |
Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, C | 2000 |
Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Dr | 2000 |
Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; D | 2000 |
Limited usefulness of a seven-day twice-a-day quadruple therapy.
Topics: Adult; Aged; Amoxicillin; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administratio | 2000 |
A short-term eradication therapy for Helicobacter pylori acute gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adolescent; Adult; Alanine; Amoxicillin; Ant | 2000 |
Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidaz | 2001 |
One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; | 2001 |
Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; | 2001 |
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Clarithr | 2001 |
[Usefulness of new triple therapy containing PPI].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Cl | 2001 |
Comparison of the efficacy and safety of different formulations of omeprazole-based triple therapies in the treatment of Helicobacter pylori-positive peptic ulcer.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Capsules; Clarithromycin; Drug Therapy, Combination; Fema | 2001 |
Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2001 |
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2001 |
Two weeks triple therapy with lansoprazole, amoxycillin and roxythromycin is better than dual therapy with lansoprazole and amoxycillin for H. pylori infection: a randomised, clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Drug Administrat | 2000 |
Comparison of two regimens on eradication of Helicobacter pylori.
Topics: Amoxicillin; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Th | 2000 |
Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Drug The | 2001 |
A randomised trial of amoxycillin versus clarithromycin in combination with omeprazole for eradication of Helicobacter pylori infection in Singapore.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co | 2000 |
cagA Status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2001 |
Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Anti-Ulcer | 2001 |
The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ul | 2001 |
Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection: advantages and outcome.
Topics: Adolescent; Amoxicillin; Anti-Ulcer Agents; Child; Child, Preschool; Clarithromycin; Drug Resistance | 2001 |
Intragastric nitric oxide/nitrite in Helicobacter pylori-infected subjects.
Topics: Adult; Biomarkers; Female; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Hydro | 2001 |
Randomised study of the efficacy of omeprazole and clarithromycin with either amoxycillin or metronidazole in the eradication of Helicobacter pylori in screened primary care patients.
Topics: Adult; Amoxicillin; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2001 |
Ranitidine bismuth citrate or omeprazole-based triple therapy for Helicobacter pylori eradication in Helicobacter pylori-infected non-ulcer dyspepsia.
Topics: Adult; Amoxicillin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Co | 2001 |
Low incidence of Helicobacter pylori infection in patients with duodenal ulcer and chronic liver disease.
Topics: Adult; Anti-Ulcer Agents; Chronic Disease; Duodenal Ulcer; Female; Helicobacter Infections; Helicoba | 2001 |
Effect of Helicobacter pylori eradication on cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) expression during gastric adaptation to aspirin (ASA) in humans.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agent | 2001 |
Eradication of Helicobacter pylori infection in patients with duodenal ulcer and non-ulcer dyspepsia and analysis of one-year reinfection rates.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duoden | 2001 |
Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under | 2001 |
Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Benz | 2001 |
[The effect of cigarette smoking and alcohol consumption on efficacy of Helicobacter pylori eradication].
Topics: Adult; Alcohol Drinking; Amoxicillin; Clarithromycin; Comorbidity; Drug Therapy, Combination; Female | 2000 |
Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarit | 2001 |
Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Analysis of Variance; Anti-Bacterial Agents; A | 2001 |
Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2001 |
Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacter | 2001 |
Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Aged, 80 and over; Aging; Amoxi | 2001 |
Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2001 |
Modified seven-day, quadruple therapy as a first line Helicobacter pylori treatment.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Sch | 2001 |
Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer?
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithrom | 2001 |
Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe?
Topics: Adult; Amoxicillin; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacte | 2001 |
Quadruple therapy for symptomatic spontaneous duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clarithr | 2001 |
Clarithromycin-based triple therapy for non-resistant Helicobacter pylori infection. How long should it be given?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2001 |
Noninvasive stool antigen assay can effectively screen Helicobacter pylori Infection and assess success of eradication therapy in hemodialysis patients.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Antigens, | 2001 |
An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity.
Topics: Adult; Aged; Amoxicillin; Antioxidants; Ascorbic Acid; beta Carotene; China; Double-Blind Method; Dr | 2001 |
The AMOR study: a randomized, double-blinded trial of omeprazole versus ranitidine together with amoxycillin and metronidazole for eradication of Helicobacter pylori.
Topics: Adolescent; Aged; Aged, 80 and over; Amoxicillin; Dose-Response Relationship, Drug; Double-Blind Met | 2001 |
Helicobacter pylori and iron deficiency anaemia in children.
Topics: Adolescent; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath T | 2001 |
A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles | 2001 |
Is untargeted outreach visiting in primary care effective? A pragmatic randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Community Pharmacy Services; Community-Instit | 2001 |
Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; | 2001 |
Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 2001 |
Effectiveness of acid suppression in preventing gastroesophageal reflux disease (GERD) after successful treatment of Helicobacter pylori infection.
Topics: Adult; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Female; Gastric Acid; Gastroesophageal Reflux | 2001 |
[Optimization of the anti-Helicobacter therapy of peptic ulcer on the basis of modern methods of pharmacokinetic analysis].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Monitoring; Drug Therapy, Combination; Female; Helico | 2000 |
Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biological Availability; Cros | 2001 |
Famotidine versus omeprazole, in combination with amoxycillin and tinidazole, for eradication of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combin | 2001 |
Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absenteeism; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2001 |
Prolonging proton pump inhibitor-based anti-Helicobacter pylori treatment from one to two weeks in duodenal ulcer: is it worthwhile?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Amoxicillin; Anti-Bacterial Ag | 2000 |
[Comparative study of the eradication of Helicobacter pylori: ranitidine bismuth citrate versus omeprazole plus two antibiotics for seven days].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Th | 2001 |
A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti | 2001 |
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2001 |
A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 1999 |
Bismuth-based quadruple therapy with bismuth subcitrate, metronidazole, tetracycline and omeprazole in the eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resist | 2001 |
Ultrashort regimen of lansoprazole-amoxicillin-azithromycin for eradicating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azit | 2001 |
Efficacy of a nitroimidazole containing tripletherapy regime in Singapore.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clar | 2001 |
Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease.
Topics: Adult; Aged; Clarithromycin; Double-Blind Method; Female; Gastroesophageal Reflux; Helicobacter Infe | 2001 |
A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia.
Topics: Administration, Oral; Adult; Amoxicillin; Ampicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azit | 2001 |
Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Drug Administration Schedule; Endoscopy; Enzyme Inhib | 2001 |
A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |
Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combinatio | 2001 |
Quantitative assessment of gastric corpus atrophy in subjects using omeprazole: a randomized follow-up study.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Atrophy; Enzyme Inhibitors; Female; Gastric M | 2001 |
Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients.
Topics: Administration, Oral; Aged; Analysis of Variance; Anti-Bacterial Agents; Anti-Ulcer Agents; Area Und | 2001 |
Omeprazole combined with amoxicillin and clarithromycin in the eradication of Helicobacter pylori in children with gastritis: A prospective randomized double-blind trial.
Topics: Adolescent; Amoxicillin; Breath Tests; Child; Child, Preschool; Clarithromycin; Double-Blind Method; | 2001 |
Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cyt | 2001 |
Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2001 |
One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Adm | 2001 |
Helicobacter pylori eradication therapy in gastric high grade non Hodgkin's lymphoma (NHL).
Topics: Aged; Anti-Ulcer Agents; Clarithromycin; Combined Modality Therapy; Drug Therapy, Combination; Gastr | 2001 |
Transfer of clarithromycin to gastric juice is enhanced by omeprazole in Helicobacter pylori-infected individuals.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biological Transport, Active; Chromatography, High | 2001 |
[Modern means of anti-Helicobacter therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti | 2001 |
Pretreatment gastric histology is helpful to predict the symptomatic response after H. pylori eradication in patients with nonulcer dyspepsia.
Topics: Adult; Anti-Ulcer Agents; Breath Tests; Dyspepsia; Female; Helicobacter Infections; Helicobacter pyl | 2001 |
Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimid | 2001 |
Two new treatment regimens for Helicobacter pylori eradication: a randomised study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; | 2001 |
Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Clarithromycin; D | 2001 |
Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2002 |
Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Delayed-Action Preparations; | 2002 |
Helicobacter pylori eradication with beta carotene, ascorbic acid and allicin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |
Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study).
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Gastritis; Gastrointe | 2001 |
[Treatment of perforated gastroduodenal ulcer by simple suture followed by Helicobacter pylori eradication].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; C | 2002 |
Therapeutic effects of antibacterial treatment for intractable skin diseases in Helicobacter pylori-positive Japanese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2002 |
Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacter | 2002 |
Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Breath T | 2002 |
Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Biopsy; | 2002 |
Effect of Helicobacter pylori eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 2002 |
Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2002 |
High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dr | 2002 |
Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome.
Topics: Adult; Aged; Amoxicillin; Antineoplastic Agents, Alkylating; Biopsy, Needle; Chlorambucil; Clarithro | 2002 |
Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Bacterial Agents; Aza Compounds; Cl | 2002 |
Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co | 2002 |
Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Car | 2002 |
Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Interactions | 2002 |
The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Cost-Benefit Analysis; Dyspepsia; Female; Health Care | 2002 |
Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen.
Topics: Adult; Aged; Amoxicillin; Biomarkers; Clarithromycin; Female; Fibrinogen; Helicobacter Infections; H | 2002 |
Influence of Helicobacter pylori infection and cetraxate on gastric mucosal blood flow during healing of endoscopic mucosal resection-induced ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Female; Gastric | 2001 |
One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents, Local; Anti-Ulcer Agents; Drug Resistance, Multiple | 2002 |
Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week.
Topics: Adult; Aged; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin | 2002 |
Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Canada; Clarithromy | 2002 |
[Triple therapy with faropenem, proton pump inhibitor (PPI), and amoxicillin for clarithromycin-resistant H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; beta-Lactams; Cla | 2002 |
Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Drug Therapy, Combination; Enzyme Inhibitors; | 2002 |
Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
Duodenal ulcer healing with 1-week eradication triple therapy followed, or not, by anti-secretory treatment: a multicentre double-blind placebo-controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2002 |
Amoxicillin and ampicillin are not transferred to gastric juice irrespective of Helicobacter pylori status or acid blockade by omeprazole.
Topics: Adult; Amoxicillin; Ampicillin; Area Under Curve; Biological Availability; Chromatography, High Pres | 2002 |
[Microflora of gastric juice in patients after eradication of Helicobacter pylori and treatment with a proton pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Candida albicans; | 2002 |
Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2002 |
Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection on healing rate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Benzi | 2002 |
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2002 |
Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer.
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Duodenum; Helicobacter Infections; Helicobacter | 1992 |
[Comparison of the efficacy of omeprazole/bismuth subcitrate or triple therapy in Helicobacter pylori gastritis. A prospective controlled study].
Topics: Antacids; Breath Tests; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helic | 1992 |
Two weeks treatment with amoxicillin/omeprazole for eradication of Helicobacter pylori.
Topics: Amoxicillin; Biopsy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, C | 1992 |
Short report: omeprazole plus antibiotic combinations for the eradication of metronidazole-resistant Helicobacter pylori.
Topics: Adult; Aged; Bismuth; Circadian Rhythm; Drug Administration Schedule; Drug Resistance, Microbial; Dr | 1992 |
[Short-term therapy with high dosage omeprazole and amoxicillin for Helicobacter pylori eradication. A pilot study].
Topics: Amoxicillin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combinati | 1992 |
Omeprazole vs. ranitidine in short-term treatment of Helicobacter pylori positive duodenal ulcer patients.
Topics: Adult; Aged; Drug Administration Schedule; Duodenal Ulcer; Endoscopy; Female; Helicobacter Infection | 1991 |
The role of omeprazole (40 mg) in the treatment of gastric Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 1991 |
Enhanced clearing of Helicobacter pylori after omeprazole plus roxithromycin treatment.
Topics: Drug Combinations; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; | 1991 |
Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication.
Topics: Adult; Aged; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Mid | 1991 |
Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori.
Topics: Adult; Chronic Disease; Double-Blind Method; Duodenal Ulcer; Female; Gastritis; Helicobacter Infecti | 1991 |
848 other studies available for omeprazole and Infections, Helicobacter
| Article | Year |
|---|---|
Specific therapeutic schemes of omeprazole affect the orientation of Helicobacter pylori.
Topics: Animals; Anti-Bacterial Agents; Gastric Mucosa; Gerbillinae; Helicobacter Infections; Helicobacter p | 2009 |
Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens.
Topics: Anaerobiosis; DNA-Directed RNA Polymerases; Helicobacter Infections; Helicobacter pylori; Humans; Ni | 2022 |
RP-HPLC-DAD Method Development and Validation for Simultaneous Determination of Lansoprazole, Tinidazole, Amoxicillin, and Naproxen in Their Raw Materials and Combined Dosage Form: DOE Approach for Optimization of the Proposed Method.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Drug Th | 2022 |
Helicobacter pylori resistance to antibiotics before and after treatment: Incidence of eradication failure.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infecti | 2022 |
Octreotide-based therapies effectively protect mice from acute and chronic gastritis.
Topics: Animals; Clarithromycin; Ethanol; Gastric Mucosa; Gastritis; Gastritis, Atrophic; Helicobacter Infec | 2022 |
Nocturnal acid breakthrough and esophageal acidification during treatment with dexlansoprazole as compared to omeprazole in patients with gastroesophageal reflux disease.
Topics: Dexlansoprazole; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Hydr | 2022 |
Clinical effect of Anwei Qingyou recipe on peptic ulcer and its effect on the levels of EGF and PGE2: A retrospective study.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dinoprostone; Drug Therapy, C | 2022 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Topics: Helicobacter Infections; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Omepra | 2023 |
Diagnosis and treatment patterns among patients with newly diagnosed Helicobacter pylori infection in the United States 2016-2019.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter I | 2023 |
Physiologically-based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Helico | 2023 |
Gastro-Protective and Therapeutic Effect of Punica granatum against Stomach Ulcer Caused by Helicobacter Pylori.
Topics: Amoxicillin; Animals; Helicobacter Infections; Helicobacter pylori; Omeprazole; Pomegranate; Rats; S | 2023 |
[Helicobacter pylori infection in the HIV + population: a comorbidity to think about].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Ulcer Agents; Clarithromycin; Comor | 2020 |
Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Child; China; Clarithromycin; | 2020 |
Gastroprotective effect of phytoncide extract from Pinus koraiensis pinecone in Helicobacter pylori infection.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Antibodies, Bacterial; Antigens, Bacterial; Bacterial P | 2020 |
Talicia - a 3-drug combination for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Combinations; Helicobacter Infections; Helicobacter pylori; | 2020 |
Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children.
Topics: Adolescent; Anti-Bacterial Agents; Bismuth; Child; Clarithromycin; Cross-Sectional Studies; Drug Hyp | 2020 |
Helicobacter pylori and antibiotic resistance in the pediatric population: an update from Vietnam.
Topics: Amoxicillin; Bismuth; Child; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; | 2020 |
Omeprazole, an inhibitor of proton pump, suppresses De novo lipogenesis in gastric epithelial cells.
Topics: Cells, Cultured; Child; Epithelial Cells; Female; Gastric Mucosa; Helicobacter Infections; Helicobac | 2020 |
Rifabutin triple therapy increased
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug The | 2020 |
Recent Developments Pertaining to H. pylori Infection.
Topics: Adenocarcinoma; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistan | 2021 |
The influence of P-glycoprotein expression in the standard treatment of Helicobacter pylori infection in Sprague Dawley rats.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; ATP Binding Cassette Transporter, Su | 2021 |
Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long-term prospective follow-up study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Female; Follow-Up Studies; | 2021 |
A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Cohort Studies; Drug Combinations; Drug Therapy, Combination; Fe | 2017 |
Gastric Hyperplastic Polyps Associated with Proton Pump Inhibitor Use in a Case without a History of Helicobacter pylori Infection.
Topics: Adenomatous Polyps; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; M | 2017 |
Helicobacter pylori in esplenectomized patients with immune primary trombocytopenia
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Chronic Disease; Clarithromycin; Drug Therapy, Combinatio | 2017 |
Eradication of Helicobacter pylori infection was associated with complete cure of resistant bleeding per gums.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Hu | 2018 |
Retrospective analysis of the use of quadruple therapy with bismuth (Pylera
Topics: Adult; Aged; Breath Tests; Cross-Sectional Studies; Drug Evaluation; Drug Therapy, Combination; Fema | 2018 |
Topics: alpha-Linolenic Acid; Animals; Anti-Bacterial Agents; Drug Resistance, Bacterial; Female; Helicobact | 2019 |
Effect of Helicobacter pylori Treatment on Unexplained Iron Deficiency Anemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Age | 2019 |
Digoxin toxicity precipitated by Helicobacter pylori eradication therapy.
Topics: Acute Kidney Injury; Aged, 80 and over; Amoxicillin; Anti-Arrhythmia Agents; Anti-Bacterial Agents; | 2019 |
Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Re | 2019 |
Effect of Drug Combination on Omeprazole Metabolism by Cytochrome P450 2C19 in Helicobacter pylori Eradication Therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Clarithromycin; Cytochrome | 2019 |
Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction.
Topics: Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Inter | 2013 |
Prevalence of Helicobacter pylori and its recurrence after successful eradication in a developing nation (Morocco).
Topics: Adult; Amoxicillin; Anti-Infective Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Developing | 2013 |
Overexpression of YKL-40 predicts plaque instability in carotid atherosclerosis with CagA-positive Helicobacter pylori infection.
Topics: Adipokines; Aged; Amoxicillin; Animals; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Protei | 2013 |
Bismuth + metronidazole + tetracycline. Why risk adding bismuth?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Combinations; Helicobact | 2013 |
Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Therapy, | 2013 |
[HP eradication prevents recurrent hemorrhages caused by acetylsalicylic acid].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cohort Studies; Drug Therapy, C | 2013 |
Increasing primary antibiotic resistance and ethnic differences in eradication rates of Helicobacter pylori infection in New Zealand--a new look at an old enemy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Asian People; Black People; Cohor | 2013 |
Helicobacter pylori and anemia with pregnancy.
Topics: Adult; Ampicillin; Anemia, Iron-Deficiency; Anti-Infective Agents; Drug Therapy, Combination; Female | 2014 |
[Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Administr | 2014 |
Efficacy and pharmacological mechanism of pronase-enhanced low-dose antibiotics for Helicobacter pylori eradication.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Disease Models, Anim | 2014 |
Gastric acid-dependent diseases: a twentieth-century revolution.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Gastric Acid; Gastroesophageal | 2014 |
Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups.
Topics: Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Fol | 2014 |
[State of mucosal barrier of the stomach after Helicobacter pylori eradication and ulcer healing in patients with duodenal ulcer disease].
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biomarkers; Clarithromycin | 2013 |
Anti-helicobacter pylori effect of total alkaloids of sophora alopecuroides in vivo.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents; Cyclooxygenase 2; Female; Helicobacter Infections; Hel | 2014 |
Gastritis due to Helicobacter pylori, an unusual cause of chronic diarrhoea in HIV infected patients.
Topics: Aged; Amoxicillin; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breath Tests; Chronic Dis | 2014 |
Helicobacter pylori is not eradicated after triple therapy: a nested PCR based study.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Amoxicillin; Bacterial Proteins; Biopsy; Bre | 2014 |
Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule | 2015 |
Seminal Helicobacter pylori treatment improves sperm motility in infertile asthenozoospermic men.
Topics: Adult; Antibodies, Bacterial; Asthenozoospermia; Clarithromycin; Cohort Studies; Confidence Interval | 2014 |
Simultaneous determination of triple therapy for Helicobacter pylori in human plasma by reversed phase chromatography with online wavelength switching.
Topics: Administration, Oral; Anti-Bacterial Agents; Blood Chemical Analysis; Chromatography, Reverse-Phase; | 2015 |
Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group).
Topics: Amoxicillin; Chronic Disease; Clarithromycin; Disease Eradication; Female; Gastritis; Helicobacter I | 2014 |
Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model.
Topics: Animals; Anti-Bacterial Agents; Chemokine CXCL10; Chemokine CXCL9; Clarithromycin; Gastric Mucosa; G | 2015 |
[THE EFFECTIVENESS OF ERADICATION IN PATIENTS WITH PEPTIC ULCER DISEASE ASSOCIATED WITH HELICOBACTER PYLORI, DEPENDING ON THE GENOTYPE OF THE DRUGMETABOLISM OF PROTON PUMP INHIBITORS].
Topics: Cytochrome P-450 CYP2C19; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Ma | 2015 |
Akkermansia muciniphila and Helicobacter typhlonius modulate intestinal tumor development in mice.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Carcinogenesis; Clarithromycin; Drug Therapy, Combinati | 2015 |
Does emerging Clarithromycin resistance signal an obituary to empirical standard triple therapy for Helicobacter pylori infection?
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combin | 2015 |
Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch.
Topics: Esomeprazole; Gastroesophageal Reflux; Helicobacter Infections; Humans; Omeprazole; Proton Pump Inhi | 2015 |
Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains.
Topics: Anti-Infective Agents; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combin | 2016 |
Impact of Helicobacter pylori Eradication Therapy on Platelet Counts in Patients With Chronic Idiopathic Thrombocytopenic Purpura.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Fema | 2015 |
Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Cytoc | 2016 |
Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacteroidetes; Dyspepsia; Female; Firmicutes; Gastric | 2016 |
Influence of CYP2C19 on Helicobacter pylori eradication in Brazilian patients with functional dyspepsia.
Topics: Adult; Aged; Amoxicillin; Brazil; Clarithromycin; Cytochrome P-450 CYP2C19; Dyspepsia; Endoscopy, Ga | 2016 |
Effect of baseline characteristics on response to proton pump inhibitors in patients with peptic ulcer bleeding.
Topics: Adult; Aged; Aged, 80 and over; Asian People; China; Esomeprazole; Europe; Female; Health Status; He | 2017 |
[Palpable purpura with severe pruritus].
Topics: Aged; Amoxicillin; Clarithromycin; Diagnosis, Differential; Drug Therapy, Combination; Female; Gastr | 2008 |
Short-term triple therapy with azithromycin for Helicobacter pylori eradication: low cost, high compliance, but low efficacy.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Azithromycin; Brazil; Drug Administration Schedule; Dru | 2008 |
A search for Helicobacter pyloriin localized vulvodynia.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Dysp | 2008 |
A rapid lateral flow stool antigen immunoassay and (14)C-urea breath test for the diagnosis and eradication of Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Breath Tests | 2008 |
By the way, doctor. I was treated for two weeks with antibiotics and a proton pump inhibitor when I had an H.pylori infection. I've continued with the proton inhibitor to cut down on stomach acid. Could that be harmful?
Topics: Anti-Bacterial Agents; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazol | 2008 |
Endoscopic findings and Helicobacter pylori in children on long-term hemodialysis.
Topics: Adolescent; Child; Child, Preschool; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylo | 2008 |
Triple therapy-based targeted nanoparticles for the treatment of Helicobacter pylori.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relati | 2008 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2008 |
Effects of a one-week treatment with acid gastric inhibitors on Helicobacter pylori-infected mice.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 2008 |
Effects of helicobacter pylori eradication on chronic nonspecific pharyngeal symptoms.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Chronic Disease; Cohort | 2008 |
[Topical issues of paediatric gastroenterology].
Topics: Child; Clarithromycin; Drug Therapy, Combination; Gastroenterology; Gastrointestinal Diseases; Helic | 2008 |
Amoxicillin, clarithromycin, and omeprazole based targeted nanoparticles for the treatment of H. pylori.
Topics: Amoxicillin; Animals; Cells, Cultured; Chitosan; Clarithromycin; Drug Carriers; Drug Combinations; D | 2009 |
Evaluation of use of proton pump inhibitors in Greece.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Prescriptions; Drug Utilization; Gastroesophage | 2009 |
Helicobacter pylori infection in patients with chronic urticaria: correlation with pathologic findings in gastric biopsies.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Biopsy; Case-Control Studies; Chronic Disease; Fema | 2009 |
Parotid mucosa-associated lymphoid tissue lymphoma regression after Helicobacter pylori eradication.
Topics: Amoxicillin; Biopsy, Needle; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; G | 2009 |
Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration | 2010 |
[Antihelicobacteric therapy for the patients with recurrent complicated postoperative gastroduodenal ulcer: indications, principles of conduction, efficacy].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; | 2009 |
[Effect of eradication therapy on nitrogen oxide activity in the gastric juice of patients with chronic gastritis and ulcer disease].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Chronic Disease; Clarithromycin; Drug Therapy, Comb | 2009 |
Interleukin-1beta promotes gastric atrophy through suppression of Sonic Hedgehog.
Topics: Animals; Atrophy; Calcium; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dogs; Epithe | 2010 |
Importance of CYP2C19 genetic polymorphism in the eradication of Helicobacter pylori in north Indians.
Topics: Alkylating Agents; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxyla | 2009 |
Efficacy of standard triple therapy in the treatment of Helicobacter pylori infection: experience from Kuwait.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinat | 2010 |
Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Doxycyc | 2010 |
Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Dose-Response Relationship, Drug; Drug Admi | 2010 |
Effect of Helicobacter pylori infection and its eradication on reflux esophagitis and reflux symptoms.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribution; Clarithromycin; Cross-Sect | 2010 |
Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; E | 2010 |
Helicobacter pylori eradication with a 7-day low-dose triple therapy in hemodialysis patients.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinati | 2010 |
Hyperprolactinaemia induced by proton pump inhibitor.
Topics: Adolescent; Anti-Ulcer Agents; Enzyme Inhibitors; Female; Galactorrhea; Helicobacter Infections; Hel | 2010 |
Quadruple therapy with ecabet sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of Helicobacter pylori after failure of first-line therapy (KDOG0201 Study).
Topics: Abietanes; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combina | 2010 |
Infection: Bismuth improves PPI-based triple therapy for H. pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; China; Clarithromycin; Dose-Response | 2010 |
De novo erosive esophagitis in duodenal ulcer patients related to pre-existing reflux symptoms, smoking, and patient age, but not to Helicobacter pylori eradication: a one-year follow-up study.
Topics: Adult; Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Cl | 2010 |
[Effects of Helicobacter pylori, omeprazole and gastrin on the proliferation and apoptosis of gastric epithelial cell].
Topics: Apoptosis; Cell Division; Cell Line; Cell Proliferation; Epithelial Cells; Gastric Mucosa; Gastrins; | 2010 |
The efficacy and safety of long-term Helicobacter species quadruple therapy in asymptomatic cats with naturally acquired infection.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Clarithromycin; DNA, Bacterial; Dru | 2011 |
Haematological side effect of Helicobacter pylori eradication.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Enzyme Inhibitors; Female; Helicobacter Infections; He | 2010 |
Remission of high-grade B-cell lymphoma in a pediatric patient following Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Drug Therapy, Combination; Helicobacter Infections; | 2011 |
Quadruple or triple therapy to eradicate H pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Combinations; Drug Therapy, Combinati | 2011 |
The efficacy of a 1-week triple therapy for eradication of Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Breath Tests; Child; Chil | 2011 |
Helicobacter pylori eradication: A new, single-capsule bismuth-containing quadruple therapy.
Topics: Anti-Bacterial Agents; Bismuth; Capsules; Drug Combinations; Drug Therapy, Combination; Helicobacter | 2011 |
Helicobacter pylori infection: is sequential therapy superior to standard triple therapy? A single-centre Italian study in treatment-naive and non-treatment-naive patients.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Drug Administration Schedule; Drug Resistanc | 2011 |
Helicobacter pylori associated with chronic urticaria.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Chronic Disease; Clari | 2011 |
[Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Chronic Di | 2011 |
Cure of alopecia areata after eradication of Helicobacter pylori: a new association?
Topics: Adult; Alopecia Areata; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dyspepsia; | 2011 |
[Characteristics of duodenogastric reflux in duodenal ulcer patients and its dynamics after Helicobacter pylori eradication].
Topics: Adult; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Duodenogastric Reflux | 2011 |
[The effects of pronase on drugs concentrations for treatment of Helicobacter pylori infection in gastric tissue].
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Gastric Mucosa; Gastritis; Helicobac | 2011 |
Seeking an optimal eradication therapy for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Asian People; Female; Helicobacter Infections; Helicobacter pylo | 2012 |
[Gastric MALT lymphoma: anatomo-clinical data and outcome of early stage H. pylori-associated gastric MALT-lymphoma resistant to treatment].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocol | 2011 |
Is quadruple therapy the new triple therapy for H pylori?
Topics: Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; He | 2012 |
Mucosal barrier defects in gastric intestinal metaplasia: in vivo evaluation by confocal endomicroscopy.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Chi-Square Distribution; | 2012 |
To compare the efficacy of triple therapy with furazolidone, amoxicillin and omeprazole for two weeks and three weeks in the eradication of Helicobacter pylori in Bangladeshi duodenal ulcer patients.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bangladesh; Drug Therapy, | 2011 |
Omeprazole-induced myositis in a child receiving triple therapy for Helicobacter pylori infection.
Topics: Adolescent; Anti-Ulcer Agents; Helicobacter Infections; Humans; Male; Myositis; Omeprazole | 2012 |
Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cohort Studies; | 2013 |
Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Schedul | 2013 |
Recurrence of Helicobacter pylori After Eradication in Patients with Peptic Ulcer.
Topics: Amoxicillin; Anti-Bacterial Agents; Female; Helicobacter Infections; Helicobacter pylori; Humans; Ma | 2012 |
Factors modulating the outcome of treatment for the eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Antibodies, Bacterial; Antigens, Bacterial; Bacterial P | 2012 |
Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: a pilot study in US Hispanics.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combi | 2012 |
[Eradication of helicobacter pylori: symptomatic treatment of reflux disease?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Double-Blind Method; Drug Ther | 2002 |
Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhib | 2002 |
Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhib | 2002 |
Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhib | 2002 |
Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhib | 2002 |
Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhib | 2002 |
Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhib | 2002 |
Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhib | 2002 |
Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhib | 2002 |
Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhib | 2002 |
Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhib | 2002 |
Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhib | 2002 |
Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhib | 2002 |
Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhib | 2002 |
Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhib | 2002 |
Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhib | 2002 |
Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.
Topics: Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhib | 2002 |
Improvement of long-standing iron-deficiency anemia in adults after eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial | 2002 |
Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2002 |
Nonhealing gastric ulcer caused by chronic alendronate administration.
Topics: Abdominal Pain; Aged; Alendronate; Anti-Ulcer Agents; Bone Resorption; Drug Administration Schedule; | 2002 |
[Antibiotic resistance of Helicobacter pylori in Reunion Island: therapeutic consequences].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribution; Ciprofloxacin; Clari | 2002 |
Normalization of phospholipids concentration of the gastric mucosa was observed in patients with peptic ulcer after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2002 |
Chronic urticaria induced by eradication therapy of Helicobacter pylori: a case report.
Topics: Amoxicillin; Anti-Bacterial Agents; Chronic Disease; Clarithromycin; Helicobacter Infections; Helico | 2002 |
Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cohort Studies; Duodenal Ul | 2002 |
Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Disease Susceptibility; Duo | 2002 |
Efficacy of a 1-week course of proton-pump inhibitor-based triple therapy for eradicating Helicobacter pylori in patients with and without chronic renal failure.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 2002 |
Functional dyspepsia: bye-bye to PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; China; Dyspepsia; Gastroesophageal R | 2002 |
Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicobacter pylori.
Topics: Adult; Aged; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacte | 2002 |
[Ranitidine-bismuth citrate versus omeprazole plus two antibiotics for seven days for the eradication of Helicobacter pylori: a non-concluding clinical essay].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infection | 2002 |
Factors associated with treatment failure of Helicobacter pylori infection in a developing country.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infect | 2002 |
[Seven-day antihelicobacter therapy of duodenal ulcer associated with Helicobacter pylori and prospects for treating patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Ad | 2002 |
[Pariet in eradication therapy plans].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; D | 2002 |
Quantification of Helicobacter pylori resistance in functional and organic dyspepsia.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Cohort Studies; Drug | 2002 |
Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2002 |
Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aryl Hydrocarbon Hydroxylases; Confidence Intervals; | 2002 |
Thrombocytopenic purpura: an unusual complication of eradication therapy for Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Fe | 2002 |
Effect of Helicobacter pylori infection on fibrinogen level in elderly patients with ischaemic heart disease.
Topics: Aged; Aged, 80 and over; Amoxicillin; Biomarkers; Breath Tests; Enzyme Inhibitors; Fibrinogen; Helic | 2002 |
A new serum antibody test kit (E plate) for evaluation of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2002 |
[Concerning the discussion article by I. A. Morozov "Choice of the gastroenterologist"].
Topics: Anti-Ulcer Agents; Duodenal Ulcer; Gastric Acid; Gastric Acidity Determination; Gastric Juice; Gastr | 2002 |
Long-term effects of Helicobacter pylori eradication in Mongolian gerbils.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Cla | 2002 |
[Microbiological factors that influence the eradication of Helicobacter pylori in adults and children].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Ch | 2002 |
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2002 |
[Pharma clinics medication of the month. Esomeprazole].
Topics: Cost Control; Drug Costs; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; | 2002 |
Pseudomembranous colitis requiring surgical intervention following triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Clarithromycin; Drug Therapy, Combination; Enterocol | 2002 |
Low-dose aspirin: protection from the panacea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2002 |
NSAIDs, Helicobacter pylori, and Pandora's Box.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; | 2002 |
[A case for proton pump blocker... When cough comes from the stomach].
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antirheumatic Age | 2002 |
Early events in proton pump inhibitor-associated exacerbation of corpus gastritis.
Topics: Adult; Anti-Ulcer Agents; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; M | 2003 |
Long-term follow up of gastric low-grade mucosa-associated lymphoid tissue lymphoma by endosonography emphasizing the application of a miniature ultrasound probe.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; | 2003 |
Anti-Helicobacter pylori therapy in India: differences in eradication efficiency associated with particular alleles of vacuolating cytotoxin (vacA) gene.
Topics: Adult; Alleles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacteria | 2003 |
[Patient with increased stomach cancer risk. Helicobacter can cause damage here].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2002 |
Monotherapy with mastic does not eradicate Helicobacter pylori infection from mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Colony Count, Microbial; Helicoba | 2003 |
Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori.
Topics: Adult; Anti-Ulcer Agents; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans | 2003 |
Helicobacter pylori hiccup.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinat | 2003 |
Acid inhibitory potency of twice a day omeprazole is not affected by eradication of Helicobacter pylori in healthy volunteers.
Topics: Adult; Antacids; Anti-Bacterial Agents; Bile Acids and Salts; Cytokines; Drug Administration Schedul | 2003 |
Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Cicatrix; Convalescence; Drug The | 2003 |
Gene expression of ornithine decarboxylase, cyclooxygenase-2, and gastrin in atrophic gastric mucosa infected with Helicobacter pylori before and after eradication therapy.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Cyclooxygenase 2; Drug Therapy, Combination; Female; | 2003 |
Treatment of Helicobacter pylori gastritis improves dyspeptic symptoms in Turkish children.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Gastritis; Helicobacter Infections; Heli | 2003 |
Utility and limitations of a method for detecting Helicobacter pylori-specific antigens in the stool.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antigens, Bact | 2003 |
Triple eradication therapy counteracts functional impairment associated with Helicobacter pylori infection in Mongolian gerbils.
Topics: Amoxicillin; Animals; Anti-Ulcer Agents; Colony Count, Microbial; Drug Therapy, Combination; Gastric | 2003 |
Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori.
Topics: Amoxicillin; Anti-Ulcer Agents; Case-Control Studies; Clarithromycin; Diabetes Mellitus, Type 2; Dru | 2003 |
Isolated granulomatous gastritis successfully treated by Helicobacter pylori eradication: a possible association between granulomatous gastritis and Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2003 |
Seven-day proton pump inhibitor, amoxicillin and clarithromycin triple therapy. factors that influence Helicobacter pylori eradications success.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
Nodular gastritis in adults is caused by Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Biopsy, Needle; Case-Control Studies; Cohort Studies | 2003 |
Acid exposure and altered acid clearance in GERD patients treated for Helicobacter pylori infection.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Thera | 2003 |
Rabeprazole treatment attenuated Helicobacter pylori-associated gastric mucosal lesion formation in Mongolian gerbils.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analysis of Variance; Animals; Anti-Ulcer Agents; Benzimida | 2003 |
Antralization at the edge of proximal gastric ulcers: does Helicobacter pylori infection play a role?
Topics: Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Gastric Mucosa; H | 2003 |
A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer | 2003 |
Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors.
Topics: Adult; Anti-Ulcer Agents; Breath Tests; Carbon Radioisotopes; False Negative Reactions; Female; Heli | 2003 |
The clinical role of cytochrome p450 genotypes in Helicobacter pylori management.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; C | 2003 |
Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Academic Medical Centers; Adult; Aryl Hydrocarbon Hydroxyla | 2003 |
Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Disease Models, Anim | 2003 |
Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Esophagitis, Peptic; Female; | 2003 |
[Medico-economic efficacy of eradication schemes in helicobacter infections in patients with duodenal ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Benzimidazoles; Cost of Illne | 2003 |
[Effectiveness of eradication anti-helicobacter therapy in patients with duodenal ulcer in different drug dosage regimens].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; | 2003 |
Gastric myoelectrical activity in patients with recurrent gastric or duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Endoscopy, Digest | 2003 |
[Helicobacter pylori eradication based upon a drug sensitivity test effectively increased platelet count in a patient with refractory idiopathic thrombocytopenic purpura].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Helicobacter Infections; Helicobacte | 2003 |
[Pharmacotherapy in complex treatment of ulcerous stenosis].
Topics: Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Cimetidine; Drug Therapy, Combinati | 2003 |
Low dose, one-week triple therapy (lanzoprazole, amoxycillin, clarithromycin) for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Com | 2003 |
Effects of primary metronidazole and clarithromycin resistance to Helicobacter pylori on omeprazole, metronidazole, and clarithromycin triple-therapy regimen in a region with high rates of metronidazole resistance.
Topics: Adult; Age Factors; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, | 2003 |
Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, | 2003 |
Summaries for patients. Effects of antibiotic treatment for Helicobacter pylori on normal bowel bacteria.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, | 2003 |
A retrospective study on efficacy of proton-pump inhibitor-based triple therapy for eradication of Helicobacter pylori in patients with chronic renal failure.
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Creatinine; Drug Therapy, Combination; Endosco | 2003 |
Effect of Helicobacter pylori eradicated therapy on water gastric emptying in patients with active duodenal ulcer.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; | 2003 |
[Hyponatremia: an unusual case report].
Topics: Addison Disease; Adrenal Insufficiency; Adult; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antitube | 2003 |
Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapy.
Topics: Adolescent; Adult; Amoxicillin; Anti-Ulcer Agents; Biopsy; Breath Tests; Clarithromycin; Cohort Stud | 2003 |
Secondary eradication of Helicobacter pylori was effective against refractory idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Blood Platelets; Drug Therapy, Combi | 2003 |
Lactoferrin: milking ulcers?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Cattle; Clarithromycin; Drug Thera | 2003 |
Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2003 |
Inhibitory potency of twice-a-day omeprazole on gastric acidity is enhanced by eradication of H. pylori in duodenal ulcer patients.
Topics: Adult; Aged; Ammonia; Anti-Bacterial Agents; Anti-Ulcer Agents; Bile Acids and Salts; Cytokines; Dru | 2003 |
[Heartburn without esophagitis. Symptoms more important than the finding?].
Topics: Androstadienes; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ul | 2003 |
Retreatment of H. pylori with dual therapy using high doses of rabeprazole or lansoprazole can be effective.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2003 |
[Level of Helicobacter pylori infection of the gastric mucosa in the optimization of a daily dose of antihelicobacter drugs].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug | 2003 |
Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Aryl Hydrocarbon Hydrox | 2004 |
Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Childhood Helicobacter pylori infection, clinical presentations, endoscopic, histologic features and results of treatment.
Topics: Adolescent; Amoxicillin; Child; Child, Preschool; Drug Therapy, Combination; Female; Gastroscopy; He | 2003 |
Helicobacter pylori eradication does not exacerbate gastro-oesophageal reflux disease.
Topics: Esophagus; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-I | 2004 |
Does eradication of Helicobacter pylori reduce the risk of carcinogenesis in the residual stomach after gastrectomy for early gastric cancer? Comparison of mucosal lesions in the residual stomach before and after Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Aged; Amoxicillin; Anti-Bacterial Agents; A | 2004 |
[Gastric uptake of gallium67 in the human immunodeficiency virus infection].
Topics: Adult; AIDS-Related Opportunistic Infections; Aluminum Hydroxide; Anti-Bacterial Agents; Anti-Ulcer | 2004 |
Parietal cell density during gastric ulcer healing in the rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cell Count; Female; Helicobacte | 2004 |
[Long-term course of reflux symptoms following Helicobacter pylori eradication].
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromyci | 2004 |
Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Fasting; Female; Gastric Acid; Gastric Mucosa; Gast | 2004 |
Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Benz | 2004 |
Mucosal concentration of basic fibroblast growth factor in the healing process in human giant gastric ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biopsy; Female; Fibroblast Growth Factor | 2004 |
Application of Maastricht 2-2000 guidelines for the management of Helicobacter pylori among specialists and primary care physicians in israel: are we missing the malignant potential of Helicobacter pylori?
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2004 |
The effects of Helicobacter pylori eradication on chemokine production in patients with immune thrombocytopenic purpura.
Topics: Amoxicillin; Anti-Ulcer Agents; Autoimmune Diseases; Chemokines; Clarithromycin; Drug Therapy, Combi | 2004 |
H pylori infection and reflux oesophagitis.
Topics: Cohort Studies; Drug Therapy, Combination; Esophagitis; Gastroesophageal Reflux; Gastrointestinal Ag | 2004 |
Helicobacter pylori: antibiotic resistance and eradication rates in Suffolk, UK, 1991-2001.
Topics: Adult; Age Factors; Amoxicillin; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combinati | 2004 |
Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria.
Topics: Achlorhydria; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinat | 2004 |
Early epigastric pain after PPI administration: exacerbation of Helicobacter pylori corpus gastritis?
Topics: Abdominal Pain; Anti-Ulcer Agents; Dyspepsia; Gastritis; Gastroesophageal Reflux; Helicobacter Infec | 2004 |
Do procalcitonin and C-reactive protein levels have a place in the diagnosis and follow-up of Helicobacter pylori infections?
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Biomarkers; Biopsy; C-Reactive Protein; Calcitonin; | 2004 |
Effect of antibacterial therapy and salivary secretion on the efficacy of Helicobacter pylori eradication in duodenal ulcer patients.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; | 2004 |
Treatment with omeprazole, metronidazole, and amoxicillin in captive South African cheetahs (Acinonyx jubatus) with spiral bacteria infection and gastritis.
Topics: Acinonyx; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; | 2004 |
[Successful treatment of long-standing iron-deficiency anemia in adults by eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anemia, Iron-Deficiency; Clarithr | 2004 |
Complete remission of cyclic thrombocytopenia after Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; D | 2004 |
DNA typing for Helicobacter pylori isolates from eradication-failed patients: comparison of the isolates before and after therapy.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Clarithromycin; DNA | 2004 |
Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Colony Count, Mic | 2004 |
Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan.
Topics: Anti-Ulcer Agents; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Hu | 2004 |
Resolution of Helicobacter pylori associated granulomatous gastritis in a child after eradication therapy.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Drug Therapy, Combi | 2004 |
Triple therapy with pantoprazole, clarithromycin and amoxicillin for eradication in patients with Helicobacter pylori positive duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Benzimidazoles; Clarithromycin; Develop | 2004 |
Effects of Helicobacter pylori eradication among adults with intellectual disability.
Topics: Adult; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Heli | 2004 |
Influence of gastritis on cyclooxygenase-2 expression before and after eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Cyclooxygenase 2; Female; Follow-Up Studies; G | 2004 |
CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Cohort Studies; | 2004 |
[Efficacy of 14 day OBMT therapy as a second-line treatment for Helicobacter pylori infection].
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Femal | 2004 |
Effect of lansoprazole for an idiopathic thrombocytopenic purpura patient with Helicobacter pylori infection who did not respond to prednisolone treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Helicobacter Infections; Helic | 2004 |
Accuracy of a monoclonal antibody-based stool antigen test in the diagnosis of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antigens, | 2004 |
Eradication of Helicobacter pylori induces apoptosis and inhibits proliferation of heterotopic proliferative glands in infected Mongolian gerbils.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Apoptosis; Cel | 2004 |
Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2004 |
Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Age | 2004 |
Results of triple eradication therapy in Japanese children: a retrospective multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; | 2004 |
[The effect of Helicobacter pylori eradication on prokinetic treatment on the quality of life in functional dyspepsia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles | 2004 |
[The best strategies against reflux disease. Acid stomach and the sequelae].
Topics: Anti-Ulcer Agents; Barrett Esophagus; Chest Pain; Esophagitis; Gastroesophageal Reflux; Helicobacter | 2004 |
Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Drug | 2004 |
Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Asian People; Clarithromycin; Drug Resistan | 2005 |
Pharmacokinetic interaction between tacrolimus and clarithromycin in a heart transplant patient.
Topics: Area Under Curve; Azathioprine; Clarithromycin; Drug Administration Schedule; Drug Interactions; Duo | 2005 |
Amoxicillin resistance in Helicobacter pylori: studies from Tokyo, Japan from 1985 to 2003.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidaz | 2005 |
Eradication of Helicobacter pylori decreases mucosal alterations linked to gastric carcinogenesis in Mongolian gerbils.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Carcinogenicity Tests; Cell Prolifer | 2005 |
Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cell Count; | 2005 |
The early effect of proton pump inhibitor therapy on the accuracy of the 13C-urea breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Breath Tests; Carbon Isotopes; Enzyme Inhibitors; Fem | 2005 |
Influence of antimicrobial treatment for Helicobacter pylori infection on the intestinal microflora in Japanese macaques.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Infective Agents; Bacteria, Aero | 2005 |
Helicobacter pylori status and symptom assessment two years after eradication in pediatric patients from a high prevalence area.
Topics: Adolescent; Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Child; | 2005 |
Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Th | 2005 |
Anti-Helicobacter pylori therapy significantly reduces Helicobacter pylori -induced gastric mucosal damage in Mongolian gerbils.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Age | 2005 |
[Is anti-helicobacter therapy a rational approach in treatment of erosive and ulcerous lesions of the gastroduodenal mucosa in patients with inflamatory bowel diseases?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti | 2005 |
New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; | 2005 |
Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura.
Topics: Amoxicillin; Breath Tests; Clarithromycin; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infect | 2005 |
Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Case-Control Studies; Chi-Squa | 2005 |
Long-term acid suppression by omeprazole in gastro-oesophageal reflux disease patients does not lead to anti-gastric autoantibody production.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antibody Formation; Autoantibodies; Blotting, Wes | 2005 |
Cure rate of high dose omeprazole and amoxicillin therapy for treatment-resistant Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Drug R | 2005 |
Comparison of proton pump inhibitor-based triple therapy with losec and the generic drug, Omepradex, for efficacy of Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Co | 2005 |
Has Helicobacter pylori eradication therapy any effect on severity of rosacea symptoms?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective A | 2005 |
[Helicobacter pylori infection in patients with chronic hives and asthma].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibodies, Bacterial; Asthma; Chronic Disease; Clarithrom | 2005 |
Effectiveness of omeprazole- versus lansoprazole-based triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2005 |
[Disappearance of gastric adenocarcinoma in hyperplastic polyp after eradication of Heliobacter pylori. Report of a case].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combin | 2005 |
Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anemia, Iron-Deficiency; Antibodies, Bacterial; Autoantibodies | 2005 |
[The effect of Helicobacter pylori eradication therapy on bismuth absorption of colloidal bismuth subcitrate].
Topics: Absorption; Amoxicillin; Animals; Antacids; Bismuth; Drug Therapy, Combination; Helicobacter Infecti | 2005 |
A new-generation H2 receptor antagonist: quicker and stronger acid inhibition than proton pump inhibitors in the clinical setting?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Benzimidazoles; Gastric Acid; Gastric Acidity D | 2005 |
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2005 |
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2005 |
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2005 |
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2005 |
Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2005 |
Helicobacter heilmannii infection: clinical, endoscopic and histopathological features in Japanese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Clarithrom | 2005 |
Lansoprazole-associated collagenous colitis: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Colitis; Collagen; Colonoscopy; Diagnosis, Differen | 2005 |
Ménétrier's disease in a patient with Helicobacter pylori infection is linked to elevated glucagon-like peptide-2 activity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Gast | 2005 |
Eradication of Helicobacter spp. from a rat breeding colony.
Topics: Amoxicillin; Animal Feed; Animals; Animals, Laboratory; Clarithromycin; DNA Primers; Electrophoresis | 2005 |
Helicobacter pylori and recurrent pain abdomen.
Topics: Abdominal Pain; Adolescent; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool; Endos | 2005 |
Helicobacter pylori eradication, CYP2C19 and omeprazole doses.
Topics: Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Dose-Response Relationsh | 2005 |
Helicobacter pylori eradication decreases the expression of glycosylphosphatidylinositol-anchored complement regulators, decay-accelerating factor and homologous restriction factor 20, in human gastric epithelium.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; CD55 Antigens; CD59 Antigens; Clarithromycin; | 2005 |
Determinants of non-response in Helicobacter pylori eradication trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl | 2005 |
Primary mucosa-associated lymphoid tissue lymphoma occurring in the rectum.
Topics: Amoxicillin; Biopsy, Needle; Clarithromycin; Colonoscopy; Drug Therapy, Combination; Endosonography; | 2005 |
Altered expression of Skp2, c-Myc and p27 proteins but not mRNA after H. pylori eradication in chronic gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2006 |
Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Disease Progression; Disease-Fre | 2005 |
CagA status and Helicobacter pylori eradication among dyspeptic patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2005 |
[The cause of failure of eradication treatment of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2005 |
Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Amoxicillin; Anti-Bacterial Agents; Anti-Ul | 2005 |
Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Amoxicillin; Anti-Bacterial Agents; A | 2005 |
How effective are quadruple therapies as first-line H. pylori eradication therapies?
Topics: Adult; Anti-Infective Agents; Australia; Bismuth; Drug Therapy, Combination; Helicobacter Infections | 2005 |
Helicobacter pylori: factors affecting eradication and recurrence.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2005 |
[What does the H. pylori eradication bring?].
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials as Topic; Double-Blind Method; Drug | 2005 |
Sporadic fundic gland polyps: clinico-pathologic features and associated diseases.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esophagitis, Peptic; Female; Gastric Fundus; Gast | 2005 |
Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Gastric Acidity Determination; Ga | 2005 |
Helicobacter pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetylcysteine; Anti-Bacterial Agents; Clarithromycin; Drug | 2005 |
[Antibacterial activity of a Chinese herbal medicine, Gosyuyu (Wu-Chu-Yu), against Helicobacter pylori].
Topics: Alkaloids; Animals; Chromatography, Thin Layer; Disease Models, Animal; Dose-Response Relationship, | 2005 |
Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Benz | 2006 |
Effect of probiotics and triple eradication therapy on the cyclooxygenase (COX)-2 expression, apoptosis, and functional gastric mucosal impairment in Helicobacter pylori-infected Mongolian gerbils.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Apoptosis; bcl-2-Associated X Protein; Cyclooxygenase 2 | 2006 |
Prevalence and treatment of Helicobacter pylori in patients with blepharitis.
Topics: Adult; Anti-Bacterial Agents; Blepharitis; Breath Tests; Chronic Disease; Drug Therapy, Combination; | 2006 |
[A Case of Cronkhite-Canada syndrome showing resolution with Helicobacter pylori eradication and omeprazole].
Topics: Anti-Ulcer Agents; Colonic Polyps; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hyp | 2006 |
Anaphylaxis to omeprazole: diagnosis and desensitization protocol.
Topics: Adult; Anaphylaxis; Desensitization, Immunologic; Enzyme Inhibitors; Gastritis; Helicobacter Infecti | 2006 |
Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2006 |
Efficacy of Helicobacter pylori eradication on the chronic mucosal inflammation of the remnant stomach after distal gastrectomy for early gastric cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer | 2005 |
"Best practice' for Helicobacter pylori eradication in the primary care setting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2006 |
[Gastric protection and treatment with low-dose aspirin].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; | 2006 |
[Medical, social, and economic effectiveness of treatment of day-case patients with peptic ulcer].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Cost-Benefit An | 2006 |
[Pseudomembranous colitis after Helicobacter pylori eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Ag | 2006 |
Comparison of pantoprazole- vs. omeprazole- based triple therapy regimens in the treatment of Helicobacter pylori infection and duodenal ulcer healing in a Turkish population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti | 2005 |
Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients.
Topics: Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; | 2006 |
Helicobacter pylori eradication in peptic dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration | 2005 |
Helicobacter pylori eradication prior to initiation of long-term non-steroidal anti-inflammatory drug therapy in Chinese patients-a cost-effectiveness analysis.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents | 2006 |
Primary cutaneous MALT-type lymphoma and Helicobacter pylori: a possible relationship.
Topics: Adult; Amoxicillin; Clarithromycin; Diagnosis, Differential; Drug Therapy, Combination; Female; Heli | 2006 |
[Long term results of treatment by simple surgical closure of perforated gastroduodenal ulcer followed by eradication of Helicobacter pylori].
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromyc | 2006 |
Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Double-Blind Method; Female; Gastroesophageal Reflux; Helic | 2006 |
Management of the dyspeptic patient: anything goes?
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Denmark; Drug Therapy, Combinat | 2006 |
Effects of rabeprazole or famotidine during cardiac surgery on perioperative gastric and esophageal pH readings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2006 |
The Efficacy of Helicobacter pylori eradication in the treatment of idiopathic thrombocytopenic purpura--the first study in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Clarithromycin | 2006 |
Complete regression of low-grade mucosa-associated lymphoid tissue (MALT) lymphoma in the gastric stump after eradication of Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinati | 2006 |
Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment.
Topics: Amoxicillin; Ampicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Dru | 2006 |
Urea, fluorofamide, and omeprazole treatments alter helicobacter colonization in the mouse gastric mucosa.
Topics: Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzamides; Enzyme Inhibitors; Female; Gastric Mu | 2006 |
Thyroxine in goiter, H. pylori infection, and gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adsorption; Anti-Ulcer Agents; Benzimidazoles; Biological A | 2006 |
[Prospective study of 420 biopsies realised in patients with duodenal ulcer with positive Helicobacter pylori].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Biopsy; D | 2006 |
[Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease].
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Female; Gastroesophageal Reflux; Gen | 2006 |
Efficacy of two triple eradication regimens in children with Helicobacter pylori infection.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Child, Preschool; Clarithromycin; Dr | 2006 |
Fundic gland polyps and PPI: the Mozart effect of gastrointestinal pathology?
Topics: Enzyme Inhibitors; Gastric Fundus; Helicobacter Infections; Helicobacter pylori; Humans; Hyperplasia | 2006 |
Eradication therapy in Helicobacter pylori-positive patients with halitosis: long-term outcome.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarit | 2007 |
Adverse events reporting.
Topics: Abdominal Pain; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Drug-Related Side Effects an | 2007 |
The management of upper gastrointestinal symptoms: is endoscopy indicated?
Topics: Age Factors; Antacids; Anti-Ulcer Agents; Dyspepsia; Endoscopy, Digestive System; Gastroesophageal R | 2007 |
Results from the pediatric European register for treatment of Helicobacter pylori (PERTH).
Topics: Adolescent; Antacids; Bismuth; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; E | 2007 |
Chest pain during triple therapy for duodenal ulcer.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Chest Pain; Clarithromycin; | 2007 |
Comparison of two invasive diagnostic tests for Helicobacter pylori after antimicrobial therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Therapy, Combina | 2007 |
[Helicobacter pylori infection and eradication are not related to glycosylated hemoglobin levels (HbA1c) in young patients with type 1 diabetes].
Topics: Adolescent; Adult; Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulce | 2007 |
[Pharmacological efficacy of bismuth tripotassium dicitrate in peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Cost-Benefit Analysis; Drug Th | 2007 |
[Antihelicobacter effects of melatonin].
Topics: Adult; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter | 2007 |
Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Dysp | 2007 |
Duodenal gastric metaplasia and Helicobacter pylori infection in patients with diffuse nodular duodenitis.
Topics: Adult; Aged; Case-Control Studies; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Duode | 2007 |
Macrolide resistance in the normal microbiota after Helicobacter pylori treatment.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteroides; Clarithromycin; Drug Resistance, | 2007 |
14-day quadruple therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure in Thailand.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Ag | 2006 |
Helicobacter pylori recurrence and infection rate in Israeli adults.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Breath Tests; Chi-Square Distribution; | 2008 |
A quintuple therapy for H. pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, C | 2007 |
An alternative salvage regimen for Helicobacter pylori-resistant patients with heart failure.
Topics: Amoxicillin; Anti-Bacterial Agents; Comorbidity; Drug Therapy, Combination; Heart Failure; Helicobac | 2008 |
Effects of a one-week treatment with acid gastric inhibitors on Helicobacter pylori-infected mice.
Topics: Analysis of Variance; Animals; Anti-Ulcer Agents; Blotting, Western; Comet Assay; DNA Damage; Helico | 2007 |
Failure of sequential therapy to eradicate Helicobacter pylori in previously treated subjects.
Topics: Adolescent; Adult; Alkylating Agents; Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Enz | 2007 |
Prospective Acid Reflux Study of Iran (PARSI): methodology and study design.
Topics: Biopsy; Comorbidity; Drug Administration Schedule; Esophagogastric Junction; Esophagus; Feasibility | 2007 |
Collagenous gastritis: a rare cause of abdominal pain and iron-deficiency anemia.
Topics: Abdominal Pain; Anemia, Iron-Deficiency; Anti-Ulcer Agents; Biopsy; Child; Collagen; Collagen Diseas | 2007 |
Clarithromycin- and omeprazole-containing gliadin nanoparticles for the treatment of Helicobacter pylori.
Topics: Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Chemistry, Pharmaceutical; Clarithromycin; Drug C | 2008 |
[Duodenal ulcer and helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Duodenoscopy; | 2007 |
[Sequential therapy regimen for Helicobacter pylori infection in children].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Resistance | 2008 |
Effect of H pylori infection and its eradication on hyperammo-nemia and hepatic encephalopathy in cirrhotic patients.
Topics: Adult; Aged; Alkylating Agents; Anti-Bacterial Agents; Anti-Ulcer Agents; China; Clarithromycin; Fem | 2008 |
[Effect of Helicobacter pylori eradication on iron deficiency anemia of unknown origin].
Topics: Adult; Aged; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarith | 2008 |
Gastroesophageal reflux disease after Helicobacter pylori eradication in gastric ulcer patients: a one-year follow-up study.
Topics: Activities of Daily Living; Adult; Aged; Anti-Ulcer Agents; Data Interpretation, Statistical; Esopha | 2008 |
Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice.
Topics: Animals; Anti-Infective Agents; Anti-Ulcer Agents; Carcinoma in Situ; Cell Proliferation; Clarithrom | 2008 |
Chronic urticaria and Helicobacter pylori.
Topics: Adolescent; Adult; Amoxicillin; Case-Control Studies; Chronic Disease; Comorbidity; Drug Therapy, Co | 2008 |
Prevalence of Helicobacter pylori infection in patients with large gastric folds: evaluation and follow-up with endoscopic ultrasound before and after antimicrobial therapy.
Topics: Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis; Helico | 1995 |
[Helicobacter pylori and peptic ulcer--1995 therapeutic indications and recommendations of a Munster Expert Group].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Dr | 1995 |
[Omeprazole + clarithromycin + metronidazole--a new standard for eradication of Helicobacter pylori].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin | 1995 |
[Combined therapy with azithromycin and omeprazole for the eradication of Helicobacter pylori].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Therapy, Combination; Helicobacter Infe | 1995 |
Schönlein-Henoch purpura associated with gastric Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Biopsy; Breath Tests; Chronic Disease; Drug Therapy, Combinat | 1995 |
Suppression of Acid Secretion by Lansoprazole and its Effects on Helicobacter pylori. II. Poster presentations from the 2nd International Colloquium on Proton Pump Inhibitors. Houston, Texas, September 29, 1994.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Helicobacter | 1995 |
Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infe | 1995 |
Treatment of Helicobacter pylori infection with a combination of itraconazole and omeprazole.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans | 1995 |
[Progress on therapy of peptic ulcer (discussion)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Gastritis; Helicobacter Infections; Helicobacter pylori; Hi | 1995 |
90% cure: which anti-Helicobacter therapy can achieve this treatment goal?
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Human | 1995 |
Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety.
Topics: Antacids; Biopsy; Endoscopy, Digestive System; Female; Gastric Mucosa; Gastritis; Gastritis, Atrophi | 1995 |
[Therapy of Helicobacter pylori associated diseases].
Topics: Amoxicillin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combinati | 1995 |
[Helicobacter heilmannii: new spiral shaped bacterium that may be responsible for ulcerated gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Amoxicillin; Anti-Ulcer Agents; Drug Therapy | 1995 |
Proceedings of the 2nd International Colloquium on Proton Pump Inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Enzyme I | 1995 |
New insight in the mechanism of omeprazole antimicrobial combinations to eradicate Helicobacter pylori.
Topics: Amoxicillin; Circadian Rhythm; Clarithromycin; Drug Interactions; Drug Therapy, Combination; Helicob | 1995 |
pH and cure of H. pylori infection: it is difficult to have insights when one is in the dark.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Huma | 1995 |
Helicobacter pylori gastritis therapy with omeprazole and clarithromycin increases serum carbamazepine levels.
Topics: Adult; Carbamazepine; Clarithromycin; Drug Interactions; Gastritis; Helicobacter Infections; Helicob | 1995 |
Toward an optimal treatment of Helicobacter pylori-positive peptic ulcers.
Topics: Bismuth; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ul | 1995 |
Helicobacter pylori eradication in the African setting, with special reference to reinfection and duodenal ulcer recurrence.
Topics: Adult; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazol | 1995 |
Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers.
Topics: Adult; Aged; Aged, 80 and over; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 1995 |
Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Female; Follow-Up Studies; Gastritis; Helicobacter Infe | 1995 |
Helicobacter pylori eradication and reinfection.
Topics: Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; He | 1995 |
Helicobacter pylori eradication and reinfection.
Topics: Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Helicobacte | 1995 |
Helicobacter pylori eradication and reinfection.
Topics: Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; | 1995 |
Antibacterial treatment of gastric ulcers.
Topics: Anti-Bacterial Agents; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Organometal | 1995 |
Helicobacter pylori eradication in the treatment and differential diagnosis of giant folds in the corpus and fundus of the stomach.
Topics: Aged; Amoxicillin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Gastritis, | 1995 |
[Course of histological lesions of the gastric mucosa after eradication of H. pylori in patients with duodenal ulcer. Initial study and 6-month follow-up].
Topics: Adult; Aged; Anti-Bacterial Agents; Biopsy; Drug Therapy, Combination; Duodenal Ulcer; Female; Follo | 1995 |
Helicobacter pylori in patients with systemic sclerosis: detection with the 13C-urea breath test and eradication.
Topics: Adult; Aged; Amoxicillin; Breath Tests; Carbon Isotopes; Drug Therapy, Combination; Dyspepsia; Esoph | 1994 |
Interaction between Helicobacter pylori and human gastric epithelial cells in culture: effect of antiulcer drugs.
Topics: Anti-Ulcer Agents; Bacterial Adhesion; Carcinoma; Cells, Cultured; Cimetidine; Duodenal Ulcer; Epith | 1994 |
Treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Human | 1995 |
Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy.
Topics: Abdominal Pain; Adolescent; Child; Chronic Disease; Drug Resistance; Esophagitis, Peptic; Gastritis; | 1995 |
Peptic ulcer disease in adolescence: changing concepts in the age of Helicobacter pylori.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Helicobacter Infections; Helicobac | 1994 |
One-week low-dose triple therapy: new standards for Helicobacter pylori treatment.
Topics: Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; He | 1995 |
[Low malignancy MALT lymphoma of the stomach: H. pyloric eradication as a therapeutic concept?].
Topics: Amoxicillin; Drug Therapy, Combination; Follow-Up Studies; Gastric Mucosa; Gastritis; Helicobacter I | 1994 |
Treatment of low-grade gastric MALT lymphoma with Helicobacter pylori eradication.
Topics: Amoxicillin; Biopsy; Gastrectomy; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B- | 1995 |
Hitting H pylori for four.
Topics: Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; | 1995 |
Duodenal ulcer healing drugs.
Topics: Amoxicillin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Hydrog | 1994 |
Drugs for treatment of peptic ulcers.
Topics: Antacids; Anti-Bacterial Agents; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagoni | 1994 |
Effective treatment after failure of omeprazole plus amoxycillin to eradicate Helicobacter pylori infection in peptic ulcer disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combinatio | 1994 |
[A Norwegian conference on updating of the treatment of Helicobacter pylori in peptic ulcer. Interessegruppe for Gastroenterologi].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Follow-Up Studies; Helicobacter Infections; Helicob | 1994 |
Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cohort Studies; Drug Therapy, Combination; Fe | 1994 |
Effects of Helicobacter pylori on histamine and carbachol stimulated acid secretion by human parietal cells.
Topics: Aminopyrine; Carbachol; Dose-Response Relationship, Drug; Gastric Acid; Helicobacter Infections; Hel | 1994 |
Helicobacter pylori: a fickle germ.
Topics: Aerobiosis; Culture Media; False Negative Reactions; Gastritis; Helicobacter Infections; Helicobacte | 1994 |
Acid-peptic disease: Helicobacter pylori and omeprazole: great advances but clinical problems remain.
Topics: Aged; Esophagitis, Peptic; Female; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; | 1993 |
Resolution of protein-losing hypertrophic lymphocytic gastritis with therapeutic eradication of Helicobacter pylori.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis, Hypertrophic; He | 1994 |
Short-term omeprazole oral/amoxicillin intravenous therapy for Helicobacter pylori eradication: a lack of therapeutic effect.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Drug Administration Schedule; Drug Therapy, Combination | 1994 |
Healing gastric MALT lymphomas by eradicating H pylori?
Topics: Amoxicillin; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell; Lymp | 1993 |
Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Fem | 1994 |
[What are the indications for proton pump inhibitors? R. Arnold, Marburg, elaborates on the clinical aspects of the controversy regarding lansoprazole. Interview by Gerrit Lichtenberg].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Carcinogenicity Tests; Carcinoi | 1994 |
Eradication of Helicobacter pylori with clarithromycin and omeprazole.
Topics: Adult; Aged; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; | 1994 |
[Quality assurance in everyday routines].
Topics: Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Helicobacter Infections; Helicobacter pylori; | 1994 |
Omeprazole/amoxicillin versus ranitidine/triple therapy for duodenal ulcer: when is the "same" the same?
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobact | 1994 |
Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori--is Helicobacter pylori a pathogenic factor in Ménétrier's disease?
Topics: Adult; Amoxicillin; Drug Therapy, Combination; Female; Gastritis, Hypertrophic; Helicobacter Infecti | 1994 |
[Azithromycin-omeprazole. Treatment for the eradication of Helicobacter pylori].
Topics: Adult; Aged; Azithromycin; Drug Evaluation; Drug Therapy, Combination; Dyspepsia; Female; Helicobact | 1994 |
Short report: treatment of Helicobacter pylori-associated duodenal ulcer with omeprazole plus antibiotics.
Topics: Adult; Aged; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infe | 1993 |
Acid inhibition and amoxicillin activity against Helicobacter pylori.
Topics: Amoxicillin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omepra | 1993 |
Combined intravenous and oral omeprazole/amoxicillin therapy in patients with Helicobacter pylori-positive acute peptic ulcer bleeding.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Drug Therapy, Combination; Female; Helicobacter Infecti | 1993 |
[New development on the study of etiological pathology of gastritis, peptic ulcer and stomach cancers in relationship to Helicobacter pylori infection].
Topics: Antibodies, Bacterial; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male | 1993 |
Long-term omeprazole therapy does not affect Helicobacter pylori status in most patients.
Topics: Aged; Esophagitis, Peptic; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; | 1993 |
Evidence for the essential role of Helicobacter pylori in gastric ulcer disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, C | 1994 |
Apparent reversal of early gastric mucosal atrophy after triple therapy for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Bismuth; Drug Therapy, Combination; Gastric Mucosa; Ga | 1993 |
Proton-pump inhibitor-refractory gastric ulcer and Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Helicobacter Infections; He | 1993 |
Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; | 1993 |
[Helicobacter pylori infection and ulcer disease].
Topics: Amoxicillin; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Stomach Ulcer | 1993 |
[The effect of omeprazole on healing of duodenal ulcers, Helicobacter pylori and gastritis].
Topics: Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middl | 1993 |
One-day therapy for treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Drug Administration Schedule; Drug Therapy, | 1993 |
Short report: high-dose omeprazole and amoxycillin in the treatment of Helicobacter pylori-associated duodenal ulcer.
Topics: Adult; Aged; Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections | 1993 |
[Peptic ulcer and Helicobacter pylori. Comments on the authors' cases].
Topics: Adult; Aged; Anti-Ulcer Agents; Colloids; Drug Evaluation; Duodenal Ulcer; Female; Helicobacter Infe | 1993 |
pH and Hp--gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism.
Topics: Amoxicillin; Duodenal Ulcer; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Hyd | 1993 |
Successful Helicobacter pylori eradication: a systemic effect of antibiotics?
Topics: Adult; Amoxicillin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; | 1993 |
Local cellular and immune response by antral mucosa in patients undergoing treatment for eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Mucosa; | 1993 |
Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cell Division; Female; Gastrins; Gastritis; Helicobacter | 1993 |
Two-week eradication regimen for metronidazole-resistant Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Breath Tests; Ciprofloxacin; Drug Resistanc | 1993 |
Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole.
Topics: Adult; Anti-Ulcer Agents; Antibodies, Bacterial; Breath Tests; Female; Gastric Acid; Gastric Acidity | 1995 |
Response to article by Forné et al.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Colloids; Drug Therapy, Combination; Helicobacter In | 1996 |
Prolonged effect of omeprazole on the 14C-urea breath test.
Topics: Anti-Bacterial Agents; Breath Tests; Carbon Radioisotopes; Dose-Response Relationship, Drug; False N | 1996 |
[Effect of prolonged treatment with proton pump inhibitors on serum gastrin levels and the fundus mucosa. Preliminary results].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Duodenal Ulcer; Enzyme Inhi | 1995 |
[One week triple therapy for eradication of Helicobacter pylori infection: simple and effective].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Adm | 1995 |
Resolution of gastric outlet obstruction after eradication of Helicobacter pylori.
Topics: Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; G | 1995 |
Deterioration of renal function in a nephropathic diabetic patient during omeprazole plus amoxicillin therapy for Helicobacter pylori-associated duodenal ulcer.
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Diabetic Nephropathies; Duodenal Ulcer; Female; Helicobacter I | 1995 |
Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1995 |
Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Cost-Benef | 1996 |
Azithromycin for the cure of Helicobacter pylori infection.
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Therapy, Combina | 1996 |
Helicobacter pylori and gastroduodenal secretory function.
Topics: Anti-Ulcer Agents; Bicarbonates; Duodenal Ulcer; Duodenum; Gastric Acid; Gastric Mucosa; Helicobacte | 1996 |
Therapy with omeprazole and clarithromycin increases serum carbamazepine levels in patients with H. pylori gastritis.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Carbamazepine; Clarithromycin; Drug Interactions; Drug The | 1996 |
Clarithromycin and omeprazole for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Co | 1996 |
[What factors influence healing of duodenal ulcer when Helicobacter pylori eradication treatment is used?].
Topics: Adult; Age Factors; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; | 1996 |
Should omeprazole be used for the treatment and prevention of duodenal ulcer as a monotherapeutic agent?
Topics: Anti-Ulcer Agents; Chronic Disease; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Hu | 1996 |
[New guidelines from the Medical Products Agency: the triple regime against Helicobacter pylori is necessary. Treat only if the ulcer is verified].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Drug | 1996 |
[Is the omeprazole and amoxicillin combination useful in the treatment eradicating Helicobacter pylori in Spain?].
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Heli | 1996 |
One-day combined therapy of children with Helicobacter pylori-associated peptic disease.
Topics: Adolescent; Amoxicillin; Anti-Ulcer Agents; Child; Child, Preschool; Drug Administration Schedule; D | 1996 |
Validity of various diagnostic tests to evaluate cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Bacteriological Techniq | 1996 |
Regression of salivary gland MALT lymphoma after treatment for Helicobacter pylori.
Topics: Bismuth; Doxycycline; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell | 1996 |
[Effectiveness of triple therapy to eradicate H. pylori in patients after failed therapy with omeprazole/amoxicillin].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ul | 1996 |
Pharmacology of the gastric mucosa: a rational approach to Helicobacter polytherapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Ga | 1996 |
Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong.
Topics: Anti-Ulcer Agents; Antitrichomonal Agents; Biopsy; Case-Control Studies; China; Drug Resistance, Mic | 1996 |
Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Cost-Benefit Analysis; Costs and Cost Analysis; D | 1996 |
Italian omeprazole triple therapy--a 1-week regimen.
Topics: Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter | 1996 |
Suppression of Helicobacter pylori colonization with omeprazole.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Helico | 1996 |
A comparative trial of short term therapy with omeprazole plus either amoxycillin or azithromycin for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Drug A | 1996 |
H. pylori treatment recognized by FDA.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter In | 1996 |
Use of PCR and culture to detect Helicobacter pylori in naturally infected cats following triple antimicrobial therapy.
Topics: Amoxicillin; Animals; Bacteriological Techniques; Cats; Cells, Cultured; Drug Therapy, Combination; | 1996 |
[Medico-economic aspects of the treatment of duodenal ulcer: from antisecretory treatment to eradication of Helicobacter pylori].
Topics: Anti-Ulcer Agents; Combined Modality Therapy; Cost-Benefit Analysis; Duodenal Ulcer; Helicobacter In | 1995 |
High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Cl | 1996 |
One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; A | 1996 |
The role of screening for Helicobacter pylori in patients with duodenal ulceration in the primary health care setting.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Antibodies, Bacterial; Drug Therapy, | 1996 |
Inhibition of Helicobacter pylori by garlic extract (Allium sativum).
Topics: Anti-Bacterial Agents; Duodenal Ulcer; Enzyme Inhibitors; Garlic; Gastritis; Helicobacter Infections | 1996 |
[Dynamic imaging of gastric ulcer healing using the most modern Morph-Software].
Topics: Amoxicillin; Anti-Ulcer Agents; Computer Systems; Drug Therapy, Combination; Gastroscopes; Helicobac | 1996 |
Helicobacter pylori and lanzoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastritis; Helicobacter | 1996 |
Short-term low-dose triple therapy with lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 1996 |
[Which factors influence the success of the classical triple therapy in the eradication of Helicobacter pylori?].
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combi | 1996 |
Helicobacter pylori stimulates gastric acid secretion via platelet activating factor.
Topics: Aminopyrine; Animals; Anti-Ulcer Agents; Azepines; Dose-Response Relationship, Drug; Gastric Acid; G | 1996 |
Atrophic gastritis and Helicobacter pylori in reflux esophagitis.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Esophagitis, Peptic; Gastritis, Atrophic; Helicobacter Inf | 1996 |
Effect of proton pump inhibitors on the detection of Helicobacter pylori in gastric biopsies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1996 |
Effect of omeprazole on movement of intravenously administered metronidazole into gastric juice and its significance in treatment of Helicobacter pylori.
Topics: Adult; Biological Transport, Active; Drug Therapy, Combination; Gastric Juice; Gastric Mucosa; Helic | 1996 |
The influence of isolated doses of drugs, feeding and colonic bacterial ureolysis on urea breath test results.
Topics: Adult; Amoxicillin; Bacteria; Bismuth; Breath Tests; Colon; Drug Therapy, Combination; Eating; False | 1995 |
Resolution of a metaplastic duodenal polyp after cure of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Neoplasms; Helicobacter Infection | 1996 |
Helicobacter pylori does not migrate from the antrum to the corpus in response to omeprazole.
Topics: Anti-Ulcer Agents; Biopsy; Colony Count, Microbial; Duodenal Ulcer; Helicobacter Infections; Helicob | 1996 |
Etiological involvement of Helicobacter pylori in "reflux" gastritis after gastrectomy.
Topics: Amoxicillin; Anti-Ulcer Agents; Chalcone; Chalcones; Drug Therapy, Combination; Female; Gastric Muco | 1996 |
Re: short-term treatment with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Helicobacter Infections; | 1996 |
[Association of chronic urticaria with Helicobacter pylori-induced antrum gastritis].
Topics: Adult; Amoxicillin; Chronic Disease; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infe | 1996 |
Helicobacter pylori eradication helps resolve pyloric and duodenal stenosis.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Obstruction; | 1996 |
Dysfunction in gastric myoelectric and motor activity in Helicobacter pylori positive gastritis patients with non-ulcer dyspesia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithrom | 1996 |
Helicobacter pylori infection and omeprazole efficacy.
Topics: Ammonia; Anti-Ulcer Agents; Gastric Acid; Gastric Acidity Determination; Helicobacter Infections; He | 1996 |
[Is there a correlation between the values of breath tests and the response to the treatment for the eradication of Helicobacter pylori?].
Topics: Amoxicillin; Anti-Ulcer Agents; Breath Tests; Duodenal Ulcer; Female; Helicobacter Infections; Helic | 1996 |
Serum pepsinogen C: a useful marker of Helicobacter pylori eradication?
Topics: Adult; Aged; Anti-Ulcer Agents; Antibodies, Bacterial; Biomarkers; Data Interpretation, Statistical; | 1996 |
Barrett's ulcer: the clinical significance today.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Esophagus; Female; Follow-Up Studies; Helicobacter Infections; | 1996 |
Relevance of the ferret model of Helicobacter-induced gastritis to evaluation of antibacterial therapies.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Disease Models, Anim | 1996 |
Is the only good H. pylori a dead H. pylori?
Topics: Anti-Ulcer Agents; Cohort Studies; Follow-Up Studies; Fundoplication; Gastroesophageal Reflux; Helic | 1996 |
Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; | 1996 |
Endoscopic topical therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Topical; Amoxicillin; Antacids; Anti-Ulcer | 1996 |
Eradication of Helicobacter pylori followed by reinfection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Blot | 1996 |
Atopic dermatitis successfully treated by eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Bacterial Agents; Anti-Ulcer Agents; Blott | 1996 |
Proton-pump inhibition and gastric giardiasis: a causal or casual association?
Topics: Aged; Amoxicillin; Animals; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mu | 1995 |
[What is the role of H2 receptor blockers today in ulcer therapy?].
Topics: Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infections; Histamine H2 Antagonists; Hum | 1996 |
Helicobacter pylori, gastric ulcer, and duodenal ulcer.
Topics: Age of Onset; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Omepr | 1996 |
[Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug | 1996 |
[Meta-analysis raises more questions, than it answers].
Topics: Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Meta-Anal | 1996 |
[Meta-analyses are hardly suitable for conclusively proving medical controversies].
Topics: Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Meta-Anal | 1996 |
[Meta-analysis should be regarded with extreme caution].
Topics: Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Meta-Anal | 1996 |
Eradication of helicobacter pylori among patients from a primary care practice.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Drug Therapy, Combination; Endosco | 1996 |
Helicobacter pylori eradication in clinical practice: one-week low-dose triple therapy is preferable to classical bismuth based triple therapy.
Topics: Antacids; Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Administration Schedule; Drug T | 1996 |
[Anti-Helicobacter pylori therapy. Who should be treated, how, how long?].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Drug Administra | 1996 |
Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis.
Topics: Adult; Anti-Ulcer Agents; Female; Gastric Mucosa; Gastrins; Gastritis; Gastroscopy; Helicobacter Inf | 1996 |
Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori, and proton pump inhibitor therapy.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Cohort Studies; Female; Gastric Acid; Gastric Acidity De | 1997 |
Helicobacter pylori reinfection is rare in peptic ulcer patients cured by antimicrobial therapy.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-U | 1996 |
Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy P | 1997 |
Percentage changes in serum pepsinogens are useful as indices of eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Duodenal Ulcer; | 1997 |
Eradication of Helicobacter pylori in patients with end-stage renal disease under dialysis treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Comb | 1997 |
[Breath test in the diagnosis of Helicobacter pylori infection: concordance with histological methods and correlation with anatomopathological lesions of the gastric mucosa].
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Breath Tests; Drug T | 1996 |
[Good results with Helicobacter pylori eradication for treatment of non-ulcer dyspepsia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; D | 1996 |
Life-threatening interaction between clarithromycin and disopyramide.
Topics: Aged; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Disopyramide | 1997 |
[A case of gastric MALT lymphoma regressed endoscopically and pathologically after eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Co | 1997 |
[Time course of disappearance of Helicobacter pylori after topical therapy and new triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Bacterial Agents; Clarithromycin | 1997 |
In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Ceftibuten; Cephalosporins; Clarithro | 1996 |
Ongoing gastric acid inhibition is a confounding factor in Helicobacter pylori diagnosis.
Topics: Amoxicillin; Anti-Ulcer Agents; Biopsy; Endoscopy, Digestive System; Female; Gastric Acid; Gastric J | 1997 |
Effective 2-wk therapy for Helicobacter pylori disease in children.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Evaluation; Drug T | 1997 |
Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Female; Gastric Mucosa; Gastrins; Gastritis; H | 1997 |
A one-week quadruple eradication regimen for Helicobacter pylori in routine clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Dru | 1997 |
The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Buffers; Chromatography, High Pressure Liquid | 1997 |
What is the best azithromycin-based therapy for Helicobacter pylori infection?
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Therapy, Combination; Helicobacter Infe | 1997 |
Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori.
Topics: Adult; Age Factors; Aged; Alcohol Drinking; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin | 1997 |
Does smoking predispose to peptic ulcer relapse after eradication of Helicobacter pylori?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Inflammatory Agents, Non-Ste | 1997 |
Lansoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Car | 1997 |
[Helicobacter pylori eradication: finally clarity].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter I | 1996 |
Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chil | 1997 |
Helicobacter pylori infection accelerates human gastric mucosal cell proliferation.
Topics: Amoxicillin; Anti-Ulcer Agents; Biopsy; Case-Control Studies; Cell Division; Drug Therapy, Combinati | 1997 |
Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1997 |
[The efficacy of using a short course of 6-day duration (OCA-6) in the treatment to eradicate Helicobacter pylori infection. Omeprazole, clarithromycin, amoxicillin].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Evaluation; Drug Therapy | 1997 |
Regression of a large gastric MALT lymphoma with antibiotic treatment to eradicate Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infec | 1997 |
Urticaria during triple therapy for Helicobacter pylori infection: clinical implications.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Eruptions; Drug Therapy, Combination; Fe | 1997 |
Acid secretion, response to omeprazole, and Helicobacter pylori status.
Topics: Anti-Ulcer Agents; Duodenal Ulcer; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Human | 1997 |
Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients.
Topics: Adult; Anti-Ulcer Agents; Biopsy; Duodenal Ulcer; Female; Follow-Up Studies; Gastric Acidity Determi | 1997 |
Proton pump inhibitors and the urea breath test: how long is long enough?
Topics: Anti-Ulcer Agents; Breath Tests; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; P | 1997 |
Evaluation of experimental therapeutics in a new mouse model of Helicobacter felis utilizing 16S rRNA polymerase chain reaction for detection.
Topics: Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Disease Models, Animal; Drug Therapy, Combination | 1997 |
Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Anti-Bacterial Agents; Anti-Ulcer Agents; Biomarke | 1997 |
[One-week treatment with omeprazole, clarithromycin and amoxicillin: high efficacy in the eradication of Helicobacter pylori and cicatrization of duodenal ulcer].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Clarithromycin; Drug | 1997 |
Evaluation of the dyspeptic patient: a cost-utility study.
Topics: Adult; Ambulatory Care; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, | 1997 |
Reversal of long-standing iron deficiency anaemia after eradication of Helicobacter pylori infection.
Topics: Adult; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; D | 1997 |
Treatment of Helicobacter pylori infection favourably affects gastric mucosal superoxide dismutases.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Drug | 1997 |
Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study.
Topics: Amoxicillin; Antigens, Bacterial; Bacterial Proteins; Drug Therapy, Combination; Female; Follow-Up S | 1997 |
Serum 13C-bicarbonate assay for the diagnosis of gastric Helicobacter pylori infection and response to treatment.
Topics: Amoxicillin; Bicarbonates; Bismuth; Carbon Isotopes; Clarithromycin; Drug Therapy, Combination; Gast | 1997 |
[Toxic megacolon after Helicobacter pylori eradication therapy].
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Colon; Diagnosis, Differential; Drug Therapy, Combination; Ent | 1997 |
Comparison of ranitidine and lansoprazole in short-term low-dose triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug | 1997 |
Successful low-dose amoxycillin, metronidazole and omeprazole combination therapy in a population with a high frequency of metronidazole-resistant Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Resistance, Microbial; Drug Therapy, Combination; | 1997 |
Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Fur | 1997 |
Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Com | 1997 |
Regression of mucosa-associated lymphoid-tissue lymphoma of rectum after eradication of Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Female; Follow-Up Studi | 1997 |
Pharmacological therapy of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Ag | 1997 |
Unhealed duodenal ulcers despite Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Case-Control Studies; Clarithromycin; Drug Ad | 1997 |
Duodenal stenosis may not regress after eradication of Helicobacter pylori.
Topics: Amoxicillin; Anti-Ulcer Agents; Constriction, Pathologic; Drug Therapy, Combination; Duodenal Ulcer; | 1997 |
Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Biopsy; Clarithromycin; Combined Modality Therapy; Dose | 1997 |
Development of duodenal ulcer concomitant with successful Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobact | 1997 |
Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer.
Topics: Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Female; Gastric Acid; Gastric Acidity Determination; | 1997 |
Short-term eradication therapy for Helicobacter pylori does not reduce the incidence of gastric metaplasia in duodenal ulcer patients.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Heli | 1997 |
[Two step therapy for education of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 1997 |
Effect of enprostil on omeprazole-induced hypergastrinemia and inhibition of gastric acid secretion in peptic ulcer patients.
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Therapy, Combination; Enprostil; Female; Gastric Acid; Gastric | 1997 |
[Effectiveness of short-term triple therapy for healing Helicobacter pylori infection in ulcer disease].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin | 1997 |
Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Amoxicillin; Anti-Ulcer Agents; Disease-Free Su | 1997 |
Regression of mucosa-associated lymphoid-tissue lymphoma after eradication of Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Helicobacter Infections; Heli | 1997 |
Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Endoscopy; Endosonography; Female; F | 1997 |
Clinical application of gastric histology to monitor treatment of dual therapy in H. pylori eradication.
Topics: Amoxicillin; Anti-Ulcer Agents; Biopsy; Colony Count, Microbial; Drug Therapy, Combination; Female; | 1997 |
H. pylori eradication by LAC.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1997 |
Low dose, short-term, triple therapy for helicobacter pylori associated peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithrom | 1997 |
Helicobacter pylori: corrections and comments.
Topics: Anti-Ulcer Agents; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole | 1997 |
Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; D | 1997 |
One-day high-dose combined therapy of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Evaluation; Drug Therapy, Combination; | 1997 |
Effect of Helicobacter pylori eradication on gastric histology, serum gastrin and pepsinogen I levels, and gastric emptying in patients with gastric ulcer.
Topics: Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Gastric Emptying; Gastrins; Helic | 1997 |
Ménétrièr's disease associated with Helicobacter pylori infection: resolution of enlarged gastric folds and hypoproteinemia after antibacterial treatment.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; | 1997 |
Erosive duodenitis: prevalence of Helicobacter pylori infection and response to eradication therapy with omeprazole plus two antibiotics.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenitis; Female | 1997 |
Lansoprazole, H. pylori, and atrophic gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Gastritis, Atrophic; Helicobacter Infect | 1997 |
Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin, and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Clinical Tr | 1996 |
Treatment of Helicobacter pylori infection: summary of a meeting at the Fourth United European Gastroenterology Week, September 20, 1995.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Resist | 1996 |
Cure of Helicobacter pylori: a hidden curse?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Duodenal Ulcer; Esop | 1997 |
[Successful eradication of H. pylori in an elderly patient with gastric cancer after effective UFT-E therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adenocarcinoma; Aged; Aged, 80 and over; Anti-Ba | 1997 |
Time of Helicobacter pylori eradication assessment following treatment.
Topics: Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Helicobacter Infections; Helico | 1997 |
[Is long-term acid suppression dangerous in existing Helicobacter pylori infection?].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esophagitis, Peptic; Female; Fundopli | 1997 |
Disappearance of multiple hyperplastic polyps after the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combinati | 1997 |
Helicobacter pylori eradication in duodenal ulcer disease is cost-beneficial: a Belgian model.
Topics: Anti-Ulcer Agents; Belgium; Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy; Duode | 1997 |
Interaction of drugs for eradication therapy against antibiotic-resistant strains of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Colony | 1997 |
Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cell Division; Epithelial C | 1997 |
Anti-Helicobacter pylori specific antibody immunohistochemistry improves the diagnostic accuracy of Helicobacter pylori in biopsy specimen from patients treated with triple therapy.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Biopsy; D | 1998 |
Pragmatic eradication of H. pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter In | 1997 |
[Gastric lymphoma--a case report].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Gastrosc | 1998 |
Regression of a primary gastric MALT lymphoma with extensive antrum lesions by Helicobacter pylori eradication.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinati | 1997 |
Enhancement of neutrophil infiltration in the corpus after failure of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biop | 1997 |
[Short-term (6 days) eradication of Helicobacter pylori infection in the practice of a health insurance physician].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Azithromycin; Benzimidazoles; Female; He | 1998 |
Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combinati | 1998 |
[Efficacy of the triple therapy in the eradication of H. pylori in peptic ulcer].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 1997 |
Evaluation of combined antibiotic-omeprazole therapies in Helicobacter pylori-infected Mongolian gerbils.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Clarithromycin; DNA Primers; Drug Therapy, Combination; | 1998 |
Cure of Helicobacter pylori infection by omeprazole-clarithromycin-based therapy in non-human primates.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therap | 1998 |
Does Helicobacter pylori infection affect gastric emptying in patients with functional dyspepsia?
Topics: Adolescent; Adult; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Dyspepsia; Female; Gastric Empty | 1997 |
New, improved Helicobacter pylori eradication therapy in children.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Therapy, Combinati | 1998 |
Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Drug Resistance, Microbial; | 1998 |
One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Clarithromycin; Drug Administ | 1998 |
[Short-term triple therapy with pantoprazole, amoxicillin and metronidazole in Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 1998 |
[Seven-day omeprazole, clarithromycin, and amoxicillin for the therapy of Helicobacter pylori infection].
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Combined Modality Therapy; Drug Administration | 1998 |
[Helicobacter pylori infection and recurrent abdominal pain in children. A proved relationship?].
Topics: Abdominal Pain; Adolescent; Adult; Age Factors; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-U | 1998 |
Natural history of severe duodenal ulcer disease.
Topics: Adult; Aged; Anti-Ulcer Agents; Chronic Disease; Drug Therapy, Combination; Duodenal Ulcer; Female; | 1998 |
Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Dru | 1998 |
[Problems in the diagnosis and treatment of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Helicobacter Infections; Helicobacter py | 1996 |
The long-term clinical outcome of elderly patients with Helicobacter pylori-associated peptic ulcer disease.
Topics: Aged; Aging; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Gastritis; | 1998 |
Influence of the NIH Consensus Conference on Helicobacter pylori on physician prescribing among a Medicaid population.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cohort Studies; Consensus D | 1998 |
Effect of Helicobacter pylori infection on gastric juice pH.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Amoxicillin; Anti-Ulcer Agents; Case-Control Studi | 1998 |
Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; F | 1998 |
[Sensitivity of Helicobacter pylori to amoxicillin and clarythromycin with special reference to eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1998 |
Effect of metronidazole resistance on bacterial eradication of Helicobacter pylori in infected children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Child; Drug Resistance, Microbial; Drug Therap | 1998 |
Analysis of risk factors for chronic hepatic encephalopathy: the role of Helicobacter pylori infection.
Topics: Ammonia; Amoxicillin; Anti-Ulcer Agents; Ascites; Chronic Disease; Diuretics; Helicobacter Infection | 1998 |
Treatment of gastric MALT lymphoma by Helicobacter pylori eradication: a study controlled by endoscopic ultrasonography.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Endosonography; Fe | 1998 |
Weekend therapy for the treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Sc | 1998 |
Clostridium difficile colitis associated with a 'triple' regimen, containing clarithromycin and metronidazole, to eradicate Helicobacter pylori.
Topics: Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Enterocolitis, Pseudom | 1998 |
The ideal therapy must be defined in each geographical area: experience with a quadruple therapy in Spain.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Femal | 1998 |
Effectiveness of omeprazole-amoxicillin-clarithromycin (OAC) therapy for Helicobacter pylori infection in a Japanese population.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Enzyme I | 1998 |
Enhanced levels of C-X-C chemokine, human GROalpha, in Helicobacter pylori-associated gastric disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Chem | 1998 |
[Is chronic laryngitis associated with Helicobacter pylori? Results of a prospective study].
Topics: Adult; Aged; Anti-Ulcer Agents; Biopsy; Chronic Disease; Esophagitis, Peptic; Female; Follow-Up Stud | 1998 |
[Polyneuropathy caused by vitamin B12 deficiency secondary to chronic atrophic gastritis and giardiasis].
Topics: Amoxicillin; Anemia, Pernicious; Anti-Bacterial Agents; Antiprotozoal Agents; Bismuth; Duodenitis; E | 1998 |
Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Breath T | 1998 |
Treatment of antibiotic-resistant Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; D | 1998 |
Four-day quadruple therapy as a routine treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 1997 |
Omeprazole efficacy and Helicobacter pylori infection.
Topics: Anti-Ulcer Agents; Dose-Response Relationship, Drug; Gastric Acid; Gastritis; Helicobacter Infection | 1998 |
Pantoprazole-based 10-day triple therapy is effective in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 1998 |
Therapies for ulcers associated with nonsteroidal antiinflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Helicobacter Infections; Helicobacter py | 1998 |
Gastric mucosal distribution and clinical efficacy of azithromycin in patients with Helicobacter pylori related gastritis.
Topics: Adult; Aged; Azithromycin; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy; Female; Gastric Muc | 1998 |
[Is dental plaque a normal Helicobacter pylori reservoir?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Benzimidazoles; Clari | 1998 |
Schönlein-Henoch purpura in association with duodenal ulcer and gastric Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Follow-Up Stu | 1998 |
Analysis of the 13C-urea breath test for detection of Helicobacter pylori infection based on the kinetics of delta-13CO2 using laser spectroscopy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Cl | 1998 |
Effect of H. pylori infection and CagA status on leukocyte counts and liver function tests: extra-gastric manifestations of H. pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Blotting, Western | 1998 |
[An unusual course of low-malignancy non-Hodgkin lymphoma of the stomach].
Topics: Amoxicillin; Biopsy; Combined Modality Therapy; Female; Follow-Up Studies; Gastrectomy; Helicobacter | 1998 |
Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Breath Tests; Diagnostic Errors; False N | 1998 |
Cure of autoimmune gastritis by Helicobacter pylori eradication in a 21-year-old male.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Autoimmune Diseases; | 1998 |
One-week treatment with omeprazole, clarithromycin, and metronidazole in children with Helicobacter pylori infection.
Topics: Adolescent; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; H | 1998 |
[Efficacy of an ultrashort protocol in the eradication of Helicobacter pylori].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 1998 |
Helicobacter pylori eradication failure--'salvage' therapies needed.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Thera | 1998 |
Pre-treatment with misoprostol increases the efficacy of omeprazole plus amoxycillin to cure Helicobacter pylori infection. A pilot study.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter Infections; H | 1998 |
Treating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bism | 1998 |
CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection.
Topics: Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P | 1998 |
Current or recent proton pump inhibitor therapy markedly impairs the accuracy of the [14C]urea breath test.
Topics: Anti-Ulcer Agents; Antigens, Bacterial; Breath Tests; Dyspepsia; False Negative Reactions; False Pos | 1998 |
Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; D | 1998 |
[Eradicating treatment against Helicobacter pylori].
Topics: Anti-Ulcer Agents; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole | 1998 |
[Proton pump inhibitor for ulcer therapy. Tolerance profile of lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Adverse Drug Reaction Reporting Systems; Aged; Anti- | 1998 |
Healing of cimetidine-resistant Ménétrier's disease by eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; | 1998 |
Helicobacter pylori and nonulcer dyspepsia.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastroint | 1998 |
Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cyto | 1998 |
One-week low-dose triple therapy is effective in treating Helicobacter pylori-infected patients with bleeding peptic ulcers.
Topics: Adult; Aged; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal | 1998 |
Relationship between the eradication of Helicobacter pylori and the healing pattern of peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Gastric urease activity is inversely associated with the success of treatment for Helicobacter pylori: effect of sofalcone.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Breath Tests; | 1998 |
[Eradication of Helicobacter pylori by triple therapy in ulcerous patients: the role of endoscopy and antibiotic sensitivity].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Th | 1998 |
Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status.
Topics: Adult; Anti-Ulcer Agents; Case-Control Studies; Enzyme Inhibitors; Female; Gastric Acid; Gastric Muc | 1999 |
[Triple treatment for the eradication of Helicobacter pylori infection].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infec | 1998 |
[Asia Pacific Consensus Conference on the management of Helicobacter pylori].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Asia; Congresses as Topic; Drug Therapy, Combination; Heli | 1999 |
Healing of Helicobacter pylori-induced gastric ulcers in Mongolian gerbils: combined treatment with omeprazole and clarithromycin.
Topics: Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Dru | 1999 |
Treatment of Helicobacter heilmannii-associated gastritis in a 14-year-old boy.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Gastritis; Granul | 1999 |
Helicobacter pylori, hyperammonemia and subclinical portosystemic encephalopathy: effects of eradication.
Topics: Aged; Ammonia; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; | 1999 |
Eradication of Helicobacter pylori heals atrophic corpus gastritis caused by long-term treatment with omeprazole.
Topics: Adult; Anti-Ulcer Agents; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; | 1999 |
[Gastric MALT lymphoma, clinical features].
Topics: Amoxicillin; Anti-Ulcer Agents; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lympho | 1999 |
Omeprazole: Helicobacter pylori makes thee greater yet.
Topics: Anti-Ulcer Agents; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion | 1999 |
Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole.
Topics: Adult; Ammonia; Anti-Ulcer Agents; Female; Follow-Up Studies; Gastric Acid; Gastric Acidity Determin | 1999 |
Understanding peptic ulcer disease pharmacotherapeutics.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicob | 1999 |
Hypergastrinaemia with long-term omeprazole treatment.
Topics: Anti-Ulcer Agents; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole | 1999 |
Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Costs and Cost Analysis; Decision Support Tec | 1996 |
Resolution of thrombocytopenia after treatment for Helicobacter pylori: a case report.
Topics: Amoxicillin; Anti-Ulcer Agents; Autoimmune Diseases; B-Lymphocytes; Gastric Mucosa; Gastritis; Helic | 1999 |
Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys.
Topics: Adjuvants, Immunologic; Animals; Anti-Bacterial Agents; Antibodies, Bacterial; Bacterial Toxins; Bac | 1999 |
Does Helicobacter pylori affect the management of gastroesophageal reflux disease?
Topics: Enzyme Inhibitors; Gastritis; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; | 1999 |
Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease.
Topics: Anti-Ulcer Agents; Case-Control Studies; Esophagitis, Peptic; Follow-Up Studies; Gastroesophageal Re | 1999 |
Helicobacter heilmannii associated erosive gastritis.
Topics: Abietanes; Aged; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Drug Therapy, Combination; Endoscopy, D | 1999 |
Helicobacter pylori infection and persistent hyperemesis gravidarum.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Famotidine | 1999 |
Combined activity of azithromycin and lansoprazole against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Azithromycin; Drug Synergism; Helico | 1999 |
A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome.
Topics: Adult; Aged; Amoxicillin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacte | 1999 |
Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Resistance, | 1999 |
Nocturnal gastric acid breakthrough on proton pump inhibitors.
Topics: Circadian Rhythm; Drug Administration Schedule; Gastric Acid; Gastroesophageal Reflux; Helicobacter | 1999 |
Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Gastroscopy; Helicobac | 1999 |
Treatment of Helicobacter pylori infection in functional dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug The | 1999 |
Effect of clarithromycin and omeprazole therapy on the diversity and stability of genotypes of Helicobacter pylori from duodenal ulcer patients.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Base Sequence; Clarithromycin; DNA Primers; Drug Therapy, | 1999 |
[Are 5 days of omeprazole plus 2 antibiotics enough for eradication of H. pylori? Comments on sample size].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Confidence Intervals; Data In | 1999 |
A second-line anti-Helicobacter pylori therapy in patients with previously failed treatment.
Topics: Adult; Aged; Amoxicillin; Clarithromycin; Dose-Response Relationship, Drug; Drug Resistance, Multipl | 1999 |
[Effect of Helicobacter pylori on gastric epithelial apoptosis].
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Apoptosis; Drug Therapy, Combination; Epithel | 1997 |
Optimum management of mild esophagitis in Japan.
Topics: Anti-Ulcer Agents; Disease Management; Esophagitis, Peptic; Famotidine; Helicobacter Infections; Hel | 1999 |
Functional dyspepsia has a good prognosis irrespective of H. pylori status. Long-term follow-up of symptoms after anti H. pylori treatment.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Dyspepsia | 1999 |
[Symptomatic improvement of patients with nonulcer dyspepsia after Helicobacter pylori eradication].
Topics: Amoxicillin; Anti-Ulcer Agents; Breath Tests; Drug Therapy, Combination; Dyspepsia; Helicobacter Inf | 1999 |
Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antigens, Bacterial; Bismuth; Breath Tes | 1999 |
A case of prurigo and lichenified plaques successfully treated with proton pump inhibitor.
Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Enzyme Inhibitors; Female; Helicobacter Infections; Heli | 1999 |
PPI-based triple therapy in the eradication of H. pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Enzyme Inhibitors; Gastrointest | 1999 |
Treatment of Helicobacter pylori: where are we now? What are the key questions?
Topics: Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Enzyme Inhibitors; Helicobacter Infections; Helicobacter | 1999 |
Is there any difference in Helicobacter pylori eradication rates in patients with active peptic ulcer, inactive peptic ulcer and functional dyspepsia?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dy | 1999 |
Omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infec | 1999 |
What can be learnt from the new data about antibiotic resistance? Are there any practical clinical consequences of Helicobacter pylori antibiotic resistance?
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, | 1999 |
Re-treatment after Helicobacter pylori eradication failure.
Topics: Adult; Ampicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistanc | 1999 |
Ulcer activity but not duodenal stenosis regresses after eradication of Helicobacter pylori.
Topics: Adult; Anti-Ulcer Agents; Duodenal Diseases; Duodenal Ulcer; Duodenoscopy; Female; Follow-Up Studies | 1999 |
Eradication of Helicobacter pylori normalizes elevated mucosal levels of epidermal growth factor and its receptor.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Chronic Disease; Drug Th | 1999 |
Rapidly growing primary gastric B-cell lymphoma after eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Gastrointestinal Neoplasms; Helicobacter I | 1999 |
[A ration proposal for the eradicating treatment of Helicobacter pylori infection].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Combined Modality Therapy; Drug Therapy, Combination | 1999 |
Will Helicobacter pylori affect short-term rebleeding rate in peptic ulcer bleeding patients after successful endoscopic therapy?
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Blood Transfusion; Confidence Intervals; Duodenal | 1999 |
Helicobacter pylori and omeprazole therapy in GERD.
Topics: Enzyme Inhibitors; Esophagitis, Peptic; Gastroesophageal Reflux; Helicobacter Infections; Helicobact | 1999 |
Ménétrier's disease and Helicobacter pylori: normalization of gastrointestinal protein loss after eradication therapy.
Topics: Amoxicillin; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis, Hypertrophic; Hel | 1999 |
CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Bism | 1999 |
[Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cost-Benefit Analysis; Drug Therapy, Com | 1999 |
Duodenal ulcer relapse is not always associated with recurrence of H. pylori infection: a prospective three-year follow-up study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; | 1999 |
Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication of Helicobacter pylori.
Topics: Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Colonic Neoplasms; Drug Therapy, Com | 2000 |
Proliferating cell nuclear antigen (PCNA) immunostaining in Helicobacter pylori infection: impact of eradication.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Biomarkers, Tumor; Drug Therapy, Combinatio | 1999 |
Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Asian People; | 1999 |
Relapse of duodenal ulcers after successful eradication of Helicobacter pylori in gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1999 |
Endoscopic and histological reversibility of gastric adenoma after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; A | 1999 |
[Resolution of an autoimmune thrombocytopenic purpura after eradicating treatment of Helicobacter pylori].
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Autoimmune Diseases; Bismuth; Drug Therapy, Combination; Fema | 1999 |
Regression of high-grade gastric mucosa-associated lymphoid tissue lymphoma with Helicobacter pylori after triple antibiotic therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter | 2000 |
Empiric eradication therapy or endoscopy in Helicobacter pylori-positive patients?
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Combined Modality Therapy; Dyspepsi | 1999 |
Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2000 |
The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Chile; Developing Countries; Drug Therapy, | 2000 |
Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Femal | 2000 |
Omeprazole and accelerated onset of atrophic gastritis.
Topics: Anti-Ulcer Agents; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Omepra | 2000 |
Omeprazole and accelerated onset of atrophic gastritis.
Topics: Anti-Ulcer Agents; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Omepra | 2000 |
Omeprazole and accelerated onset of atrophic gastritis.
Topics: Anti-Ulcer Agents; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Omepra | 2000 |
Lack of effect of acid suppression therapy on gastric atrophy.
Topics: Anti-Ulcer Agents; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Omepra | 2000 |
Continued use of the proton-pump inhibitor lansoprazole following Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Female; Helicobacter Infections; Helicob | 2000 |
Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy.
Topics: Adult; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Resistance; Enzyme | 2000 |
Prevention of hemorrhage from intradiverticular ulcer in the duodenum by Helicobacter pylori eradication.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diverticulum; Drug Ther | 2000 |
Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Fe | 2000 |
Successful eradication of Helicobacter pylori as determined by ((13))C-urea breath test does not alter fibrinogen and acute phase response markers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute-Phase Reaction; Adult; Aged; Anti-Bacterial Agents; A | 2000 |
Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therap | 2000 |
[Does eliminating Helicobacter pylori mean the healing of the duodenal ulcer? The results of a prospective study in Spain].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett Esophagus; Child; Drug Resist | 2000 |
Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Drug Therapy, Combination; Female | 2000 |
The effect of ammonia on omeprazole-induced reduction of gastric acidity in subjects with Helicobacter pylori infection.
Topics: Adult; Ammonia; Anti-Ulcer Agents; Female; Follow-Up Studies; Gastric Acidity Determination; Gastrit | 2000 |
[Analysis of indications and diagnosis of the gastroscopies requested by primary care physicians].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diagnosis, Differential; Drug | 2000 |
Effect of acid-suppressive therapy on Helicobacter pylori production of interleukin-8 in the gastric mucosa.
Topics: Adult; Aged; Enzyme Inhibitors; Esophagitis, Peptic; Female; Gastric Mucosa; Helicobacter Infections | 2000 |
A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Cel | 2000 |
Details of hyperplastic polyps of the stomach shrinking after anti-Helicobacter pylori therapy.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Biomarkers, Tumor; Cell Division; Cyclooxygenase 2; Drug T | 2000 |
[Usefulness of Helicobacter pylori antigen detection in stools in the diagnosis of infection and confirming eradication after treatment].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Antigens, | 2000 |
Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agent | 2000 |
Histopathological features of gastritis before and after treatment for Helicobacter pylori.
Topics: Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infection | 2000 |
Studies of the effect of Clostridium butyricum on Helicobacter pylori in several test models including gnotobiotic mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Antibiosis; Bacterial Adhesion; Butyric Acid; Clos | 2000 |
Iron-deficiency anemia associated with Helicobacter pylori gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anemia, Iron-Deficiency; Anti-Bacterial Agents; | 2000 |
[Short-term intervention in ulcer and reflux. New acid blocker halves duration of therapy].
Topics: Anti-Ulcer Agents; Drug Administration Schedule; Esophagitis, Peptic; Helicobacter Infections; Helic | 2000 |
Should we eradicate Helicobacter pylori in patients with recurrent gastro-oesophageal reflux disease?
Topics: Esophagitis; Gastritis; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Human | 2000 |
Omeprazole, Helicobacter pylori status, and alterations in the intragastric milieu facilitating bacterial N-nitrosation.
Topics: Adult; Anti-Ulcer Agents; Ascorbic Acid; Female; Gastric Juice; Gastritis; Helicobacter Infections; | 2000 |
Helicobacter pylori infection influences nocturnal gastric acid breakthrough.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; | 2000 |
Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co | 2000 |
OAM for cure of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug C | 2000 |
[The role of omeprazole in the eradication of Helicobacter pylori in patients with duodenal ulcers].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combin | 2000 |
[Helicobacter pylori eradication in gastroduodenal ulcer: good, fine and not expensive].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost-Benefit Analysis; Drug T | 2000 |
By the way, doctor... No need to take Prilosec forever.
Topics: Antacids; Anti-Ulcer Agents; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole | 2000 |
Long-term safety and efficacy of omeprazole in gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Drug Administration Schedule; Esophageal Neoplasms; Esophagiti | 2000 |
Helicobacter acinonychis eradication leading to the resolution of gastric lesions in tigers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Age | 2000 |
No H pylori: less dyspepsia?
Topics: Anti-Ulcer Agents; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Rese | 2000 |
Treatment of Helicobacter pylori infection: is less more?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2000 |
[Effects of Helicobacter pylori eradication on the recurrence of gastric ulcer during a 12-month follow up].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Da | 2000 |
Two enzyme immunoassays and PCR for detection of Helicobacter pylori in stool specimens from pediatric patients before and after eradication therapy.
Topics: Adolescent; Amoxicillin; Antibodies, Bacterial; Breath Tests; Child; Child, Preschool; Clarithromyci | 2000 |
Efficacy of a 1-week pantoprazole triple therapy in eradicating Helicobacter pylori in Asian patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2000 |
Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug | 2000 |
Helicobacter pylori infection in recurrent abdominal pain.
Topics: Abdominal Pain; Adolescent; Amoxicillin; Anti-Ulcer Agents; Breath Tests; Child; Child, Preschool; C | 2000 |
[Upgrading efficiency and safety of combined antihelicobacterial treatment of ulcer patients using modern clinicopharmacological approaches].
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug Therapy, Com | 2000 |
Effect of cure rate on reinfection with H. pylori: a three-year follow-up study.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Follow-Up Studie | 2000 |
CagA seropositivity and the severity of Helicobacter pylori infection in dyspeptic children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Bacterial | 2000 |
Endoscopic characteristics of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2000 |
Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; He | 2000 |
Helicobacter pylori infection in renal transplant recipients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug | 2000 |
Helicobacter pylori, a frequent and potentially dangerous guest in the gastroduodenal mucosa of anticoagulated patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Amoxicillin; Anti-Ulcer Agents; | 2000 |
Effect of amoxicillin, clarithromycin, and rabeprazole, a new proton pump inhibitor, in eradication therapy for relapsing peptic ulcer diseases with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2000 |
[Efficacy of a multistep strategy for Helicobacter pylori eradication: quadruple therapy with omeprazole, metronidazole, tetracycline and bismuth after failure of a combination of omeprazole, clarithromycin and amoxycillin].
Topics: Anti-Ulcer Agents; Bismuth; Combined Modality Therapy; Drug Therapy, Combination; Female; Helicobact | 2000 |
[High eradication rates in Helicobacter pylori infection in patients with duodenal ulcer who failed previous eradication therapy].
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulc | 2000 |
Lactobacillus acidophilus administration added to omeprazole/amoxycillin-based double therapy in Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Defensins; Drug Therapy, Combination; Gastrointestinal Agents; G | 2000 |
Current approaches to reducing gastrointestinal toxicity of low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2001 |
The use of AP-PCR and flaA-RFLP typing to investigate treatment failure in Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Clar | 2000 |
Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2001 |
Antibiotic-resistance patterns of Helicobacter pylori in Croatia: cohort study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles | 2001 |
Effect of the treatment of Helicobacter pylori infection on gastric emptying and its influence on the glycaemic control in type 1 diabetes mellitus.
Topics: Adult; Aged; Amoxicillin; Antibodies, Bacterial; Blood Glucose; Clarithromycin; Diabetes Mellitus, T | 2001 |
[Ulcer therapy with a new proton pump inhibitor. One week of treatment is enough].
Topics: Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylor | 2001 |
Early stage gastric MALT lymphoma with high-grade component cured by Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; D | 2001 |
A case of gastric plasmacytoma associated with Helicobacter pylori infection: improvement of abnormal endoscopic and EUS findings after H. pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Biopsy, Needle; Clarithromycin; Drug Therapy, | 2001 |
Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Biop | 2001 |
[Prevalence and treatment of Helicobacter pylori in gastro-duodenal ulcers. An experience in Liege].
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Belgium; Clar | 2001 |
Recurrence of Helicobacter pylori infection and duodenal ulcer relapse, following successful eradication in an urban east Asian population.
Topics: Adolescent; Adult; Age Distribution; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Ch | 2000 |
Effects of lansoprazole, clarithromycin and pH gradient on uptake of [14C]amoxycillin into rat gastric tissue.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Ulcer Agents; Biological Transpo | 2001 |
Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Cell Transformation, Neoplastic; Fem | 2001 |
Intragastric acidification reduces the occurrence of false-negative urea breath test results in patients taking a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Breath Tests; False Negative Reactions; Female; Gastric Aci | 2001 |
Peptic ulcer occurrence in follow-up of chronic gastritis in patients with treated and not eradicated CagA-positive Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Chronic Diseas | 2001 |
Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Cla | 2001 |
Prevalence of gastric myoelectrical abnormalities in patients with nonulcer dyspepsia and H. pylori infection: resolution after H. pylori eradication.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dyspepsia; Electromyography; | 2001 |
Eradication of Helicobacter pylori from the stomach and duodenum of patients with duodenal ulcers.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Duodenal Ulcer; Duodenum; Enzyme-Linked Immunosorbent Assay; | 2001 |
Helicobacter pylori eradication therapy for high-grade mucosa-associated lymphoid tissue lymphomas of the stomach with analysis of p53 and K-ras alteration and microsatellite instability.
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Female; Follow-Up Studies; Genetic Markers; He | 2001 |
4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles | 2001 |
Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cell Division; Clarithromycin; Dose-Respons | 2001 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |
Regression of primary lymphoma of the ampulla of Vater after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Ampulla of Vater; Biopsy; Clarithromycin; Comm | 2001 |
Lansoprazole triple therapy for Turkish children with Helicobacter pylori infections.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Child; Female; Helicobacter | 2001 |
A prospective study of a one-week nonbismuth quadruple therapy for childhood Helicobacter pylori infection.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool; C | 2001 |
Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Alleles; Amoxicillin; Aryl Hydrocarbon Hydroxy | 2001 |
Preventing upper gastrointestinal bleeding in patients with Helicobacter pylori infection.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Gastrointestinal Hemorrhage; He | 2001 |
The effectiveness of one-week triple eradication therapy for perforated duodenal ulcer patients treated with simple closure.
Topics: Adult; Amoxicillin; Clarithromycin; Combined Modality Therapy; Dose-Response Relationship, Drug; Dru | 2001 |
Pseudomembranous colitis without diarrhoea following Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents | 2001 |
Disappearance of antiphospholipid antibodies syndrome after Helicobacter pylori eradication.
Topics: Adult; Antiphospholipid Syndrome; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Heli | 2001 |
The relationship between gastric-oral Helicobacter pylori and oral hygiene in patients with vitamin B12-deficiency anemia.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anemia, Pernicious; Anti-Bacterial Agents; Anti-Ulcer A | 2001 |
Short-term changes in Helicobacter pylori gastritis and bulbitis during and after 2 weeks of treatment with omeprazole and amoxicillin in duodenal ulcer patients.
Topics: Adult; Aged; Amoxicillin; Biopsy; Drug Therapy, Combination; Duodenal Ulcer; Duodenitis; Endoscopy, | 2001 |
Gastric leptin and Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Biomarkers; Biopsy; Body Mass Index; Case-Control Studies; Cl | 2001 |
[Current principles of the use of laparoscopic surgery in gastroduodenal ulcer].
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duode | 2001 |
[The effectiveness of 7-day combined Helicobacter eradication therapy in patients with peptic ulcer and chronic gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Chronic Disease | 2001 |
Intragastric volatile N-nitrosamines, nitrite, pH, and Helicobacter pylori during long-term treatment with omeprazole.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Biopsy; Female; Gastric Juice; Helicobacter Infec | 2001 |
Eradication rates of Helicobacter pylori between metronidazole-sensitive and metronidazole-resistant strains with metronidazole containing regimen in Thai patients with peptic ulcer disease.
Topics: Adult; Aged; Chi-Square Distribution; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Fe | 2001 |
Resolution of Ménétrier's disease after Helicobacter pylori eradicating therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 2001 |
Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Case-Control Studies; Clarithromycin; Drug Therapy, Combin | 2001 |
[Results of child observation during 3 years after the eradication treatment].
Topics: Adolescent; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Drug Therapy, Combination; Duodenal Ulc | 2001 |
Disappearance of both MALT lymphoma and hyperplastic polyps in the stomach after eradication of Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Female; Helicobacter Infectio | 2001 |
Noninvasive Helicobacter pylori testing for the "test-and-treat" strategy: a decision analysis to assess the effect of past infection on test choice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antibodies, Bacterial; Antigens, Bacterial; Br | 2001 |
Impairment of gastric secretion modulation in duodenal ulcer and in long-term PPI treatment: quantitative morphologic findings and pathophysiologic implications.
Topics: Adult; Aged; Cell Count; Duodenal Ulcer; Female; Gastric Acid; Gastric Mucosa; Gastrin-Secreting Cel | 2001 |
Remission of a high-grade gastric mucosa associated lymphoid tissue (MALT) lymphoma following Helicobacter pylori eradication and highly active antiretroviral therapy in a patient with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Age | 2001 |
Remission of idiopathic thrombocytopenic purpura by eradicating Helicobacter pylori after omeprazole monotherapy.
Topics: Aged; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; P | 2001 |
Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bangladesh; Body Mass Index; Breath Tests; Carbon Isotopes; D | 2001 |
Clarithromycin resistance of Helicobacter pylori has a major impact on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Biopsy; Clarithromycin; DNA, Bacterial; Dru | 2001 |
First successful treatment of a primary high-grade gastric MALT lymphoma by eradication therapy for Helicobacter pylori.
Topics: Biopsy; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pyl | 2001 |
Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2001 |
Key topics in Helicobacter pylori eradication in the management of the dyspeptic patient: a panel discussion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Resistance; Drug Therapy, Combination; Dyspepsia; Heli | 2001 |
Helicobacter pylori eradication in functional dyspepsia: new evidence for symptomatic benefit.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chronic Disease; Dyspepsia; Gastritis; Helicobacter Infecti | 2001 |
Regression of primary high-grade gastric B-cell lymphoma following Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Female; Helicobacter Infections; Helicobacter pylori; | 2001 |
Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 2001 |
The role of treatment with proton pump inhibitors and anti-Helicobacter therapy in functional dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Helicob | 2001 |
Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Female; Follo | 2001 |
Fundic gland polyps are not induced by proton pump inhibitor therapy.
Topics: Enzyme Inhibitors; Female; Gastric Fundus; Gastritis; Helicobacter Infections; Helicobacter pylori; | 2001 |
Diagnostic methods for detecting forms and strains of Helicobacter pylori and evaluation of its eradication.
Topics: Adolescent; Adult; Aged; Antibodies, Bacterial; Bismuth; DNA Fingerprinting; Duodenal Ulcer; Female; | 2001 |
Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 | 2001 |
Duodenal mucosa-associated lymphoid tissue lymphoma treated by eradication of Helicobacter pylori: report of 2 cases including EUS findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Benzimidazoles; Biopsy, Needle; Clarithr | 2001 |
Hypergastrinemia in response to gastric inflammation suppresses somatostatin.
Topics: Animals; Anti-Ulcer Agents; Female; Gastric Acid; Gastric Fundus; Gastric Mucosa; Gastrins; Gastriti | 2002 |
Genetic or chemical hypochlorhydria is associated with inflammation that modulates parietal and G-cell populations in mice.
Topics: Achlorhydria; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; B-Lymphocytes; Bacteriological Tech | 2002 |
Treatment of erosive oesophagitis with omeprazole: a comparison with different delivery system.
Topics: Anti-Ulcer Agents; Drug Delivery Systems; Esophagitis; Gastroesophageal Reflux; Helicobacter Infecti | 2001 |
[Diagnostics and treatment of helicobacter infection. Treatment recommendation from Finnish Gastroenterological Association].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter | 2000 |
Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2002 |
Regression of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: possible association with p16 hypermethylation.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; DNA Methylation; | 2002 |
[Successful treatment of refractory idiopathic thrombocytopenic purpura by eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 2001 |
[Dyspepsia and Helicobacter pylori infection in employees of a large industry. Results of a prospective BASF Helicobacter pylori prevention campaign].
Topics: Adolescent; Adult; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Female; Gastritis; Germany; | 2002 |
Helicobacter pylori eradication: do we have another ace up our sleeve?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Anti-Infective Agents; Be | 2001 |
Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Drug Therapy, Combination; | 2001 |
Does Helicobacter pylori eradication reduce the long-term requirements for acid suppressants in patients with a history of peptic ulcer disease in general practice? Results from a four-year longitudinal study.
Topics: Amoxicillin; Antacids; Clarithromycin; Drug Therapy, Combination; Follow-Up Studies; Helicobacter In | 2002 |
Absence of platelet response after eradication of Helicobacter pylori infection in patients with chronic idiopathic thrombocytopenic purpura.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Clarithromycin; Drug Therapy, Combination; | 2001 |
[Long-term prophylaxis with omeprazol is superior to eradication therapy in H. pylori-positive NSAIDs taking patients].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Helicobacter Inf | 2002 |
Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Dose-Response Relationship, Drug; | 2002 |
Resolution of collagenous colitis after treatment for Helicobacter pylori.
Topics: Aged; Biopsy, Needle; Clarithromycin; Colitis; Collagen; Diarrhea; Drug Therapy, Combination; Female | 2002 |
The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Combinations | 2002 |
Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials as Topic; Helicobacter I | 2002 |
Vitamin C inhibits corpus gastritis in Helicobacter pylori-infected patients during acid-suppressive therapy.
Topics: Acids; Anti-Ulcer Agents; Ascorbic Acid; Drug Therapy, Combination; Female; Gastritis; Helicobacter | 2001 |
[Helicobacter pylori increases the antisecretory activity of omeprazole in the parietal cell and the proton pump].
Topics: Animals; Anti-Ulcer Agents; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Pariet | 2001 |
[Acquisition of secondary resistance after failure of a first treatment of Helicobacter pylori infection in children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Age Factors; Amoxicillin; Anti-Bacterial Agents | 2002 |
Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2002 |
Regression of duodenal gastric metaplasia in Helicobacter pylori positive patients with duodenal ulcer disease.
Topics: Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Gastric Mucosa; | 2002 |
pH-Hp: implications for dyspepsia management.
Topics: Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Omepraz | 2002 |
[Gastroduodenal ulcer in childhood].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Inflammatory Agents, Non-Ster | 2002 |
Failure of Helicobacter pylori eradication: is poor compliance the main cause?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2002 |
Esomeprazole: a review of its use in the management of acid-related disorders in the US.
Topics: Animals; Anti-Ulcer Agents; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Gastrointestin | 2002 |
Influence of Helicobacter pylori infection on healing and relapse of acetic acid ulcers in Mongolian gerbils.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cyclooxygenase Inh | 2002 |
Localization of antigen-presenting cells in Helicobacter pylori-infected gastric mucosa.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Antigen-Presenting Cells; CD28 Antigens; Cell Count; Clari | 2002 |
[Management of dyspepsia, gastroduodenal ulcer and Helicobacter pylori infection in primary care].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribution; Clarithromycin; Drug | 2002 |
Prevalence of H. pylori-infection in family members of H. pylori positive and its influence on the reinfection rate after successful eradication therapy: a two-year follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breath Tests; Child; Child, Preschool; Clarithromycin; D | 2002 |
Primary hyperparathyroidism with duodenal ulcer and H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Aged; Anti-Ulcer Agents; Benzimidazoles; Duodenal | 2002 |
Detection of Helicobacter pylori colonization in dental plaques and tongue scrapings of patients with chronic gastritis.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Chronic Disease; Clarith | 2001 |
DNA fingerprints of Helicobacter pylori before and after treatment with omeprazole.
Topics: DNA Fingerprinting; DNA, Bacterial; Electrophoresis; Gastric Acid; Genome, Bacterial; Helicobacter I | 1992 |
Clarithromycin and omeprazole for Helicobacter pylori.
Topics: Clarithromycin; Erythromycin; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole | 1992 |
[Drug therapy of peptic ulcer disease].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Helicobacter Infections; Histamine H2 Ant | 1991 |
Preliminary observations in the fasting serum gastrin in patients with duodenal ulcer; further evidence of the "clearing" effect of omeprazole on H pylori?
Topics: Adult; Aged; Duodenal Ulcer; Fasting; Female; Gastrins; Helicobacter Infections; Helicobacter pylori | 1992 |
Omeprazole therapy for Helicobacter pylori infection.
Topics: Adolescent; Adult; Child; DNA Fingerprinting; Duodenal Ulcer; Female; Gastritis; Helicobacter Infect | 1992 |
[Modified combined omeprazole/amoxicillin therapy for Helicobacter pylori eradication: a pilot study].
Topics: Adult; Aged; Amoxicillin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Thera | 1992 |
Helicobacter pylori and hypergastrinaemia during proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Benzimidazoles; Duodenal Ulcer; | 1992 |
Long-term omeprazole monotherapy is ineffective against Helicobacter pylori infection.
Topics: Adult; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omep | 1992 |
Lack of eradication of Helicobacter pylori after omeprazole.
Topics: Adult; Aged; Drug Administration Schedule; Duodenal Ulcer; Esophagitis, Peptic; Helicobacter Infecti | 1991 |
Omeprazole in short-term treatment of Helicobacter pylori positive duodenal ulcer.
Topics: Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Ome | 1991 |
Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis.
Topics: Adult; Aged; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Middle | 1991 |
Antral Helicobacter pylori-like organisms in different states of gastric acid secretion.
Topics: Adolescent; Adult; Aged; Duodenal Ulcer; Esophagitis, Peptic; Female; Gastric Acid; Gastritis; Helic | 1991 |
Omeprazole therapy modifies the gastric localization of Helicobacter pylori.
Topics: Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Pyloric Antrum | 1991 |
Lack of activity of omeprazole against Helicobacter pylori.
Topics: Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole | 1991 |
[Current perspectives in ulcer disease].
Topics: Anti-Bacterial Agents; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter pylori; Huma | 1990 |
Elimination of Helicobacter pylori under treatment with omeprazole.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; | 1990 |